(dp0
S'sleep disturbance-Behavioral'
p1
(dp2
S'NCT02162862'
p3
(lp4
S'- ibd group:'
p5
aS'- meeting criteria for active alcohol or substance abuse or dependence'
p6
aS'- current ongoing treatment with wellbutrin'
p7
aS'- females who are pregnant or plan to become pregnant within three months'
p8
aS'- sleep disorder such as apnea, restless leg syndrome or use of continuous positive airway pressure therapy (c-pap)/bilevel positive airway pressure (bi-pap)'
p9
aS'- current ibd flare requiring hospitalization with intravenous steroid treatment'
p10
aS'- other acute medical conditions or a history of chronic inflammatory condition other than ibd'
p11
aS'- hemoglobin <10 with age and gender adjustments'
p12
aS'- history of seizure disorder'
p13
aS'- acute infection within seven days'
p14
aS'- healthy volunteer group:'
p15
aS'- history or current episode of psychiatric disorder by diagnositic and statistical manual (dsm-iv)'
p16
aS'- current ongoing treatment with psychoactive medications'
p17
aS'- medications for sleep in previous two weeks'
p18
aS'- females who are pregnant or plan to become pregnant within three months'
p19
aS'- history of ibd, epilepsy, rheumatoid arthritis, lupus'
p20
aS'- sleep disorder such as apnea, restless leg syndrome or use of continuous positive airway pressure therapy (c-pap)/bilevel positive airway pressure (bi-pap)'
p21
assS'rectal cancer-Drug'
p22
(dp23
S'NCT02266849'
p24
(lp25
S'- complications associated with surgery'
p26
aS'- non-radical surgery'
p27
aS'- chemotherapy'
p28
aS'- poor compliance'
p29
aS'- other serious illness'
p30
assS'malnutrition-Other'
p31
(dp32
S'NCT02275676'
p33
(lp34
S'- underlying malignant disease'
p35
aS'- diabetes mellitus, type i or ii'
p36
aS'- pregnancy'
p37
aS'- lactating'
p38
aS'- chronic alcohol or drug abuse'
p39
aS'- known anorexia nervosa or binge eating disorder'
p40
aS'- known metabolic disorders, such as e.g. cushing disease, hypothyroidism'
p41
aS'- participation in other interventional studies within the last 6 months prior to study enrollment'
p42
aS'- patient not fully able to understand the study concept and to give his or her written consent'
p43
assS'neutrophilic urticaria-Procedure'
p44
(dp45
sS'chronic inflammation-Device'
p46
(dp47
S'NCT02395354'
p48
(lp49
S'- no patient informed consent.'
p50
aS'- stenosis complicated with abscess, fistula or important activity associated with your ec not limited to the stenosis area.'
p51
aS'- patients with stenosis already known and previously treated with stent and / or dilation with <1 year asymptomatic.'
p52
aS'- pregnancy and lactation'
p53
aS'- any clinical situation that prevents the performance of endoscopy'
p54
aS'- stenosis not accessible by endoscopy'
p55
aS'- asymptomatic patient'
p56
aS'- length of stenosis \xe2\x89\xa5 10 cm.'
p57
aS'- submit> 2 stenosis.'
p58
aS'- severe coagulation disorders (platelets <70000; inr> 1.8)'
p59
assS'anoperineal fistula-Procedure'
p60
(dp61
S'NCT01388257'
p62
(lp63
S'- pregnant or breastfeeding women,'
p64
aS'- patient having a perineal abscess,'
p65
aS'- patient with a high anovaginal fistula that cannot be treated, according to the investigator ,with fistulotomy, gluing, biodegradable plug or advancement flap,'
p66
aS'- patient treated with a daily dose of corticosteroids of more than 20 mg (a dose of more than 20 mg daily will be authorized during the study),'
p67
aS'- contraindication to proctological surgery on the drained fistula(s),'
p68
aS'- patient presenting with somatic or psychic signs or symptoms that are not compatible with his/her participation in the trial according to the investigator,'
p69
aS'- patient who participate in another clinical trial.'
p70
assS'non-radiographic evidence-axspa-Procedure'
p71
(dp72
S'NCT02019602'
p73
(lp74
S'- subject has participated in a study of an investigational medicinal product (imp) or medical device within the previous 30 days or 5 half-lives (whichever is longer) prior to screening or is currently participating in another study of an imp or medical device - unless the study is ucb up0016 [nct02154425] or a registry study'
p75
aS"- subject has any obstetrical or psychiatric condition, or she or her infant(s) has any medical condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study or the outcome of the pregnancy"
p76
aS'- subject has history of chronic alcohol abuse or drug abuse during pregnancy'
p77
aS'- subject has any pregnancy-related clinically significant abnormality noted on obstetric ultrasound, or other imaging assessment, or the subject has significant laboratory abnormalities during her pregnancy, as judged by the investigator'
p78
aS'- subject is taking or has taken any medication with strong positive evidence of a human fetal risk of teratogenicity (e.g., methotrexate or leflunomide) during pregnancy'
p79
aS'- subject has evidence of a condition suggesting chronic or acute uteroplacental insufficiency such as intrauterine growth restriction, severe maternal hypertensive disorders of pregnancy, or abruption'
p80
aS'- subject has a documented history of primary or secondary antiphospholipid syndrome or hypercoagulable state'
p81
aS'- subject has received treatment with any biological therapeutic agent, including anti-tnfs other than certolizumab pegol (czp), during pregnancy'
p82
aS'- subject has previously participated in this study'
p83
aS'- subject has a positive or indeterminate quantiferon\xc2\xae-tb gold in tube test at screening. in case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the subject'
p84
aS"- subject with known tuberculosis (tb) infection, at high risk of acquiring tb infection, or latent tb infection (ltb). if tested within the 6 months prior to screening and the test was negative for tb, and there is no change in the subject's clinical status, nor social, family, or travel history, there is no need for an additional tb testing at screening"
p85
assS'fecal microbiota transplantation-Procedure'
p86
(dp87
S'NCT01790061'
p88
(lp89
S'- diagnosed as uc first time. no history of using biologic,immunomodulatory therapy or corticosteroid therapy. with contraindication of endoscopy.'
p90
assS'healthy-Device'
p91
(dp92
S'NCT02020382'
p93
(lp94
S'- no health insurance ,'
p95
aS'- mental disability,'
p96
aS'- pregnancy'
p97
assS'colorectal cancer-Biological'
p98
(dp99
S'NCT02156557'
p100
(lp101
S'- subjects with known allergy or negative reaction to fluorescein or derivatives.'
p102
aS'- subjects on active chemotherapy or radiation treatment'
p103
aS'- pregnant or trying to conceive'
p104
assS'ischemic heart disease-Drug'
p105
(dp106
sS'benign colorectal neoplasm-Procedure'
p107
(dp108
S'NCT01626963'
p109
(lp110
S'- patients not capable of informed consent and/or quality of life assessment'
p111
aS'- planned open procedure for surgical reason'
p112
aS'- multiple previous abdominal operations'
p113
aS'- body-mass index > 40'
p114
assS'depression-Behavioral'
p115
(dp116
S'NCT02264275'
p117
(lp118
S'- refusal to give necessary oral or written informed consent by patient and/or parent (legal caregiver)'
p119
aS'- not aged 7 through 20 at start of study'
p120
aS'- not willing and able to volunteer in the study'
p121
aS'- has sibling enrolled in this study'
p122
aS'- has severe physical diseases of the locomotor apparatus, psychotic disorders, severe affective disorders, eating disorders, mental retardation, autism spectrum disorder'
p123
aS'- inability to communicate and complete questionnaires in german'
p124
aS'- does not own a functional and nintendo wii-compatible television at home'
p125
aS'- among female adolescents, pregnancy, breastfeeding or intention to get pregnant during the study'
p126
aS'- has clinically significant cardiovascular disease'
p127
aS'- enrolment of the investigator, his/her family members, employees and other dependent persons'
p128
asS'NCT02265588'
p129
(lp130
S'- ibd patients with parental report of mental retardation'
p131
aS'- ibd patients receiving psychopharmacological treatment (antidepressants or benzodiazepines) for depression or anxiety'
p132
aS'- no mastery of the dutch language'
p133
aS'- ibd patients with diagnosed: bipolar disorder, schizophrenia/psychotic disorder, autism spectrum disorders, obsessive-compulsive disorder, posttraumatic stress disorder/acute stress disorder, or substance use disorder'
p134
aS'- physician reported substance abuse (alcohol, drugs) in the past month'
p135
aS'- clinician reported selective mutism'
p136
aS'- ibd patients already participating in an (psychological of psychopharmacological) intervention study'
p137
aS'- ibd patients who received 8 sessions of manualized cognitive behavioral therapy last year'
p138
aS'- current psychological treatment'
p139
assS'diabetes-Behavioral'
p140
(dp141
sS'inflammatory bowel disease-Other'
p142
(dp143
S'NCT02624037'
p144
(lp145
S'- patients do not consent to participate in study'
p146
aS'- patients unable to comply with protocol'
p147
asS'NCT02526251'
p148
(lp149
S'- ibd patients with severe disease activity ( hb > 16 sccai \xe2\x89\xa5 5 )'
p150
aS'- ibd patients with social, medical or psychological issues of a more complex character'
p151
aS'- ibd patients with complex issues such as drug and alcohol problems, severe mental / psychiatric disorders and / or serious social impact.'
p152
aS'- ibd patients who cannot attend due to language barrier or cognitive disorder.'
p153
aS'- age less than 18 years.'
p154
asS'NCT02492555'
p155
(lp156
S'- ibd patients with severe disease activity ( hb > 16 sccai \xe2\x89\xa5 5 )'
p157
aS'- ibd patients with social, medical or psychological issues of a more complex character'
p158
aS'- ibd patients with particularly complex issues such as drug and alcohol problems, severe mental / psychiatric disorders and / or serious social impact.'
p159
aS'- ibd patients who cannot attend due language barrier or cognitive disorder.'
p160
aS'- age less 18.'
p161
aS'- when the patient has agreed to participate in the study'
p162
asS'NCT00360022'
p163
(lp164
S'- the patients will be excluded from the study if one or more of the following apply:'
p165
aS'- 1. unable to give consent.'
p166
aS'- 2. does not meet inclusion criteria above.'
p167
asS'NCT02173002'
p168
(lp169
S'- not able to give informed consent'
p170
aS'- not able to understand and use the dutch language'
p171
aS'- in the two weeks after a hospital admission patients can not be included'
p172
asS'NCT02614911'
p173
(lp174
S'- subject having participated to any therapeutical clinical study in the 30 days preceding the inclusion in this study,'
p175
asS'NCT02351635'
p176
(lp177
S'- 1. individuals unable or unwilling to provide a stool specimen.'
p178
aS'- 2. individuals with known intestinal cancer, intestinal infection, upper gastrointestinal disease'
p179
aS'- 3. individuals receiving chemotherapy or systemic immunosuppressive drugs.'
p180
aS'- 4. individuals who have taken, within the previous 2 weeks, protein pump inhibitors or h2-receptor antagonists.'
p181
aS'- 5. individuals with previously diagnosed inflammatory bowel disease managed with immunomodulators, 5-asa (5-aminosalicylic acid) or biologic therapies or who have undergone a surgical resection or diversion procedure.'
p182
aS'- 6. individuals who have taken nsaids (nonsteroidal anti-inflammatory drugs), including aspirin, on 7 or more days during the 2 weeks before providing the sample.'
p183
asS'NCT01590043'
p184
(lp185
S'- medically compromised children'
p186
aS'- congenital syndromes'
p187
aS'- children on medication chronically or on the day of the examination'
p188
aS'- children treated with radiotherapy or chemotherapy.'
p189
asS'NCT02481687'
p190
(lp191
S'- failure to provide informed consent'
p192
aS'- patients with a contraindication to colonoscopy'
p193
aS'- known allergy to fluorescein'
p194
aS'- pregnant or breast-feeding patients'
p195
aS'- ongoing systemic immunosuppressive therapy with prednisolone, azathioprine or biological agents.'
p196
asS'NCT02367326'
p197
(lp198
S'- patients with intolerance to thiopurines resulting in reduction or discontinuation of thiopurines by the referring physician.'
p199
aS"- post operative crohn's disease patients for whom thiopurines were indicated preventively or in the event of endoscopic abnormalities."
p200
aS'- extensive colic resection, (sub)total colectomy.'
p201
aS'- history of > 3 resections of the small intestine or diagnosis of a short bowel'
p202
aS"- crohn's disease with a perianal lesion whether the latter is isolated or the focus of the disease"
p203
aS'- patient with a enterocutaneous, abdominal or pelvic fistula with abscess or fistula likely to require surgery during the study'
p204
aS'- ileostomy, colostomy or known intestinal stenosis'
p205
aS'- severe active infection'
p206
aS'- active neoplasia'
p207
aS'- known tpmpt homozygote mutation'
p208
aS'- patients on anti-tnf or methotrexate in the last 3 months or during thiopurine therapy'
p209
aS'- patients on allopurinol.'
p210
aS'- patient who expressed his/her refusal to participate in the study'
p211
asS'NCT02463916'
p212
(lp213
S'- history of coronary artery disease, congenital heart disease or any cardiovascular disease, including a family history of coronary artery disease before 45 years of age'
p214
aS'- uncontrolled hypertension (>140/90mmhg) (not white coat)'
p215
aS'- course of antibiotics or bowel preparation for endoscopy one month prior to the commencement of the exercise program'
p216
aS'- psychiatric disorders'
p217
aS'- any medical condition deemed exclusionary by the principle investigator'
p218
aS'- a history of substance abuse'
p219
aS'- history of total colectomy'
p220
aS'- currently treated with high dose corticosteroids or disease flare within 2 weeks of starting exercise program'
p221
aS'- pregnant'
p222
aS'- history of faecal incontinence'
p223
aS'- have a malignant disease or any concomitant end stage organ disease'
p224
aS'- patients may not be receiving any experimental drug or have been involved in a recent experimental trial in the last 30 days'
p225
asS'NCT02322307'
p226
(lp227
S'- presence of short bowel syndrome, stoma or pouch.'
p228
aS'- presence of a condition or disease that, in the opinion of the investigators, may make it exceedingly difficult for the patient to use healthpromise app, including, but not limited to, advanced dementia.'
p229
asS'NCT02016469'
p230
(lp231
S'- 1. women who are pregnant or lactating at the time of enrollment, or who intend to be during the study period'
p232
aS'- 2. patients may confuse the findings or there exist any other additional risk history'
p233
aS'- 3. patients with end-stage disease or is expected likely to die during the study'
p234
aS'- 4. patients are participating in other clinical trials or participated within 3 months prior to transplantation'
p235
aS'- 5. outbreaks, infectious (viruses, bacteria, parasites, or other microorganisms) colitis, scheduled for abdominal surgery,take probiotics / prebiotics / synbiotics / antibiotic / ppi (past 1 month) orally, severe anemia (hbg <6g/dl), heart cerebrovascular accident, bypass, stent implantation surgery in the last 6 months, coagulation disorders, immune suppression status (defined as: immunosuppressive drugs, a history of opportunistic infections within one year recurrent ,oral ulcers, multiple lymphadenopathy, neutropenia, etc.), major abdominal transplant surgery in the last 3 months, have took tnf-\xce\xb1 monoclonal antibody 2 month before transplantation or planned to take within one month after transplantation, a history of megacolon -'
p236
asS'NCT02128503'
p237
(lp238
S'- lack of consent'
p239
aS'- patients with evidence of other chronic liver disease,metabolic syndrome, men consuming more than 30 g of alcohol per day and women consuming more than 20 g of alcohol per day, patients with liver decompensation, hcc, previous liver surgery or liver transplantation'
p240
asS'NCT02364973'
p241
(lp242
S'- pregnancy'
p243
aS'- diabetes'
p244
aS'- the patient is unable to give informed consent'
p245
asS'NCT02027727'
p246
(lp247
S'- 1. not receiving infliximab'
p248
aS'- 2. on 10 mg/kg of ifx'
p249
aS'- 3. not able to obtain consent'
p250
asg33
(lp251
S'- underlying malignant disease'
p252
aS'- diabetes mellitus, type i or ii'
p253
aS'- pregnancy'
p254
aS'- lactating'
p255
aS'- chronic alcohol or drug abuse'
p256
aS'- known anorexia nervosa or binge eating disorder'
p257
aS'- known metabolic disorders, such as e.g. cushing disease, hypothyroidism'
p258
aS'- participation in other interventional studies within the last 6 months prior to study enrollment'
p259
aS'- patient not fully able to understand the study concept and to give his or her written consent'
p260
asS'NCT01984879'
p261
(lp262
S'- patients who refuse to participate in the study'
p263
asS'NCT02733276'
p264
(lp265
S'- patients who are participating in other clinical studies.'
p266
aS'- associated tumor disease .'
p267
aS'- pregnant or breast feeding women .'
p268
aS'- anemia hemoglobin determined under 12 in women and 14 in men.'
p269
aS'- patients who have suffered minor adverse reactions to acupuncture.'
p270
aS'- prior acupuncture.'
p271
asS'NCT02704026'
p272
(lp273
S'- a male or female < 6 years or > 18 years old at the enrollment'
p274
aS'- for children with ibd : presence of other chronic diseases'
p275
aS'- for healthy control: any coexisting chronic disease known to affect growth, nutritional status, dietary intake, or development'
p276
assS'clostridium difficile colitis-Drug'
p277
(dp278
S'NCT01477320'
p279
(lp280
S'- evidence of active gi bleeding during current hospitalization prior to study entry'
p281
aS'- admission to icu with primary diagnosis of burn injury'
p282
aS'- closed head injury or increased intracranial pressure'
p283
aS'- partial or complete gastrectomy'
p284
aS'- pregnancy or lactation'
p285
assS'unclassified periodic fever syndromes / autoinflammatory syndromes-Procedure'
p286
(dp287
sS'gastric cancer-Device'
p288
(dp289
S'NCT02426762'
p290
(lp291
S'- pregnant woman or lactating woman.'
p292
aS'- with confirmed distant metastasis in liver, lung, bones, or other organs.'
p293
aS'- intolerable laparoscopic operation or converted to open surgery.'
p294
aS'- with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.'
p295
aS'- with bad compliance or contraindication to enrollment.'
p296
assS'dysplasia-Other'
p297
(dp298
g190
(lp299
S'- failure to provide informed consent'
p300
aS'- patients with a contraindication to colonoscopy'
p301
aS'- known allergy to fluorescein'
p302
aS'- pregnant or breast-feeding patients'
p303
aS'- ongoing systemic immunosuppressive therapy with prednisolone, azathioprine or biological agents.'
p304
assS'hiv-Behavioral'
p305
(dp306
sS'bowel diseases, inflammatory-Biological'
p307
(dp308
S'NCT02255227'
p309
(lp310
S'- patients vaccinated against pneumo23 for less than 5 years'
p311
aS'- other vaccination during the month before inclusion'
p312
aS'- patient develops a febrile illness (at least 37 \xc2\xb0 c 5 measured orally) or acute infection in the week before vaccination'
p313
aS"- the patient has a flare up of ibd the day of vaccination (harvey-brasdshaw score of at least 6 or cdai > 220 for crohn's disease or mayo clinic score of at least 4 for uc and indeterminate colitis)"
p314
aS'- patients with an ongoing pregnancy the day of vaccination'
p315
aS'- patient with a known history of neuropathy as guillain-barr\xc3\xa9 syndrome.'
p316
aS'- patients with known infection with hiv and / or hbv (hbsag positive) and / or hcv'
p317
aS'- patient with other severe immune deficiency'
p318
aS'- patients who received immunoglobulin infusions of blood products, or of monoclonal antibodies (except anti-tnf) in the 3 months prior to vaccination'
p319
aS'- patient institutionalized, or deprived of liberty administrative or judicial'
p320
aS'- patients treated without immunosuppressive therapy or biotherapies'
p321
assS"takayasu's disease-Drug"
p322
(dp323
S'NCT01988506'
p324
(lp325
S'- known intolerance for il2 (see spc),'
p326
aS'- administration of a non-authorized treatment and/or iv bolus of corticosteroids in the last 2 months,'
p327
aS'- vaccination with live attenuated virus in the months preceding the inclusion or planned during the study'
p328
aS'- other severe or progressive autoimmune/inflammatory pathology,'
p329
aS'- low white blood cell count<2000/mm3, lymphocytes <600/mm3, platelets <80 000/mm3,'
p330
aS"- heart failure (\xe2\x89\xa5 grade iii nyha), renal insufficiency (cockcroft< 60ml/mn except patients with lupus or wegener's granulomatosis) or hepatic insufficiency (transaminases> 5n except for patients with autoimmune hepatitis), or lung failure,"
p331
aS'- significant abnormality in chest x-ray other than these linked to the diseases under investigation'
p332
aS'- cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or basocellular carcinoma)'
p333
aS'- poor venous access not allowing repeated blood tests,'
p334
aS'- restrictive diet or parenteral nutrition,'
p335
aS'- surgery during the last 2 months or surgery planned during the study,'
p336
aS'- participation in other biomedical research in the last 3 months or planned during the study.'
p337
aS'- pregnant or lactating women,'
p338
aS'- concomitant psychiatric disease or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give informed consent,'
p339
aS'- positive hiv serology, active hepatitis b or ebv infection,'
p340
aS'- patients under a measure of legal protection'
p341
assS'dementia-Behavioral'
p342
(dp343
sS'pathologic processes-Device'
p344
(dp345
S'NCT02445365'
p346
(lp347
S'- pancolitis or acute severe ulcerative colitis requiring immediate treatment'
p348
aS'- need for admission due to active ulcerative colitis'
p349
aS'- ulcerative colitis with systemic symptoms (abdominal pain, fever > 37.5 degrees, weight loss exceeding 3 kilograms).'
p350
aS'- patient with anemia (haemoglobin < 8.3 mmol/l for males and < 7.3 mmol/l for females).'
p351
aS'- patient with ostomy or pouch.'
p352
aS'- the patient has had a bowel resection (except appendectomy)'
p353
aS'- the patient has constipation and/or another known bowel condition than ulcerative colitis such as ibs.'
p354
aS'- the patient has diabetes.'
p355
aS'- regular intake of acetylsalicylic acid or nsaids'
p356
aS'- the patient cannot understand the information material.'
p357
aS'- the patient has had colon cancer, dysplasia or adenomatous polyps in the colon during the recent 5 year'
p358
aS'- the patient is in a poor general condition.'
p359
aS'- the patient has had a food poisoning within the last three months.'
p360
aS'- the patient is pregnant at the time of inclusion or has planned pregnancy during the period of study.'
p361
aS'- the patient is in medical treatment with cyclosporine at the beginning of the run in period.'
p362
aS'- treatment for ulcerative colitis treatment has been changed within two weeks before the first day in the run in period'
p363
aS'- the patient has commenced treatment with azathioprine, 6-mercaptopurine or methotrexate within 12 weeks before the first day in the run in period.'
p364
aS'- the patient has commenced treatment with tnf-\xce\xb1 inhibitors within 12 weeks before the first day of the run in period.'
p365
aS'- the patient suffers from coeliac disease or lactose intolerance.'
p366
aS'- antibiotic treatment within two weeks before the first day of the run in period.'
p367
aS'- patient has any medical, surgical condition that excludes the use of ric.'
p368
assS'cryopyrin-associated periodic syndromes /tnf-receptor associated periodic syndrome-Other'
p369
(dp370
S'NCT02466217'
p371
(lp372
S'- for iads patients'
p373
aS'- unauthorized treatment (anticancer chemotherapy)'
p374
aS'- for healthy volunteers'
p375
aS'- contra-indications for donating blood except from age'
p376
aS'- known history of iad (eg: psoriasis)'
p377
aS'- common exclusion criteria:'
p378
aS'- pregnant woman'
p379
aS'- still under the exclusion period from another biomedical study'
p380
aS'- psychiatric or addiction pathology who could interfere with the ability to fulfill the protocol needs or to provide an informed consent'
p381
aS'- patient under a legal protection'
p382
aS'- chronic lifelong viral infection unrelated to the pathology'
p383
aS'- mild infection within the last 3 months'
p384
assS'microbiota-Drug'
p385
(dp386
g88
(lp387
S'- diagnosed as uc first time. no history of using biologic,immunomodulatory therapy or corticosteroid therapy. with contraindication of endoscopy.'
p388
assS'sleep disturbance-Drug'
p389
(dp390
g3
(lp391
S'- ibd group:'
p392
aS'- meeting criteria for active alcohol or substance abuse or dependence'
p393
aS'- current ongoing treatment with wellbutrin'
p394
aS'- females who are pregnant or plan to become pregnant within three months'
p395
aS'- sleep disorder such as apnea, restless leg syndrome or use of continuous positive airway pressure therapy (c-pap)/bilevel positive airway pressure (bi-pap)'
p396
aS'- current ibd flare requiring hospitalization with intravenous steroid treatment'
p397
aS'- other acute medical conditions or a history of chronic inflammatory condition other than ibd'
p398
aS'- hemoglobin <10 with age and gender adjustments'
p399
aS'- history of seizure disorder'
p400
aS'- acute infection within seven days'
p401
aS'- healthy volunteer group:'
p402
aS'- history or current episode of psychiatric disorder by diagnositic and statistical manual (dsm-iv)'
p403
aS'- current ongoing treatment with psychoactive medications'
p404
aS'- medications for sleep in previous two weeks'
p405
aS'- females who are pregnant or plan to become pregnant within three months'
p406
aS'- history of ibd, epilepsy, rheumatoid arthritis, lupus'
p407
aS'- sleep disorder such as apnea, restless leg syndrome or use of continuous positive airway pressure therapy (c-pap)/bilevel positive airway pressure (bi-pap)'
p408
assS'sclerosing cholangitis-Drug'
p409
(dp410
g324
(lp411
S'- known intolerance for il2 (see spc),'
p412
aS'- administration of a non-authorized treatment and/or iv bolus of corticosteroids in the last 2 months,'
p413
aS'- vaccination with live attenuated virus in the months preceding the inclusion or planned during the study'
p414
aS'- other severe or progressive autoimmune/inflammatory pathology,'
p415
aS'- low white blood cell count<2000/mm3, lymphocytes <600/mm3, platelets <80 000/mm3,'
p416
aS"- heart failure (\xe2\x89\xa5 grade iii nyha), renal insufficiency (cockcroft< 60ml/mn except patients with lupus or wegener's granulomatosis) or hepatic insufficiency (transaminases> 5n except for patients with autoimmune hepatitis), or lung failure,"
p417
aS'- significant abnormality in chest x-ray other than these linked to the diseases under investigation'
p418
aS'- cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or basocellular carcinoma)'
p419
aS'- poor venous access not allowing repeated blood tests,'
p420
aS'- restrictive diet or parenteral nutrition,'
p421
aS'- surgery during the last 2 months or surgery planned during the study,'
p422
aS'- participation in other biomedical research in the last 3 months or planned during the study.'
p423
aS'- pregnant or lactating women,'
p424
aS'- concomitant psychiatric disease or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give informed consent,'
p425
aS'- positive hiv serology, active hepatitis b or ebv infection,'
p426
aS'- patients under a measure of legal protection'
p427
assS'psoriatic arthritis-Procedure'
p428
(dp429
g73
(lp430
S'- subject has participated in a study of an investigational medicinal product (imp) or medical device within the previous 30 days or 5 half-lives (whichever is longer) prior to screening or is currently participating in another study of an imp or medical device - unless the study is ucb up0016 [nct02154425] or a registry study'
p431
aS"- subject has any obstetrical or psychiatric condition, or she or her infant(s) has any medical condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study or the outcome of the pregnancy"
p432
aS'- subject has history of chronic alcohol abuse or drug abuse during pregnancy'
p433
aS'- subject has any pregnancy-related clinically significant abnormality noted on obstetric ultrasound, or other imaging assessment, or the subject has significant laboratory abnormalities during her pregnancy, as judged by the investigator'
p434
aS'- subject is taking or has taken any medication with strong positive evidence of a human fetal risk of teratogenicity (e.g., methotrexate or leflunomide) during pregnancy'
p435
aS'- subject has evidence of a condition suggesting chronic or acute uteroplacental insufficiency such as intrauterine growth restriction, severe maternal hypertensive disorders of pregnancy, or abruption'
p436
aS'- subject has a documented history of primary or secondary antiphospholipid syndrome or hypercoagulable state'
p437
aS'- subject has received treatment with any biological therapeutic agent, including anti-tnfs other than certolizumab pegol (czp), during pregnancy'
p438
aS'- subject has previously participated in this study'
p439
aS'- subject has a positive or indeterminate quantiferon\xc2\xae-tb gold in tube test at screening. in case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the subject'
p440
aS"- subject with known tuberculosis (tb) infection, at high risk of acquiring tb infection, or latent tb infection (ltb). if tested within the 6 months prior to screening and the test was negative for tb, and there is no change in the subject's clinical status, nor social, family, or travel history, there is no need for an additional tb testing at screening"
p441
assS'arthritis-Drug'
p442
(dp443
S'NCT02538757'
p444
(lp445
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p446
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p447
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p448
aS'- known hiv/aids'
p449
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p450
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p451
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p452
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p453
aS'- participated in an investigational study within 1 month prior to study entry'
p454
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p455
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p456
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p457
assS'psoriatic arthritis-Biological'
p458
(dp459
g73
(lp460
S'- subject has participated in a study of an investigational medicinal product (imp) or medical device within the previous 30 days or 5 half-lives (whichever is longer) prior to screening or is currently participating in another study of an imp or medical device - unless the study is ucb up0016 [nct02154425] or a registry study'
p461
aS"- subject has any obstetrical or psychiatric condition, or she or her infant(s) has any medical condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study or the outcome of the pregnancy"
p462
aS'- subject has history of chronic alcohol abuse or drug abuse during pregnancy'
p463
aS'- subject has any pregnancy-related clinically significant abnormality noted on obstetric ultrasound, or other imaging assessment, or the subject has significant laboratory abnormalities during her pregnancy, as judged by the investigator'
p464
aS'- subject is taking or has taken any medication with strong positive evidence of a human fetal risk of teratogenicity (e.g., methotrexate or leflunomide) during pregnancy'
p465
aS'- subject has evidence of a condition suggesting chronic or acute uteroplacental insufficiency such as intrauterine growth restriction, severe maternal hypertensive disorders of pregnancy, or abruption'
p466
aS'- subject has a documented history of primary or secondary antiphospholipid syndrome or hypercoagulable state'
p467
aS'- subject has received treatment with any biological therapeutic agent, including anti-tnfs other than certolizumab pegol (czp), during pregnancy'
p468
aS'- subject has previously participated in this study'
p469
aS'- subject has a positive or indeterminate quantiferon\xc2\xae-tb gold in tube test at screening. in case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the subject'
p470
aS"- subject with known tuberculosis (tb) infection, at high risk of acquiring tb infection, or latent tb infection (ltb). if tested within the 6 months prior to screening and the test was negative for tb, and there is no change in the subject's clinical status, nor social, family, or travel history, there is no need for an additional tb testing at screening"
p471
asg444
(lp472
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p473
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p474
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p475
aS'- known hiv/aids'
p476
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p477
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p478
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p479
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p480
aS'- participated in an investigational study within 1 month prior to study entry'
p481
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p482
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p483
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p484
assS"ulcerative colitis and crohn's disease-Drug"
p485
(dp486
S'NCT02674308'
p487
(lp488
S'- 1. the participant is enrolled in a clinical trial in which treatment for cd or uc is managed through a protocol.'
p489
aS'- 2. prior treatment with vedolizumab.'
p490
aS"- 3. any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study."
p491
assS'methicillin-resistant staphylococcus aureus-Other'
p492
(dp493
S'NCT02390622'
p494
(lp495
S'- 1.infectious diarrhea caused by other pathogenic bacteria'
p496
assS'arthritis-Behavioral'
p497
(dp498
sS'gastrointestinal hemorrhage-Other'
p499
(dp500
g279
(lp501
S'- evidence of active gi bleeding during current hospitalization prior to study entry'
p502
aS'- admission to icu with primary diagnosis of burn injury'
p503
aS'- closed head injury or increased intracranial pressure'
p504
aS'- partial or complete gastrectomy'
p505
aS'- pregnancy or lactation'
p506
assS'triclosan effects on microbial flora.-Other'
p507
(dp508
S'NCT01509976'
p509
(lp510
S'- pregnancy'
p511
aS'- recent travel to the developing world (within 3 months)'
p512
aS'- recent use of antibiotics (within 3 months)'
p513
aS'- unwillingness to change personal care/hygiene products'
p514
aS'- recent gastrointestinal illness (within 3 months)'
p515
aS'- individuals who are unlikely to be available for the 10 months of the study period.'
p516
assS'perianal fistula-Other'
p517
(dp518
S'NCT01828190'
p519
(lp520
S"- pregnancy or plans to conceive during the next year inability (such as previous adverse effects, tuberculosis, concurrent infection etc.)or unwillingness to start or continue with tnf alpha blockers treatment. any past or current malignancy treatment with hbot in the last year claustrophobia middle ear problems inability to equalize pressure in the middle ear medical status that precludes treatment with hbot such as chest x-ray abnormality, epilepsy, severe congestive heart failure, uncontrolled diabetes or uncontrolled hypertension any perianal surgery in the last 6 months any change in crohn's disease medications in the last 3 months"
p521
assS'neutrophilic eccrine hidradenitis-Procedure'
p522
(dp523
sS'inflammatory bowel disease-Behavioral'
p524
(dp525
S'NCT02707068'
p526
(lp527
S'- participants are not eligible for the study, if they do not fulfil the inclusion criteria.'
p528
aS'- suicidal patients will be directly referred to liaison psychiatry or their gp and will not be able to access the study as the intensity of the manual intervention is within the low-moderate range and thus not suitable to address severe symptoms appropriately.'
p529
asS'NCT01536509'
p530
(lp531
S'- diagnosis of pervasive developmental disorder in patient or parent'
p532
aS'- diagnosis of serious mental illness (e.g., schizophrenia) in patient or parent'
p533
asg129
(lp534
S'- ibd patients with parental report of mental retardation'
p535
aS'- ibd patients receiving psychopharmacological treatment (antidepressants or benzodiazepines) for depression or anxiety'
p536
aS'- no mastery of the dutch language'
p537
aS'- ibd patients with diagnosed: bipolar disorder, schizophrenia/psychotic disorder, autism spectrum disorders, obsessive-compulsive disorder, posttraumatic stress disorder/acute stress disorder, or substance use disorder'
p538
aS'- physician reported substance abuse (alcohol, drugs) in the past month'
p539
aS'- clinician reported selective mutism'
p540
aS'- ibd patients already participating in an (psychological of psychopharmacological) intervention study'
p541
aS'- ibd patients who received 8 sessions of manualized cognitive behavioral therapy last year'
p542
aS'- current psychological treatment'
p543
asS'NCT01860651'
p544
(lp545
S'- insufficient danish language skills'
p546
aS'- lack of intellectual capacity'
p547
aS'- growth retardation'
p548
asS'NCT02620514'
p549
(lp550
S'- pregnancy or plans to be pregnant'
p551
aS'- inability to make own health care decisions'
p552
aS'- inability to participate in the study phone calls'
p553
aS'- uncontrolled psychiatric illness'
p554
aS'- enrollment in another clinical trial outside of the standard clinic ibd registry'
p555
asS'NCT02350920'
p556
(lp557
S'- patients under 18 years,'
p558
aS'- patients over 65 years,'
p559
aS'- pregnant females,'
p560
aS'- patients currently attending psychiatric services,'
p561
aS'- patients currently receiving antidepressant medication,'
p562
aS'- patients who have received steroid medications in the past three months,'
p563
aS'- patients who have previously undergone a stress management programme (relaxation techniques, autogenic training, psychodynamic psychotherapy, cognitive behavioural therapy, hypnosis).'
p564
asg3
(lp565
S'- ibd group:'
p566
aS'- meeting criteria for active alcohol or substance abuse or dependence'
p567
aS'- current ongoing treatment with wellbutrin'
p568
aS'- females who are pregnant or plan to become pregnant within three months'
p569
aS'- sleep disorder such as apnea, restless leg syndrome or use of continuous positive airway pressure therapy (c-pap)/bilevel positive airway pressure (bi-pap)'
p570
aS'- current ibd flare requiring hospitalization with intravenous steroid treatment'
p571
aS'- other acute medical conditions or a history of chronic inflammatory condition other than ibd'
p572
aS'- hemoglobin <10 with age and gender adjustments'
p573
aS'- history of seizure disorder'
p574
aS'- acute infection within seven days'
p575
aS'- healthy volunteer group:'
p576
aS'- history or current episode of psychiatric disorder by diagnositic and statistical manual (dsm-iv)'
p577
aS'- current ongoing treatment with psychoactive medications'
p578
aS'- medications for sleep in previous two weeks'
p579
aS'- females who are pregnant or plan to become pregnant within three months'
p580
aS'- history of ibd, epilepsy, rheumatoid arthritis, lupus'
p581
aS'- sleep disorder such as apnea, restless leg syndrome or use of continuous positive airway pressure therapy (c-pap)/bilevel positive airway pressure (bi-pap)'
p582
asS'NCT02085083'
p583
(lp584
S'- we will exclude any subjects who will not be residing in canada or who will not be enrolled in the ontario health insurance plan (ohip) after exiting pediatric care. registration with ohip, even if residing in a different province, is required for the monitoring of health utilization.'
p585
asS'NCT02614014'
p586
(lp587
S'- severe mental disease'
p588
aS'- other severe concomitant disease'
p589
assS'intestine perforation-Dietary Supplement'
p590
(dp591
S'NCT01674478'
p592
(lp593
S'- 1. infant with birth weight > 1250g;'
p594
aS'- 2. infant with colostomy;'
p595
aS'- 3. infants with enterostomy but'
p596
aS'- unable to obtain written informed consent from parent;'
p597
aS'- presence of congenital liver, renal, or metabolic diseases or syndromes or perinatal asphyxia;'
p598
aS'- ostomy caused by surgical treatment for a condition other than nec or small intestine perforation; and'
p599
aS'- unable to initiate enteral feeding for more than 28 days since ostomy placement.'
p600
assS'dehydration, diverting ileostomy, loperamide-Drug'
p601
(dp602
S'NCT02263365'
p603
(lp604
S'- 1. mentally incompetent or unable or unwilling to provide informed consent or comply with study procedures'
p605
aS'- 2. american society of anesthesiologists (asa) class iv or v; emergency surgeries'
p606
aS'- 3. children <18'
p607
aS'- 4. pregnant patients'
p608
aS'- 5. patients who have intra-abdominal sepsis or partial or intermittent bowel obstruction or enteritis'
p609
aS'- 6. patients who are on long term steroids, opioids or antidiarrheals pre operatively'
p610
aS'- 7. patients who are administered pro kinetics eg. metoclopromide'
p611
aS"- 8. patients with recurrent disease in their small bowel - crohn's disease, or previous irradiated pelvis resulting in irradiation bowel disease"
p612
aS'- 9. end ileostomies'
p613
assS'rectal cancer-Device'
p614
(dp615
S'NCT02598414'
p616
(lp617
S'- subjects present with bowel obstruction or perforation'
p618
aS'- subject undergo emergency surgery'
p619
aS'- subject with asa iv, v'
p620
aS'- history of allergy or hypersensitivity against indocyanine green'
p621
aS'- pregnant or breast-feeding women'
p622
aS'- subject has uremia (serum creatinine >2.5 mg/dl)'
p623
aS'- subject is undergoing palliative surgery or who is terminally ill'
p624
aS'- subject who is unable to discontinue warfarin anticoagulation 5 days before surgery'
p625
aS'- subject taking phenobarbital, phenylbutazone, primidone, phenytoin, haloperidol, nitrofurantoin, probenecid'
p626
assS'diabetic retinopathy-Drug'
p627
(dp628
S'NCT00695682'
p629
(lp630
S'- are participating in another clinical study requiring follow up examinations'
p631
aS'- have received any other experimental drug within 12 weeks prior to enrollment'
p632
aS'- are unwilling or unable to follow or comply with all study-related procedures'
p633
aS'- inability to obtain photographs, fluorescein angiography, or optical coherence tomography to document cnv, e.g. due to media opacity, allergy to fluorescein dye or lack of venous access'
p634
aS'- aphakia or pseudophakia with the absence of posterior capsule (unless it resulted from a yttrium aluminum garner [yag]) posterior capsulotomy)'
p635
aS'- within two months prior to screening, have had intraocular surgery (including cataract surgery) in the study eye'
p636
aS'- within 1 month prior to screening had yag laser in the study eye'
p637
aS'- have had intravitreal anti vegf or intravitreal steroids in the last 6 weeks'
p638
aS'- have had previous pars plana vitrectomy in the study eye'
p639
aS'- are pregnant or are trying to become pregnant'
p640
aS'- any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated'
p641
aS'- have a history of allergies to murine monoclonal antibodies, mice or mouse products.'
p642
assS'polyps-Device'
p643
(dp644
S'NCT01688557'
p645
(lp646
S'- age < 40 and > 65 years'
p647
aS'- large bowel resection in history'
p648
aS'- colonoscopy performed during last 10 years'
p649
aS'- contraindications for general anaesthesia'
p650
aS'- asa > iv'
p651
aS'- pregnancy'
p652
aS'- confirmed neoplastic disease'
p653
aS'- cirrhosis (child b or c) or ascites'
p654
aS'- immunosuppressive therapy or steroids intake'
p655
aS'- malabsorption syndrome'
p656
assS'linear iga bullous dermatosis-Procedure'
p657
(dp658
sS'chronic arthritis-Drug'
p659
(dp660
sS'infections, pneumococcal-Biological'
p661
(dp662
g309
(lp663
S'- patients vaccinated against pneumo23 for less than 5 years'
p664
aS'- other vaccination during the month before inclusion'
p665
aS'- patient develops a febrile illness (at least 37 \xc2\xb0 c 5 measured orally) or acute infection in the week before vaccination'
p666
aS"- the patient has a flare up of ibd the day of vaccination (harvey-brasdshaw score of at least 6 or cdai > 220 for crohn's disease or mayo clinic score of at least 4 for uc and indeterminate colitis)"
p667
aS'- patients with an ongoing pregnancy the day of vaccination'
p668
aS'- patient with a known history of neuropathy as guillain-barr\xc3\xa9 syndrome.'
p669
aS'- patients with known infection with hiv and / or hbv (hbsag positive) and / or hcv'
p670
aS'- patient with other severe immune deficiency'
p671
aS'- patients who received immunoglobulin infusions of blood products, or of monoclonal antibodies (except anti-tnf) in the 3 months prior to vaccination'
p672
aS'- patient institutionalized, or deprived of liberty administrative or judicial'
p673
aS'- patients treated without immunosuppressive therapy or biotherapies'
p674
assS'multimorbidity-Behavioral'
p675
(dp676
sS'anemia-Drug'
p677
(dp678
sS'infantile acropustulosis-Procedure'
p679
(dp680
sS'chronic graft versus host disease-Procedure'
p681
(dp682
S'NCT02352064'
p683
(lp684
S'- adult patient under tutelage.'
p685
aS'- pregnant or lactating women or women of childbearing potential not currently practicing an adequate method of contraception'
p686
aS'- age<18 years'
p687
aS'- evolutive infectious disease'
p688
aS'- glycemia >10mmol/l'
p689
assS"sweet's syndrome-Procedure"
p690
(dp691
sS'diverticulosis, colonic-Procedure'
p692
(dp693
S'NCT02752360'
p694
(lp695
S'- patients with severe cardiopulmonary disease or other severe disease.'
p696
aS'- patients who are psychopath, pregnant, and child without capacity for civil conduct.'
p697
aS'- patients with complete intestinal obstruction.'
p698
aS'- patients with abdominal cavity infection.'
p699
aS'- patients who are treating by drug such as adrenal cortical hormone and immune inhibitors, chemotherapy drugs, radiation and so on.'
p700
aS'- patients who need to accept the anastomosis between rectum and colon.'
p701
aS'- patients who are required to accept intestinal anastomosis twice or more.'
p702
aS'- patients who are required to accept the treatment of colostomy.'
p703
aS'- other conditions that render a patient unsuitable for the trial as determined by the study investigators.'
p704
assS"crohn's disease-Other"
p705
(dp706
S'NCT01728870'
p707
(lp708
S'- 1. patients with no disease activity ( pcdai <10) or severe disease ( pcdai \xe2\x89\xa5 40).'
p709
aS'- 2. patients who have received corticosteroids of any kind in the previous 4 weeks.'
p710
aS'- 3. patients who have started an immunomodulator in the previous 8 weeks'
p711
aS'- 4. any current biological treatment'
p712
aS'- 5. isolated large bowel disease ( l2) involving the recto-sigmoid or descending colon'
p713
aS'- 6. patients with penetrating disease (abscess or fistula)'
p714
aS'- 7. active perianal disease'
p715
aS'- 8. fixed stricture or small bowel obstruction'
p716
aS'- 9. normal crp and esr'
p717
aS'- 10. active joint disease.'
p718
aS'- 11. patients who have undergone an intestinal resection.'
p719
aS'- 12. sclerosing cholangitis'
p720
aS'- 13. pregnancy'
p721
asS'NCT02610101'
p722
(lp723
S'- 1. severe disease with pcdai >45'
p724
aS"- 2. active or history of intra abdominal abscess, intra abdominal fistula, stricturing crohn's disease"
p725
aS'- 3. other serious medical conditions such as neurological, liver, kidney, autoimmune or systemic disease.'
p726
aS'- 4. has begun tnf inhibitors within two months prior to study'
p727
aS'- 5. has had change of maintenance medication within the last month'
p728
aS'- 6. tobacco, alcohol or illicit drug abuse'
p729
aS'- 7. pregnant subject recipients will be excluded'
p730
asS'NCT02641171'
p731
(lp732
S'- disease compromising immune system (such as hiv positive status or patients after organ transplantation'
p733
aS'- liver disease'
p734
aS'- active and untreated tuberculosis'
p735
aS'- chemotherapy agents'
p736
asg190
(lp737
S'- failure to provide informed consent'
p738
aS'- patients with a contraindication to colonoscopy'
p739
aS'- known allergy to fluorescein'
p740
aS'- pregnant or breast-feeding patients'
p741
aS'- ongoing systemic immunosuppressive therapy with prednisolone, azathioprine or biological agents.'
p742
asS'NCT01145365'
p743
(lp744
S'- any of inclusion criteria is not met;'
p745
aS'- females who are pregnant or breast feeding;'
p746
aS'- anti-tnf use within 6 weeks prior to study entry;'
p747
aS'- patients who cannot take, or refuse to take concomitant immunosuppressive therapy with either azathioprine, 6-mercaptopurine, or methotrexate; unless patient has been intolerant of these therapies in the past or is contraindicated as determined by the investigator.'
p748
aS'- patients who cannot take, or refuse to take concomitant antibiotic therapy;'
p749
aS'- patients with severe anal stenosis or tenderness which would preclude colonoscopy and / or rectal eus;'
p750
aS'- patients who cannot take or refuse to take certolizumab;'
p751
aS'- patients with active or latent tuberculosis;'
p752
aS"- patients who have had systemic antibiotic, antiviral or antifungal treatment(s) within 3 weeks prior to screening for all non-crohn's related infections;"
p753
aS'- patients concurrently taking anakinra (kineret);'
p754
aS'- patients with a history of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinomain-situ of the cervix;'
p755
aS'- patients with chronic hematologic problems such as bleeding dyscrasias;'
p756
aS'- patients with a history of demyelinating disease (i.e. multiple sclerosis); and'
p757
aS'- patients with congestive heart failure'
p758
asS'NCT02225795'
p759
(lp760
S'- 1. pregnancy or unwillingness to use adequate contraception during the study- if a woman is of childbearing age.'
p761
aS'- 2. hiv infection.'
p762
aS'- 3. organ function criteria- 1. renal: creatinine clearance < 50 ml/min/1.73m2 (measured or estimated). 2. cardiac: left ventricular ejection fraction <30% by multigated radionuclide angiography (muga) or a shortening fraction of < 25% by cardiac echocardiogram. 3. pulmonary function tests: dlco < 30% or patient on oxygen.'
p763
aS'- 4. hepatic: serum bilirubin > 3 mg%; ast and alt > 3x uln for the institutional lab. 4. uncontrolled hypertension (using age based criteria) despite at least 2 anti- hypertensive agents.'
p764
aS'- 5. active infection or risk thereof- 1. current abscess or significant active infection 2. perianal infection is not an exclusion criterion, provided there is drainage with or without placement of drain. 3. abnormal chest x- ray (cxr) consistent with active infection or neoplasm.'
p765
aS'- 6. severe diarrhea due to short small bowel; patients believed to have < 700 mm of small bowel and diarrhea attributable to this will be excluded.'
p766
aS'- 7. patients with toxic megacolon, active bowel obstruction or intestinal perforation.'
p767
aS'- 8. unable to collect minimum of 3 x106/kg cd34+ cell dose. these patients will be excluded from receiving the preparative regimen.'
p768
asS'NCT02412553'
p769
(lp770
S'- 1. if female, is pregnant or is breast feeding'
p771
aS'- 2. known celiac disease or subjects with a positive screen for celiac disease (elevated tissue transglutaminase antibodies)'
p772
aS'- 3. inability to provide informed consent or unwilling to participate'
p773
aS'- 4. evidence of untreated infection e.g. clostridium difficile'
p774
aS'- 5. presence of stoma or j pouch'
p775
aS'- 6. presence of enterocutaneous, abdominal or pelvic fistulae with abscesses or fistulae likely to require surgery during the study period'
p776
aS'- 7. bowel surgery within 12 weeks prior to screen and/or has surgery planned or deemed likely for ibd during the study period'
p777
aS'- 8. fixed symptomatic stenosis of small bowel or colon'
p778
aS'- 9. chronic use of narcotics for chronic pain defined as a daily use of one or more doses of narcotic containing medication'
p779
aS'- 10. use of oral or intravenous antibiotics within 4 weeks prior to screening'
p780
aS'- 11. use of tube or enteral feeding, elemental diet, or parenteral alimentation within 2 weeks prior to screening.'
p781
asS'NCT02499783'
p782
(lp783
S'- subject with ulcerative colitis or indeterminate colitis.'
p784
aS'- subject who has had a surgical bowel resection within the past 6 months or who is planning any resection at any time point in the future.'
p785
aS'- subject with an ostomy or ileoanal pouch.'
p786
aS'- subject who has short bowel syndrome.'
p787
aS'- subject with symptomatic known obstructive strictures.'
p788
aS'- subject with an internal or external fistula (with the exception of an anal fistula without abscess).'
p789
aS'- active, or chronic or recurring infections, or active tuberculosis.'
p790
asg519
(lp791
S"- pregnancy or plans to conceive during the next year inability (such as previous adverse effects, tuberculosis, concurrent infection etc.)or unwillingness to start or continue with tnf alpha blockers treatment. any past or current malignancy treatment with hbot in the last year claustrophobia middle ear problems inability to equalize pressure in the middle ear medical status that precludes treatment with hbot such as chest x-ray abnormality, epilepsy, severe congestive heart failure, uncontrolled diabetes or uncontrolled hypertension any perianal surgery in the last 6 months any change in crohn's disease medications in the last 3 months"
p792
asS'NCT02193048'
p793
(lp794
S'- pre-treatment with 5-asa > 10 days'
p795
aS'- treatment with steroids > 10 days'
p796
aS'- treatment with antibiotics, immunosuppressants or biological agents > 10 days'
p797
asS'NCT02704728'
p798
(lp799
S'- 1. subjects who are pregnant or breastfeeding.'
p800
aS'- 2. subject who are experiencing an exacerbation at the time of screening or up to the time of the first dose.'
p801
aS'- 3. subjects who have undergone previous surgery for resection of bowel.'
p802
aS'- 4. subjects who have fistulisation.'
p803
aS'- 5. subjects who have had a significant change in their immune-modulating maintenance medication in the 3 months prior to screening and/or the start of dosing.'
p804
aS'- 6. subjects who have taken systemic steroids in the last 3 months.'
p805
aS'- 7. subjects who are unable to take any oral feeding.'
p806
aS'- 8. subjects with feeding gastrostomies.'
p807
aS'- 9. subjects who have non-food dietary supplementation for any reason changed within 1 month prior to dosing.'
p808
aS'- 10. subjects who have received monoclonal antibodies in the 6 months prior to dosing.'
p809
aS'- 11. subjects who have received antibiotics or probiotic dietary supplementation in the two weeks before dosing. subjects who have received foods with probiotics e.g. yoghurts will be permitted to volunteer for the study.'
p810
aS'- 12. subjects who are receiving exclusive enteral feeding or have completed a course of exclusive enteral feeding in the 3 months prior to dosing.'
p811
aS'- 13. subjects with concomitant autoimmune diseases.'
p812
aS'- 14. female subjects of child bearing potential unwilling to use effective contraception from the signing of the consent form until completion of two periods after the last dose. an effective method of birth control is defined as one which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, intrauterine device (iud), condoms, occlusive caps (cervical/vault caps) with spermicidal foam/gel/film/cream/pessary. true sexual abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject.'
p813
aS'- 15. subjects with clinically significantly, in the opinion of the investigator, elevated platelets, white cell count, c-reactive protein, erythrocyte sedimentation rate (esr), low albumin or haemoglobin.'
p814
aS'- 16. subjects who are positive for the following viruses: hiv, hepatitis b and hepatitis c.'
p815
aS'- 17. subjects who smoke cigarettes or use other tobacco or nicotine containing products, including e-cigarettes.'
p816
aS'- 18. subjects who have a known sensitivity to any of the constituents of the investigational medicinal compound.'
p817
aS'- 19. diastolic blood pressure <50 or >90 mmhg, a systolic blood pressure <100 or >150 mmhg, a pulse <40 or >100 beats per minute (bpm) after resting for 5 minutes.'
p818
aS'- 20. subjects with clinically significantly abnormal ecgs or structural cardiac abnormalities e.g. valvular heart disease, patent foramen ovale.'
p819
aS'- 21. bmi z score less than -2.6 or greater than 2.6 (0 \xc2\xb1 2.6); i.e. below the 2nd centile or greater than the 98th centile.'
p820
aS'- 22. any condition that, in the opinion of the investigator, might interfere with the primary study objective.'
p821
aS'- 23. subjects allergic to metronidazole and co-amoxiclav'
p822
asg163
(lp823
S'- the patients will be excluded from the study if one or more of the following apply:'
p824
aS'- 1. unable to give consent.'
p825
aS'- 2. does not meet inclusion criteria above.'
p826
asS'NCT02426567'
p827
(lp828
S'- 1. acute or chronic illness (defined as illness which requires regular visits to health services)'
p829
aS'- 2. positive or negative energy balance (recent weight gain or loss, \xc2\xb12 kg the past month)'
p830
aS'- 3. history of gut surgery'
p831
aS'- 4. use of antibiotics or steroids the last 3 months'
p832
asS'NCT01231217'
p833
(lp834
S'- pregnancy or the wish to become pregnant, breastfeeding,'
p835
aS'- concomitant treatment with methotrexate, azathioprine or 6-mercaptopurine for < 3 months,'
p836
aS'- treatment with tnf-alpha-antagonists, cyclosporine or tacrolimus < 4 weeks prior to study entry,'
p837
aS'- participation in another study within the last 4 weeks,'
p838
aS'- ulcerative colitis or indeterminate colitis,'
p839
aS'- infectious colitis, including cytomegalovirus or clostridium difficile induced colitis,'
p840
aS'- colitis for other reasons like known diverticulitis, radiation colitis, ischemic colitis or microscopic colitis,'
p841
aS'- malabsorption syndromes, lactose intolerance, celiac disease, exocrine pancreas insufficiency,'
p842
aS'- bleeding hemorrhoids,'
p843
aS'- other inflammatory or bleeding disorders of the colon and intestine, or diseases that may cause diarrhea or gastrointestinal bleeding,'
p844
aS'- intolerance / aversion to tea and/or coffee,'
p845
aS'- current treatment with antibiotics.'
p846
asS'NCT02423460'
p847
(lp848
S"- crohn's disease and ulcerative colitis"
p849
aS'- uncontrolled inflammation which will likely require surgery or escalation of therapy in the next 4 weeks'
p850
aS'- concomitant treatment:corticosteroids > 20mg/day'
p851
aS'- subject who cannot be expected to comply with the study procedures. - subjects not treated and followed by the gastroenterology team at mt. sinai hospital, toronto'
p852
asg237
(lp853
S'- lack of consent'
p854
aS'- patients with evidence of other chronic liver disease,metabolic syndrome, men consuming more than 30 g of alcohol per day and women consuming more than 20 g of alcohol per day, patients with liver decompensation, hcc, previous liver surgery or liver transplantation'
p855
asS'NCT02476643'
p856
(lp857
S'- participation in other clinical studies'
p858
asS'NCT02649075'
p859
(lp860
S'- positive stool test for pathogenic bacteria including clostridium difficile or o&p.'
p861
aS'- intestinal strictures.'
p862
aS'- bowel resection within the previous 6 months.'
p863
aS'- change in medical therapy: must have been on a stable dose of'
p864
aS'- corticosteroids for 2 weeks,'
p865
aS'- 5-aminosalicylates for 4 weeks, and'
p866
aS'- immunomodulators for 8 weeks.'
p867
aS'- taking greater than 30 mg per day of a corticosteroid.'
p868
aS'- received biologic therapy.'
p869
aS'- diagnosis of one or more co-morbid condition (s) requiring medical or surgical therapy that may affect bowel function, gastrointestinal symptoms.'
p870
aS'- serious infection in the 3 months prior to enrollment.'
p871
aS'- allergy or intolerance to beef or to any ingredient used in the product.'
p872
aS'- participated in an investigational drug or device study within 30 days.'
p873
aS'- does not have access to the internet.'
p874
asg371
(lp875
S'- for iads patients'
p876
aS'- unauthorized treatment (anticancer chemotherapy)'
p877
aS'- for healthy volunteers'
p878
aS'- contra-indications for donating blood except from age'
p879
aS'- known history of iad (eg: psoriasis)'
p880
aS'- common exclusion criteria:'
p881
aS'- pregnant woman'
p882
aS'- still under the exclusion period from another biomedical study'
p883
aS'- psychiatric or addiction pathology who could interfere with the ability to fulfill the protocol needs or to provide an informed consent'
p884
aS'- patient under a legal protection'
p885
aS'- chronic lifelong viral infection unrelated to the pathology'
p886
aS'- mild infection within the last 3 months'
p887
asS'NCT02763293'
p888
(lp889
S'- conversely, patients with non-specific inflammatory bowel, abdominal tenderness, infection, ischaemia, physical damage, or specific immunologic sensitivity or pregnancy be excluded of this study were discarded for the study.'
p890
asg226
(lp891
S'- presence of short bowel syndrome, stoma or pouch.'
p892
aS'- presence of a condition or disease that, in the opinion of the investigators, may make it exceedingly difficult for the patient to use healthpromise app, including, but not limited to, advanced dementia.'
p893
asS'NCT01817426'
p894
(lp895
S'- initial indication for ifx being predominantly fistulizing perianal disease.'
p896
aS'- any contraindications for continuing ifx treatment, including prior acute or delayed infusion reaction to a tnf- inhibiting agent, any active infection requiring parenteral or oral antibiotic treatment, known infection with tuberculosis, human immunodeficiency virus (hiv) or hepatitis virus.'
p897
aS'- any condition including physician finds incompatible with participation in the study or the patient being unwilling or unable to follow protocol requirements.'
p898
asS'NCT02472457'
p899
(lp900
S'- discontinuation of biologic or immunomodulator therapy by the subject without the approval of the primary gastroenterologist.'
p901
aS'- those subjects who in the judgment of the investigative team are unable to complete the study endpoints.'
p902
asS'NCT02777034'
p903
(lp904
S'- those patients were excluded\xef\xbc\x9aprevious bowel resection or strictureplasty, preoperative radiological evidence of large phlegmons/abscesses/enteric fistulas (assessed by magnetic resonance imaging or computed tomography), emergency surgery, and anesthesiological contraindications to laparoscopy.'
p905
asS'NCT02341248'
p906
(lp907
S'- children who have taken antibiotics in the previous 4 weeks'
p908
aS"- children found not to have crohn's disease after colonoscopy will not be required to take any further part in the study"
p909
asS'NCT02772458'
p910
(lp911
S'- 1. malignant disease'
p912
aS'- 2. bmi <18 and >35'
p913
aS'- 3. significant cardiovascular or respiratory disease'
p914
aS'- 4. diabetes mellitus'
p915
aS'- 5. current infection'
p916
aS'- 6. neurological or cognitive impairment\xcd\xbe significant physical disability'
p917
aS'- 7. significant hepatic disease or renal failure'
p918
aS'- 8. abnormal blood results other than those explained by cd including bleeding diatheses (apart from in the case of hv where all unexplained blood results are an exclusion criteria)'
p919
aS'- 9. subjects currently participating in (or in the last three months) any other research project'
p920
aS'- 10. pregnancy or breastfeeding or'
p921
aS'- 11. if mri is contraindicated (e.g. pacemaker).'
p922
aS"- 12. severe crohn's disease where a delay in a change in medical treatment for 23 weeks would not be clinically advisable."
p923
aS'- 13. as for healthy volunteer participants all exclusion criteria apart from no.12.'
p924
asS'NCT02097797'
p925
(lp926
S'- fistulizing disease'
p927
aS'- anoperineal or abdominal abscess'
p928
aS'- complication requiring surgical treatment'
p929
aS'- treatment with anti-tnfa (ongoing or stopped in the 1 month preceding randomization)'
p930
aS'- immunosuppressant treatment started or stopped in the 3 months preceding randomization'
p931
aS'- non-steroidal anti inflammatory drugs (nsaids) intake in the 4 weeks preceding randomization'
p932
aS'- antibiotics or antifungic treatment in the 4 weeks preceding colonoscopy'
p933
aS'- probiotics intake in the 4 weeks preceding colonoscopy'
p934
aS'- clostridium difficile infection in the 10 days preceding randomization'
p935
aS'- contraindication to colonoscopy or anesthesia'
p936
aS'- pregnancy donor inclusion criteria:'
p937
aS'- age > 20 years and < 50 years'
p938
aS'- 27kg/m\xc2\xb2 > bmi > 17 kg/m\xc2\xb2'
p939
aS'- regular bowel movement with usually one bowel movement in the morning'
p940
aS'- subject with health insurance'
p941
aS'- written consent obtained'
p942
assS"moderate to severe crohn's disease-Biological"
p943
(dp944
S'NCT02148718'
p945
(lp946
S'- previous treatment with any anti-tumor necrosis factor agent.'
p947
aS"- surgical bowel resection within the previous 6 months, ostomy, extensive bowel resection (> 100 cm), short bowel syndrome, fistulising crohn's disease."
p948
aS'- treatment with cyclosporine or tacrolimus within the previous 8 weeks.'
p949
aS'- clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months from screening, congestive heart failure of worse than grade ii new york criteria (new york heart association functional classification).'
p950
aS'- subject with an ostomy or ileoanal pouch, proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch anal anastomosis (subjects with a previous ileo-rectal anastomosis are not excluded).'
p951
aS'- screening laboratory values (according to central laboratory)'
p952
aS'- known of hepatitis c (hc) infection.'
p953
aS'- serologic evidence of hepatitis b (hb) infection based on the results of testing for hepatitis b surface antigen (hbsag), hepatitis b core antibody (anti-hbc) and hepatitis b surface antibody (anti-hbs) antibodies.'
p954
assS'ankylosing spondylitis-Biological'
p955
(dp956
g73
(lp957
S'- subject has participated in a study of an investigational medicinal product (imp) or medical device within the previous 30 days or 5 half-lives (whichever is longer) prior to screening or is currently participating in another study of an imp or medical device - unless the study is ucb up0016 [nct02154425] or a registry study'
p958
aS"- subject has any obstetrical or psychiatric condition, or she or her infant(s) has any medical condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study or the outcome of the pregnancy"
p959
aS'- subject has history of chronic alcohol abuse or drug abuse during pregnancy'
p960
aS'- subject has any pregnancy-related clinically significant abnormality noted on obstetric ultrasound, or other imaging assessment, or the subject has significant laboratory abnormalities during her pregnancy, as judged by the investigator'
p961
aS'- subject is taking or has taken any medication with strong positive evidence of a human fetal risk of teratogenicity (e.g., methotrexate or leflunomide) during pregnancy'
p962
aS'- subject has evidence of a condition suggesting chronic or acute uteroplacental insufficiency such as intrauterine growth restriction, severe maternal hypertensive disorders of pregnancy, or abruption'
p963
aS'- subject has a documented history of primary or secondary antiphospholipid syndrome or hypercoagulable state'
p964
aS'- subject has received treatment with any biological therapeutic agent, including anti-tnfs other than certolizumab pegol (czp), during pregnancy'
p965
aS'- subject has previously participated in this study'
p966
aS'- subject has a positive or indeterminate quantiferon\xc2\xae-tb gold in tube test at screening. in case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the subject'
p967
aS"- subject with known tuberculosis (tb) infection, at high risk of acquiring tb infection, or latent tb infection (ltb). if tested within the 6 months prior to screening and the test was negative for tb, and there is no change in the subject's clinical status, nor social, family, or travel history, there is no need for an additional tb testing at screening"
p968
asg444
(lp969
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p970
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p971
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p972
aS'- known hiv/aids'
p973
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p974
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p975
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p976
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p977
aS'- participated in an investigational study within 1 month prior to study entry'
p978
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p979
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p980
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p981
assS'ulcerative colitis-Drug'
p982
(dp983
g324
(lp984
S'- known intolerance for il2 (see spc),'
p985
aS'- administration of a non-authorized treatment and/or iv bolus of corticosteroids in the last 2 months,'
p986
aS'- vaccination with live attenuated virus in the months preceding the inclusion or planned during the study'
p987
aS'- other severe or progressive autoimmune/inflammatory pathology,'
p988
aS'- low white blood cell count<2000/mm3, lymphocytes <600/mm3, platelets <80 000/mm3,'
p989
aS"- heart failure (\xe2\x89\xa5 grade iii nyha), renal insufficiency (cockcroft< 60ml/mn except patients with lupus or wegener's granulomatosis) or hepatic insufficiency (transaminases> 5n except for patients with autoimmune hepatitis), or lung failure,"
p990
aS'- significant abnormality in chest x-ray other than these linked to the diseases under investigation'
p991
aS'- cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or basocellular carcinoma)'
p992
aS'- poor venous access not allowing repeated blood tests,'
p993
aS'- restrictive diet or parenteral nutrition,'
p994
aS'- surgery during the last 2 months or surgery planned during the study,'
p995
aS'- participation in other biomedical research in the last 3 months or planned during the study.'
p996
aS'- pregnant or lactating women,'
p997
aS'- concomitant psychiatric disease or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give informed consent,'
p998
aS'- positive hiv serology, active hepatitis b or ebv infection,'
p999
aS'- patients under a measure of legal protection'
p1000
asS'NCT02678052'
p1001
(lp1002
S'- for the uc/cd prospective cohort:'
p1003
aS'- 1. is greater than (>) 19 completed weeks gestation prior to enrollment,'
p1004
aS'- 2. has first contact with otis after prenatal diagnosis of any major structural defect,'
p1005
aS'- 3. has enrolled in this registry with a previous pregnancy,'
p1006
aS"- 4. has had an exposure to the known or suspected human teratogens: chlorambucil. cyclophosphamide, mycophenylate mofetil. for the 'no chronic disease' prospective cohort:"
p1007
aS'- 5. is >19 completed weeks gestation prior to enrollment,'
p1008
aS'- 6. has first contact with otis after prenatal diagnosis of any major structural defect,'
p1009
aS'- 7. has enrolled in this registry with a previous pregnancy,'
p1010
aS'- 8. has had an exposure to the known or suspected human teratogens: chlorambucil, cyclophosphamide, mycophenylate mofetil. note: women exposed to entyvio during pregnancy but not meeting the above criteria can enroll into the entyvio pregnancy exposure case series component of this registry.'
p1011
asS'NCT02261636'
p1012
(lp1013
S'- patients receiving treatment with one or more of the following: locally acting steroids (e.g. budesonide, beclomethasone), systemic steroids, immunosuppressants (e.g. thiopurines), biologicals (e.g. anti-tumor necrosis factor-alpha)'
p1014
asS'NCT01418131'
p1015
(lp1016
S"- 1. has crohn's disease."
p1017
aS'- 2. has colitis extending more than 25cm from the anal verge.'
p1018
aS'- 3. has a known hypersensitivity/allergic reaction to tacrolimus.'
p1019
aS'- 4. is pregnant or is breast-feeding.'
p1020
aS'- 5. has unstable, or poorly controlled, hypertension.'
p1021
aS'- 6. has an abnormal serum potassium level defined as outside the range of 3.4-5mmol/l.'
p1022
aS'- 7. has chronic renal failure defined as a glomerular filtration rate <60 ml/min.'
p1023
aS'- 8. is currently using a potassium-sparing diuretic agent.'
p1024
aS'- 9. has received a trial medication within 12 weeks of screening.'
p1025
aS'- 10. has documented hiv infection.'
p1026
aS'- 11. has a known malignancy, a pre-malignant lesion, or any history of malignancy within the past 5 years (excluding squamous and/or basal cell carcinomas).'
p1027
aS'- 12. presence of alcoholism, alcoholic liver disease, or other chronic liver disease.'
p1028
aS'- 13. has known dementia and the inability to understand the trial requirements.'
p1029
asS'NCT02280629'
p1030
(lp1031
S"- crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis), diverticular disease associated colitis"
p1032
aS'- toxic megacolon or fulminant colitis'
p1033
aS'- colon resection'
p1034
aS'- malabsorption syndromes'
p1035
aS'- celiac disease'
p1036
aS'- bleeding hemorrhoids'
p1037
aS'- other inflammatory or bleeding disorders of the colon and intestine, or diseases that may cause diarrhea or gastrointestinal bleeding'
p1038
aS'- history or presence of ischemic heart disease, myocardial infarction, peripheral arterial disease, ischemic stroke, or transient ischemic attack'
p1039
aS"- any severe concomitant renal, endocrine, or psychiatric disorder, which in the opinion of the investigator might have an influence on the patient's compliance or the interpretation of the results"
p1040
aS'- any relevant known systemic disease (e.g., aids, active tuberculosis)'
p1041
aS'- severe co-morbidity substantially reducing life expectancy'
p1042
aS'- history of cancer in the last five years'
p1043
aS'- abnormal hepatic function at screening visit, liver cirrhosis'
p1044
aS'- abnormal renal function at screening visit'
p1045
aS'- patients with known hypersensitivity to soy'
p1046
aS'- known intolerance/hypersensitivity to investigational medicinal product (imp: lt-02 or mesalamine)'
p1047
aS'- treatment with steroids (oral, inhalative, or intravenous [iv]), cyclosporine or tacrolimus within last 4 weeks prior to randomization'
p1048
aS'- treatment with methotrexate within last 6 weeks prior to randomization'
p1049
aS'- treatment with tnf-alpha-antagonists, azathioprine, 6-mercaptopurine, or anti-integrin therapy within last 8 weeks prior to randomization'
p1050
aS'- treatment with rectal mesalamine or corticosteroid formulations within last 2 weeks prior to randomization'
p1051
aS'- treatment with other investigational drug within last 12 weeks prior to randomization except lt-02'
p1052
aS'- existing or intended pregnancy or breast-feeding'
p1053
asS'NCT02289417'
p1054
(lp1055
S'- the presence of any of the following will exclude a subject from enrollment:'
p1056
aS"- 1. diagnosis of crohn's disease, indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis."
p1057
aS'- 2. ulcerative colitis restricted to the distal 15 cm or less (eg, ulcerative proctitis).'
p1058
aS'- 3. subjects who have had surgery as a treatment for uc or who, in the opinion of the investigator, are likely to require surgery for uc during the study.'
p1059
aS'- 4. clinically significant abnormality, based upon cxr, with at least pa view (the radiograph must be taken within 12 weeks prior to screening [visit 1] or during the screening visit). an additional lateral view is strongly recommended but not required.'
p1060
aS'- 5. clinical signs suggestive of fulminant colitis or toxic megacolon.'
p1061
aS'- 6. evidence of pathogenic enteric infection.'
p1062
aS'- 7. history of colorectal cancer or colorectal dysplasia.'
p1063
aS'- 8. prior use of any tnf inhibitor (or any biologic agent).'
p1064
aS'- 9. prior use of mycophenolic acid, tacrolimus, sirolimus, cyclosporine or thalidomide.'
p1065
aS'- 10. use of oral corticosteroids within 6 weeks of study randomization.'
p1066
aS'- 11. use of iv corticosteroids within 2 weeks of study randomization.'
p1067
aS'- 12. use of immunosuppressants (aza, 6-mp or mtx) within 8 weeks of study randomization.'
p1068
aS'- 13. use of topical treatment with 5-asa or corticosteroid enemas or suppositories within 2 weeks of study randomization.'
p1069
aS"- 14. history of any clinically significant neurological, renal, hepatic, gastrointestinal, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, or any other medical condition that, in the investigator's opinion, would preclude participation in the study."
p1070
aS"- 15. prior history of suicide attempt at any time in the subject's lifetime prior to ramdomization in the study or major psychiatric illness requiring hospitalization within 3 years of study randomization."
p1071
aS'- 16. any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she was to participate in the study or confounds the ability to interpret data from the study.'
p1072
aS'- 17. pregnant or breast feeding.'
p1073
aS'- 18. history of any of the following cardiac conditions within 6 months of screening: myocardial infarction, acute coronary syndrome, unstable angina, new onset atrial fibrillation, new onset atrial flutter, second- or third-degree atrioventricular block, ventricular fibrillation, ventricular tachycardia, heart failure, cardiac surgery, interventional cardiac catheterization (with or without a stent placement), interventional electrophysiology procedure, or presence of implanted defibrillator.'
p1074
aS'- 19. known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease and herpes zoster), human immunodeficiency virus (hiv), or any major episode of infection requiring hospitalization or treatment with intravenous (iv) or oral antibiotics within 4 weeks of screening.'
p1075
aS'- 20. subjects with active hepatitis b infection as described in appendix e are ineligible for the study. subjects without current hepatitis b infection described in appendix f may participate in the study.'
p1076
aS'- 21. subjects who are positive for the hepatitis c antibody are not eligible for the study.'
p1077
aS'- 22. history of congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease).'
p1078
aS'- 23. history of malignancy, except for: 1. treated (ie, cured) basal cell or squamous 2. treated (ie, cured) cervical intraepithelial neoplasia (cin) or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years'
p1079
aS'- 24. any condition that could affect oral drug absorption, including gastric resections, gastroparesis or bariatric surgery, such as gastric bypass.'
p1080
aS'- 25. subjects who have received any investigational drug or device within 3 months of study randomization.'
p1081
aS'- 26. history of alcohol, drug, or chemical abuse within the 6 months prior to screening.'
p1082
aS'- 27. known hypersensitivity to apremilast or any excipients in the formulation'
p1083
asS'NCT02579733'
p1084
(lp1085
S'- patients with azathioprine or biologics therapy'
p1086
asS'NCT02217722'
p1087
(lp1088
S'- any proven infection such as positive stool culture, parasite or c.difficile.'
p1089
aS'- use of antibiotics'
p1090
aS'- use of steroids in the previous two weeks only'
p1091
aS'- patients that are refractory to full dose steroids ( 1 mg/kg/day)'
p1092
aS'- past acute severe uc.'
p1093
aS'- current extra intestinal manifestation of uc.'
p1094
aS'- pregnancy. a subset of patients who are on steroids and relapse during steroids treatment \xe2\x89\xa40.5 mg/kg with mild to moderate disease activity will act as a second subset for this exploratory study.'
p1095
asS'NCT02171429'
p1096
(lp1097
S"- a history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, suspicion of ischemic, radiation or microscopic colitis, crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, intestinal obstruction, toxic megacolon, or unremoved adenomatous colonic polyps"
p1098
aS'- prior or planned surgery for uc'
p1099
aS'- past or present ileostomy or colostomy'
p1100
aS'- have received non-permitted inflammatory bowel disease (ibd) therapies (including natalizumab, vedolizumab, and efalizumab) as stated in the protocol'
p1101
aS'- chronic hepatitis b or c infection, hiv or tuberculosis (active or latent)'
p1102
asS'NCT02611830'
p1103
(lp1104
S'- 1. evidence of abdominal abscess or toxic megacolon at the initial screening visit.'
p1105
aS'- 2. extensive colonic resection, subtotal or total colectomy.'
p1106
aS'- 3. ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.'
p1107
aS'- 4. prior exposure to investigational or approved non-biologic therapies (eg, cyclosporine, tacrolimus, thalidomide, or tofacitinib) for the treatment of underlying disease within 30 days or 5 half-lives of screening (whichever is longer).'
p1108
aS'- 5. prior exposure to any investigational or approved biologic or biosimilar agent within 60 days or 5 half-lives of screening (whichever is longer).'
p1109
aS'- 6. prior exposure to vedolizumab'
p1110
aS'- 7. surgical intervention for uc required at any time during the study.'
p1111
aS'- 8. history or evidence of adenomatous colonic polyps that have not been removed, or has a history or evidence of colonic mucosal dysplasia.'
p1112
aS"- 9. suspected or confirmed diagnosis of crohn's entercolitis, indeterminate colitis, ischaemic colitis, radiation colitis, diverticular disease associated with colitis, or microscopic colitis."
p1113
aS'- 10. active infections'
p1114
aS'- 11. chronic hepatitis b or c infection, hiv or tuberculosis (active or latent), identified congenital or acquired immunodeficiency'
p1115
aS'- 12. history of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, demyelinating or neurodegenerative disease.'
p1116
asS'NCT02335281'
p1117
(lp1118
S'- diarrhea activity scores < 3'
p1119
aS'- severely active disease with perianal diseases'
p1120
aS'- severely active disease with indication of surgery.'
p1121
aS'- diagnosis as ibd first time or first year.'
p1122
aS'- no history of using 5-asa, biological (antibody), immunomodulatory therapy, corticosteroid therapy'
p1123
asS'NCT02200445'
p1124
(lp1125
S'- a diagnosis of crohn\'s disease or inflammatory bowel disease - unspecified (ibd-u, a diagnostic classification formerly termed "indeterminate colitis").'
p1126
aS'- requirement for immediate surgical, endoscopic or radiological intervention for toxic megacolon, massive hemorrhage, perforation, sepsis, or intra-abdominal or perianal abscess.'
p1127
aS'- ileostomy, proctocolectomy or subtotal colectomy with ileorectal anastomosis.'
p1128
aS'- history of colorectal cancer or dysplasia.'
p1129
aS'- positive stool test for clostridium difficile.'
p1130
aS'- current medically significant infection.'
p1131
aS'- significant laboratory abnormalities, including;'
p1132
aS'- 1. hb < 8.0 g/dl, wbc < 2.5 x 103/mm3, plt < 100 x 103/mm3.'
p1133
aS'- 2. creatinine \xe2\x89\xa5 1.5x institutional upper limit of normal (uln).'
p1134
aS"- 3. total bilirubin > 2.0 mg/dl, alt > 2x institutional uln, ggt > 2x institutional uln. elevated unconjugated bilirubin related to gilbert's syndrome is allowed."
p1135
aS'- 4. abnormal thyroid function tests.'
p1136
aS'- positive serology for hiv, hepatitis b virus (hbv) or hcv.'
p1137
aS'- positive screening test for tuberculosis (tb).'
p1138
aS'- first dose of an anti-tnf medication within 4 weeks of anticipated study commencement, or a subsequent dose within 2 weeks of commencement; or ciclosporin or tacrolimus within 2 weeks of anticipated study commencement.'
p1139
aS'- received another investigational new drug (ind) within 5 half-lives of that agent before the planned commencement of sc il-2.'
p1140
aS'- malignancy within the last 5 years.'
p1141
aS'- allergy to any component of the study drug.'
p1142
aS'- pregnant or lactating women.'
p1143
aS'- inability to comply with the study protocol or inability to give informed consent.'
p1144
aS'- prior exposure to il-2.'
p1145
aS'- uncontrolled cardiac angina or symptomatic congestive cardiac failure (nyha class iii or iv).'
p1146
asS'NCT02413047'
p1147
(lp1148
S'- previous noncompliant with medications'
p1149
aS'- < 18 years of age or >80 years of age.'
p1150
aS'- congestive heart failure'
p1151
aS'- abnormal liver tests alanine aminotransferase (alt) or aspartate aminotransferase (ast) 2 \xc3\x97 the upper limit of normal (uln) or leucopenia wbc count <3 \xc3\x97 109/l'
p1152
aS'- pregnant or planning on becoming pregnant.'
p1153
aS'- active tuberculosis or hepatitis b infection'
p1154
aS'- any cancer within the past 5 years. (exception non-melanomatous skin cancer.)'
p1155
aS'- receiving any immunomodulator therapy within the past 3 months'
p1156
aS'- evidence of or treatment for c. difficile infection within 60 days or other intestinal pathogen within 30 days prior to enrollment'
p1157
aS'- clinically significant extra-intestinal infection (e.g., pneumonia, pyelonephritis) within 30 days of the initial screening visit'
p1158
aS'- any live vaccinations within 30 days prior to study drug administration except for the influenza vaccine'
p1159
aS'- any identified congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, human immunodeficiency virus [hiv] infection, organ transplantation)'
p1160
aS'- any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise patient safety'
p1161
aS'- unable to give own informed consent'
p1162
asS'NCT02463305'
p1163
(lp1164
S'- abnormal baseline laboratory tests:'
p1165
aS'- albumin < 3.0 g/dl'
p1166
aS'- alt, ast, total bilirubin, or alkaline phosphatase > 1.5 x uln'
p1167
aS'- potassium < 3.0 mmol/l or > 5.5 mmol/l'
p1168
aS'- creatinine or cystatin c > uln'
p1169
aS'- wbc \xe2\x89\xa4 3000'
p1170
aS'- platelets \xe2\x89\xa4 105'
p1171
aS'- hemoglobin \xe2\x89\xa4 10g/dl'
p1172
aS'- positive stool test for clostridium difficile, ova and parasites, or routine stool culture'
p1173
aS'- pregnancy (as confirmed by urine pregnancy test at study outset), stated desire to become pregnant during the study period, or refusal/inability to use effective methods of contraception during the study period.'
p1174
aS'- concomitant major comorbidities (renal, hepatic, cardiac, pulmonary or malignancy) to include any medical conditions requiring therapeutic anti-coagulation or anti-platelet therapy.'
p1175
aS'- diagnosis of severe uc (mayo score > 10)'
p1176
aS'- evidence or history of toxic megacolon'
p1177
aS'- patients who received anti-tnf agents within 3 months of screening, or who used oral or rectal corticosteroids within 4 weeks of screening will be excluded.'
p1178
aS'- use of over-the-counter herbal or dietary supplements (excluding vitamin and minerals) two weeks prior to or during the study period.'
p1179
aS'- use of known nephrotoxic medications (including non-steroidal anti-inflammatory drugs (nsaids), cyclosporin a, tacrolimus, aminoglycoside antibiotics, diuretics, angiotensin converting enzyme (ace) inhibitors, or angiotensin receptor blockers) 2 weeks prior to or during the study period'
p1180
aS'- prior surgical bowel resections (excluding appendectomy)'
p1181
aS'- local or systemic complications or other pathological states requiring therapy with corticosteroids and/or immunosuppressive agents.'
p1182
asS'NCT02522767'
p1183
(lp1184
S'- disease limited to proctitis <15 cm'
p1185
aS'- short bowel syndrome'
p1186
aS'- prior colon resection surgery'
p1187
aS'- history of severe/fulminant uc'
p1188
aS'- evidence of other forms of inflammatory bowel disease'
p1189
aS'- infectious disease (including human immunodeficiency virus [hiv], hepatitis b virus [hbv], or hepatitis c virus [hcv])'
p1190
aS'- intolerant or allergic to aspirin or salicylate derivatives'
p1191
aS'- use of rectal formulations (5-aminosalicylic acid [5-asa], steroids) within \xe2\x89\xa47 days'
p1192
aS'- women who are pregnant or nursing'
p1193
aS'- history or known malignancy'
p1194
aS'- history of bleeding disorders, active gastric or active duodenal ulcers, autoimmune diseases, or mental/emotional disorders, that would interfere with their participation in the trial'
p1195
asS'NCT02683759'
p1196
(lp1197
S'- patients who are currently experiencing symptomatic flares of mild or moderate ulcerative colitis, or have a partial mayo index score of 2 or greater'
p1198
aS'- patients who have been taking azathioprine or mercaptopurine for <12 weeks for the treatment of their ulcerative colitis'
p1199
aS'- patients who are taking steroids, immunosuppressants, or biologic agents for the treatment of their ulcerative colitis'
p1200
aS'- patients who have severe ulcerative colitis'
p1201
aS'- patients who are noncompliant with medication or regular follow up visits'
p1202
aS'- patients who are unable or unwilling to record their responses in survey form'
p1203
aS'- patients with comorbid illnesses, including: diabetes mellitus, stage iii or above congestive heart failure, chronic pancreatitis, severe liver or renal disease'
p1204
aS'- patients who have current gallstones or biliary dysfunction'
p1205
aS'- patients with anemia (hemoglobin <10), thrombocytopenia, abnormal lymphocyte counts, or coagulation abnormalities'
p1206
aS'- patients with current sepsis or current ongoing infection, including c. difficile colitis or enteritis'
p1207
aS'- patients with a history of malignancy'
p1208
aS'- patients who are currently pregnant or nursing'
p1209
aS'- patients who are current smokers'
p1210
asS'NCT02447302'
p1211
(lp1212
S'- within 30 days prior to randomization, receipt of any of the following for the treatment of underlying disease: non-biologic therapies (eg, cyclosporine, tacrolimus, tofacitinib, thalidomide), a non-biologic investigational therapy or an approved non-biologic therapy in an investigational protocol'
p1213
aS'- within 60 days prior to randomization, receipt of any of the following: infliximab, adalimumab, golimumab, certolizumab or any other investigational or approved biologic agent'
p1214
aS'- any prior exposure to natalizumab, efalizumab, or rituximab'
p1215
asS'NCT02163759'
p1216
(lp1217
S"- a history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, suspicion of ischemic, radiation or microscopic colitis, crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, intestinal obstruction, toxic megacolon, or unremoved adenomatous colonic polyps"
p1218
aS'- prior or planned surgery for uc'
p1219
aS'- past or present ileostomy or colostomy'
p1220
aS'- have received non-permitted inflammatory bowel disease (ibd) therapies (including natalizumab, vedolizumab, and efalizumab) as stated in the protocol'
p1221
aS'- chronic hepatitis b or c infection, hiv or tuberculosis (active or latent)'
p1222
asS'NCT01458574'
p1223
(lp1224
S'- subjects who had major protocol violation (as determined by the sponsor) in study a3921094 or a3921095'
p1225
aS"- presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of crohn's disease"
p1226
aS'- subjects who have had surgery for uc or in the opinion of the investigator, are likely to require surgery for uc during the study period.'
p1227
asS'NCT02442960'
p1228
(lp1229
S'- 1. are nursing or pregnant.'
p1230
aS'- 2. patients who are in critical condition'
p1231
aS"- 3. crohn's disease or indeterminate colitis."
p1232
aS'- 4. known sensitivity to any ingredients in the study drug.'
p1233
aS'- 5. a change in therapy within 2 weeks before the baseline visit.'
p1234
aS'- 6. use of immunomodulators (cyclosporine, mercaptopurine, azathioprine, etc.).'
p1235
aS'- 7. diagnosis of diabetes, heart failure, unstable angina, liver or kidney disease, or any other unstable medical condition.'
p1236
aS'- 8. any clinically meaningful laboratory abnormality that in the judgment of the investigator should preclude participation in the study.'
p1237
aS'- 9. impaired renal function (serum creatinine levels >2.0 mg/dl) at screening.'
p1238
aS'- 10. alanine transaminase (alt) or aspartate transaminase (ast) laboratory values >1.5 times upper limit of normal at screening.'
p1239
aS'- 11. diagnosis of clostridium difficile, salmonella, shigella, yersinia, campylobacter, enteropathogenic e. coli in stool.'
p1240
aS'- 12. positive test for hepatitis c virus (hcv) antibody or hepatitis b surface antigen (hbsag) at screening.'
p1241
aS'- 13. active malignancy (except basal cell carcinoma).'
p1242
aS'- 14. active alcohol or drug abuse.'
p1243
aS'- 15. tobacco smoking within 2 weeks before study entry.'
p1244
asS'NCT02522780'
p1245
(lp1246
S'- evidence of other forms of inflammatory bowel disease'
p1247
aS'- infectious disease (including human immunodeficiency virus [hiv], hepatitis b virus [hbv], or hepatitis c virus [hcv])'
p1248
aS'- disease limited to proctitis <15 cm'
p1249
aS'- short bowel syndrome'
p1250
aS'- prior colon resection surgery'
p1251
aS'- history of severe/fulminant uc'
p1252
aS'- intolerant or allergic to aspirin or salicylate derivatives'
p1253
aS'- use of rectal formulations (5-aminosalicylic acid [5-asa], steroids) within \xe2\x89\xa47 days'
p1254
aS'- women who are pregnant or nursing'
p1255
aS'- history of known malignancy'
p1256
aS'- history of bleeding disorders, active gastric or active duodenal ulcers, autoimmune diseases, or mental/ emotional disorders, that would interfere with their participation in the trial'
p1257
asS'NCT02683733'
p1258
(lp1259
S'- patients who are in remission from ulcerative colitis, or who have a partial mayo index score of 0 or 1'
p1260
aS'- patients who have been taking azathioprine or mercaptopurine for <12 weeks for the treatment of their ulcerative colitis'
p1261
aS'- patients who are taking steroids or biologic agents for the treatment of their ulcerative colitis'
p1262
aS'- patients who have severe ulcerative colitis, or who have a partial mayo index score of 7 or above'
p1263
aS'- patients who are noncompliant with medication or regular follow up visits'
p1264
aS'- patients who are unable to or unwilling to record their responses in survey form'
p1265
aS'- patients with comorbid illnesses, including: diabetes mellitus, stage iii or above congestive heart failure, chronic pancreatitis, severe liver or renal disease'
p1266
aS'- patients who have current gallstones or any biliary dysfunction'
p1267
aS'- patients with anemia (hemoglobin <10), thrombocytopenia, abnormal lymphocyte counts, or coagulation abnormalities'
p1268
aS'- patients who currently have an ongoing severe infection/sepsis'
p1269
aS'- patients with a history of malignancy'
p1270
aS'- patients who are currently pregnant or nursing'
p1271
aS'- patients who are current smokers'
p1272
asS'NCT02165215'
p1273
(lp1274
S"- a history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, intestinal obstruction, toxic megacolon, or unremoved adenomatous colonic polyps"
p1275
aS'- prior or planned surgery for uc'
p1276
aS'- past or present ileostomy or colostomy'
p1277
aS'- have received non-permitted inflammatory bowel disease (ibd) therapies (including natalizumab, vedolizumab, and efalizumab) as stated in the protocol'
p1278
aS'- chronic hepatitis b or c infection, hiv or tuberculosis (active or latent)'
p1279
asS'NCT01494857'
p1280
(lp1281
S'- 1. history of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, koch pouch, or ileostomy for uc or is planning bowel surgery.'
p1282
aS'- 2. received previous treatment with adalimumab or previous participation in an adalimumab clinical study.'
p1283
aS'- 3. received cyclosporine, tacrolimus, or mycophenolate mofetil, within 30 days prior to baseline.'
p1284
aS'- 4. received intravenous corticosteroids within 14 days prior to screening or during the screening period.'
p1285
aS'- 5. received therapeutic enema or suppository, other than required for endoscopy, within 14 days prior to the screening endoscopy and during the remainder of screening period.'
p1286
aS'- 6. current diagnosis of fulminant colitis and/or toxic megacolon.'
p1287
aS'- 7. subject with disease limited to the rectum (ulcerative proctitis).'
p1288
aS'- 8. current diagnosis of indeterminate colitis.'
p1289
aS"- 9. current diagnosis and/or history of crohn's disease."
p1290
aS'- 10. currently receiving total parenteral nutrition (tpn).'
p1291
aS'- 11. subject using aminosalicylates for less than 90 days prior to baseline or not on a stable dose for at least 28 days prior to baseline or discontinued use within 28 days of baseline.'
p1292
aS'- 12. subject with positive clostridium difficile (c. difficile) stool assay.'
p1293
aS'- 13. subject who has previously used infliximab or any anti-tnf agent within 56 days of baseline.'
p1294
aS'- 14. subject who has previously used infliximab or any anti-tnf agent and has not clinically responded at any time ("primary non-responder") unless subject experienced a treatment limiting reaction.'
p1295
asS'NCT02267694'
p1296
(lp1297
S'- treatment with immunomodulators and/or biologic agents, active disease flare, patients younger than 18 years old, patients who are pregnant or trying to get pregnant, breast feeding and those with reported history of allergy or hypersensitivity to berry products. patients who are using nsaids will also be excluded from the study but low dose asa (81-162 mg) is permitted if needed.'
p1298
asS'NCT02745678'
p1299
(lp1300
S'- known infection with clostridium difficile (c. difficile) and/or other enteric pathogens'
p1301
aS'- 5-aminosalicylic acid (5-asa) intolerance'
p1302
aS'- current or recent (3 weeks) oral or rectal steroids'
p1303
aS'- history of thiopurine or anti-tumor necrosis factor (anti-tnf) alpha treatment for colitis'
p1304
aS'- abnormal creatinine'
p1305
aS'- previous small bowel or colonic resection,'
p1306
aS'- anal sphincter incompetence,'
p1307
aS'- current smokers.'
p1308
aS"- history or current diagnosis of crohn's disease or indeterminate colitis."
p1309
aS'- history of diverticulitis, collagenous colitis, celiac disease, recurrent pancreatic or known gallbladder disease.'
p1310
aS'- unstable significant cardiovascular, endocrine, neurologic or pulmonary disease.'
p1311
aS'- hemoglobin levels < 7.5 g/dl.'
p1312
aS'- history of sclerosing cholangitis, cirrhosis, or hepatic impairment'
p1313
aS'- pregnant or at risk of pregnancy.'
p1314
aS'- some medications to treat uc are prohibited during participation in the study, including laxatives and anti-diarrhea medications; oral 5-asa agents and daily fiber supplements are allowed.'
p1315
asS'NCT01171807'
p1316
(lp1317
S'- uncontrolled diabetes'
p1318
aS'- severe comorbidities (renal failure, heart failure, cirrhosis, neoplasia)'
p1319
aS'- previous exposure to biologic therapy'
p1320
aS'- pregnancy of breast feeding'
p1321
aS'- alcohol or drug abuse'
p1322
aS'- mental illness'
p1323
asS'NCT02537210'
p1324
(lp1325
S'- allergic to mesalazine'
p1326
aS'- prior bowel surgery except appendectomy'
p1327
aS'- hepatic or renal dysfunction'
p1328
aS'- malignant disease within 5 years'
p1329
aS'- pregnancy or breast feeding or women of child-bearing age without regular use of contraception'
p1330
aS'- on anti-tumor necrosis factor therapy'
p1331
aS'- terminal illness'
p1332
asS'NCT02550418'
p1333
(lp1334
S"- crohn's disease, indeterminate colitis, ischaemic colitis, radiation colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis, incomplete microscopic colitis), diverticular disease associated colitis,"
p1335
aS'- toxic megacolon or fulminant colitis,'
p1336
aS'- colon resection,'
p1337
aS'- evidence of infectious colitis (e.g., pathogenic bacteria or clostridium difficile toxin in stool culture at screening),'
p1338
aS'- malabsorption syndromes,'
p1339
aS'- celiac disease,'
p1340
aS'- bleeding hemorrhoids,'
p1341
aS'- active peptic ulcer disease'
p1342
aS'- other inflammatory or bleeding disorders of the colon and intestine, or diseases that may cause diarrhea or gastrointestinal bleeding,'
p1343
aS'- hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease, glaucoma, cataract, or infection if careful medical monitoring is not ensured,'
p1344
aS'- any severe infectious disease (e.g., tuberculosis, aids),'
p1345
aS'- severe co-morbidity substantially reducing life expectancy,'
p1346
aS'- history of colorectal cancer,'
p1347
aS'- history of cancer (other than colorectal) in the last 5 years, except for basal cell carcinoma'
p1348
asg24
(lp1349
S'- complications associated with surgery'
p1350
aS'- non-radical surgery'
p1351
aS'- chemotherapy'
p1352
aS'- poor compliance'
p1353
aS'- other serious illness'
p1354
asS'NCT01941589'
p1355
(lp1356
S'- pregnant women'
p1357
aS'- allergy/unable to take study medications'
p1358
aS'- active infection'
p1359
aS'- severe renal/liver/cardiorespiratory condition'
p1360
aS'- toxic megacolon or signs of imminent colectomy'
p1361
aS'- treatment with an anti-tumor necrosis factor in 3 months prior to admission'
p1362
aS'- prior treatment with cyclosporin or tacrolimus'
p1363
aS'- alcohol dependancy'
p1364
aS'- unwilling/ unable to give an informed consent'
p1365
aS'- participation in clinical trials in the last 2 months prior to admission'
p1366
asS'NCT02601300'
p1367
(lp1368
S'- the presence of any of the following will exclude a subject from enrollment:'
p1369
aS"- 1. subject has a diagnosis of crohn's disease (cd), indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis."
p1370
aS'- 2. subject has ulcerative colitis restricted to distal 15 cm or less (eg, ulcerative proctitis).'
p1371
aS'- 3. subject had surgery as a treatment for ulcerative colitis (uc)or who, in the opinion of the investigator, is likely to require surgery for ulcerative colitis (uc) during the study.'
p1372
aS'- 4. subject has clinical signs suggestive of fulminant colitis or toxic megacolon.'
p1373
aS'- 5. subject is stool positive for any enteric pathogen or clostridium difficile (c. difficile) toxin at screening.'
p1374
aS'- 6. subject has history of colorectal cancer or colorectal dysplasia.'
p1375
aS'- 7. prior treatment with more than 2 tumor necrosis factor (tnf)-\xce\xb1 blockers (eg, infliximab, adalimumab, or golimumab).'
p1376
aS'- 8. prior treatment with any integrin antagonists (eg, natalizumab or vedolizumab).'
p1377
aS'- 9. use of tumor necrosis factor (tnf)-\xce\xb1 blockers within 8 weeks of the screening.'
p1378
aS'- 10. subject had prior treatment with mycophenolic acid, tacrolimus, sirolimus, cyclosporine, thalidomide or apheresis (eg, adacolumn\xc2\xae) for the treatment of ulcerative colitis (uc). in addition, prior use of any of these treatment modalities for an indication other than ulcerative colitis (uc) within 8 weeks of screening is also excluded.'
p1379
aS'- 11. subject has received intravenous (iv) corticosteroids within 2 weeks of screening.'
p1380
aS'- 12. subject has received topical treatment with 5 aminosalicylic acid (5-asa) or corticosteroid enemas or suppositories within 2 weeks of screening.'
p1381
aS'- 13. subject has received total parenteral nutrition (tpn) within 4 weeks of screening.'
p1382
aS"- 14. subject has a history of any clinically significant neurological, renal, hepatic, gastrointestinal, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, or any other medical condition that, in the investigator's opinion, would prevent the subject from participation in the study."
p1383
aS'- 15. subject has any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she was to participate in the study or confounds the ability to interpret data from the study.'
p1384
aS'- 16. subject is pregnant or breastfeeding.'
p1385
aS'- 17. subject has a history of any of the following cardiac conditions within 6 months of screening: myocardial infarction, acute coronary syndrome, unstable angina, new onset atrial fibrillation, new onset atrial flutter, second- or third-degree atrioventricular block, ventricular fibrillation, ventricular tachycardia, heart failure, cardiac surgery, interventional cardiac catheterization (with or without a stent placement), interventional electrophysiology procedure, or presence of implanted defibrillator.'
p1386
aS'- 18. subject has a known active current or history of medically important recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease and herpes zoster), human immunodeficiency virus (hiv), or any major episode of infection requiring hospitalization or treatment with intravenous (iv) or oral antibiotics within 4 weeks of screening.'
p1387
aS'- 19. subject has a history of congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease).'
p1388
aS'- 20. subject has a history of malignancy, except for: 1. treated (ie, cured) basal cell or squamous cell in situ skin carcinomas 2. treated (ie, cured) cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years'
p1389
aS'- 21. subject has received investigational drug or device within 1 month of screening.'
p1390
aS'- 22. subject has a history of alcohol, drug, or chemical abuse within the 6 months prior to screening.'
p1391
aS'- 23. subject has a known hypersensitivity to oligonucleotides or any ingredient in the investigational product (ip).'
p1392
aS'- 24. subject has prior treatment with ged-0301 or participated in a clinical study involving ged-0301.'
p1393
asS'NCT02065622'
p1394
(lp1395
S"- subject with crohn's disease (cd) or indeterminate colitis (ic)."
p1396
aS'- current diagnosis of fulminant colitis and/or toxic megacolon.'
p1397
aS'- subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.'
p1398
aS'- chronic recurring infections or active tuberculosis (tb).'
p1399
asS'NCT02368717'
p1400
(lp1401
S'- patients receiving > 2g/day of oral 5-aminosalicylic acid (5-asa) products, or receiving topical rectal 5-asa > 3g/week, within 7 days prior to screening'
p1402
aS'- severe/fulminant ulcerative colitis or toxic dilatation of the colon'
p1403
aS'- prior bowel resection surgery'
p1404
aS'- patients allergic to 5-asa and derivative, any of the excipients, aspirin, or salicylates'
p1405
aS"- patients with one or more of the diseases: bacillary dysentery, amebic dysentery, chronic schistosomiasis, intestinal tuberculosis and crohn's disease"
p1406
aS'- patients who are unable to fill in the patient daily diary or follow data-capturing procedures'
p1407
asS'NCT02618187'
p1408
(lp1409
S'- 1. fever > 38.3\xc2\xb0c'
p1410
aS'- 2. known or suspected toxic megacolon and/or known small bowel ileus'
p1411
aS"- 3. known history of crohn's disease"
p1412
aS'- 4. subjects with serum albumin <2.5 g/dl at baseline'
p1413
aS'- 5. cmv polymerase chain reaction (pcr) positive from blood plasma at screening'
p1414
aS'- 6. known stool studies positive for ova and/or parasites or stool culture within the 30 days before enrollment'
p1415
aS'- 7. subjects on cyclosporine or triple immunosuppression, triple immunosuppression will include any three of the following classes of drugs taken in combination: steroids (i.e., prednisone/budesonide/budesonide mmx), immunosuppressant (i.e., methotrexate/azathioprine/6-mercaptopurine), and/or other immunosuppressant (i.e., tacrolimus, cellcept).'
p1416
aS'- 8. biologic medication (infliximab/ adalimumab/ golimumab/ certolizumab/vedolizumab/ustekinumab/natalizumab) use within 3 months prior to screening'
p1417
aS'- 9. known active malignancy except for basal cell skin cancer, squamous cell skin cancer'
p1418
aS'- 10. subjects with previous colectomy, ostomy, j-pouch, or previous intestinal surgery (excluding cholecystectomy, appendectomy)'
p1419
aS'- 11. subjects with known history of celiac disease or gluten enteropathy'
p1420
aS'- 12. subjects with clostridium difficile positive stool at screening visit'
p1421
aS'- 13. antibiotic use within the prior 1 month before randomization'
p1422
aS'- 14. expected to receive antibiotics within 8 weeks of signing the informed consent form (icf) (i.e., for planned/anticipated procedure)'
p1423
aS'- 15. received an investigational drug within 1 month before study entry'
p1424
aS'- 16. received an investigational antibody or vaccine within 3 months before study entry'
p1425
aS'- 17. previously enrolled in a ser-109/ser-287 study'
p1426
aS'- 18. received an fmt within the last 6 months'
p1427
aS'- 19. subjects with anatomic or medical contraindications to flexible sigmoidoscopy, including but not necessarily limited to toxic megacolon, gastrointestinal (gi) fistulas, immediate post-operative status from abdominal surgery, severe coagulopathy, large or symptomatic abdominal aortic aneurysm, or any subject where study physician deems subject at significant risk of complications of flexible sigmoidoscopy'
p1428
aS'- 20. unable to stop steroid enemas or suppositories or mesalamine enemas or suppositories before screening visit'
p1429
aS'- 21. unable to stop opiate treatment unless on a stable dose and no increase in dose planned for the duration of the study'
p1430
aS'- 22. unable to stop probiotics before screening visit'
p1431
aS'- 23. concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy (subjects on maintenance chemotherapy may only be enrolled after consultation with medical monitor)'
p1432
aS'- 24. known allergy or intolerance to oral vancomycin'
p1433
asS'NCT02493712'
p1434
(lp1435
S"- 1. patients diagnosed with crohn's disease, indeterminate colitis, or ischemic colitis"
p1436
aS'- 2. female patients who are pregnant or breastfeeding'
p1437
aS'- 3. ulcerative proctitis with \xe2\x89\xa415 cm of disease'
p1438
aS'- 4. patients with infectious colitis as determined by assessment for clostridium difficile (c. difficile) and fecal pathogens at screening or treatment for c. difficile within 30 days prior to screening'
p1439
aS'- 5. history of or current evidence of toxic megacolon, fulminant colitis (e.g., lichtiger score of \xe2\x89\xa510), colonic perforation'
p1440
asS'NCT02412085'
p1441
(lp1442
S"- crohn's disease or undetermined colitis"
p1443
aS'- active infections or previous infections not completely resolved at baseline'
p1444
aS'- malignancies in the previous 5 years'
p1445
aS'- suspected latent tuberculosis infection'
p1446
aS'- every other potentially harmful clinical condition, in the opinion of the investigator'
p1447
aS'- patients with moderately to severe heart failure (nyha class iii/iv)'
p1448
aS'- hepatic or renal failure'
p1449
aS'- pregnant or lactating women or women planning a pregnancy between baseline and the 3 months after study completion'
p1450
aS'- not permitted concomitant medications'
p1451
asS'NCT02136069'
p1452
(lp1453
S"- a history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, suspicion of ischemic, radiation or microscopic colitis, crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, intestinal obstruction, toxic megacolon, or unremoved adenomatous colonic polyps"
p1454
aS'- prior or planned surgery for uc'
p1455
aS'- past or present ileostomy or colostomy'
p1456
aS'- have received non-permitted inflammatory bowel disease (ibd) therapies (including natalizumab, vedolizumab, and efalizumab) as stated in the protocol'
p1457
aS'- history of moderate or severe allergic or anaphylactic/anaphylactoid reactions to chimeric, human, or humanized antibodies; fusion proteins, or murine proteins; hypersensitivity to etrolizumab or any of its excipients'
p1458
aS'- chronic hepatitis b or c infection, hiv or tuberculosis (active or latent)'
p1459
asS'NCT01470612'
p1460
(lp1461
S'- subjects who had a major protocol violation in study a3921094, a3921095 or a3921096.'
p1462
aS"- presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of crohn's disease."
p1463
aS'- subjects who have had surgery for ulcerative colitis or in the opinion of the investigator, are likely to require surgery for ulcerative colitis during the study period.'
p1464
asS'NCT02646657'
p1465
(lp1466
S'- 1. prior treatment with vedolizumab.'
p1467
aS'- 2. contraindication for endoscopy.'
p1468
aS'- 3. history of colonic dysplasia/cancer'
p1469
aS'- 4. extensive colonic resection, i.e. subtotal or total colectomy with <15 cm colon remaining'
p1470
aS'- 5. received other biologics within the last 6 weeks of screening'
p1471
aS'- 6. use of 5-asa or corticosteroid enemas/suppositories within 2 weeks of enrollment'
p1472
aS'- 7. chronic hepatitis b or c infection'
p1473
aS'- 8. evidence of or treatment for c. difficile infection or other intestinal pathogen at screening within 4 weeks prior to enrollment'
p1474
aS'- 9. active or latent tuberculosis'
p1475
aS"- 10. conditions which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures."
p1476
aS'- 11. received any investigational drug in the past 30 days or 5 half-lives, whichever is longer.'
p1477
aS'- 12. positive progressive multifocal leukoencephalopathy (pml) subjective symptom checklist before enrollment'
p1478
asS'NCT02073526'
p1479
(lp1480
S'- patients refusing to participate by not giving their informed consent'
p1481
asS'NCT02142725'
p1482
(lp1483
S"- crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, microscopic colitis, diverticular disease associated colitis,"
p1484
aS'- toxic megacolon or fulminant colitis'
p1485
aS'- colon resection'
p1486
aS'- evidence of infectious colitis'
p1487
aS'- celiac disease'
p1488
aS'- bleeding hemorrhoids'
p1489
aS'- history or presence of ischemic heart disease, myocardial infarction, peripheral arterial disease, ischemic stroke, or transient ischemic attack'
p1490
aS'- any severe concomitant renal, endocrine, or psychiatric disorder'
p1491
aS'- any relevant known systemic disease'
p1492
aS'- history of cancer in the last five years'
p1493
aS'- abnormal hepatic function or liver cirrhosis'
p1494
aS'- abnormal hba1c at screening visit'
p1495
aS'- patients with known hypersensitivity to soy'
p1496
aS'- known intolerance/hypersensitivity to investigational medicinal product (imp)'
p1497
aS'- treatment with steroids/methotrexate/tumor necrosis factor-alpha-antagonists/azathioprine/ 6-mercaptopurine/anti-integrin/coumarins'
p1498
aS'- treatment with other investigational drug'
p1499
aS'- existing or intended pregnancy or breast-feeding'
p1500
asS'NCT02531126'
p1501
(lp1502
S'- require initiation of other therapies used in the treatment of uc'
p1503
aS'- pregnant, lactating, or have a positive serum pregnancy test'
p1504
aS'- have clinically relevant cardiovascular conditions or other relevant disease that would put the patient at risk or make interpretation of the trial difficult'
p1505
asS'NCT01393405'
p1506
(lp1507
S'- failure to respond to 40 mg of prednisone or higher/day in the last 2 weeks before inclusion'
p1508
aS'- concomitant use of azathioprine (aza) or 6-mercaptopurine (6-mp) must be discontinued at least 2 weeks before inclusion into the study (week 0 visit)'
p1509
aS'- anti-tnf therapy in the 2 weeks before the week 0 visit'
p1510
aS'- failure of cyclosporine therapy in the previous 6 months prior to screening visit'
p1511
aS'- patients with serum albumin < 2.5 g/dl at baseline'
p1512
aS'- low serum folate defined as decrease of >10% below normal range'
p1513
aS'- patients with wbc< 3.0 x109th/l at baseline'
p1514
aS'- patients with platelet count < 100 x109th/l'
p1515
aS'- patients with an underlying infection with c. difficile at screening visit'
p1516
aS'- patients with pre-existing hepatic disease'
p1517
aS'- patients with known non-alcoholic fatty liver disease (nafld)'
p1518
aS'- patients with known hepatitis b or hepatitis c'
p1519
aS'- patients with pre-existing renal dysfunction (creatinine >1.5 mg/dl).'
p1520
aS'- patients with a pre-existing chronic lung disease other than well controlled asthma'
p1521
aS'- patients with interstitial lung disease of unknown cause'
p1522
aS'- patients with a bmi >35'
p1523
aS'- known previous or concurrent malignancy (other than that considered surgically cured, with no evidence for recurrence for 5 years - basal cell does not exclude)'
p1524
aS'- existing pregnancy, lactation, or planned pregnancy* (men and women) within the next 12 months. (*methotrexate should not be used for at least 3 months before planned pregnancy for men and women and should not be used during pregnancy or breast feeding)'
p1525
aS'- high alcohol consumption (more than seven drinks per week)'
p1526
aS'- non - steroidal inflammatory medications (nsaids) as long-term treatment, defined as use for at least 4 days a week each month'
p1527
aS'- continuous treatment with one of the following drugs:'
p1528
aS'- probenecid,'
p1529
aS'- trimethoprim/sulfamethoxazole'
p1530
aS'- sulfasalazine'
p1531
aS'- acitretin'
p1532
aS'- streptozocin'
p1533
aS'- non-use of appropriate contraceptives in females of childbearing potential (e.g. condoms, intrauterine device {iud}, hormonal contraception, or other means considered adequate by the responsible investigator) or in males with a child-fathering potential (condoms, or other means considered adequate by the responsible investigator during treatment'
p1534
aS'- participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial'
p1535
aS"- well-founded doubt about the patient's cooperation."
p1536
asS'NCT02407236'
p1537
(lp1538
S'- has severe extensive colitis and is at imminent risk of colectomy'
p1539
aS'- has uc limited to the rectum only or to < 20 centimeters (cm) of the colon'
p1540
aS'- presence of a stoma or history of a fistula'
p1541
aS'- participants with history of extensive colonic resection (for example, less than 30 cm of colon remaining) that would prevent adequate evaluation of the effect of study agent on clinical disease activity'
p1542
aS'- participants with history of colonic mucosal dysplasia. participants will not be excluded from the study because of a pathology finding of "indefinite dysplasia with reactive atypia\'\''
p1543
asS'NCT02589665'
p1544
(lp1545
S"- have been diagnosed with indeterminate colitis, proctitis (distal disease involving the rectum only; less than 15 cm from the anal verge) or crohn's disease"
p1546
aS'- have had surgery for treatment of uc or are likely to require surgery for uc during the study'
p1547
aS'- have received any of the following for treatment of uc: cyclosporine or thalidomide within 30 days of screening, corticosteroid enemas, corticosteroid suppositories, or topical treatment with 5-aminosalicyclic acid within 30 days of screening'
p1548
asS'NCT02345733'
p1549
(lp1550
S'- exclusion criteria:'
p1551
aS'- 1. any proven current infection such as positive stool culture, parasite or c. difficile.'
p1552
aS'- 2. antibiotic or steroids use in the past 2 weeks.'
p1553
aS'- 3. pucai >45'
p1554
aS'- 4. acute severe uc in the previous 12 months.'
p1555
aS'- 5. current extra intestinal manifestation of uc.'
p1556
aS'- 6. psc or liver disease'
p1557
aS'- 7. pregnancy.'
p1558
aS'- 8. allergy to one of the antibiotics or age <11 will exclude patients from entering the antibiotic arm'
p1559
asS'NCT02100696'
p1560
(lp1561
S"- a history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, intestinal obstruction, toxic megacolon, or unremoved adenomatous colonic polyps"
p1562
aS'- prior or planned surgery for uc'
p1563
aS'- past or present ileostomy or colostomy'
p1564
aS'- have received non-permitted inflammatory bowel disease (ibd) therapies (including natalizumab, vedolizumab, and efalizumab) as stated in the protocol'
p1565
aS'- chronic hepatitis b or c infection, hiv or tuberculosis (active or latent)'
p1566
asS'NCT02586259'
p1567
(lp1568
S'- patients with severe active / fulminant ulcerative colitis'
p1569
aS'- patients treated with antibiotics or corticosteroids for the current flare'
p1570
aS'- history of total / sub-total colectomy'
p1571
aS'- hypersensitivity to the active substance, lecithin (derived soya oil, peanut oil) or to any of the excipients'
p1572
aS'- patients enrolled and involved in an interventional study'
p1573
aS'- patients whom investigators consider inappropriate to participate in the study'
p1574
asS'NCT02497469'
p1575
(lp1576
S'- 1. clinical evidence of abdominal abscess or toxic megacolon at screening.'
p1577
aS'- 2. the subject has had an extensive colonic resection, subtotal or total colectomy.'
p1578
aS'- 3. the subject has had ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.'
p1579
aS"- 4. the subject has a diagnosis of crohn's colitis or indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, or microscopic colitis."
p1580
aS'- 5. the subject has received any of the following within 30 days of screening: 1. non-biologic therapies other than those specifically listed in section permitted medications for treatment of uc. 2. an approved non-biologic therapy in an investigational protocol.'
p1581
aS'- 6. the subject has received any investigational or approved biologic or biosimilar agent within 60 days or 5 half lives prior to the screening (whichever is longer).'
p1582
aS'- 7. the subject has previously received natalizumab, efalizumab, adalimumab, or rituximab.'
p1583
aS'- 8. the subject has history or evidence of adenomatous colonic polyps that have not been removed, or colonic mucosal dysplasia.'
p1584
aS'- 9. evidence of an active infection during screening.'
p1585
aS'- 10. evidence of, or treatment for, c. difficile or other intestinal pathogen within 28 days prior to the 1st dose of study drug.'
p1586
aS'- 11. the subject has chronic hbv or hcv infection.'
p1587
aS'- 12. the subject has active or latent tb, regardless of treatment history.'
p1588
aS'- 13. the subject has used a topical (rectal) treatment with (5-asa) or corticosteroid enemas/suppositories within 2 weeks of the administration of the 1st dose of study drug.'
p1589
aS'- 14. the subject has a history of hypersensitivity or allergies to vedolizumab or adalimumab.'
p1590
aS'- 15. the subject has a positive pml subjective symptom checklist prior to the administration of the first dose of study drug.'
p1591
asS'NCT02536404'
p1592
(lp1593
S'- patients who did not complete the apd334-003 study'
p1594
asS'NCT02129439'
p1595
(lp1596
S'- colectomy and presence of ileal pouch-anal anastomosis or ileorectal anastomosis'
p1597
aS"- diagnosis of ulcerative proctitis, fulminant colitis, toxic megacolon, of colitis indeterminata or crohn's disease"
p1598
aS'- ileostoma'
p1599
aS'- anti-tnf\xce\xb1 treatment with adalimumab, certolizumab, etanercept, golimumab, or infliximab \xe2\x89\xa44 weeks prior to screening visit.'
p1600
aS'- change in systemic glucocorticoid treatment \xe2\x89\xa41 weeks prior to screening visit'
p1601
aS'- change in 5-aminosalicylic acid (asa) therapy \xe2\x89\xa41 week prior to screening visit'
p1602
aS'- start of treatment with an immunosuppressive agent \xe2\x89\xa43 months prior to screening visit'
p1603
aS'- change in treatment with an immunosuppressive agent \xe2\x89\xa44 weeks prior to baseline visit'
p1604
aS'- planned concomitant therapeutic administration of suppositories or foams or enema other than the imp.'
p1605
aS'- impaired blood coagulation (quick value <50% and/or partial thromboplastin time (ptt) >55sec and/or platelet count <50.000/\xce\xbcl.)'
p1606
aS'- signs of renal insufficiency'
p1607
aS'- signs of hepatic insufficiency.'
p1608
aS'- current treatment with drugs of high hepatotoxic potential.'
p1609
aS'- evidence of recent alcohol abuse.'
p1610
aS'- acute or chronic heart failure with nyha functional class iii or iv.'
p1611
aS'- known active tuberculosis.'
p1612
aS'- known acute serious infections or sepsis.'
p1613
aS'- known current malignant disease.'
p1614
aS'- positive blood test against hbs antigen, anti-hbc antibodies, anti-hcv antibodies or anti-hiv-1/2 antibodies.'
p1615
aS'- known opportunistic infections including invasive fungal infections.'
p1616
aS'- known hypersensitivity to the imp or any of their formulation ingredients.'
p1617
aS'- any condition that is thought to reduce the compliance to cooperate with the trial procedures.'
p1618
aS'- employee of the department of the investigator, of the center for clinical studies (ccs) or of the sponsor.'
p1619
aS'- prior participation in this clinical trial.'
p1620
aS'- participation in an interventional clinical trial within the last three months (six months in case of a biological imp) or be under the exclusion period from another clinical trial.'
p1621
aS'- known or planned absence that may collide with the clinical trial visit schedule.'
p1622
asS'NCT02539368'
p1623
(lp1624
S'- 1. any reported contraindications for inflectra or remicade, according to the smpc.'
p1625
aS'- 2. known hypersensitivity (including severe, acute infusion reactions) to infliximab, its excipients or other murine proteins, at the time of enrolment.'
p1626
aS'- 3. prior history of failure to respond to remicade or inflectra.'
p1627
asS'NCT01479660'
p1628
(lp1629
S'- pregnant or lactating women'
p1630
aS'- any patient who has received probiotic in the preceding 4 weeks'
p1631
aS'- patient with life threatening cardiac, renal, pulmonary or cardiovascular disease'
p1632
aS'- inability to obtain the informed consent'
p1633
aS'- severe disease requiring hospitalization / steroids/ anti-cytokine therapy'
p1634
aS'- patient taking aspirin and other antiplatelet drugs'
p1635
aS'- patient with uncontrolled diabetes'
p1636
aS'- patient with gall stone disease'
p1637
aS'- patient currently on antibiotic,nsaids or indigenous medicine'
p1638
asS'NCT02647866'
p1639
(lp1640
S'- 1. subject, who, for any reason, is judged by the investigator to be inappropriate for this study;'
p1641
aS'- 2. subject has a medical history of other clinically significant diseases/disorders;'
p1642
aS"- 3. subject's uc had failed to respond to more than one biologic treatment (e.g., infliximab, adalimumab, or golimumab);"
p1643
aS'- 4. subject requires prescription treatment for uc, except for the stable, oral treatment of uc for 4 weeks prior to screening.'
p1644
aS'- 5. subject has received any of the following prior treatments or treatments within the specified time prior to the baseline visit:'
p1645
aS'- natalizumab, efalizumab, rituximab or other lymphocyte-depleting treatments, including but not limited, to alkylating agents (such as cyclophosphamide or chlorambucil) and total lymphoid irradiation at any time;'
p1646
aS'- tnf antagonists within 8 weeks, or 5 half-lives (up to 12 weeks);'
p1647
aS'- vedolizumab within 16 weeks;'
p1648
aS'- methotrexate, cyclosporine, mycophenolate, tacrolimus, thalidomide, or other immune altering drugs within 4 weeks (ophthalmologic preparations are permitted);'
p1649
aS'- 5-asa enema, steroid enema or suppository use within 2 weeks ; and/or'
p1650
aS'- investigational agents within 8 weeks or 5 half-lives (whichever is longer).'
p1651
aS'- 6. subject with recent, suspected or confirmed symptomatic stenosis of the colon, abdominal abscess, or ischemic colitis based on clinical or radiographic data; a history of toxic megacolon; or who had any previous surgery for uc;'
p1652
aS'- 7. subject with known colonic dysplasia, adenomas or polyposis;'
p1653
aS'- 8. subject had major surgery within 4 weeks prior to screening or an anticipated requirement for major surgery;'
p1654
aS'- 9. subject with enteric pathogens (including clostridium difficile);'
p1655
aS'- 10. subject with any of the following hematological and chemistry laboratory values:'
p1656
aS'- platelet count < 100,000/mm3;'
p1657
aS'- neutrophils < 1500/mm3;'
p1658
aS'- serum creatinine \xe2\x89\xa5 1.6 mg/dl (\xe2\x89\xa5 144.4 \xce\xbcmol/l);'
p1659
aS'- alkaline phosphatase > 3 times the upper limit of normal (uln);'
p1660
aS'- ast or alt > 2 times uln;'
p1661
aS"- total bilirubin > 2 mg/dl, unless due to gilbert's syndrome;"
p1662
aS'- serum albumin < 3 g/dl;'
p1663
aS'- hemoglobin < 9 g/dl;'
p1664
aS'- glycated serum hemoglobin a1c \xe2\x89\xa5 9%.'
p1665
aS'- 11. subject has clinically significant cardiac disease;'
p1666
aS'- 12. subject is pregnant or breastfeeding;'
p1667
aS'- 13. subject has had major immunologic reaction;'
p1668
aS'- 14. subject is hepatitis b core antibody or surface antigen positive and/or hepatitis c antibody positive with detectable rna;'
p1669
aS'- 15. subject has a history of human immunodeficiency virus (hiv) positivity, tests positive for hiv, or has congenital or acquired immunodeficiency;'
p1670
aS'- 16. subject has or has had active tb, suspected extra-pulmonary tb, a history of incompletely treated tb, or latent tb or other latent infection. subjects with latent tb (clinical findings, purified protein derivative [ppd] or interferon gamma release assay [igra]) may be included in the study if prophylactic therapy for latent tb is started at least 4 weeks prior to screening. subjects with a potentially untreated other infection (clinical findings) are to be excluded.'
p1671
aS'- 17. subject has bacterial infections requiring treatment with oral or parenteral antibiotics, within 2 and 4 weeks, respectively.'
p1672
aS'- 18. subject has a history of systemic opportunistic infection or recurrent infections'
p1673
aS'- 19. subject has malignancy or history of malignancy, except for adequately treated basal cell skin cancer or adequately treated carcinoma in-situ of the cervix without recurrence at least 5 years.'
p1674
aS'- 20. subject who received a bacille calmette-gu\xc3\xa9rin (bcg) vaccine within 6 months of randomization or live vaccination (e.g., measles, mumps, rubella [mmr]; herpes zoster; varicella, intranasal influenza; and oral poliomyelitis) within 4 weeks of randomization.'
p1675
aS'- 21. subject with a history of or active substance abuse.'
p1676
aS'- 22. subject has other severe acute or chronic medical or psychiatric condition or laboratory abnormality.'
p1677
asS'NCT02463045'
p1678
(lp1679
S'- healthy subjects and ulcerative colitis subjects'
p1680
aS'- participation in another study of investigational medication within the last 3 months or 5 half-lives of the investigational medication, whichever is longer'
p1681
aS'- positive for hiv 1/2 antibodies, hepatitis b surface antigen or hepatitis c antibodies'
p1682
aS'- any prescription or non-prescription medications within prior 14 days (other than ulcerative colitis for subjects in part 3 for whom a stable dose regimen of oral 5-asa (no more than 2.4g/day) for at least 4 weeks before day 1 is allowed and required)'
p1683
aS'- consumption of any products containing caffeine or xanthine-related substances, foods or beverages containing seville-type oranges or poppy seeds within 72 hours prior to admission'
p1684
aS"- any acute or chronic illness (other than ulcerative colitis in part 3) affecting the colon and/or rectum and/or anus, including haemorrhoids and irritable bowel syndrome, sufficient to cause symptoms and/or that in the judgement of the investigator and the sponsor's study physician/medical monitor would interfere with the subject's participation in the study"
p1685
aS'- cardiovascular or cerebrovascular disease, including hypertension, angina, ischemic heart disease, transient ischaemic attacks, stroke and peripheral arterial disease sufficient to cause symptoms and/or require therapy to maintain stable status'
p1686
aS'- abnormalities in haematology or ecg.'
p1687
aS'- renal or liver impairment'
p1688
aS'- active neoplastic disease or history of neoplastic disease within 5 years before screening specific to ulcerative colitis subjects'
p1689
aS'- documented history of ulcerative colitis in immediate need of dose escalation of maintenance 5-aminosalicylate therapy.'
p1690
aS'- proctitis at baseline endoscopy (on day 1).'
p1691
aS'- started oral 5-aminosalicylate within 4 weeks prior to baseline endoscopy or is not yet on a stable dose.'
p1692
aS'- any medication administered per rectum within 1 week prior to baseline endoscopy.'
p1693
aS'- oral or parenteral steroid within 2 weeks before the baseline endoscopy.'
p1694
aS'- systemic immunomodulatory therapy (with the exception of azathioprine or 6-mercaptopurine in a dose regimen that is deemed acceptable for participation in the judgement of the principal investigator) within 12 weeks prior to baseline endoscopy.'
p1695
aS'- previous treatment with biologic agents (including anti-tnf agents and vedolizumab) prior to baseline endoscopy.'
p1696
aS"- mayo score physician's global assessment of 3, i.e., severe disease."
p1697
asS'NCT01040910'
p1698
(lp1699
S'- 1. patients with a known mental disorder'
p1700
aS'- 2. patients who are deemed to be at a high risk of abuse or addiction to the study drug.'
p1701
aS'- 3. pregnant women'
p1702
aS'- 4. patients who are sensitive to any of the ingredients of the study medication.'
p1703
aS'- 5. patients who are unable to give informed consent.'
p1704
aS'- 6. patients who may need surgery in the near future.'
p1705
asS'NCT02093663'
p1706
(lp1707
S'- 1. severe uc (defined by pga=3).'
p1708
aS"- 2. crohn's disease, bleeding disorders, active peptic ulcer disease, or uc known to be confined to the rectum (isolated rectal proctitis)."
p1709
aS'- 3. asthma, only if known to be 5 asa sensitive.'
p1710
aS'- 4. positive stool culture for enteric pathogens (including salmonella, shigella, yersinia, aeromonas, plesiomonas, or campylobacter). clostridium difficile toxin, ova, or parasites present.'
p1711
aS'- 5. systemic or rectal corticosteroid use within 4 weeks prior to the screening visit. topical, intranasal, or inhaled use is not exclusionary.'
p1712
aS'- 6. immunomodulator (6-mercaptopurine, azathioprine) use within 6 weeks prior to the screening visit.'
p1713
aS'- 7. history of biologic (eg, anti-tumor necrosis factor agents, integrin receptor antagonists) use at any time.'
p1714
aS'- 8. antibiotic use within 7 days prior to the screening visit.'
p1715
aS'- 9. any anti-inflammatory drugs, not including 5-asa treatment but including non-steroidal anti-inflammatory drugs such as aspirin, cox-2 inhibitors or ibuprofen, within 7 days prior to the screening visit unless used at over-the-counter levels for <3 days. however, prophylactic use of a stable dose of aspirin up to 325mg/day for cardiac disease is permitted.'
p1716
aS'- 10. prebiotic/probiotic use within 7 days prior to the screening visit. yogurt products are permitted.'
p1717
asS'NCT01914887'
p1718
(lp1719
S'- mental disability that impedes adequate understanding of the study and of the associated procedures'
p1720
aS'- extensive colitis'
p1721
aS'- patients with an impaired general state which requires, according to the investigator judgment, immediate treatment with corticosteroids and/or anti-tumor necrosis factor (tnf) and/or surgery'
p1722
aS'- patients that fulfill criteria of corticodependency and in ongoing treatment with corticosteroids'
p1723
aS'- patients with previous colectomies'
p1724
aS'- known history of alcohol or other addictive substances abuse'
p1725
aS'- history of malignant disease - patients having participated in clinical trials with any investigational drug within 6 months prior to enrolment in this study'
p1726
aS"- patients with known allergies to penicillin, gentamicin, aminoglycosides, human serum albumin (hsa), dulbecco's modified eagle medium (dmem), or materials of bovine origin"
p1727
aS'- pregnant or breastfeeding women'
p1728
aS'- presence of severe concomitant diseases'
p1729
aS'- patients with suspicion of crohn?s enterocolitis, indeterminate colitis, ischaemic colitis, radiation colitis, diverticular disease associated colitis, or microscopic colitis'
p1730
asS'NCT02435992'
p1731
(lp1732
S"- diagnosis of crohn's disease or indeterminate colitis or the presence or history of a fistula consistent with crohn's disease or microscopic colitis or radiation colitis or ischemic colitis"
p1733
aS'- clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk'
p1734
aS'- history of uveitis macular edema'
p1735
aS'- pregnancy, lactation, or a positive serum \xce\xb2-human chorionic gonadotropin (\xce\xb2-hcg) measured during screening'
p1736
asS'NCT02186886'
p1737
(lp1738
S'- cancer'
p1739
aS'- type one diabetes'
p1740
aS'- current infection and/or inflammation other than related to ulcerative colitis'
p1741
aS'- autoimmune diseases'
p1742
aS'- any contraindications stated by golimumab product label'
p1743
asS'NCT02665845'
p1744
(lp1745
S'- pregnant women'
p1746
aS'- allergy / unable to take prednisone / hydrocortisone/ 5-asa.'
p1747
aS'- active infection - either enteric or elsewhere'
p1748
aS'- severe renal, liver or cardio respiratory comorbidity'
p1749
aS'- toxic megacolon, or clinical features suggestive of a need for imminent colectomy'
p1750
aS'- treatment with an anti-tnf within the prior 3 months'
p1751
aS'- prior treatment with cyclosporine or tacrolimus within the prior 3 months'
p1752
aS'- alcohol dependency'
p1753
aS'- unable or unwilling to provide informed consent'
p1754
aS'- participating in other clinical trial within the 2 months prior to admission'
p1755
asg88
(lp1756
S'- diagnosed as uc first time. no history of using biologic,immunomodulatory therapy or corticosteroid therapy. with contraindication of endoscopy.'
p1757
asS'NCT02033408'
p1758
(lp1759
S'- change in dose or intervals of anti-tnf within the past 2 months prior to admission.'
p1760
aS'- disease confined to the rectum (proctitis).'
p1761
aS'- antibiotic use in the past 4 weeks.'
p1762
aS'- any known erosive inflammation anywhere in the small bowel or esophagus.'
p1763
aS'- any proven infection such as positive stool culture, parasite or c. difficile, urinary tract infection, cellulitis, abscess, pneumonia, line-infections etc.'
p1764
aS'- fever >38.5, or >38.0c thought to be unrelated to the inflammatory process of active uc.'
p1765
aS'- the probable need for second line medical therapy (infliximab, cyclosporine, tacrolimus) or colectomy within 5 days of enrollment, as judged by the caring physician.'
p1766
aS'- known allergy to more than one antibiotic regimen from the list below.'
p1767
aS'- pregnancy.'
p1768
asS'NCT02118584'
p1769
(lp1770
S'- part 1 (open-label extension)'
p1771
aS'- any new, significant, uncontrolled condition part 2 (safety monitoring)'
p1772
aS'- no exclusion criteria'
p1773
asS'NCT02465385'
p1774
(lp1775
S'- prisoner'
p1776
aS'- woman who is currently pregnant or breastfeeding'
p1777
aS'- allergy to linaclotide'
p1778
aS'- patients with known or suspected mechanical gastrointestinal obstruction'
p1779
asS'NCT00309660'
p1780
(lp1781
S'- age < 18 years'
p1782
aS'- severe ulcerative colitis'
p1783
aS'- systemic treatment with steroids or azathioprin within the last 3 month'
p1784
aS'- known liver or kidney disease'
p1785
aS'- severe heart failure'
p1786
aS'- pregnancy or breast feeding'
p1787
asS'NCT00606346'
p1788
(lp1789
S"- c0168z02: 17 years of age or older, with the exception of patients who participated in the sponsor's conducted pediatric ibd clinical trials. have other crohn's-like diseases that are associated with genetic diseases (eg, glycogen storage disease). the patient and parent/guardian are not able to adhere to the protocol requirements. are participating in any clinical trial for an investigational agent that is not commercially available. remicadepib4002 and remicadepib4003: less than 6 years of age or 17 years of age or older."
p1790
assS'colitis-Drug'
p1791
(dp1792
g1639
(lp1793
S'- 1. subject, who, for any reason, is judged by the investigator to be inappropriate for this study;'
p1794
aS'- 2. subject has a medical history of other clinically significant diseases/disorders;'
p1795
aS"- 3. subject's uc had failed to respond to more than one biologic treatment (e.g., infliximab, adalimumab, or golimumab);"
p1796
aS'- 4. subject requires prescription treatment for uc, except for the stable, oral treatment of uc for 4 weeks prior to screening.'
p1797
aS'- 5. subject has received any of the following prior treatments or treatments within the specified time prior to the baseline visit:'
p1798
aS'- natalizumab, efalizumab, rituximab or other lymphocyte-depleting treatments, including but not limited, to alkylating agents (such as cyclophosphamide or chlorambucil) and total lymphoid irradiation at any time;'
p1799
aS'- tnf antagonists within 8 weeks, or 5 half-lives (up to 12 weeks);'
p1800
aS'- vedolizumab within 16 weeks;'
p1801
aS'- methotrexate, cyclosporine, mycophenolate, tacrolimus, thalidomide, or other immune altering drugs within 4 weeks (ophthalmologic preparations are permitted);'
p1802
aS'- 5-asa enema, steroid enema or suppository use within 2 weeks ; and/or'
p1803
aS'- investigational agents within 8 weeks or 5 half-lives (whichever is longer).'
p1804
aS'- 6. subject with recent, suspected or confirmed symptomatic stenosis of the colon, abdominal abscess, or ischemic colitis based on clinical or radiographic data; a history of toxic megacolon; or who had any previous surgery for uc;'
p1805
aS'- 7. subject with known colonic dysplasia, adenomas or polyposis;'
p1806
aS'- 8. subject had major surgery within 4 weeks prior to screening or an anticipated requirement for major surgery;'
p1807
aS'- 9. subject with enteric pathogens (including clostridium difficile);'
p1808
aS'- 10. subject with any of the following hematological and chemistry laboratory values:'
p1809
aS'- platelet count < 100,000/mm3;'
p1810
aS'- neutrophils < 1500/mm3;'
p1811
aS'- serum creatinine \xe2\x89\xa5 1.6 mg/dl (\xe2\x89\xa5 144.4 \xce\xbcmol/l);'
p1812
aS'- alkaline phosphatase > 3 times the upper limit of normal (uln);'
p1813
aS'- ast or alt > 2 times uln;'
p1814
aS"- total bilirubin > 2 mg/dl, unless due to gilbert's syndrome;"
p1815
aS'- serum albumin < 3 g/dl;'
p1816
aS'- hemoglobin < 9 g/dl;'
p1817
aS'- glycated serum hemoglobin a1c \xe2\x89\xa5 9%.'
p1818
aS'- 11. subject has clinically significant cardiac disease;'
p1819
aS'- 12. subject is pregnant or breastfeeding;'
p1820
aS'- 13. subject has had major immunologic reaction;'
p1821
aS'- 14. subject is hepatitis b core antibody or surface antigen positive and/or hepatitis c antibody positive with detectable rna;'
p1822
aS'- 15. subject has a history of human immunodeficiency virus (hiv) positivity, tests positive for hiv, or has congenital or acquired immunodeficiency;'
p1823
aS'- 16. subject has or has had active tb, suspected extra-pulmonary tb, a history of incompletely treated tb, or latent tb or other latent infection. subjects with latent tb (clinical findings, purified protein derivative [ppd] or interferon gamma release assay [igra]) may be included in the study if prophylactic therapy for latent tb is started at least 4 weeks prior to screening. subjects with a potentially untreated other infection (clinical findings) are to be excluded.'
p1824
aS'- 17. subject has bacterial infections requiring treatment with oral or parenteral antibiotics, within 2 and 4 weeks, respectively.'
p1825
aS'- 18. subject has a history of systemic opportunistic infection or recurrent infections'
p1826
aS'- 19. subject has malignancy or history of malignancy, except for adequately treated basal cell skin cancer or adequately treated carcinoma in-situ of the cervix without recurrence at least 5 years.'
p1827
aS'- 20. subject who received a bacille calmette-gu\xc3\xa9rin (bcg) vaccine within 6 months of randomization or live vaccination (e.g., measles, mumps, rubella [mmr]; herpes zoster; varicella, intranasal influenza; and oral poliomyelitis) within 4 weeks of randomization.'
p1828
aS'- 21. subject with a history of or active substance abuse.'
p1829
aS'- 22. subject has other severe acute or chronic medical or psychiatric condition or laboratory abnormality.'
p1830
assS'complications of surgical procedures-Procedure'
p1831
(dp1832
g290
(lp1833
S'- pregnant woman or lactating woman.'
p1834
aS'- with confirmed distant metastasis in liver, lung, bones, or other organs.'
p1835
aS'- intolerable laparoscopic operation or converted to open surgery.'
p1836
aS'- with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.'
p1837
aS'- with bad compliance or contraindication to enrollment.'
p1838
assS"perianal crohn's disease-Drug"
p1839
(dp1840
sS'stroke-Behavioral'
p1841
(dp1842
sS'gastrointestinal bleeding-Drug'
p1843
(dp1844
g1774
(lp1845
S'- prisoner'
p1846
aS'- woman who is currently pregnant or breastfeeding'
p1847
aS'- allergy to linaclotide'
p1848
aS'- patients with known or suspected mechanical gastrointestinal obstruction'
p1849
assS'healthy volunteer-Other'
p1850
(dp1851
g371
(lp1852
S'- for iads patients'
p1853
aS'- unauthorized treatment (anticancer chemotherapy)'
p1854
aS'- for healthy volunteers'
p1855
aS'- contra-indications for donating blood except from age'
p1856
aS'- known history of iad (eg: psoriasis)'
p1857
aS'- common exclusion criteria:'
p1858
aS'- pregnant woman'
p1859
aS'- still under the exclusion period from another biomedical study'
p1860
aS'- psychiatric or addiction pathology who could interfere with the ability to fulfill the protocol needs or to provide an informed consent'
p1861
aS'- patient under a legal protection'
p1862
aS'- chronic lifelong viral infection unrelated to the pathology'
p1863
aS'- mild infection within the last 3 months'
p1864
assS"crohn's disease-Behavioral"
p1865
(dp1866
g530
(lp1867
S'- diagnosis of pervasive developmental disorder in patient or parent'
p1868
aS'- diagnosis of serious mental illness (e.g., schizophrenia) in patient or parent'
p1869
asS'NCT00290524'
p1870
(lp1871
S'- class asa iv or v patient'
p1872
aS'- documented problem of gastro-intestinal motility'
p1873
aS'- pregnancy'
p1874
aS'- any acute or recent (<10 days) septic event'
p1875
aS'- chemotherapy during the 4 weeks preceding surgery'
p1876
aS'- previous irradiation surrounding the planned anastomosis location'
p1877
aS'- small intestine iatrogenic transparietal laceration done during surgery'
p1878
aS'- small intestine synchrone resection without continuity with the colon'
p1879
aS'- intra-peritoneal chemotherapy administered during or following surgery'
p1880
aS'- presence of residual peritoneal carcinosis at the end of surgery'
p1881
aS'- colic surgery associated with another major intra-abdominal surgery'
p1882
aS'- creation of a colo-anal or ileo-anal anastomosis'
p1883
aS'- any per-surgery discovery which requires the use of a gastric drainage procedure following surgery'
p1884
aS'- any post-surgery change in patient condition which requires naso-gastric tube holding after surgery'
p1885
asg544
(lp1886
S'- insufficient danish language skills'
p1887
aS'- lack of intellectual capacity'
p1888
aS'- growth retardation'
p1889
asg117
(lp1890
S'- refusal to give necessary oral or written informed consent by patient and/or parent (legal caregiver)'
p1891
aS'- not aged 7 through 20 at start of study'
p1892
aS'- not willing and able to volunteer in the study'
p1893
aS'- has sibling enrolled in this study'
p1894
aS'- has severe physical diseases of the locomotor apparatus, psychotic disorders, severe affective disorders, eating disorders, mental retardation, autism spectrum disorder'
p1895
aS'- inability to communicate and complete questionnaires in german'
p1896
aS'- does not own a functional and nintendo wii-compatible television at home'
p1897
aS'- among female adolescents, pregnancy, breastfeeding or intention to get pregnant during the study'
p1898
aS'- has clinically significant cardiovascular disease'
p1899
aS'- enrolment of the investigator, his/her family members, employees and other dependent persons'
p1900
asS'NCT02084290'
p1901
(lp1902
S"- participant in a pilot study/focus group for development of crohn's shared decision making program"
p1903
aS'- currently taking any medication that is contraindicated to take together with an immunomodulator or anti-tnf agent'
p1904
aS'- known intolerance to either immunomodulators or anti-tnf agents'
p1905
aS'- lack of accessibility to e-mail for follow-up surveys'
p1906
asg549
(lp1907
S'- pregnancy or plans to be pregnant'
p1908
aS'- inability to make own health care decisions'
p1909
aS'- inability to participate in the study phone calls'
p1910
aS'- uncontrolled psychiatric illness'
p1911
aS'- enrollment in another clinical trial outside of the standard clinic ibd registry'
p1912
asg129
(lp1913
S'- ibd patients with parental report of mental retardation'
p1914
aS'- ibd patients receiving psychopharmacological treatment (antidepressants or benzodiazepines) for depression or anxiety'
p1915
aS'- no mastery of the dutch language'
p1916
aS'- ibd patients with diagnosed: bipolar disorder, schizophrenia/psychotic disorder, autism spectrum disorders, obsessive-compulsive disorder, posttraumatic stress disorder/acute stress disorder, or substance use disorder'
p1917
aS'- physician reported substance abuse (alcohol, drugs) in the past month'
p1918
aS'- clinician reported selective mutism'
p1919
aS'- ibd patients already participating in an (psychological of psychopharmacological) intervention study'
p1920
aS'- ibd patients who received 8 sessions of manualized cognitive behavioral therapy last year'
p1921
aS'- current psychological treatment'
p1922
assS"ulcerative colitis and crohn's disease-Other"
p1923
(dp1924
g487
(lp1925
S'- 1. the participant is enrolled in a clinical trial in which treatment for cd or uc is managed through a protocol.'
p1926
aS'- 2. prior treatment with vedolizumab.'
p1927
aS"- 3. any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study."
p1928
assS'abscess-Other'
p1929
(dp1930
g743
(lp1931
S'- any of inclusion criteria is not met;'
p1932
aS'- females who are pregnant or breast feeding;'
p1933
aS'- anti-tnf use within 6 weeks prior to study entry;'
p1934
aS'- patients who cannot take, or refuse to take concomitant immunosuppressive therapy with either azathioprine, 6-mercaptopurine, or methotrexate; unless patient has been intolerant of these therapies in the past or is contraindicated as determined by the investigator.'
p1935
aS'- patients who cannot take, or refuse to take concomitant antibiotic therapy;'
p1936
aS'- patients with severe anal stenosis or tenderness which would preclude colonoscopy and / or rectal eus;'
p1937
aS'- patients who cannot take or refuse to take certolizumab;'
p1938
aS'- patients with active or latent tuberculosis;'
p1939
aS"- patients who have had systemic antibiotic, antiviral or antifungal treatment(s) within 3 weeks prior to screening for all non-crohn's related infections;"
p1940
aS'- patients concurrently taking anakinra (kineret);'
p1941
aS'- patients with a history of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinomain-situ of the cervix;'
p1942
aS'- patients with chronic hematologic problems such as bleeding dyscrasias;'
p1943
aS'- patients with a history of demyelinating disease (i.e. multiple sclerosis); and'
p1944
aS'- patients with congestive heart failure'
p1945
assS'hepatitis b, chronic-Other'
p1946
(dp1947
g237
(lp1948
S'- lack of consent'
p1949
aS'- patients with evidence of other chronic liver disease,metabolic syndrome, men consuming more than 30 g of alcohol per day and women consuming more than 20 g of alcohol per day, patients with liver decompensation, hcc, previous liver surgery or liver transplantation'
p1950
assS"crohn's disease, active-Other"
p1951
(dp1952
S'NCT02421705'
p1953
(lp1954
S'- for all groups:'
p1955
aS'- 1. co-morbidity: severe kidney- and/or liver disease or thyroid abnormalities and impaired clotting'
p1956
aS'- 2. abdominal chirurgy (except for an uncomplicated appendectomy)'
p1957
assS'exacerbation of ulcerative colitis-Drug'
p1958
(dp1959
g1758
(lp1960
S'- change in dose or intervals of anti-tnf within the past 2 months prior to admission.'
p1961
aS'- disease confined to the rectum (proctitis).'
p1962
aS'- antibiotic use in the past 4 weeks.'
p1963
aS'- any known erosive inflammation anywhere in the small bowel or esophagus.'
p1964
aS'- any proven infection such as positive stool culture, parasite or c. difficile, urinary tract infection, cellulitis, abscess, pneumonia, line-infections etc.'
p1965
aS'- fever >38.5, or >38.0c thought to be unrelated to the inflammatory process of active uc.'
p1966
aS'- the probable need for second line medical therapy (infliximab, cyclosporine, tacrolimus) or colectomy within 5 days of enrollment, as judged by the caring physician.'
p1967
aS'- known allergy to more than one antibiotic regimen from the list below.'
p1968
aS'- pregnancy.'
p1969
assS'systemic lupus erythematosus/antiphospholipid syndrome-Other'
p1970
(dp1971
g371
(lp1972
S'- for iads patients'
p1973
aS'- unauthorized treatment (anticancer chemotherapy)'
p1974
aS'- for healthy volunteers'
p1975
aS'- contra-indications for donating blood except from age'
p1976
aS'- known history of iad (eg: psoriasis)'
p1977
aS'- common exclusion criteria:'
p1978
aS'- pregnant woman'
p1979
aS'- still under the exclusion period from another biomedical study'
p1980
aS'- psychiatric or addiction pathology who could interfere with the ability to fulfill the protocol needs or to provide an informed consent'
p1981
aS'- patient under a legal protection'
p1982
aS'- chronic lifelong viral infection unrelated to the pathology'
p1983
aS'- mild infection within the last 3 months'
p1984
assS'intestinal diseases-Drug'
p1985
(dp1986
g1639
(lp1987
S'- 1. subject, who, for any reason, is judged by the investigator to be inappropriate for this study;'
p1988
aS'- 2. subject has a medical history of other clinically significant diseases/disorders;'
p1989
aS"- 3. subject's uc had failed to respond to more than one biologic treatment (e.g., infliximab, adalimumab, or golimumab);"
p1990
aS'- 4. subject requires prescription treatment for uc, except for the stable, oral treatment of uc for 4 weeks prior to screening.'
p1991
aS'- 5. subject has received any of the following prior treatments or treatments within the specified time prior to the baseline visit:'
p1992
aS'- natalizumab, efalizumab, rituximab or other lymphocyte-depleting treatments, including but not limited, to alkylating agents (such as cyclophosphamide or chlorambucil) and total lymphoid irradiation at any time;'
p1993
aS'- tnf antagonists within 8 weeks, or 5 half-lives (up to 12 weeks);'
p1994
aS'- vedolizumab within 16 weeks;'
p1995
aS'- methotrexate, cyclosporine, mycophenolate, tacrolimus, thalidomide, or other immune altering drugs within 4 weeks (ophthalmologic preparations are permitted);'
p1996
aS'- 5-asa enema, steroid enema or suppository use within 2 weeks ; and/or'
p1997
aS'- investigational agents within 8 weeks or 5 half-lives (whichever is longer).'
p1998
aS'- 6. subject with recent, suspected or confirmed symptomatic stenosis of the colon, abdominal abscess, or ischemic colitis based on clinical or radiographic data; a history of toxic megacolon; or who had any previous surgery for uc;'
p1999
aS'- 7. subject with known colonic dysplasia, adenomas or polyposis;'
p2000
aS'- 8. subject had major surgery within 4 weeks prior to screening or an anticipated requirement for major surgery;'
p2001
aS'- 9. subject with enteric pathogens (including clostridium difficile);'
p2002
aS'- 10. subject with any of the following hematological and chemistry laboratory values:'
p2003
aS'- platelet count < 100,000/mm3;'
p2004
aS'- neutrophils < 1500/mm3;'
p2005
aS'- serum creatinine \xe2\x89\xa5 1.6 mg/dl (\xe2\x89\xa5 144.4 \xce\xbcmol/l);'
p2006
aS'- alkaline phosphatase > 3 times the upper limit of normal (uln);'
p2007
aS'- ast or alt > 2 times uln;'
p2008
aS"- total bilirubin > 2 mg/dl, unless due to gilbert's syndrome;"
p2009
aS'- serum albumin < 3 g/dl;'
p2010
aS'- hemoglobin < 9 g/dl;'
p2011
aS'- glycated serum hemoglobin a1c \xe2\x89\xa5 9%.'
p2012
aS'- 11. subject has clinically significant cardiac disease;'
p2013
aS'- 12. subject is pregnant or breastfeeding;'
p2014
aS'- 13. subject has had major immunologic reaction;'
p2015
aS'- 14. subject is hepatitis b core antibody or surface antigen positive and/or hepatitis c antibody positive with detectable rna;'
p2016
aS'- 15. subject has a history of human immunodeficiency virus (hiv) positivity, tests positive for hiv, or has congenital or acquired immunodeficiency;'
p2017
aS'- 16. subject has or has had active tb, suspected extra-pulmonary tb, a history of incompletely treated tb, or latent tb or other latent infection. subjects with latent tb (clinical findings, purified protein derivative [ppd] or interferon gamma release assay [igra]) may be included in the study if prophylactic therapy for latent tb is started at least 4 weeks prior to screening. subjects with a potentially untreated other infection (clinical findings) are to be excluded.'
p2018
aS'- 17. subject has bacterial infections requiring treatment with oral or parenteral antibiotics, within 2 and 4 weeks, respectively.'
p2019
aS'- 18. subject has a history of systemic opportunistic infection or recurrent infections'
p2020
aS'- 19. subject has malignancy or history of malignancy, except for adequately treated basal cell skin cancer or adequately treated carcinoma in-situ of the cervix without recurrence at least 5 years.'
p2021
aS'- 20. subject who received a bacille calmette-gu\xc3\xa9rin (bcg) vaccine within 6 months of randomization or live vaccination (e.g., measles, mumps, rubella [mmr]; herpes zoster; varicella, intranasal influenza; and oral poliomyelitis) within 4 weeks of randomization.'
p2022
aS'- 21. subject with a history of or active substance abuse.'
p2023
aS'- 22. subject has other severe acute or chronic medical or psychiatric condition or laboratory abnormality.'
p2024
asS'NCT02044952'
p2025
(lp2026
S'- bacterial, viral or other microbial infection(including hiv).'
p2027
aS'- orally administered corticosteroids within 3 weeks before enrollment, inhaled or dermatologic preparations for the treatment of other diseases are acceptable.'
p2028
aS'- used of infliximab or immunosuppressant within 2 months before enrollment.'
p2029
aS'- previous use of prescription doses of nsaids without efficacy.'
p2030
aS'- treatment with narcotic pain medications(anti-diarrheal agents such as loperamide and diphenoxylate are permitted).'
p2031
aS'- history of pancreatitis, except for subjects with a known but removed cause(such as gallstone pancreatitis).'
p2032
aS'- history of abnormal liver function tests, including ast or alt >1.5 times upper limit of normal, alkaline phosphatase >2 times upper limit of normal, total bilirubin >2.5 mg/dl at screening (or within the previous 6 months, if known).'
p2033
aS'- history of malignancy.'
p2034
aS'- women who are pregnant or lactating at the time of enrollment, or who intend to be during the study period.'
p2035
aS'- participation in other clinical trial within the past 3 months.'
p2036
assS'necrotizing enterocolitis (nec)-Dietary Supplement'
p2037
(dp2038
g592
(lp2039
S'- 1. infant with birth weight > 1250g;'
p2040
aS'- 2. infant with colostomy;'
p2041
aS'- 3. infants with enterostomy but'
p2042
aS'- unable to obtain written informed consent from parent;'
p2043
aS'- presence of congenital liver, renal, or metabolic diseases or syndromes or perinatal asphyxia;'
p2044
aS'- ostomy caused by surgical treatment for a condition other than nec or small intestine perforation; and'
p2045
aS'- unable to initiate enteral feeding for more than 28 days since ostomy placement.'
p2046
assS'ulcerative colitis-Biological'
p2047
(dp2048
S'NCT02487238'
p2049
(lp2050
S'- active participation in another therapeutic trial'
p2051
aS'- unable to give informed consent, or assent'
p2052
aS'- active clostridium difficile infection'
p2053
aS'- significant change in medication dose or treatment modality within preceding 12 weeks of start of trial'
p2054
aS'- new treatments or significant change in medication dosing during trial'
p2055
aS'- significant, consecutive rise in pucai score during trial'
p2056
aS'- hospitalization during trial'
p2057
asS'NCT02330653'
p2058
(lp2059
S'- 1. patients in a clinical remission (pucai < 9).'
p2060
aS'- 2. patients considered to have toxic megacolon.'
p2061
aS'- 3. treatment na\xc3\xafve patients, i.e., patients must be intolerant to or not have responded to aminosalicylates.'
p2062
aS'- 4. patients with a known drug allergy to vancomycin, metronidazole or polymyxin.'
p2063
aS'- 5. patients with a history of aspiration, gastroparesis, surgery involving the upper gastrointestinal tract (that might affect upper gastrointestinal motility) or unable to swallow pills.'
p2064
aS'- 6. patients with esophageal dysmotility or swallowing dysfunction.'
p2065
aS'- 7. patients with known food allergies.'
p2066
aS'- 8. patients with positive test results for hbv, hcv, or hiv.'
p2067
aS'- 9. female patients with a positive test result on a urine hcg test.'
p2068
aS'- 10. patients unwilling or unable to give consent or participate in all study requirements.'
p2069
aS'- 11. patients unable or unwilling to receive a retention enema for purposes of induction therapy'
p2070
aS'- 12. children with recent (within 4 weeks) dose change of biologics, 5-asa, steroids or immunomodulators'
p2071
asS'NCT02575040'
p2072
(lp2073
S'- no informed consent'
p2074
aS'- non active inflammatory bowel disease.'
p2075
aS'- active infection in either the donor or the recipient,'
p2076
aS'- response to biological agents'
p2077
asS'NCT01671956'
p2078
(lp2079
S'- 1. history of colonic or rectal surgery other than hemorrhoidal surgery or appendectomy.'
p2080
aS'- 2. currently receiving total parenteral nutrition (tpn).'
p2081
aS'- 3. positive clostridium difficile toxin stool assay.'
p2082
aS'- 4. tested positive for active/latent mycobacterium tuberculosis (tb) infection.'
p2083
aS'- 5. pregnant or breast-feeding, or plan to become pregnant during the study.'
p2084
aS'- 6. males who are young and childless or planning to have more children in the future.'
p2085
aS'- 7. known hypersensitivity to bertilimumab or any of the drug excipients.'
p2086
aS'- 8. history of infection requiring administration of any iv antibiotic, antiviral or antifungal medication within 30 days of screening or any oral anti-infective agent within 14 days of screening.'
p2087
aS'- 9. severe uc evidenced by the following signs of toxicity: heart rate >100 beats/min at rest, temperature >37.8\xc2\xb0c, hemoglobin <10.0 g/dl.'
p2088
aS'- 10. ulcerative proctitis, defined as disease limited to less than 15 cm from the anal verge.'
p2089
aS'- 11. received a vaccine or other immunostimulator within 4 weeks prior to screening.'
p2090
aS'- 12. use of >4.8 g mesalazine or equivalent within 2 weeks prior to the screening visit. mesalazine \xe2\x89\xa44.8 g is allowed if the dose during the 2 weeks prior to the screening visit was stable.'
p2091
aS'- 13. use of systemic corticosteroids exceeding the equivalent of 20 mg/day of prednisone within four weeks prior to the screening visit (see section 6.9.1).'
p2092
aS'- 14. change in dose of immunosuppressive drugs (e.g., corticosteroids, 6-mercaptopurine [6-mp], azathioprine) within four weeks prior to the screening visit.'
p2093
aS'- 15. use of tnf-blockers (e.g., infliximab or adalimumab) within 60 days of the screening visit.'
p2094
aS'- 16. use of chronic non-steroidal anti-inflammatory (nsaid) therapy. occasional use of nsaids or acetaminophen for headache, arthritis, myalgias, menstrual cramps, etc., or daily use of low dose (81-162 mg) aspirin for cardiovascular prophylaxis is allowed.'
p2095
aS'- 17. patients diagnosed with:'
p2096
aS"- crohn's disease"
p2097
aS'- diverticulitis or diverticulosis'
p2098
aS"- indeterminate colitis (inability to distinguish between uc and crohn's disease [as assessed by the investigator])"
p2099
aS'- microscopic colitis (collagenous or lymphocytic colitis)'
p2100
aS'- ischemic or infectious colitis'
p2101
aS'- clostridium difficile colitis within 90 days of the screening visit'
p2102
aS'- parasitic disease within 90 days of the screening visit'
p2103
aS'- systemic fungal infection within 90 days of the screening visit.'
p2104
aS'- 18. history of positive serology of hepatitis b or c, or human immunodeficiency virus (hiv) infection.'
p2105
aS'- 19. congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, organ transplantation).'
p2106
aS'- 20. clinically significant abnormal laboratory test results, unless regarded by the investigator as related to uc, including but not limited to:'
p2107
aS'- hemoglobin level <10.0 g/dl'
p2108
aS'- white blood cell count < 3 x 103/\xc2\xb5l'
p2109
aS'- lymphocyte count < 0.5 x 103/\xc2\xb5l'
p2110
aS'- platelet count <100 x 103/\xc2\xb5l or >1200 x 103/\xc2\xb5l'
p2111
aS'- alanine aminotransferase (alt) or aspartate aminotransferase (ast) >3 the upper limit of normal (uln)'
p2112
aS'- alkaline phosphatase >3 uln'
p2113
aS'- serum creatinine >2 uln.'
p2114
aS'- 21. active abuse of alcohol or drugs.'
p2115
aS'- 22. known malignancy or history of malignancy that could reduce life expectancy.'
p2116
aS'- 23. any condition, which in the opinion of the investigator, would place the patient at an unacceptable risk if participating in the study protocol.'
p2117
aS'- 24. participation in a clinical trial of an investigational (unapproved) product'
p2118
asS'NCT02636517'
p2119
(lp2120
S'- 1. patients <3 years old'
p2121
aS'- 2. patients with other co-morbid intestinal infectious processes'
p2122
aS'- 3. patients will be excluded if on immunosuppressive therapy within 2 weeks of fmt. clinical care will not be adjusted in order to meet criteria of this study.'
p2123
aS'- 4. patients currently receiving chemotherapy'
p2124
aS'- 5. recipients with a history of severe (anaphylactic) food allergy'
p2125
aS'- 6. if female, participants of childbearing potential (females aged 11 and older or those who have already begun menstruating) will be required to have a urine pregnancy test on the day of the fmt procedure. patients who are pregnant will not be enrolled.'
p2126
asg1001
(lp2127
S'- for the uc/cd prospective cohort:'
p2128
aS'- 1. is greater than (>) 19 completed weeks gestation prior to enrollment,'
p2129
aS'- 2. has first contact with otis after prenatal diagnosis of any major structural defect,'
p2130
aS'- 3. has enrolled in this registry with a previous pregnancy,'
p2131
aS"- 4. has had an exposure to the known or suspected human teratogens: chlorambucil. cyclophosphamide, mycophenylate mofetil. for the 'no chronic disease' prospective cohort:"
p2132
aS'- 5. is >19 completed weeks gestation prior to enrollment,'
p2133
aS'- 6. has first contact with otis after prenatal diagnosis of any major structural defect,'
p2134
aS'- 7. has enrolled in this registry with a previous pregnancy,'
p2135
aS'- 8. has had an exposure to the known or suspected human teratogens: chlorambucil, cyclophosphamide, mycophenylate mofetil. note: women exposed to entyvio during pregnancy but not meeting the above criteria can enroll into the entyvio pregnancy exposure case series component of this registry.'
p2136
asS'NCT02291523'
p2137
(lp2138
S'- 1. children who are known to be resistant to steroid therapy, immunomodulators or biologics, or on a steroid dose greater than 0.5 mg/kg/day (maximum 20 mg)'
p2139
aS'- 2. children with recent dose change of biologics (within 8 weeks), 5-asa, steroids or immunomodulators (within 4 weeks)'
p2140
aS'- 3. allergy to pentasa or other 5-asa products.'
p2141
aS'- 4. any evidence of infectious colitis'
p2142
aS'- 5. concurrent infections that require anti-microbial therapy (such as abdominal abscess, pneumonia, etc\xe2\x80\xa6)'
p2143
aS'- 6. unable to give informed consent/assent'
p2144
aS'- 7. have received probiotic preparations at least 4 weeks prior to randomization'
p2145
aS'- 8. pregnancy in subjects with childbearing potential (a pregnancy test will be performed on the day of colonoscopy).'
p2146
asS'NCT02442037'
p2147
(lp2148
S'- patient with associated diseases such as diabetes mellitus, hypertension, dyslipidemia, atherosclerosis and malabsorption syndrome.'
p2149
aS"- with autoimmune diseases (lupus, hiv, cancer and hepatitis), colitis (infectious, post-radiation, post-drug, indeterminate) and crohn's disease."
p2150
aS'- abnormal hepatic or renal function'
p2151
aS'- prior history of malignancy'
p2152
aS'- pregnant or unwilling to practice contraceptive therapy or breast feeding females'
p2153
asS'NCT02318667'
p2154
(lp2155
S'- history of asthma'
p2156
aS'- history of autoimmune diseases'
p2157
aS'- history of hypertension'
p2158
asg1788
(lp2159
S"- c0168z02: 17 years of age or older, with the exception of patients who participated in the sponsor's conducted pediatric ibd clinical trials. have other crohn's-like diseases that are associated with genetic diseases (eg, glycogen storage disease). the patient and parent/guardian are not able to adhere to the protocol requirements. are participating in any clinical trial for an investigational agent that is not commercially available. remicadepib4002 and remicadepib4003: less than 6 years of age or 17 years of age or older."
p2160
asS'NCT02065557'
p2161
(lp2162
S"- subject with crohn's disease (cd) or indeterminate colitis (ic)."
p2163
aS'- current diagnosis of fulminant colitis and/or toxic megacolon.'
p2164
aS'- subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.'
p2165
aS'- chronic recurring infections or active tuberculosis (tb).'
p2166
asS'NCT02520284'
p2167
(lp2168
S"- diagnose of crohn's disease or indeterminate colitis"
p2169
aS'- pregnant or lactating females'
p2170
aS'- any chronic medical condition (including, but not limited to cardiac or pulmonary disease, alcohol or drug abuse)'
p2171
aS'- exhibit severe uc / clinically significant active infection'
p2172
aS'- history of malignancy in the last 5 years'
p2173
asS'NCT01908283'
p2174
(lp2175
S"- current relapse defined as a crohn's disease activity index (cdai) >150 for patients with crohn's disease or a modified truelove-witts activity index (mtwai) >10 for patients with ulcerative colitis"
p2176
aS'- actually pregnant or planned pregnancy in the next month'
p2177
aS'- immunization with a pneumococcal vaccine (conjugated or polysaccharide) in the previous 5 years'
p2178
aS'- previous severe systemic reaction to immunization (respiratory or circulative)'
p2179
aS'- episode of fever in the last 24 hours'
p2180
asS'NCT02516384'
p2181
(lp2182
S"- biopsy-proven crohn's disease or indeterminate colitis"
p2183
aS'- acute abdomen or other clinical emergencies requiring emergent management (for example: stricture, bowel obstruction, perforation and/or abscess)'
p2184
aS'- primary sclerosing cholangitis (psc)'
p2185
aS'- pregnancy'
p2186
aS'- concurrent clostridium difficile infection or other known infection'
p2187
aS'- prior history of fecal microbiota transplantation'
p2188
aS'- other causes of diarrhea, including but not limited to tube feeds and medications (for example, kayaxelate, metformin, lactulose, laxatives, magnesium)'
p2189
aS'- major congenital defects'
p2190
aS'- subjects with recent malignancy in the last 5 years, excluding non-melanoma skin malignancies'
p2191
aS'- anaphylactic reactions to any foods'
p2192
aS'- any antibiotic use within the last 3 months'
p2193
aS'- subject having any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of the participant participating in the study, would make it unlikely for the participant to complete the study, or would confound the study'
p2194
assS'neutrophilic dermatosis of the dorsal hands (pustular vasculitis)-Procedure'
p2195
(dp2196
sS"crohn's disease-Radiation"
p2197
(dp2198
S'NCT00731809'
p2199
(lp2200
S'- pregnancy'
p2201
aS'- breastfeeding'
p2202
aS'- infectious colitis determined at the initial checkup'
p2203
aS'- allergy to iodine contrast'
p2204
assS'left-sided ulcerative colitis-Drug'
p2205
(dp2206
S'NCT01149707'
p2207
(lp2208
S"- 1. history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatological, neurological, or psychiatric disease, that could compromise patient's ability to participate in the study, and/or interfere with absorption of the study drug or the interpretation of the study data."
p2209
aS"- 2. patients with a diagnosis of crohn's disease."
p2210
aS'- 3. patients with a modified mayo score of \xe2\x89\xa511 at the screening (day -7 & day -3) visits.'
p2211
aS'- 4. patients at immediate or significant risk of toxic megacolon; those with bowel stricture, colonic dysplasia, adenoma or carcinoma.'
p2212
aS'- 5. use of botanical treatments and supplements for ulcerative colitis within 14 days prior to the baseline visit.'
p2213
aS'- 6. patients with any enteric pathogens, ova or parasites, or clostridium difficile toxin in stool.'
p2214
aS'- 7. female patients with a positive pregnancy test or lactating at the screening/baseline visits.'
p2215
aS'- 8. history of allergic reaction or hypersensitivity to spinach, spinach tablet, spinach powder or spinach extract; and to latex, molds and mushrooms.'
p2216
aS'- 9. history of gout, pseudogout or hyperuricemia, or kidney stones.'
p2217
aS'- 10. history of pseudoallergic hypersensitivity to the food color additives, tartrazine (e102), sunset yellow (e110) and fd & c blue no.1 (brilliant blue fcf; e133), allergic asthma, aspirin intolerance, and severe or multiple allergies.'
p2218
aS'- 11. past medical history of significant gastrointestinal surgery including but not limited to colostomy, ileostomy, or previous colonic surgery other than appendectomy.'
p2219
aS'- 12. patients with anatomical abnormalities of the colon, e.g., short bowel or other abnormalities.'
p2220
aS'- 13. patients with any current infectious, ischemic, or immunologic disease with gastrointestinal involvement.'
p2221
aS'- 14. patients with a history of failure to retain enemas.'
p2222
aS'- 15. use of antibiotics for reasons related to the primary diagnosis or for other gastrointestinal-related conditions within 14 days of baseline visit.'
p2223
aS'- 16. patients who used non-steroidal anti-inflammatory drugs (nsaids), including cyclooxygenase-2 (cox-2) inhibitors, within 14 days prior to baseline visit. except aspirin \xe2\x89\xa4325 mg/day for cardiovascular prophylaxis.'
p2224
aS'- 17. patients who used the following medications used for treating ulcerative colitis from the times indicated below to the end of week 3 (visit 6):'
p2225
aS'- topical intrarectal corticosteroids or topical intrarectal mesalamine within 14 days of baseline visit;'
p2226
aS'- systemic corticosteroids (oral or injectable, including adrenocorticotropic hormone [acth]) within 30 days of baseline visit;'
p2227
aS'- immunosuppressant therapy (methotrexate, azathioprine, 6-mercatopurine or cyclosporine) within 60 days of baseline visit; and'
p2228
aS'- biologic therapy (tumor necrosis factor-\xce\xb1 inhibitors, monoclonal antibodies, etc.) within 90 days of baseline visit.'
p2229
aS'- 18. patients with a history of active malignancy within the past 5 years except for squamous cell or basal cell cancers of the skin.'
p2230
aS'- 19. history of any clinical laboratory abnormality deemed significant by the principal investigator.'
p2231
aS'- 20. history of significant alcohol or drug abuse within one year prior to the screening visit.'
p2232
aS'- 21. patients who tested positive at screening for human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag) or hepatitis c virus (hcv).'
p2233
aS'- 22. exposure to any investigational or non-registered drug within 30 days prior to administration of study drug.'
p2234
assS'inflammatory bowel disease-Device'
p2235
(dp2236
g290
(lp2237
S'- pregnant woman or lactating woman.'
p2238
aS'- with confirmed distant metastasis in liver, lung, bones, or other organs.'
p2239
aS'- intolerable laparoscopic operation or converted to open surgery.'
p2240
aS'- with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.'
p2241
aS'- with bad compliance or contraindication to enrollment.'
p2242
asS'NCT02622139'
p2243
(lp2244
S'- age < 18 years'
p2245
aS'- mental retardation of the patient with restriction of general judgment and awareness'
p2246
asg645
(lp2247
S'- age < 40 and > 65 years'
p2248
aS'- large bowel resection in history'
p2249
aS'- colonoscopy performed during last 10 years'
p2250
aS'- contraindications for general anaesthesia'
p2251
aS'- asa > iv'
p2252
aS'- pregnancy'
p2253
aS'- confirmed neoplastic disease'
p2254
aS'- cirrhosis (child b or c) or ascites'
p2255
aS'- immunosuppressive therapy or steroids intake'
p2256
aS'- malabsorption syndrome'
p2257
asS'NCT00988273'
p2258
(lp2259
S'- 1. under 18 years of age.'
p2260
aS'- 2. cognitively impaired.'
p2261
aS'- 3. residing in institutions (eg. prison, extended care facility)'
p2262
aS"- 4. employees of research(s)' organization"
p2263
aS'- 5. in emergency or life-threatening situations'
p2264
aS'- 6. have language barriers (eg. illiterate, not english-speaking, dysphasic) preventing adequate consent process'
p2265
aS'- 7. resides in another country'
p2266
asS'NCT02478944'
p2267
(lp2268
S'- pregnancy'
p2269
asS'NCT02048137'
p2270
(lp2271
S'- contraindication to transcranial direct current stimulation'
p2272
aS'- pregnancy'
p2273
aS'- sever internal or psychiatric condition'
p2274
asS'NCT02182947'
p2275
(lp2276
S'- ibd diagnosis not established'
p2277
aS'- recent intestinal tract surgery / resection involving small bowel'
p2278
aS'- use of nsaids 4 weeks prior to the capsule endoscopy study.'
p2279
aS'- patients are on prokinetic medication.'
p2280
aS'- swallowing disorders, esophageal stricture or patients unable to swallow the capsule.'
p2281
aS'- presence of gastrointestinal obstruction or ileus.'
p2282
aS'- patient with implanted electro-medical device or pacemakers.'
p2283
asS'NCT02341742'
p2284
(lp2285
S'- 1. acute intercurrent events (less than 15 days) at the inclusion day leading to decreased physical activity according to the investigator judgment (fracture(s), recent arthritis, perineal lesions, severe skin lesions)'
p2286
aS'- 2. patient refusing to participate to the study'
p2287
aS"- 3. one of the child's parents refusing to participate to the study"
p2288
aS'- 4. lack of adherence foreseeable'
p2289
aS'- 5. participation to another study'
p2290
aS'- 6. pregnant girls'
p2291
aS'- 7. under a justice protect measure'
p2292
asS'NCT02129972'
p2293
(lp2294
S'- will not be included in this study are patients:'
p2295
aS'- presenting a contra indication for colonoscopy under general sedation or for the ingestion of the colon video capsule, especially those for who exist a clinical or radiological suspicion of upper gastrointestinal strictures (esophageal surgery or eosinophil esophagitis) and who presents a dysphagia to solids, swallowing disorders with or without impaired consciousness.'
p2296
aS'- who underwent an abdominal surgery during the last 3 months prior to the inclusion visit or who presents signs of bowel stenosis or occlusion'
p2297
aS'- who presents a toxic mega colon, radic enteritis, intestinal bowel carcinoma or who receives a chronically non-steroidal anti-inflammatory treatment'
p2298
aS'- presenting a contra indication for the bowel preparation agents'
p2299
aS'- with cardiac pacemaker or other implanted electro medical devices susceptible to interfere with the colon video capsule'
p2300
aS'- scheduled for a magnetic resonance imaging (mri) examination within 7 days following the ingestion of the colon video capsule (and until the evacuation of the capsule has been confirmed) or any other life-threatening conditions'
p2301
asg616
(lp2302
S'- subjects present with bowel obstruction or perforation'
p2303
aS'- subject undergo emergency surgery'
p2304
aS'- subject with asa iv, v'
p2305
aS'- history of allergy or hypersensitivity against indocyanine green'
p2306
aS'- pregnant or breast-feeding women'
p2307
aS'- subject has uremia (serum creatinine >2.5 mg/dl)'
p2308
aS'- subject is undergoing palliative surgery or who is terminally ill'
p2309
aS'- subject who is unable to discontinue warfarin anticoagulation 5 days before surgery'
p2310
aS'- subject taking phenobarbital, phenylbutazone, primidone, phenytoin, haloperidol, nitrofurantoin, probenecid'
p2311
asS'NCT02560727'
p2312
(lp2313
S'- diagnosed as ulcerative colitis first time.'
p2314
aS'- no history of using biologic, immunomodulatory therapy or corticosteroid therapy.'
p2315
aS'- with contraindication of endoscopy.'
p2316
asS'NCT02433470'
p2317
(lp2318
S'- contraindication to transcranial direct current stimulation'
p2319
aS'- contraindications to magnetic resonance imaging (mri)'
p2320
aS'- pregnancy'
p2321
aS'- sever internal or psychiatric condition'
p2322
asg346
(lp2323
S'- pancolitis or acute severe ulcerative colitis requiring immediate treatment'
p2324
aS'- need for admission due to active ulcerative colitis'
p2325
aS'- ulcerative colitis with systemic symptoms (abdominal pain, fever > 37.5 degrees, weight loss exceeding 3 kilograms).'
p2326
aS'- patient with anemia (haemoglobin < 8.3 mmol/l for males and < 7.3 mmol/l for females).'
p2327
aS'- patient with ostomy or pouch.'
p2328
aS'- the patient has had a bowel resection (except appendectomy)'
p2329
aS'- the patient has constipation and/or another known bowel condition than ulcerative colitis such as ibs.'
p2330
aS'- the patient has diabetes.'
p2331
aS'- regular intake of acetylsalicylic acid or nsaids'
p2332
aS'- the patient cannot understand the information material.'
p2333
aS'- the patient has had colon cancer, dysplasia or adenomatous polyps in the colon during the recent 5 year'
p2334
aS'- the patient is in a poor general condition.'
p2335
aS'- the patient has had a food poisoning within the last three months.'
p2336
aS'- the patient is pregnant at the time of inclusion or has planned pregnancy during the period of study.'
p2337
aS'- the patient is in medical treatment with cyclosporine at the beginning of the run in period.'
p2338
aS'- treatment for ulcerative colitis treatment has been changed within two weeks before the first day in the run in period'
p2339
aS'- the patient has commenced treatment with azathioprine, 6-mercaptopurine or methotrexate within 12 weeks before the first day in the run in period.'
p2340
aS'- the patient has commenced treatment with tnf-\xce\xb1 inhibitors within 12 weeks before the first day of the run in period.'
p2341
aS'- the patient suffers from coeliac disease or lactose intolerance.'
p2342
aS'- antibiotic treatment within two weeks before the first day of the run in period.'
p2343
aS'- patient has any medical, surgical condition that excludes the use of ric.'
p2344
assS"crohn's ileocolitis-Drug"
p2345
(dp2346
S'NCT02281916'
p2347
(lp2348
S'- subject who use of azathioprine, anti-tnf (tumor necrosis factor), methotrexate, and other immunosuppressors for 8 weeks before first injection of p28gst'
p2349
aS'- subject who use of corticosteroids for 15 days before first injection of p28gst'
p2350
aS'- subject with history of vaccine hyper sensitivity or allergy.'
p2351
aS'- subject with any other clinical manifestation determined by the investigator'
p2352
aS'- subject wih aids, b or c hepatitis.'
p2353
assS'proctosigmoiditis-Drug'
p2354
(dp2355
g2207
(lp2356
S"- 1. history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatological, neurological, or psychiatric disease, that could compromise patient's ability to participate in the study, and/or interfere with absorption of the study drug or the interpretation of the study data."
p2357
aS"- 2. patients with a diagnosis of crohn's disease."
p2358
aS'- 3. patients with a modified mayo score of \xe2\x89\xa511 at the screening (day -7 & day -3) visits.'
p2359
aS'- 4. patients at immediate or significant risk of toxic megacolon; those with bowel stricture, colonic dysplasia, adenoma or carcinoma.'
p2360
aS'- 5. use of botanical treatments and supplements for ulcerative colitis within 14 days prior to the baseline visit.'
p2361
aS'- 6. patients with any enteric pathogens, ova or parasites, or clostridium difficile toxin in stool.'
p2362
aS'- 7. female patients with a positive pregnancy test or lactating at the screening/baseline visits.'
p2363
aS'- 8. history of allergic reaction or hypersensitivity to spinach, spinach tablet, spinach powder or spinach extract; and to latex, molds and mushrooms.'
p2364
aS'- 9. history of gout, pseudogout or hyperuricemia, or kidney stones.'
p2365
aS'- 10. history of pseudoallergic hypersensitivity to the food color additives, tartrazine (e102), sunset yellow (e110) and fd & c blue no.1 (brilliant blue fcf; e133), allergic asthma, aspirin intolerance, and severe or multiple allergies.'
p2366
aS'- 11. past medical history of significant gastrointestinal surgery including but not limited to colostomy, ileostomy, or previous colonic surgery other than appendectomy.'
p2367
aS'- 12. patients with anatomical abnormalities of the colon, e.g., short bowel or other abnormalities.'
p2368
aS'- 13. patients with any current infectious, ischemic, or immunologic disease with gastrointestinal involvement.'
p2369
aS'- 14. patients with a history of failure to retain enemas.'
p2370
aS'- 15. use of antibiotics for reasons related to the primary diagnosis or for other gastrointestinal-related conditions within 14 days of baseline visit.'
p2371
aS'- 16. patients who used non-steroidal anti-inflammatory drugs (nsaids), including cyclooxygenase-2 (cox-2) inhibitors, within 14 days prior to baseline visit. except aspirin \xe2\x89\xa4325 mg/day for cardiovascular prophylaxis.'
p2372
aS'- 17. patients who used the following medications used for treating ulcerative colitis from the times indicated below to the end of week 3 (visit 6):'
p2373
aS'- topical intrarectal corticosteroids or topical intrarectal mesalamine within 14 days of baseline visit;'
p2374
aS'- systemic corticosteroids (oral or injectable, including adrenocorticotropic hormone [acth]) within 30 days of baseline visit;'
p2375
aS'- immunosuppressant therapy (methotrexate, azathioprine, 6-mercatopurine or cyclosporine) within 60 days of baseline visit; and'
p2376
aS'- biologic therapy (tumor necrosis factor-\xce\xb1 inhibitors, monoclonal antibodies, etc.) within 90 days of baseline visit.'
p2377
aS'- 18. patients with a history of active malignancy within the past 5 years except for squamous cell or basal cell cancers of the skin.'
p2378
aS'- 19. history of any clinical laboratory abnormality deemed significant by the principal investigator.'
p2379
aS'- 20. history of significant alcohol or drug abuse within one year prior to the screening visit.'
p2380
aS'- 21. patients who tested positive at screening for human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag) or hepatitis c virus (hcv).'
p2381
aS'- 22. exposure to any investigational or non-registered drug within 30 days prior to administration of study drug.'
p2382
assS'fatigue-Drug'
p2383
(dp2384
g3
(lp2385
S'- ibd group:'
p2386
aS'- meeting criteria for active alcohol or substance abuse or dependence'
p2387
aS'- current ongoing treatment with wellbutrin'
p2388
aS'- females who are pregnant or plan to become pregnant within three months'
p2389
aS'- sleep disorder such as apnea, restless leg syndrome or use of continuous positive airway pressure therapy (c-pap)/bilevel positive airway pressure (bi-pap)'
p2390
aS'- current ibd flare requiring hospitalization with intravenous steroid treatment'
p2391
aS'- other acute medical conditions or a history of chronic inflammatory condition other than ibd'
p2392
aS'- hemoglobin <10 with age and gender adjustments'
p2393
aS'- history of seizure disorder'
p2394
aS'- acute infection within seven days'
p2395
aS'- healthy volunteer group:'
p2396
aS'- history or current episode of psychiatric disorder by diagnositic and statistical manual (dsm-iv)'
p2397
aS'- current ongoing treatment with psychoactive medications'
p2398
aS'- medications for sleep in previous two weeks'
p2399
aS'- females who are pregnant or plan to become pregnant within three months'
p2400
aS'- history of ibd, epilepsy, rheumatoid arthritis, lupus'
p2401
aS'- sleep disorder such as apnea, restless leg syndrome or use of continuous positive airway pressure therapy (c-pap)/bilevel positive airway pressure (bi-pap)'
p2402
assS'keratoderma blenorrhagicum-Procedure'
p2403
(dp2404
sS'enteritis-Dietary Supplement'
p2405
(dp2406
S'NCT02639416'
p2407
(lp2408
S'- specific cause of malnutrition (e.g. cerebral palsy, other organ disease)'
p2409
aS'- sibling admitted with sam at the same time'
p2410
aS'- unwilling to stay on ward for at least 2 weeks'
p2411
aS'- declined to give consent'
p2412
aS'- participating in another study'
p2413
assS'arthritis-Biological'
p2414
(dp2415
g444
(lp2416
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p2417
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p2418
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p2419
aS'- known hiv/aids'
p2420
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p2421
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p2422
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p2423
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p2424
aS'- participated in an investigational study within 1 month prior to study entry'
p2425
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p2426
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p2427
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p2428
assS'bullous systemic lupus erythematosus-Procedure'
p2429
(dp2430
sS'anxiety-Behavioral'
p2431
(dp2432
g129
(lp2433
S'- ibd patients with parental report of mental retardation'
p2434
aS'- ibd patients receiving psychopharmacological treatment (antidepressants or benzodiazepines) for depression or anxiety'
p2435
aS'- no mastery of the dutch language'
p2436
aS'- ibd patients with diagnosed: bipolar disorder, schizophrenia/psychotic disorder, autism spectrum disorders, obsessive-compulsive disorder, posttraumatic stress disorder/acute stress disorder, or substance use disorder'
p2437
aS'- physician reported substance abuse (alcohol, drugs) in the past month'
p2438
aS'- clinician reported selective mutism'
p2439
aS'- ibd patients already participating in an (psychological of psychopharmacological) intervention study'
p2440
aS'- ibd patients who received 8 sessions of manualized cognitive behavioral therapy last year'
p2441
aS'- current psychological treatment'
p2442
assS'pancreatitis-Drug'
p2443
(dp2444
S'NCT02281799'
p2445
(lp2446
S"- previous severe pancreatitis requiring prolonged hospital admission or intensive care involvement, or ranson's criteria \xe2\x89\xa5 3"
p2447
aS'- no clinical need to reintroduce a thiopurine for management of ibd at the time of the study (e.g. stable on another medication, or mild phenotype of disease), based on clinical assessment of treating gastroenterologist'
p2448
aS'- diagnosis of recurrent pancreatitis syndrome'
p2449
aS'- diabetes mellitus or any other neuropathy which may dampen the clinical presentation of pancreatitis'
p2450
aS'- known or suspected allergy or intolerance to thiopurines, besides previous pancreatitis'
p2451
aS'- any other laboratory or clinical condition that the investigator considers clinically significant that could impact the outcome of the study or the safety of the patient.'
p2452
assS'neoplasms-Device'
p2453
(dp2454
g645
(lp2455
S'- age < 40 and > 65 years'
p2456
aS'- large bowel resection in history'
p2457
aS'- colonoscopy performed during last 10 years'
p2458
aS'- contraindications for general anaesthesia'
p2459
aS'- asa > iv'
p2460
aS'- pregnancy'
p2461
aS'- confirmed neoplastic disease'
p2462
aS'- cirrhosis (child b or c) or ascites'
p2463
aS'- immunosuppressive therapy or steroids intake'
p2464
aS'- malabsorption syndrome'
p2465
assS'rheumatoid arthritis-Other'
p2466
(dp2467
g371
(lp2468
S'- for iads patients'
p2469
aS'- unauthorized treatment (anticancer chemotherapy)'
p2470
aS'- for healthy volunteers'
p2471
aS'- contra-indications for donating blood except from age'
p2472
aS'- known history of iad (eg: psoriasis)'
p2473
aS'- common exclusion criteria:'
p2474
aS'- pregnant woman'
p2475
aS'- still under the exclusion period from another biomedical study'
p2476
aS'- psychiatric or addiction pathology who could interfere with the ability to fulfill the protocol needs or to provide an informed consent'
p2477
aS'- patient under a legal protection'
p2478
aS'- chronic lifelong viral infection unrelated to the pathology'
p2479
aS'- mild infection within the last 3 months'
p2480
asg212
(lp2481
S'- history of coronary artery disease, congenital heart disease or any cardiovascular disease, including a family history of coronary artery disease before 45 years of age'
p2482
aS'- uncontrolled hypertension (>140/90mmhg) (not white coat)'
p2483
aS'- course of antibiotics or bowel preparation for endoscopy one month prior to the commencement of the exercise program'
p2484
aS'- psychiatric disorders'
p2485
aS'- any medical condition deemed exclusionary by the principle investigator'
p2486
aS'- a history of substance abuse'
p2487
aS'- history of total colectomy'
p2488
aS'- currently treated with high dose corticosteroids or disease flare within 2 weeks of starting exercise program'
p2489
aS'- pregnant'
p2490
aS'- history of faecal incontinence'
p2491
aS'- have a malignant disease or any concomitant end stage organ disease'
p2492
aS'- patients may not be receiving any experimental drug or have been involved in a recent experimental trial in the last 30 days'
p2493
assS'rheumatoid arthritis-Biological'
p2494
(dp2495
g73
(lp2496
S'- subject has participated in a study of an investigational medicinal product (imp) or medical device within the previous 30 days or 5 half-lives (whichever is longer) prior to screening or is currently participating in another study of an imp or medical device - unless the study is ucb up0016 [nct02154425] or a registry study'
p2497
aS"- subject has any obstetrical or psychiatric condition, or she or her infant(s) has any medical condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study or the outcome of the pregnancy"
p2498
aS'- subject has history of chronic alcohol abuse or drug abuse during pregnancy'
p2499
aS'- subject has any pregnancy-related clinically significant abnormality noted on obstetric ultrasound, or other imaging assessment, or the subject has significant laboratory abnormalities during her pregnancy, as judged by the investigator'
p2500
aS'- subject is taking or has taken any medication with strong positive evidence of a human fetal risk of teratogenicity (e.g., methotrexate or leflunomide) during pregnancy'
p2501
aS'- subject has evidence of a condition suggesting chronic or acute uteroplacental insufficiency such as intrauterine growth restriction, severe maternal hypertensive disorders of pregnancy, or abruption'
p2502
aS'- subject has a documented history of primary or secondary antiphospholipid syndrome or hypercoagulable state'
p2503
aS'- subject has received treatment with any biological therapeutic agent, including anti-tnfs other than certolizumab pegol (czp), during pregnancy'
p2504
aS'- subject has previously participated in this study'
p2505
aS'- subject has a positive or indeterminate quantiferon\xc2\xae-tb gold in tube test at screening. in case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the subject'
p2506
aS"- subject with known tuberculosis (tb) infection, at high risk of acquiring tb infection, or latent tb infection (ltb). if tested within the 6 months prior to screening and the test was negative for tb, and there is no change in the subject's clinical status, nor social, family, or travel history, there is no need for an additional tb testing at screening"
p2507
asg444
(lp2508
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p2509
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p2510
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p2511
aS'- known hiv/aids'
p2512
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p2513
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p2514
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p2515
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p2516
aS'- participated in an investigational study within 1 month prior to study entry'
p2517
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p2518
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p2519
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p2520
assS'inflammatory bowel disease-Dietary Supplement'
p2521
(dp2522
g230
(lp2523
S'- 1. women who are pregnant or lactating at the time of enrollment, or who intend to be during the study period'
p2524
aS'- 2. patients may confuse the findings or there exist any other additional risk history'
p2525
aS'- 3. patients with end-stage disease or is expected likely to die during the study'
p2526
aS'- 4. patients are participating in other clinical trials or participated within 3 months prior to transplantation'
p2527
aS'- 5. outbreaks, infectious (viruses, bacteria, parasites, or other microorganisms) colitis, scheduled for abdominal surgery,take probiotics / prebiotics / synbiotics / antibiotic / ppi (past 1 month) orally, severe anemia (hbg <6g/dl), heart cerebrovascular accident, bypass, stent implantation surgery in the last 6 months, coagulation disorders, immune suppression status (defined as: immunosuppressive drugs, a history of opportunistic infections within one year recurrent ,oral ulcers, multiple lymphadenopathy, neutropenia, etc.), major abdominal transplant surgery in the last 3 months, have took tnf-\xce\xb1 monoclonal antibody 2 month before transplantation or planned to take within one month after transplantation, a history of megacolon -'
p2528
asS'NCT01771224'
p2529
(lp2530
S'- patient with associated diseases such as diabetes mellitus, hypertension, dyslipidemia, atherosclerosis and malabsorption syndrome.'
p2531
aS"- with autoimmune diseases (lupus, hiv, cancer and hepatitis), colitis (infectious, post-radiation, post-drug, indeterminate) and crohn's disease."
p2532
aS'- if the patient use drugs that inhibit fat absorption.'
p2533
aS'- patients after partial or total resection of stomach or small intestine.'
p2534
aS'- steroid users.'
p2535
aS'- patients in remission histology, clinical and endoscopic.'
p2536
aS'- patients treated with fan-3,6 or 9.'
p2537
asS'NCT00621257'
p2538
(lp2539
S'- patients unable to take medications by mouth, pregnant, with liver/kidney failure, receiving anticonvulsant medications (specifically, phenobarbital, carbamazepine and phenytoin, since they lead to increased vitamin d metabolism through hepatic induction of the cytochrome p450 (cyp450) hydroxylase enzymes), regularly attending a tanning salon (once weekly or more), currently being treated for hypovitaminosis d with therapeutic doses of vitamin d (> 800 iu per day) and unwilling to discontinue this regimen.'
p2540
aS'- patients on growth hormone, anabolic steroid hormones, calcitonin, bisphosphonates (maintenance trial only)'
p2541
asS'NCT01496053'
p2542
(lp2543
S'- serious disease,'
p2544
aS'- biological treatment,'
p2545
aS'- pregnancy.'
p2546
assS'ulcerative colitis, active moderate-Biological'
p2547
(dp2548
S'NCT02390726'
p2549
(lp2550
S'- patient who are asymptomatic'
p2551
aS'- patients with severe, refractory disease (defined as mayo scores of > 10, or endoscopic disease activity score of > 3) or patients with any other significant condition which, in the opinion of the investigator, could confound or interfere with evaluation of safety, tolerability of the investigational treatment or prevent compliance with the study protocol'
p2552
aS'- prior colectomy'
p2553
aS'- positive stool test for any of the following: clostridium difficile by pcr, salmonella, shigella, yersinia, campylobacter, enteropathogenic e. coli by standard stool culture.'
p2554
aS'- use of the steroid medications (any formulation) in the prior 6 weeks to enrollment'
p2555
aS'- systemic antibiotic use within prior 6 weeks to enrollment'
p2556
aS'- regular probiotic supplement use within prior 4 weeks to enrollment'
p2557
aS'- pregnancy or breastfeeding'
p2558
aS'- severe immunodeficiency, inherited or acquired (e.g. hiv, chemotherapy, or radiation therapy)'
p2559
aS'- history of anaphylaxis (severe allergic reaction)'
p2560
aS'- documented allergy to fluoroquinolones, metronidazole'
p2561
aS'- life expectancy less than 12 months'
p2562
aS'- age less than 18 or greater than 75 years of age'
p2563
aS'- history of esophageal or gastric motility disorders.'
p2564
asg2078
(lp2565
S'- 1. history of colonic or rectal surgery other than hemorrhoidal surgery or appendectomy.'
p2566
aS'- 2. currently receiving total parenteral nutrition (tpn).'
p2567
aS'- 3. positive clostridium difficile toxin stool assay.'
p2568
aS'- 4. tested positive for active/latent mycobacterium tuberculosis (tb) infection.'
p2569
aS'- 5. pregnant or breast-feeding, or plan to become pregnant during the study.'
p2570
aS'- 6. males who are young and childless or planning to have more children in the future.'
p2571
aS'- 7. known hypersensitivity to bertilimumab or any of the drug excipients.'
p2572
aS'- 8. history of infection requiring administration of any iv antibiotic, antiviral or antifungal medication within 30 days of screening or any oral anti-infective agent within 14 days of screening.'
p2573
aS'- 9. severe uc evidenced by the following signs of toxicity: heart rate >100 beats/min at rest, temperature >37.8\xc2\xb0c, hemoglobin <10.0 g/dl.'
p2574
aS'- 10. ulcerative proctitis, defined as disease limited to less than 15 cm from the anal verge.'
p2575
aS'- 11. received a vaccine or other immunostimulator within 4 weeks prior to screening.'
p2576
aS'- 12. use of >4.8 g mesalazine or equivalent within 2 weeks prior to the screening visit. mesalazine \xe2\x89\xa44.8 g is allowed if the dose during the 2 weeks prior to the screening visit was stable.'
p2577
aS'- 13. use of systemic corticosteroids exceeding the equivalent of 20 mg/day of prednisone within four weeks prior to the screening visit (see section 6.9.1).'
p2578
aS'- 14. change in dose of immunosuppressive drugs (e.g., corticosteroids, 6-mercaptopurine [6-mp], azathioprine) within four weeks prior to the screening visit.'
p2579
aS'- 15. use of tnf-blockers (e.g., infliximab or adalimumab) within 60 days of the screening visit.'
p2580
aS'- 16. use of chronic non-steroidal anti-inflammatory (nsaid) therapy. occasional use of nsaids or acetaminophen for headache, arthritis, myalgias, menstrual cramps, etc., or daily use of low dose (81-162 mg) aspirin for cardiovascular prophylaxis is allowed.'
p2581
aS'- 17. patients diagnosed with:'
p2582
aS"- crohn's disease"
p2583
aS'- diverticulitis or diverticulosis'
p2584
aS"- indeterminate colitis (inability to distinguish between uc and crohn's disease [as assessed by the investigator])"
p2585
aS'- microscopic colitis (collagenous or lymphocytic colitis)'
p2586
aS'- ischemic or infectious colitis'
p2587
aS'- clostridium difficile colitis within 90 days of the screening visit'
p2588
aS'- parasitic disease within 90 days of the screening visit'
p2589
aS'- systemic fungal infection within 90 days of the screening visit.'
p2590
aS'- 18. history of positive serology of hepatitis b or c, or human immunodeficiency virus (hiv) infection.'
p2591
aS'- 19. congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, organ transplantation).'
p2592
aS'- 20. clinically significant abnormal laboratory test results, unless regarded by the investigator as related to uc, including but not limited to:'
p2593
aS'- hemoglobin level <10.0 g/dl'
p2594
aS'- white blood cell count < 3 x 103/\xc2\xb5l'
p2595
aS'- lymphocyte count < 0.5 x 103/\xc2\xb5l'
p2596
aS'- platelet count <100 x 103/\xc2\xb5l or >1200 x 103/\xc2\xb5l'
p2597
aS'- alanine aminotransferase (alt) or aspartate aminotransferase (ast) >3 the upper limit of normal (uln)'
p2598
aS'- alkaline phosphatase >3 uln'
p2599
aS'- serum creatinine >2 uln.'
p2600
aS'- 21. active abuse of alcohol or drugs.'
p2601
aS'- 22. known malignancy or history of malignancy that could reduce life expectancy.'
p2602
aS'- 23. any condition, which in the opinion of the investigator, would place the patient at an unacceptable risk if participating in the study protocol.'
p2603
aS'- 24. participation in a clinical trial of an investigational (unapproved) product'
p2604
assS'anemia, iron-deficiency-Drug'
p2605
(dp2606
S'NCT02680756'
p2607
(lp2608
S'- anaemia due to any cause other than iron deficiency'
p2609
aS'- received intramuscular or intravenous injection or administration of a depot iron preparation within 8 weeks of screening'
p2610
aS'- received blood transfusion within 2 weeks of screening'
p2611
aS"- active inflammatory bowel disease as defined by a simple clinical colitis activity index (sccai) score greater than 4 or a crohn's disease activity index (cdai) score greater than 220"
p2612
aS'- known hypersensitivity or allergy to components of ferric maltol or ferric carboxymaltose'
p2613
aS'- reactions to previous doses of intravenous iron (e.g., required observation for > 2 hours, in-patient admission or medical treatment for infusion reactions)'
p2614
aS'- known contraindications for treatment with iron preparations'
p2615
aS'- vitamin b12 or folic acid deficiency'
p2616
aS'- concomitant medical conditions including neurologic or psychiatric symptoms that, in the opinion of the investigator and sponsor would make the subject unsuitable for participation in the study'
p2617
assS"behcet's disease-Procedure"
p2618
(dp2619
sS'heart failure-Behavioral'
p2620
(dp2621
sS'rheumatoid neutrophilic dermatitis-Procedure'
p2622
(dp2623
sS'colorectal neoplasms-Behavioral'
p2624
(dp2625
g1870
(lp2626
S'- class asa iv or v patient'
p2627
aS'- documented problem of gastro-intestinal motility'
p2628
aS'- pregnancy'
p2629
aS'- any acute or recent (<10 days) septic event'
p2630
aS'- chemotherapy during the 4 weeks preceding surgery'
p2631
aS'- previous irradiation surrounding the planned anastomosis location'
p2632
aS'- small intestine iatrogenic transparietal laceration done during surgery'
p2633
aS'- small intestine synchrone resection without continuity with the colon'
p2634
aS'- intra-peritoneal chemotherapy administered during or following surgery'
p2635
aS'- presence of residual peritoneal carcinosis at the end of surgery'
p2636
aS'- colic surgery associated with another major intra-abdominal surgery'
p2637
aS'- creation of a colo-anal or ileo-anal anastomosis'
p2638
aS'- any per-surgery discovery which requires the use of a gastric drainage procedure following surgery'
p2639
aS'- any post-surgery change in patient condition which requires naso-gastric tube holding after surgery'
p2640
assS'chronic fatigue-Drug'
p2641
(dp2642
S'NCT02517151'
p2643
(lp2644
S'- known hypersensibility to active principle or excipients'
p2645
aS'- pregnant or lactating women'
p2646
aS'- clinically active ibd (harvey bradshaw index >6; mayo clinical score >3 or c-reactive protein >2.5 mg/l'
p2647
aS'- renal failure (egfr<60)'
p2648
aS'- history of adrenal insufficiency'
p2649
aS'- history of autoimmune diseases'
p2650
aS'- history of malignancies'
p2651
aS'- depression'
p2652
aS'- any current or recent signs or symptoms of viral infectious diseases'
p2653
aS'- recent psycho-traumatic events'
p2654
aS'- hemoglobin levels < 12.5 g/dl (men) or <11.5 g/dl (women)'
p2655
assS'polyp of large intestine-Device'
p2656
(dp2657
S'NCT02343601'
p2658
(lp2659
S'- pregnant women'
p2660
aS'- black skin'
p2661
aS'- chronic renal insufficiency (mdrd <30 ml/min)'
p2662
assS'gastric cancer-Procedure'
p2663
(dp2664
g290
(lp2665
S'- pregnant woman or lactating woman.'
p2666
aS'- with confirmed distant metastasis in liver, lung, bones, or other organs.'
p2667
aS'- intolerable laparoscopic operation or converted to open surgery.'
p2668
aS'- with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.'
p2669
aS'- with bad compliance or contraindication to enrollment.'
p2670
assS'insulin resistance-Other'
p2671
(dp2672
S'NCT01686477'
p2673
(lp2674
S'- major congenital or life threatening abnormalities or congenital abnormalities that preclude early milk feeding'
p2675
aS'- inability to randomise infant within 48 hours'
p2676
assS'thyroid disorder-Behavioral'
p2677
(dp2678
sS'recurrence-Procedure'
p2679
(dp2680
S'NCT01876264'
p2681
(lp2682
S'- patients unable to give informed consent'
p2683
aS'- patients requiring formation of a stoma at the time of surgical resection'
p2684
aS'- patients having less than 200cm of small bowel as assessed intra-operatively'
p2685
aS'- simultaneous strictureplasty or small bowel resection'
p2686
aS'- age <16 or >80'
p2687
assS"crohn's disease-Drug"
p2688
(dp2689
S'NCT02321280'
p2690
(lp2691
S'- 1. monoclonal antibody or experimental agent use within 12 weeks before screening.'
p2692
aS'- 2. use of non-approved drugs for cd.'
p2693
aS'- 3. anticipated need for surgery within 12 weeks'
p2694
aS'- 4. active sepsis, or use of antibiotics within two weeks prior to screening for the treatment of infection.'
p2695
aS'- 5. pregnant, lactating or planning to become pregnant during the study'
p2696
aS'- 6. inability to reliably use birth control for men and women during the course of therapy.'
p2697
aS'- 7. known allergy to denosumab or ingredients in formulation'
p2698
aS'- 8. treatment of cancer within the last 5 years (except for non-melanoma skin cancers).'
p2699
aS'- 9. recent jaw infection, invasive dental procedures (tooth extraction, dental implants or surgery), anti-angiogenic medications, or hypocalcemia within 1 month prior to screening.'
p2700
aS'- 10. patients will also be excluded if they meet any of the following criteria: proctocolectomy or total colectomy; stoma; a history of allergy to murine proteins; or treatment with parenteral corticosteroids or corticotropin within four weeks before screening. serum hg < 80 g/l, liver enzymes \xe2\x89\xa5 2-fold elevated, or other serum biochemistry considered unsafe, or requiring treatment, in the opinion of the investigator.'
p2701
asg324
(lp2702
S'- known intolerance for il2 (see spc),'
p2703
aS'- administration of a non-authorized treatment and/or iv bolus of corticosteroids in the last 2 months,'
p2704
aS'- vaccination with live attenuated virus in the months preceding the inclusion or planned during the study'
p2705
aS'- other severe or progressive autoimmune/inflammatory pathology,'
p2706
aS'- low white blood cell count<2000/mm3, lymphocytes <600/mm3, platelets <80 000/mm3,'
p2707
aS"- heart failure (\xe2\x89\xa5 grade iii nyha), renal insufficiency (cockcroft< 60ml/mn except patients with lupus or wegener's granulomatosis) or hepatic insufficiency (transaminases> 5n except for patients with autoimmune hepatitis), or lung failure,"
p2708
aS'- significant abnormality in chest x-ray other than these linked to the diseases under investigation'
p2709
aS'- cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or basocellular carcinoma)'
p2710
aS'- poor venous access not allowing repeated blood tests,'
p2711
aS'- restrictive diet or parenteral nutrition,'
p2712
aS'- surgery during the last 2 months or surgery planned during the study,'
p2713
aS'- participation in other biomedical research in the last 3 months or planned during the study.'
p2714
aS'- pregnant or lactating women,'
p2715
aS'- concomitant psychiatric disease or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give informed consent,'
p2716
aS'- positive hiv serology, active hepatitis b or ebv infection,'
p2717
aS'- patients under a measure of legal protection'
p2718
asg1001
(lp2719
S'- for the uc/cd prospective cohort:'
p2720
aS'- 1. is greater than (>) 19 completed weeks gestation prior to enrollment,'
p2721
aS'- 2. has first contact with otis after prenatal diagnosis of any major structural defect,'
p2722
aS'- 3. has enrolled in this registry with a previous pregnancy,'
p2723
aS"- 4. has had an exposure to the known or suspected human teratogens: chlorambucil. cyclophosphamide, mycophenylate mofetil. for the 'no chronic disease' prospective cohort:"
p2724
aS'- 5. is >19 completed weeks gestation prior to enrollment,'
p2725
aS'- 6. has first contact with otis after prenatal diagnosis of any major structural defect,'
p2726
aS'- 7. has enrolled in this registry with a previous pregnancy,'
p2727
aS'- 8. has had an exposure to the known or suspected human teratogens: chlorambucil, cyclophosphamide, mycophenylate mofetil. note: women exposed to entyvio during pregnancy but not meeting the above criteria can enroll into the entyvio pregnancy exposure case series component of this registry.'
p2728
asS'NCT01836289'
p2729
(lp2730
S'- pregnant or nursing women'
p2731
aS'- sexually active men and women who do not agree to use effective means of birth control during treatment period'
p2732
aS'- evidence of primarily fibrostenosing disease without active inflammatory disease on disease staging'
p2733
aS"- co-morbid conditions including cardiac disease with an ejection fraction of < 45%, chronic renal failure with serum creatinine > 2.0, liver disease with total bilirubin > 2.0, (excluding hyperbilirubinemia secondary to gilbert's disease) or transaminitis > 3x upper limit of normal."
p2734
aS'- history of serious allergic reaction to cyclophosphamide'
p2735
aS'- history of malignancy in the last 5 years (excluding non-melanomatous skin cancers)'
p2736
aS'- patients who are pre-terminal'
p2737
aS'- toxic megacolon'
p2738
aS'- active infection'
p2739
aS'- white blood cell count < 3000 cells/ul, platelets < 100k / ul, hemoglobin < 10.0 g/dl'
p2740
aS'- any use of thiopurines, methotrexate or anti-tnf agents in the previous four weeks prior to treatment'
p2741
asS'NCT02611817'
p2742
(lp2743
S'- 1. evidence of abdominal abscess extensive colonic resection, subtotal or total colectomy.'
p2744
aS'- 2. history of >3 small bowel resections or diagnosis of short bowel syndrome.'
p2745
aS'- 3. ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.'
p2746
aS'- 4. prior exposure to investigational or approved non-biologic therapies (eg, cyclosporine, tacrolimus, thalidomide, or tofacitinib) for the treatment of underlying disease within 30 days or 5 half-lives of screening (whichever is longer).'
p2747
aS'- 5. prior exposure to any investigational or approved biologic or biosimilar agent within 60 days or 5 half-lives of screening (whichever is longer).'
p2748
aS'- 6. prior exposure to vedolizumab'
p2749
aS'- 7. surgical intervention for cd required at any time during the study.'
p2750
aS'- 8. history or evidence of adenomatous colonic polyps that have not been removed, or of colonic mucosal dysplasia.'
p2751
aS'- 9. suspected or confirmed diagnosis of ulcerative colitis, indeterminate colitis, ischaemic colitis, radiation colitis, diverticular disease associated with colitis, or microscopic colitis.'
p2752
aS'- 10. active infections'
p2753
aS'- 11. chronic hepatitis b virus (hbv) or c (hcv) infection, tb (active or latent), or congenital or acquired immunodeficiency'
p2754
aS'- 12. history of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.'
p2755
asS'NCT00513552'
p2756
(lp2757
S'- any patient with ulcerative colitis'
p2758
aS'- all women of child-bearing age must have a negative urine pregnancy test within 1 week prior to the initial clinic visit.'
p2759
aS"- patients receiving a biological therapy for crohn's disease including remicade"
p2760
aS'- patients with a known allergy to any of the three antibiotics used in this protocol.'
p2761
asS'NCT00599625'
p2762
(lp2763
S'- patients less than 18 or greater than 65'
p2764
aS'- current therapy with a statin or alternative medication for hyperlipidemia'
p2765
aS'- hypersensitivity or known adverse reaction to statin therapy in the past'
p2766
aS'- pregnancy'
p2767
aS'- use of cyclosporin, erythromycin, and/or greater than 20mg of prednisone or its equivalent per day during the 4 weeks prior to study entry and/or during the 6 week study drug administration period.'
p2768
aS'- use of infliximab during 8 weeks prior to study entry and/or during the 6 week study drug administration period.'
p2769
aS'- ast, alt or ck more than twice the upper limits of normal on baseline laboratory data'
p2770
aS'- serum creatinine greater than 1.5 or estimated creatinine clearance less than 40ml/min on baseline laboratory data.'
p2771
aS'- clinically significant perianal fistulae'
p2772
aS'- patients with diverting or end ostomy.'
p2773
aS"- experimental therapy for crohn's disease in the 4 weeks prior to study entry"
p2774
aS'- presence of medical condition or disease that, in the opinion of the investigators, may place the patient at unacceptable risk for study participation, including, but not limited to, pregnancy, lactation, and/or inability/unwillingness to adhere to a contraceptive regimen.'
p2775
asS'NCT02240108'
p2776
(lp2777
S'- pregnant or lactating females. females of childbearing (reproductive) potential must have a negative serum pregnancy test at screening and agree to use a highly effective method(s) of contraception throughout their participation in the study.'
p2778
aS'- diagnosis of ulcerative or indeterminate colitis.'
p2779
aS'- diagnosis of celiac disease.'
p2780
aS"- bowel surgery within 12 weeks prior to screening and/or has surgery planned or deemed likely for crohn's disease during the study period."
p2781
aS'- presence of an ileostomy or colostomy.'
p2782
aS'- known fixed symptomatic stenosis/stricture of the small or large bowel.'
p2783
aS'- had more than one segmental colonic resection.'
p2784
aS'- had more than 3 small bowel resections or symptoms associated with short bowel syndrome.'
p2785
aS'- current evidence of peritonitis.'
p2786
aS'- history or evidence of colonic mucosal dysplasia.'
p2787
aS'- history or evidence of adenomatous colonic polyps that have not been removed.'
p2788
aS'- unwilling to be tapered off corticosteroids by week 8 or the subject is known by the investigator to be steroid dependent.'
p2789
aS'- has used a biologic within 12 weeks of randomization.'
p2790
aS'- used cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, or similar drugs within 8 weeks prior to randomization.'
p2791
aS'- had rectal administration of 5-aminosalicylic acid (5-asa) or corticosteroid enemas/foams/ suppositories within 2 weeks prior to screening visit.'
p2792
asS'NCT01015391'
p2793
(lp2794
S'- bacterial,viral or other microbial infection(including hiv)'
p2795
aS'- any of the following medications taken within 12 weeks before surgery: cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, or other investigational drugs'
p2796
aS"- any of ongoing therapy for crohn's disease with: 5-asa compounds, steroids, immune modifiers, systemic antibiotics, and tube feeding"
p2797
aS'- needing orally administered corticosteroids for the treatment of other diseases. inhaled or dermatologic preparations are acceptable.'
p2798
aS'- previous or current use of infliximab.'
p2799
aS'- current use of prescription doses or chronic/frequent use of nsaids'
p2800
aS'- treatment with narcotic pain medications. (anti-diarrheal agents such as loperamide and diphenoxylate are permitted, providing that the dose is not increased during the study period.)'
p2801
aS'- with an ileal or colonic stoma.'
p2802
aS'- history of pancreatitis, except for subjects with a known but removed cause(such as gallstone pancreatitis)'
p2803
aS'- wbc <3.0 x 109/l, hemoglobin <80 g/l, platelets<50,000/mm3 at the time of enrollment (or within the previous 6 months, if known)'
p2804
aS'- history of abnormal liver function tests, including ast or alt >1.5 times upper limit of normal, alkaline phosphatase >2 times upper limit of normal, total bilirubin >2.5 mg/dl at screening (or within the previous 6 months, if known)'
p2805
aS'- with short bowel syndrome (defined as requiring oral or parenteral supplemental or total nutrition to maintain stable body weight, or more than 100 cm of small bowel resected)'
p2806
aS'- history of malignancy'
p2807
aS'- women who are pregnant or lactating at the time of enrollment, or who intend to be during the study period.'
p2808
aS'- participation in other clinical trial within the past 6 months'
p2809
asS'NCT02256462'
p2810
(lp2811
S'- 1. pregnancy.'
p2812
aS'- 2. renal failure.'
p2813
aS'- 3. current abscess or perforation of the bowel.'
p2814
aS'- 4. small bowel obstruction within the last 6 months.'
p2815
aS'- 5. fixed non inflammatory stricture with related symptoms.'
p2816
aS'- 6. complicated or heavily draining perianal fistula (indolent non draining or minimally draining fistula are not an exclusion criteria).'
p2817
aS'- 7. prior treatment with infliximab or adalimumab.'
p2818
aS'- 8. previous malignancy.'
p2819
aS'- 9. sepsis or active bacterial infection.'
p2820
aS"- 10. surgery related to crohn's disease in the previous 8 weeks."
p2821
aS'- 11. positive hepatitis b surface antigen or evidence for tb.'
p2822
aS'- 12. ibd unclassified.'
p2823
asS'NCT02186275'
p2824
(lp2825
S'- patient diagnosed with severe complex perianal fistulizing cd (defined as the presence at diagnosis of a high intersphincteric, transsphincteric, extrasphincteric, or suprasphincteric complex perianal fistula)'
p2826
aS'- known chronic liver cholestasis (defined by an elevation of conjugated bilirubin and/or gamma glutamyl transferase > 3 upper limit normal)'
p2827
aS'- known renal dysfunction requiring chronic dialysis or creatinine \xe2\x89\xa5 100 micromol/l.'
p2828
aS'- known congenital bone disease'
p2829
aS'- known cystic fibrosis or other exocrine pancreatic insufficiency.'
p2830
aS'- currently treated with anticonvulsants metabolized through cytochrome p-450'
p2831
aS'- unable to take oral capsule form.'
p2832
asS'NCT02240121'
p2833
(lp2834
S'- pregnant or lactating females. females of childbearing (reproductive) potential must have a negative serum pregnancy test at screening and agree to use a highly effective method(s) of contraception throughout their participation in the study. diagnosis of ulcerative or indeterminate colitis.'
p2835
aS'- diagnosis of celiac disease.'
p2836
aS"- bowel surgery within 12 weeks prior to screening and/or has surgery planned or deemed likely for crohn's disease during the study period."
p2837
aS'- presence of an ileostomy or colostomy.'
p2838
aS'- known fixed symptomatic stenosis/stricture of the small or large bowel.'
p2839
aS'- had more than one segmental colonic resection.'
p2840
aS'- had more than 3 small bowel resections or symptoms associated with short bowel syndrome.'
p2841
aS'- current evidence of peritonitis.'
p2842
aS'- history or evidence of colonic mucosal dysplasia.'
p2843
aS'- history or evidence of adenomatous colonic polyps that have not been removed.'
p2844
aS'- unwilling to be tapered off corticosteroids by week 8 or the subject is known by the investigator to be steroid dependent.'
p2845
aS'- has used a biologic within 12 weeks of randomization.'
p2846
aS'- used cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, or similar drugs within 8 weeks prior to randomization.'
p2847
aS'- had rectal administration of 5-aminosalicylic acid (5-asa) or corticosteroid enemas/foams/ suppositories within 2 weeks prior to screening visit.'
p2848
asS'NCT02453607'
p2849
(lp2850
S'- age< 18 years;'
p2851
aS'- patients treated with ifx at non-standard doses;'
p2852
aS"- diagnosis of ulcerative colitis, pouchitis, indeterminate colitis or crohn's disease involving the upper gi tract or perianal disease without involvement of small bowel or colon;"
p2853
aS'- concomitant therapy with cyclosporine, methotrexate or other immunosuppressant other than thiopurine and ifx, treatment with ifx or ifx/thiopurine combination for > 12 months;'
p2854
aS'- pregnancy'
p2855
asg1117
(lp2856
S'- diarrhea activity scores < 3'
p2857
aS'- severely active disease with perianal diseases'
p2858
aS'- severely active disease with indication of surgery.'
p2859
aS'- diagnosis as ibd first time or first year.'
p2860
aS'- no history of using 5-asa, biological (antibody), immunomodulatory therapy, corticosteroid therapy'
p2861
asS'NCT01470599'
p2862
(lp2863
S'- subjects who have been discontinued due to protocol violation(s) (as determined by the sponsor) in the a3921084 study.'
p2864
aS'- subjects who were discontinued from the a3921084 study due to an adverse event.'
p2865
aS'- subjects likely to require any non-elective surgery or surgery requiring overnight stay (with the exception of minor same day outpatient procedures that will not interfere with study drug dosing).'
p2866
asS'NCT02685683'
p2867
(lp2868
S'- diagnosis of ulcerative colitis (uc), indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis'
p2869
aS"- local manifestations of crohn's disease (cd) such as symptomatic strictures, abscesses, short bowel syndrome; or other disease complications for which surgery might be indicated or could confound the evaluation of efficacy"
p2870
aS'- intestinal resection within 6 months or any intra-abdominal surgery within 3 months prior to the screening visit'
p2871
aS'- ileostomy or a colostomy'
p2872
aS'- prior treatment with more than 2 tnf-\xce\xb1 blockers (eg, infliximab or adalimumab).'
p2873
aS'- prior treatment with any integrin antagonists (eg, natalizumab or vedolizumab).'
p2874
aS'- subject is pregnant or breastfeeding.'
p2875
aS'- subject has received prior treatment with mongersen (ged-0301), or participation in a clinical study involving mongersen (ged-0301).'
p2876
asS'NCT00265772'
p2877
(lp2878
S'- antibiotic therapy within 4 weeks prior to inclusion immunosuppressive therapy within 4 weeks prior to inclusion not willing to collaborate isolated oral or perianal involvement'
p2879
asS'NCT01632462'
p2880
(lp2881
S'- patients with ulcerative colitis (uc)'
p2882
aS'- subjects with documented intestinal stricture, stenosis, obstruction, fistula, abscess, ileostomy'
p2883
aS'- patients with perianal or active cd'
p2884
aS'- treatment with anti-tnf\xce\xb1, ciprofloxacin, metronidazole, systemic corticosteroids, infliximab within 12 weeks of the start of the trial'
p2885
aS'- patients with systemic or intestinal infection'
p2886
aS'- renal, hepatic, haematological, pulmonary, cardiac, neurologic or cerebral diseases'
p2887
aS'- probiotic use in the previous 2 months'
p2888
aS'- inability or unwillingness to give an informed consent'
p2889
aS'- subjects who require outpatient antibiotic therapy.'
p2890
aS'- patients who require surgery for complications related to cd.'
p2891
aS'- concurrent participation in an investigational drug trial'
p2892
aS'- documented history of allergic reaction to lactobacillus or other probiotic compound'
p2893
aS'- use of lactobacillus, bifidobacterium, enterococcus, saccharomyces, or any other probiotic bacterial supplement within the past 10 days'
p2894
aS'- history of endocarditis, rheumatic valvular disease, congenital cardiac malformations, or cardiac surgery'
p2895
aS'- presence of any other significant medical condition'
p2896
aS'- pregnant or breastfeeding female subjects'
p2897
asS'NCT01881464'
p2898
(lp2899
S'- patients who had been treated with anti tnf \xce\xb1 4 weeks before the study'
p2900
aS'- as well as those who received corticosteroids within 1 week before the study.'
p2901
aS'- dm, ihd, crf, smoker'
p2902
asS'NCT02177071'
p2903
(lp2904
S'- patients who have presented a severe acute or delayed reaction to infliximab.'
p2905
aS'- perianal fistulae as the main indication for infliximab treatment'
p2906
aS'- active perianal/abdominal fistulae at time of inclusion, defined by active drainage'
p2907
aS'- patients with ostomy or ileoanal pouch'
p2908
aS'- pregnancy or planned pregnancy during the study'
p2909
aS'- inability to follow study procedures as judged by the investigator'
p2910
aS'- non-compliant subjects.'
p2911
aS'- participation in another therapeutic study'
p2912
aS'- steroid use \xe2\x89\xa46 months prior to screening'
p2913
aS'- currently receiving steroids, immunosuppressive agents (other than purine, methotrexate), biologic treatment (other than infliximab) or thalidomide'
p2914
asS'NCT02255370'
p2915
(lp2916
S'- ulcerative colitis'
p2917
aS'- pregnant or nursing woman'
p2918
aS'- refusal of contraceptive measure for childbearing potential, woman or fertile man'
p2919
aS'- indication of anti-tnf\xce\xb1 treatment'
p2920
aS'- concomitant treatment including antibiotics, probiotics, mesalazine, methotrexate, cyclosporine, tacrolimus, anti-tnf\xce\xb1, ustekinumab, vedolizumab'
p2921
aS'- concomitant treatment with corticosteroids, except in case of tapering a treatment initiated before surgery'
p2922
aS'- renal insufficiency ( serum creatinine 2n)'
p2923
aS'- chronic hepatic disease except for primary sclerosing cholangitis'
p2924
aS'- alat , asat, alkaline phosphatases, or bilirubin > 3n'
p2925
aS'- current infection to hiv, hbv (except if hbv ac positives), hcv'
p2926
aS'- contraindication to thiopurines'
p2927
aS'- unwillingness of the patient'
p2928
asS'NCT02038920'
p2929
(lp2930
S'- patients with an evidence of or suspected abdominal abscess'
p2931
aS'- 2. patients with a history of subtotal or total colectomy'
p2932
aS'- 3. patients who have had a resection of the small intestine in at least 3 locations or have a diagnosis of short bowel syndrome'
p2933
aS'- 4. patients with ileostomy,colostomy,or internal fistula, or severe intestinal stenosis'
p2934
aS"- 5. patients who started 5-aminosalicylic acid oral drug or probiotics treatment, antimicrobials to treat crohn's disease, or 30 mg/day or less of oral corticosteroids within 13 days before initiation of study drug administration. if these drugs were used within 14 days before initiation of study drug administration, the dosage must have been changed or their use discontinued within 13 days before the initiation of study drug administration"
p2935
aS"- 6. patients who have received 5-aminosalicylic acid or corticosteroid enemas/suppositories, intravenous corticosteroid injections, or more than 30 mg/day of oral corticosteroids, medications for diarrhea-predominant irritable bowel syndrome, or chinese herbal medicine for the treatment of crohn's disease (e.g., daikenchuto) within 13 days before initiation of study drug administration"
p2936
aS'- 7. patients who have received azathioprine, 6-mercaptopurine, or methotrexate within 27 days before initiation of study drug administration. however, this shall not apply to patients who have received these drugs for 83 or more days before initiation of the study drug administration and continued the steady dose administration of the drugs for 27 or more days before initiation of the study drug administration'
p2937
aS'- 8. patients who have received cyclosporin, tacrolimus, tofacitinib or any study drugs for treatment of ulcerative colitis within 27 days before initiation of the study drug administration'
p2938
aS'- 9. patients who have received adalimumab within 27 days before initiation of study drug administration or any biological drugs other than adalimumab within 55 days before initiation of study drug administration.topical administration (such as intraocular implantation for treatment of age-related maculopacy) is allowed'
p2939
aS'- 10. patients who have received any live vaccinations within 27 days before initiation of study drug administration'
p2940
aS'- 11. patients who have undergone intestinal resection within 27 days before initiation of study drug administration or those anticipated to require intestinal resection during the study'
p2941
aS'- 12. patients who have received leukocytapheresis or granulocyte apheresis within 27 days before initiation of the study drug administration'
p2942
aS'- 13. patients who have received intravenous hyperalimentation or total enteral nutrition within the 20 days before initiation of the study drug administration. or patients who are fasted'
p2943
aS'- 14. patients who have received enteral nutrition at > 900 kcal/day or started enteral nutrition at <= 900 kcal/day within the 20 days before initiation of the study drug administration. patients receiving 900 kcal/day or less of enteral nutrition for at least 21 days before initiation of the study drug administration whom these dosage was changed or the medications were discontinued within 20 days before initiation of the study drug administration'
p2944
aS'- 15. patients with evidence of adenomatous colonic polyps that need to be removed at the start of study drug administration'
p2945
aS'- 16. patients with a history or an an complication of dysplasia of the small or large intestine'
p2946
asS'NCT02675153'
p2947
(lp2948
S'- allergic to sirolimus or serious side effects'
p2949
aS'- need emergency surgery'
p2950
aS'- accompanied with other severe disease (involve c.diff infection)'
p2951
aS'- follow-up less than 1 year'
p2952
asS'NCT02403323'
p2953
(lp2954
S'- part 1 open-label extension:'
p2955
aS'- any new, significant, uncontrolled condition part 2 safety monitoring:'
p2956
aS'- no exclusion criteria'
p2957
asS'NCT01793831'
p2958
(lp2959
S'- diarrhea activity scores < 3)'
p2960
aS'- severely active disease with perianal diseases'
p2961
aS'- severely active disease with indication of surgery.'
p2962
aS'- diagnosis as cd first time or first year.'
p2963
aS'- no history of using 5-asa, biological (antibody), immunomodulatory therapy, corticosteroid therapy'
p2964
asS'NCT02324699'
p2965
(lp2966
S'- concurrent use of anti-tnf\xce\xb1 antibodies.'
p2967
aS'- no corticosteroids within prior 3 months (other than budesonide controlled ileal release)'
p2968
aS'- no stoma at the time of enrollment'
p2969
aS'- no absolute contraindication to systemic corticosteroid use such as hypersensitivity to any part of the formulation, systemic fungal infection, or recent administration of live or live attenuated vaccine within prior two weeks.'
p2970
aS'- pregnant women or plans for pregnancy within 3 months of study inclusion'
p2971
aS'- presence of stoma, more than three small-bowel resections, or documented history of short bowel syndrome'
p2972
aS'- intestinal stricture requiring surgery'
p2973
aS'- abdominal abscess'
p2974
aS'- inability or unwillingness to provide informed consent'
p2975
aS'- any other condition, which, in the opinion of the investigators would impede competence or compliance or possibly hinder completion of the study'
p2976
asS'NCT02450513'
p2977
(lp2978
S'- patients with ulcerative colitis.'
p2979
aS'- patients treated in placebo controlled trials.'
p2980
aS'- patients unwilling to participate or withdrawing informed consent for this study.'
p2981
asS'NCT02596893'
p2982
(lp2983
S'- the presence of any of the following will exclude a subject from enrollment:'
p2984
aS'- diagnosis of ulcerative colitis (uc), indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis'
p2985
aS"- local manifestations of crohn's disease (cd) such as symptomatic strictures, abscesses, short bowel syndrome; or other disease complications for which surgery might be indicated or could confound the evaluation of efficacy"
p2986
aS'- intestinal resection within 6 months or any intra-abdominal surgery within 3 months prior to the screening visit'
p2987
aS'- ileostomy or a colostomy'
p2988
aS"- subject has a history of any clinically significant medical condition that, in the investigator's opinion, would prevent the subject from participating in the study."
p2989
asS'NCT02394028'
p2990
(lp2991
S'- a history of, or current conditions affecting the digestive tract, such as ulcerative colitis, indeterminant colitis, fistulizing disease, abdominal or perianal abscess, adenomatous colonic polyps not excised, colonic mucosal dysplasia, and short bowel syndrome'
p2992
aS'- planned surgery for cd'
p2993
aS'- ileostomy or colostomy'
p2994
aS'- has received non-permitted inflammatory bowel disease (ibd) therapies (including natalizumab, vedolizumab, and efilizumab, as stated in the protocol)'
p2995
aS'- chronic hepatitis b or c infection, hiv, active or latent tuberculosis (patients with prior history of bcg vaccination must pass protocol-defined screening criteria)'
p2996
asS'NCT01826188'
p2997
(lp2998
S'- 1. patients with a diagnosis of a mental disorder'
p2999
aS'- 2. patients who by the judgment of their physician are likely to develop drug addiction.'
p3000
aS'- 3. pregnant women or women who are intending to become pregnant'
p3001
aS'- 4. patients with a known cannabis allergy'
p3002
aS'- 5. patients who are not capable of giving an informed consent'
p3003
aS"- 6. patients with an impending operation due to crohn's disease."
p3004
asS'NCT02619552'
p3005
(lp3006
S'- previous primary non-response to an anti-tnf'
p3007
aS'- uncontrolled medical or psychiatric disease (a. degenerative neurologic condition, b.unstable angina, c.class iii/iv congestive heart failure, d.severe asthma or chronic obstructive pulmonary disease, e.symptomatic peripheral vascular disease, f. chronic renal insufficiency (creatinine > 2.0), g. malignancy within the last 3 years (excluding squamous or basal cell cancers of the skin), h. poorly controlled depression, mania, and schizophrenia, i. active infection, j. acquired immunodeficiency syndrome)'
p3008
aS'- inability to adhere to the protocol'
p3009
aS'- need for imminent surgery other than an exam under anesthesia'
p3010
aS'- under 18 years of age.'
p3011
aS'- pregnancy'
p3012
aS'- use of concurrent prednisone >30 mg per day in the anti-tnf groups'
p3013
asS'NCT02060318'
p3014
(lp3015
S'- not able to consent in an ethical manner (e.g. severe mental illness)'
p3016
aS'- significant co-morbidity (e.g. cancer, hiv)'
p3017
aS'- other immunological disease (e.g. psoriasis)'
p3018
aS'- current treatment with biological agents healthy controls inclusion criteria:'
p3019
aS'- no current disease'
p3020
aS'- no daily drug use'
p3021
aS'- can understand and write danish'
p3022
aS'- european ancestry'
p3023
asS'NCT01823042'
p3024
(lp3025
S'- bacterial,viral or other microbial infection(including hiv)'
p3026
aS'- any of the following medications taken within 12 weeks before surgery: cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, or other investigational drugs'
p3027
aS"- any of ongoing therapy for crohn's disease with: 5-asa compounds, steroids, immune modifiers, systemic antibiotics, and tube feeding"
p3028
aS'- needing orally administered corticosteroids for the treatment of other diseases. inhaled or dermatologic preparations are acceptable.'
p3029
aS'- previous or current use of infliximab.'
p3030
aS'- current use of prescription doses or chronic/frequent use of nsaids'
p3031
aS'- treatment with narcotic pain medications. (anti-diarrheal agents such as loperamide and diphenoxylate are permitted, providing that the dose is not increased during the study period.)'
p3032
aS'- history of pancreatitis, except for subjects with a known but removed cause(such as gallstone pancreatitis)'
p3033
aS'- wbc <3.0 x 109/l, hemoglobin <80 g/l, platelets<50,000/mm3 at the time of enrollment (or within the previous 6 months, if known)'
p3034
aS'- history of abnormal liver function tests, including ast or alt >1.5 times upper limit of normal, alkaline phosphatase >2 times upper limit of normal, total bilirubin >2.5 mg/dl at screening (or within the previous 6 months, if known)'
p3035
aS'- with short bowel syndrome (defined as requiring oral or parenteral supplemental or total nutrition to maintain stable body weight, or more than 100 cm of small bowel resected)'
p3036
aS'- history of malignancy'
p3037
aS'- women who are pregnant or lactating at the time of enrollment, or who intend to be during the study period.'
p3038
aS'- participation in other clinical trial within the past 6 months'
p3039
asS'NCT02010762'
p3040
(lp3041
S'- patients in whom not all visible cd has been resected'
p3042
aS'- active fistulizing perianal disease (requiring anti tnf treatment)'
p3043
aS'- extensive small bowel resection'
p3044
aS'- third, fourth or later ileocolonic resection'
p3045
aS'- patients undergoing ileocoecal resection in the lir!c trial (ntr 1150, http://www.trialregister.nl/trialreg/admin/rctview.asp?tc=1150)'
p3046
aS'- a history of primary hyperparathyroidism'
p3047
aS'- a history of osteoporosis for which calcium and vitamin d treatment are mandatory'
p3048
aS'- a history of another granulomatous diseases (sarcoidosis, tuberculosis)'
p3049
aS'- pregnant or breastfeeding (at index date) female patients'
p3050
aS'- patients undergoing other resections than ileocolonic resections'
p3051
aS'- patients who prefer to use open-label vitamin d preparations'
p3052
aS'- patients who will continue to use tanning beds'
p3053
asS'NCT02574637'
p3054
(lp3055
S'- severe underlying immunosuppression'
p3056
aS'- severe gastrointestinal complications; e.g., short bowel syndromes, obstructing strictures, recent or planned bowel surgery, ileostomy and/or colostomy, recent bowel perforation'
p3057
aS'- significant infections at screening; infected abscess, positive for clostridium difficile, recent infectious hospitalization,'
p3058
aS"- recent treatment with approved or investigational biologic therapy for crohn's disease"
p3059
aS'- recent or planned live attenuated vaccine'
p3060
aS'- history of cancer, except for basal cell carcinoma or cis of the cervix with apparent cure \xe2\x89\xa5 12 months before screening'
p3061
aS'- pregnancy/breast feeding'
p3062
aS'- drug abuse'
p3063
asS'NCT02425111'
p3064
(lp3065
S'- 1. has received a diagnosis of ulcerative colitis or indeterminate colitis.'
p3066
aS'- 2. has clinical evidence of abdominal abscess.'
p3067
aS'- 3. has a history of >3 small bowel resections or diagnosis of short bowel syndrome.'
p3068
aS'- 4. has extensive colonic resection, ie, subtotal or total colectomy with <15 cm colon remaining.'
p3069
aS'- 5. has ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.'
p3070
aS'- 6. has a history or evidence of adenomatous colonic polyps that have not been removed.'
p3071
aS'- 7. has a history or evidence of colonic mucosal dysplasia.'
p3072
aS'- 8. has intolerance or contraindication to undergo ileocolonoscopy.'
p3073
aS'- 9. has active or latent tuberculosis, regardless of treatment history, as evidenced by any of the following: 1. history of tuberculosis (tb). 2. a diagnostic tb test performed during screening that is positive, as defined by: i. a positive quantiferon\xc2\xae test or 2 successive indeterminate quantiferon tests or ii. a tuberculin skin test reaction \xe2\x89\xa510 mm (\xe2\x89\xa55 mm in patients receiving the equivalent of >15 mg/day prednisone).'
p3074
aS'- 10. has chronic hepatitis b (hbv) or hepatitis c (hcv) infection.'
p3075
aS'- 11. has any identified congenital or acquired immunodeficiency (eg, common variable immunodeficiency, human immunodeficiency virus [hiv] infection, organ transplantation).'
p3076
aS'- 12. has evidence of active c. difficile infection or is having treatment for c. difficile infection or other intestinal pathogens during screening.'
p3077
aS'- 13. has evidence of an active infection during screening.'
p3078
aS'- 14. currently requires or has a planned surgical intervention for cd during the study.'
p3079
aS'- 15. has received any investigational compound within 60 days of enrollment.'
p3080
aS'- 16. has received any biologics within 60 days of enrollment.'
p3081
aS'- 17. has received any live vaccinations within 30 days prior to enrollment.'
p3082
aS"- 18. has conditions which, in the opinion of the investigator, may interfere with the participant's ability to comply with the study procedures."
p3083
aS'- 19. has any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, gastrointestinal (gi), genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise participant safety.'
p3084
aS'- 20. has a history of hypersensitivity or allergies to vedolizumab or its components.'
p3085
aS'- 21. has had prior exposure to vedolizumab, natalizumab, efalizumab, or rituximab.'
p3086
aS'- 22. had a surgical procedure requiring general anesthesia within 30 days prior to screening or is planning to undergo major surgery during the study period.'
p3087
aS'- 23. has a history of malignancy, except for the following: adequately-treated nonmetastatic basal cell skin cancer; squamous cell skin cancer that has been adequately treated and that has not recurred for at least 1 year prior to screening; and history of cervical carcinoma in situ that has been adequately treated and that has not recurred for at least 3 years prior to screening. participants with a remote history of malignancy (eg, >10 years since completion of curative therapy without recurrence) will be considered based on the nature of the malignancy and the therapy received and must be discussed with the sponsor on a case-by-case basis prior to enrollment.'
p3088
aS'- 24. has a history of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.'
p3089
aS'- 25. has a positive progressive multifocal leukoencephalopathy (pml) subjective symptom checklist prior to the administration of study drug.'
p3090
aS'- 26. has any of the following laboratory abnormalities during the screening period: i. hemoglobin level <8 g/dl. ii. white blood cell (wbc) count <3 x 10^9/l. iii. lymphocyte count <0.5 x 10^9/l. iv. platelet count <100 x 10^9/l or >1200 x 10^9/l. v. alanine aminotransferase (alt) or aspartate aminotransferase (ast) >3 x the upper limit of normal (uln). vi. alkaline phosphatase >3 x uln. vii. serum creatinine >2 x uln.'
p3091
aS'- 27. has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to enrollment.'
p3092
aS"- 28. has an active psychiatric problem that, in the investigator's opinion, may interfere with compliance with study procedures."
p3093
aS'- 29. is unable to attend all the study visits or comply with study procedures.'
p3094
aS'- 30. if female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 18 weeks after participating in this study; or intending to donate ova during such time period.'
p3095
aS'- 31. if male, the participant intends to donate sperm during the course of this study or for 18 weeks thereafter.'
p3096
aS'- 32. is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.'
p3097
aS'- 33. participants who are at sites participating in the magnetic resonance enterography (mren) substudy may not participate if they have intolerance or contraindication to the procedure or if any of the following exclusions apply: 1. has certain implanted medical devices, such as pacemakers or implantable cardioverter defibrillators (icds), or ferromagnetic metallic foreign bodies, such as shrapnel or certain tattoos. 2. has allergy to gadolinium-based magnetic resonance (mr) iv contrast agents. 3. has known claustrophobia. 4. has estimated glomerular filtration rate (egfr) <30 ml/min/1.73 m^2 at screening.'
p3098
asS'NCT02520843'
p3099
(lp3100
S'- - disease of crohn activates mainly luminal with a cdai = 220 requiring an immediate treatment'
p3101
aS'- patients having never received specific treatments of the anal died disease of crohn with fistula, including by antibiotics'
p3102
aS'- presence of an abscess or collections of more than 2 cms unless this problem is solved during the period of preparation'
p3103
aS'- rectal and/or anal stenosis and/or active proctitis, if it means a limitation of the surgical procedure'
p3104
aS'- patient having undergone an operation of the fistula other than the drainage'
p3105
aS'- patients under corticoids or by having receiving in the previous four weeks'
p3106
aS'- active malignant tumors or history of malignant tumors'
p3107
asg2025
(lp3108
S'- bacterial, viral or other microbial infection(including hiv).'
p3109
aS'- orally administered corticosteroids within 3 weeks before enrollment, inhaled or dermatologic preparations for the treatment of other diseases are acceptable.'
p3110
aS'- used of infliximab or immunosuppressant within 2 months before enrollment.'
p3111
aS'- previous use of prescription doses of nsaids without efficacy.'
p3112
aS'- treatment with narcotic pain medications(anti-diarrheal agents such as loperamide and diphenoxylate are permitted).'
p3113
aS'- history of pancreatitis, except for subjects with a known but removed cause(such as gallstone pancreatitis).'
p3114
aS'- history of abnormal liver function tests, including ast or alt >1.5 times upper limit of normal, alkaline phosphatase >2 times upper limit of normal, total bilirubin >2.5 mg/dl at screening (or within the previous 6 months, if known).'
p3115
aS'- history of malignancy.'
p3116
aS'- women who are pregnant or lactating at the time of enrollment, or who intend to be during the study period.'
p3117
aS'- participation in other clinical trial within the past 3 months.'
p3118
asS'NCT02378688'
p3119
(lp3120
S'- diagnosis of ulcerative colitis, indeterminate colitis, pseudomembranous colitis or coeliac disease'
p3121
aS'- enterocutaneous, abdominal or pelvic active fistulae, abscesses or fistulae likely to require surgery during the study'
p3122
aS'- gi surgery (including appendectomy) within 12 weeks prior to visit 2 (baseline) or has surgery planned or deemed likely to require surgery for cd during the study'
p3123
asS'NCT02332356'
p3124
(lp3125
S'- contraindication for infliximab, adalimumab, or azathioprine'
p3126
aS'- lactating woman'
p3127
aS'- presence of malignancy'
p3128
aS'- within 3 month from intestinal surgery'
p3129
aS'- presence of an end stoma'
p3130
aS'- planned surgery'
p3131
asS'NCT00731172'
p3132
(lp3133
S'- 1. diagnosis of indeterminate, microscopic, lymphocytic, collagenous, or ulcerative colitis.'
p3134
aS'- 2. subjects with clinically significant active systemic infection.'
p3135
aS'- 3. subjects who in the opinion of the investigator have another clinically significant or unstable medical or surgical condition such as: cardiovascular, pulmonary, hepatic, renal, autoimmune, endocrine, metabolic or malignancy or any other condition that places the subject at undue risk by participating in the study.'
p3136
aS'- 4. short bowel syndrome or a bowel surgery within 3 month before randomization.'
p3137
aS'- 5. clinically significant obstructive symptoms with radiologic evidence of intestinal strictures. ileostomy, colostomy, or parenteral nutrition subjects who have fistula with abscess formation.'
p3138
aS'- 6. the use of the following medications within the last 12 weeks prior to screening: tnf-a antibodies, thalidomide, methotrexate, cyclosporine, tacrolimus, or mycophenolate mofetil.'
p3139
aS'- 7. the use of more than 100mg/d aspirin.'
p3140
aS'- 8. use of another investigational drug within 3 months before screening.'
p3141
aS'- 9. pregnant or lactating woman.'
p3142
aS'- 10. concomitant substance or alcohol abuse.'
p3143
aS'- 11. subjects with known sensitivity to mannitol.'
p3144
aS'- 12. subjects unable to self-inject or do not have a designee or healthcare professional who can inject the study medication.'
p3145
aS'- 13. subject unable to comply with the planned schedule of study visits and study procedures'
p3146
asS'NCT01046773'
p3147
(lp3148
S'- children less than 8 years or greater than 18 years at the time of study screening'
p3149
aS'- patients with a documented history of hypercalcemia, renal insufficiency, or nephrolithiasis'
p3150
aS'- patients taking cholestyramine'
p3151
aS'- patients who have a gi tract in discontinuity (ostomy)'
p3152
aS'- patients who have serum 25-oh vitamin d levels of >50 ng/ml at the time of study screening'
p3153
asS'NCT01338740'
p3154
(lp3155
S"- exclusively fistulising crohn's disease or exclusive involvement of the upper gastrointestinal (gi) tract."
p3156
aS'- subject with abscess or suspicion of abscess.'
p3157
aS'- subject with obstructive fibrotic strictures (with prestenotic dilatation).'
p3158
aS'- subject with short bowel syndrome.'
p3159
aS'- subject who has had a surgical bowel resection within the past 6 months or planning of any resection at the time while enrolled in the study.'
p3160
aS'- subject with ulcerative colitis or indeterminant colitis.'
p3161
aS'- subject with ostomy or ileoanal pouch.'
p3162
aS'- subject who is currently receiving total parenteral nutrition.'
p3163
aS'- subject who has previously been treated with infliximab or certolizumab pegol.'
p3164
aS'- subject with positive stool cultures for enteric pathogens or positive c. difficile toxins during screening period.'
p3165
aS'- subject who has received any investigational drug within 12 weeks prior to screening.'
p3166
aS'- subject with a history of drug or alcohol abuse within the past 3 years.'
p3167
aS'- females who are pregnant or breast feeding.'
p3168
aS'- females of child bearing age not practicing effective birth control.'
p3169
aS'- subject with a history of malignancy irrespective of time (except carcinoma- in situ of cervix or basal cell carcinoma or squamous cell carcinoma that was successfully treated).'
p3170
aS'- subject with a history or symptoms of lymphoproliferative disease.'
p3171
aS'- subject with a history of human immunodeficiency virus (hiv), chronic or active hepatitis b.'
p3172
aS'- history of congestive heart failure (chf), including medically controlled asymptomatic chf.'
p3173
aS'- subject who currently has or had an opportunistic infection (e.g. cytomegalovirus (cmv), pneumocystis carinii, aspergillosis, histoplasmosis, coccidioidomycosis) within 6 months prior to screening.'
p3174
aS'- subject who currently has an active infection.'
p3175
aS'- subject who has a transplanted organ (except for corneal transplant).'
p3176
aS'- history of known demyelinating disease such as optic neuritis or multiple sclerosis.'
p3177
aS'- signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, psychiatric or cerebral disease. concomitant medication'
p3178
aS'- 1. corticosteroids (prednisone, (methyl)prednisolone, budesonide): stable dose for 2 weeks prior to baseline, then tapering at the discretion of the investigator.'
p3179
aS'- 2. immunosuppressants (azathioprine, 6-mercaptopurine, methotrexate): patients taking this medication prior to baseline: stable dose for 8 weeks prior to baseline, then stable dose until week 26 of the study. starting or restarting of immunosuppressants is allowed until week 2, then stable dose until week 26 of the study.'
p3180
aS'- 3. 5-asa analogues (sulphasalazine, mesalazine): stable dose for 4 weeks prior to baseline, stable dose until week 26 of the study.'
p3181
aS'- 4. antibiotics (e.g. quinolone, metronidazole): stable dose for 2 weeks prior to baseline.'
p3182
aS'- 5. adalimumab: at least 2 week washout period prior to first infliximab infusion. starting or increasing the dose of other medication for crohn\'s disease than infliximab during the study will be considered as "treatment failure". (except for immunosuppressants as described above under 2.)'
p3183
asg1147
(lp3184
S'- previous noncompliant with medications'
p3185
aS'- < 18 years of age or >80 years of age.'
p3186
aS'- congestive heart failure'
p3187
aS'- abnormal liver tests alanine aminotransferase (alt) or aspartate aminotransferase (ast) 2 \xc3\x97 the upper limit of normal (uln) or leucopenia wbc count <3 \xc3\x97 109/l'
p3188
aS'- pregnant or planning on becoming pregnant.'
p3189
aS'- active tuberculosis or hepatitis b infection'
p3190
aS'- any cancer within the past 5 years. (exception non-melanomatous skin cancer.)'
p3191
aS'- receiving any immunomodulator therapy within the past 3 months'
p3192
aS'- evidence of or treatment for c. difficile infection within 60 days or other intestinal pathogen within 30 days prior to enrollment'
p3193
aS'- clinically significant extra-intestinal infection (e.g., pneumonia, pyelonephritis) within 30 days of the initial screening visit'
p3194
aS'- any live vaccinations within 30 days prior to study drug administration except for the influenza vaccine'
p3195
aS'- any identified congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, human immunodeficiency virus [hiv] infection, organ transplantation)'
p3196
aS'- any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise patient safety'
p3197
aS'- unable to give own informed consent'
p3198
asS'NCT01986127'
p3199
(lp3200
S'- patients with large intestinal stenosis (more than 6cm) and multiples'
p3201
aS'- patients with previous or actual treatment with anti-tumor necrosis factor (anti-tnf) drugs'
p3202
aS'- patients with positive serology to hepatitis b virus(hbv),hepatitis c virus (hcv), or hiv'
p3203
aS'- patients with positive screening to tuberculosis(positive ppd)'
p3204
aS'- established contraindication to anti-tnf drugs'
p3205
aS'- existence of fistulous tracts associated with intestinal stenosis'
p3206
aS'- neoplastic process associated with stenosis or in another location'
p3207
aS'- pregnancy or breastfeeding'
p3208
asg1758
(lp3209
S'- change in dose or intervals of anti-tnf within the past 2 months prior to admission.'
p3210
aS'- disease confined to the rectum (proctitis).'
p3211
aS'- antibiotic use in the past 4 weeks.'
p3212
aS'- any known erosive inflammation anywhere in the small bowel or esophagus.'
p3213
aS'- any proven infection such as positive stool culture, parasite or c. difficile, urinary tract infection, cellulitis, abscess, pneumonia, line-infections etc.'
p3214
aS'- fever >38.5, or >38.0c thought to be unrelated to the inflammatory process of active uc.'
p3215
aS'- the probable need for second line medical therapy (infliximab, cyclosporine, tacrolimus) or colectomy within 5 days of enrollment, as judged by the caring physician.'
p3216
aS'- known allergy to more than one antibiotic regimen from the list below.'
p3217
aS'- pregnancy.'
p3218
asg1788
(lp3219
S"- c0168z02: 17 years of age or older, with the exception of patients who participated in the sponsor's conducted pediatric ibd clinical trials. have other crohn's-like diseases that are associated with genetic diseases (eg, glycogen storage disease). the patient and parent/guardian are not able to adhere to the protocol requirements. are participating in any clinical trial for an investigational agent that is not commercially available. remicadepib4002 and remicadepib4003: less than 6 years of age or 17 years of age or older."
p3220
asS'NCT02365649'
p3221
(lp3222
S'- subjects with ulcerative colitis (uc), collagenous colitis or indeterminate colitis.'
p3223
aS'- subject who has had surgical bowel resections in the past 6 months or is planning resection.'
p3224
aS'- subjects with an ostomy or ileoanal pouch.'
p3225
aS'- subject with symptomatic bowel stricture or abdominal or peri-anal abcess.'
p3226
aS'- subject who has short bowel syndrome.'
p3227
aS'- subject with recurring infections or active tuberculosis (tb).'
p3228
asS'NCT02405442'
p3229
(lp3230
S'- evidence of abscess at screening'
p3231
aS'- extensive colonic resection (subtotal or total colectomy) or history of > 2 small bowel resections'
p3232
aS'- ileostomy, colostomy, or symptomatic stenosis of the intestine'
p3233
aS'- current use of oral corticosteroids at a dose equivalent to > 30 mg/day of prednisone'
p3234
aS'- ulcerative colitis or indeterminate colitis'
p3235
aS'- short bowel syndrome'
p3236
aS'- stool sample positive for clostridium difficile (c. difficile) toxin, e. coli, salmonella, shigella, campylobacter or yersinia'
p3237
aS'- treatment with any monoclonal antibody within 4 weeks of screening'
p3238
aS'- history or evidence of colonic mucosal dysplasia'
p3239
aS'- hiv, hepatitis b, hepatitis c, or tuberculosis (tb) infection'
p3240
aS'- participated in a clinical study with an investigational drug or biologic within the last 30 days'
p3241
aS'- any chronic medical condition (including, but not limited to, cardiac or pulmonary disease) that, in the opinion of the investigator, would make the individual unsuitable for the study or would prevent compliance with the study protocol'
p3242
asS'NCT02269358'
p3243
(lp3244
S'- 1. patients who are primary non responders after first two doses'
p3245
aS'- 2. patients who have had to stop infliximab due to side effects.'
p3246
aS'- 3. patients with known intolerance to methotrexate.'
p3247
aS'- 4. elevated alt >1.5 normal.'
p3248
aS'- 5. pregnancy.'
p3249
aS'- 6. patients who have insulin-dependent diabetes'
p3250
aS'- 7. patients who have significantly impaired renal function'
p3251
aS'- 8. current bacterial infection/ inflammation including hepatitis b or c and pneumonia.'
p3252
asS'NCT02392286'
p3253
(lp3254
S'- patients in whom corticosteroid therapy is contraindicated: immunocompromised (active cancer on chemotherapy or radiation treatment), severe liver disease (decompensated cirrhosis, active alcoholic hepatitis), end-stage renal disease on dialysis, aids or aids-defining illness; myocardial infarction within the past year; nyha class 4 heart failure'
p3255
aS'- patients on systemic corticosteroid therapy currently or within the past 8 weeks'
p3256
aS'- patients not on stable doses of immunomodulators or biologics for at least 8 weeks'
p3257
aS'- infectious colitis (e.g., c. difficile, cmv, hsv)'
p3258
aS'- systemic infections (bacteremia, fungal infections)'
p3259
aS"- fulminant crohn's disease"
p3260
aS'- patients who require imminent surgery'
p3261
aS'- abscess'
p3262
aS'- pregnancy'
p3263
aS'- weight <35 kg'
p3264
asS'NCT02531113'
p3265
(lp3266
S'- diagnosis of ulcerative colitis or indeterminate colitis'
p3267
aS'- known strictures/stenosis leading to symptoms of obstruction'
p3268
aS'- current stoma or need for ileostomy or colostomy'
p3269
aS'- clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk'
p3270
aS'- history of uveitis or known macular edema'
p3271
aS'- history of colonic dysplasia'
p3272
asS'NCT02367183'
p3273
(lp3274
S"- 1. diagnosis of crohn's colitis restricted to the left colon , ulcerative colitis (uc), indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis."
p3275
aS"- 2. local manifestations of crohn's disease (cd) such as strictures, abscesses, fistula, short bowel syndrome or other disease complications for which surgery might be indicated or could confound the evaluation of efficacy."
p3276
aS'- 3. intestinal resection within 6 months or any intra-abdominal surgery within 3 months prior to screening.'
p3277
aS'- 4. subjects with an ileostomy or a colostomy.'
p3278
aS'- 5. stool positive for any enteric pathogen or c. difficile toxin at screening.'
p3279
aS'- 6. history of colorectal cancer or colorectal dysplasia.'
p3280
aS'- 7. prior use of mycophenolic acid, tacrolimus, sirolimus, cyclosporine, thalidomide or apheresis (eg, adacolumn) for the treatment of cd. in addition, prior use of any of these treatment modalities for an indication other than cd within 8 weeks of screening is also excluded.'
p3281
aS'- 8. use of intravenous (iv) corticosteroids within 2 weeks of screening.'
p3282
aS'- 9. use of topical treatment with 5 aminosalicylic acid (5-asa) or corticosteroid enemas or suppositories within 2 weeks of screening'
p3283
aS"- 10. use of antibiotic therapy for the treatment of crohn's disease (cd) within 3 weeks of screening."
p3284
aS'- 11. use of cholestyramine within 3 weeks of screening.'
p3285
aS'- 12. prior treatment with more than 2 tumor necrosis factor-\xce\xb1 (tnf-\xce\xb1) blockers.'
p3286
aS'- 13. prior treatment with any integrin antagonists (eg, natalizumab or vedolizumab).'
p3287
aS'- 14. use of tumor necrosis factor-\xce\xb1 (tnf-\xce\xb1) blockers within 12 weeks of the screening'
p3288
aS'- 15. administration of total parenteral nutrition (tpn) within 4 weeks of screening.'
p3289
aS"- 16. history of any clinically significant neurological, renal, hepatic, gastrointestinal, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, or any other medical condition that, in the investigator's opinion, would prevent the subject from participation in the study."
p3290
aS'- 17. any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she was to participate in the study or confounds the ability to interpret data from the study.'
p3291
aS'- 18. pregnant or breastfeeding.'
p3292
aS'- 19. history of any of the following cardiac conditions within 6 months of screening: myocardial infarction, acute coronary syndrome, unstable angina, new onset atrial fibrillation, new onset atrial flutter, second- or third-degree atrioventricular block, ventricular fibrillation, ventricular tachycardia, heart failure, cardiac surgery, interventional cardiac catheterization (with or without a stent placement), interventional electrophysiology procedure, or presence of implanted defibrillator.'
p3293
aS'- 20. known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease and herpes zoster), human immunodeficiency virus (hiv), or any major episode of infection requiring hospitalization or treatment with intravenous (iv) or oral antibiotics within 4 weeks of screening.'
p3294
aS'- 21. history of congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease).'
p3295
aS'- 22. history of malignancy, except for: 1. treated (ie, cured) basal cell or squamous cell in situ skin carcinomas 2. treated (ie, cured) cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years'
p3296
aS'- 23. subjects who have received any investigational drug or device within 1 months of screening.'
p3297
aS'- 24. prior treatment with ged-0301, or participation in a clinical study involving ged-0301.'
p3298
aS'- 25. history of alcohol, drug, or chemical abuse within the 6 months prior to screening.'
p3299
aS'- 26. known hypersensitivity to oligonucleotides or any ingredient in the ip.'
p3300
asS'NCT00609752'
p3301
(lp3302
S"- previous treatment for crohn's disease with liquid diet or glucocorticoid therapy"
p3303
aS'- isolated orofacial granulomatosis'
p3304
aS'- intravenous glucocorticoid therapy immediately indicated'
p3305
aS'- planned surgical intervention for cd'
p3306
asg1623
(lp3307
S'- 1. any reported contraindications for inflectra or remicade, according to the smpc.'
p3308
aS'- 2. known hypersensitivity (including severe, acute infusion reactions) to infliximab, its excipients or other murine proteins, at the time of enrolment.'
p3309
aS'- 3. prior history of failure to respond to remicade or inflectra.'
p3310
asS'NCT01820247'
p3311
(lp3312
S'- bacterial,viral or other microbial infection(including hiv)'
p3313
aS'- needing orally administered corticosteroids for the treatment of other diseases. inhaled or dermatologic preparations are acceptable.'
p3314
aS'- previous or current use of infliximab. current use of prescription doses or chronic/frequent use of nsaids'
p3315
aS'- treatment with narcotic pain medications. (anti-diarrheal agents such as loperamide and diphenoxylate are permitted)'
p3316
aS'- history of pancreatitis, except for subjects with a known but removed cause(such as gallstone pancreatitis)'
p3317
aS'- history of abnormal liver function tests, including ast or alt >1.5 times upper limit of normal, alkaline phosphatase >2 times upper limit of normal, total bilirubin >2.5 mg/dl at screening (or within the previous 6 months, if known)'
p3318
aS'- history of malignancy'
p3319
aS'- women who are pregnant or lactating at the time of enrollment, or who intend to be during the study period.'
p3320
aS'- participation in other clinical trial within the past 6 months'
p3321
asS'NCT01783106'
p3322
(lp3323
S'- patients under 18 or unable to give informed consent.'
p3324
aS'- any antibiotic use within the previous 4 weeks'
p3325
aS'- known sensitivity to ciprofloxacin, doxycycline, hydroxychloroquine, or budesonide'
p3326
aS'- patients with a history of tendon disorders related to fluoroquinoline administration'
p3327
aS'- any change to immunosuppressive therapy (azathioprine, or mercaptopurine) within the previous 3 months.'
p3328
aS'- use of infliximab or adalimumab (anti-tnf antibody) or methotrexate within the previous 3 months'
p3329
aS'- concurrent use of systemic corticosteroids in excess of oral prednisolone 5 mgs/day or budesonide 3mg/day)'
p3330
aS"- any change to medication for crohn's disease in previous 4 weeks."
p3331
aS'- patients with complications requiring surgery (significant intestinal obstruction, perforation or abscess)'
p3332
aS'- cdai >450'
p3333
aS'- participation in other trials in the last 3 months.'
p3334
aS'- serious intercurrent infection or other clinically important active disease (including renal and hepatic disease)'
p3335
aS'- pregnant, post-partum (<3months) or breast feeding females'
p3336
aS'- patients with abnormal visual acuity (that does not correct with glasses) or unexplained visual symptoms'
p3337
aS'- women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period (double barrier methods such as condoms or diaphragms with spermicidal gel or foam), and for up to 4 weeks after the study.'
p3338
aS'- patients who need to continue to receive oral contraceptives (if unwilling to use double barrier methods), oral anticoagulants tricyclic antidepressants, non-steroidal anti-inflammatory drugs (nsaids), anticonvulsants, sucralfate, or cyclosporine'
p3339
asS'NCT00275418'
p3340
(lp3341
S"- active crohn's disease (cdai>150), partial bowel obstruction, impending surgery, pregnancy, serious other diseases"
p3342
asS'NCT00603616'
p3343
(lp3344
S'- evidence of active infection which may include any of the following'
p3345
aS'- febrile ( > 38.5\xc2\xbac)'
p3346
aS'- positive blood culture within 2 weeks prior to randomization'
p3347
aS'- evidence of toxic megacolon or abscess'
p3348
aS'- positive stool culture for enteric pathogens, pathogenic ova or parasite, or a positive assay for c. difficile toxin at screening'
p3349
aS'- subjects with cdai > 450'
p3350
aS'- any current use or use within the last 8 weeks of an investigational drug'
p3351
aS'- current or past use (within past 12 wks) of biological treatment'
p3352
aS'- current or use within the last 4 weeks of any oral or intravenous antibiotic'
p3353
aS'- anticipated increased dosage of any medication to treat cd'
p3354
aS'- anticipated need for surgery within 12 weeks'
p3355
aS'- known obstructive diseases of the gastrointestinal system'
p3356
aS'- medical conditions requiring in-patient hospitalization'
p3357
aS'- proctocolectomy, total colectomy, ileostomy, or stoma'
p3358
aS'- severe cardiopulmonary disease:'
p3359
aS'- congestive heart failure (nyha class iii or iv)'
p3360
aS'- severe cardiovascular or peripheral vascular disease'
p3361
aS'- myocardial infarction, percutaneous coronary intervention, or bypass surgery within the past 6 months'
p3362
aS'- significant liver disease:'
p3363
aS'- levels of sgot [ast], sgpt [alt], or alkaline phosphatase > 2.5x the upper limit of the normal range for the laboratory performing test'
p3364
aS'- history of cirrhosis'
p3365
aS'- renal insufficiency, defined as serum creatinine > 150% of the upper limit of the normal range for the laboratory performing the test'
p3366
aS'- abnormal hematology parameters defined as severe anemia with hemoglobin < 8.5 g/dl and/or white blood cell count of < 3,500/ul'
p3367
aS'- malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (cin i-ii)'
p3368
aS'- history of dysplasia or carcinoma of the colon'
p3369
aS'- pregnant, lactating, or planning to become pregnant during the course of the investigational study'
p3370
aS'- known history of allergic reaction to rifaximin or allergy to any of the rifamycin antimicrobial agents (which include rifampin, rifabutin, and rifapentine)'
p3371
asg1698
(lp3372
S'- 1. patients with a known mental disorder'
p3373
aS'- 2. patients who are deemed to be at a high risk of abuse or addiction to the study drug.'
p3374
aS'- 3. pregnant women'
p3375
aS'- 4. patients who are sensitive to any of the ingredients of the study medication.'
p3376
aS'- 5. patients who are unable to give informed consent.'
p3377
aS'- 6. patients who may need surgery in the near future.'
p3378
asg444
(lp3379
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p3380
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p3381
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p3382
aS'- known hiv/aids'
p3383
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p3384
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p3385
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p3386
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p3387
aS'- participated in an investigational study within 1 month prior to study entry'
p3388
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p3389
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p3390
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p3391
asS'NCT02646683'
p3392
(lp3393
S'- 1. prior treatment with vedolizumab.'
p3394
aS'- 2. contraindication for endoscopy.'
p3395
aS'- 3. history of colonic dysplasia/cancer'
p3396
aS'- 4. presence of stoma'
p3397
aS'- 5. received other biologics within the last 6 weeks of screening'
p3398
aS'- 6. use of 5-aminosalicylic acid (5-asa) or corticosteroid enemas/suppositories within 2 weeks of enrollment'
p3399
aS'- 7. chronic hepatitis b or c infection'
p3400
aS'- 8. evidence of or treatment for c. difficile infection or other intestinal pathogen at screening within 4 weeks prior to enrollment'
p3401
aS'- 9. active or latent tuberculosis'
p3402
aS"- 10. conditions which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures."
p3403
aS'- 11. received any investigational drug in the past 30 days or 5 half-lives, whichever is longer.'
p3404
aS'- 12. positive progressive multifocal leukoencephalopathy ( pml) subjective symptom checklist before enrollment.'
p3405
aS'- 13. subjects with known allergy or hyposensitivity to vedolizumab or its components'
p3406
asS'NCT02389790'
p3407
(lp3408
S'- permanent discontinuation of study medication prior to the end of treatment visit in mt-1303-e13'
p3409
asS'NCT02164877'
p3410
(lp3411
S'- infection with enteric pathogen'
p3412
aS'- usage of probiotics, antibiotics, or prebiotics within the last month'
p3413
aS'- change in dose of oral steroids or 5-asa within the last 4 weeks or aza or mtx in the last 3 months'
p3414
aS'- dose of steroids exceeds 10 mg prednisolone per day or equivalent'
p3415
aS'- infusion of ifx or any alternative biological therapy within the last 3 months'
p3416
aS'- use of rectal 5-asa or steroids within the last 2 weeks.'
p3417
aS'- imminent need for surgery or presence of severe disease (cdai >450)'
p3418
aS'- pregnancy or lactation'
p3419
aS'- short bowel syndrome or subtotal/total colectomy'
p3420
aS'- pure anal disease and previous proctocolectomy'
p3421
aS'- significant hepatic, renal, endocrine, respiratory, neurological or cardiovascular disease as determined by the principal investigator'
p3422
aS'- history of cancer with a disease-free state of less than two years'
p3423
aS'- patients with penetrating disease or small bowel lesion only.'
p3424
asg1479
(lp3425
S'- patients refusing to participate by not giving their informed consent'
p3426
asS'NCT00353756'
p3427
(lp3428
S'- variety of concurrent medical conditions'
p3429
aS'- various concomitant medications'
p3430
asS'NCT02769494'
p3431
(lp3432
S'- contraindications to study drugs.'
p3433
aS'- underwent or will accept oral surgery.'
p3434
aS'- patients are not able to sign the informed consent or not comply with the study protocol.'
p3435
aS'- planning for pregnancy, pregnancy and lactating women.'
p3436
aS'- enrolled in other clinical trials in the past 30 days.'
p3437
aS'- patients with concurrent / new other serious diseases will affect the effectiveness and safety evaluation.'
p3438
asg894
(lp3439
S'- initial indication for ifx being predominantly fistulizing perianal disease.'
p3440
aS'- any contraindications for continuing ifx treatment, including prior acute or delayed infusion reaction to a tnf- inhibiting agent, any active infection requiring parenteral or oral antibiotic treatment, known infection with tuberculosis, human immunodeficiency virus (hiv) or hepatitis virus.'
p3441
aS'- any condition including physician finds incompatible with participation in the study or the patient being unwilling or unable to follow protocol requirements.'
p3442
asS'NCT02539849'
p3443
(lp3444
S'- subjects consuming prebiotic supplements (inulin, fos, galactooligosaccharides (gos)) in their regular diet.'
p3445
aS'- antibiotic use within the past 2 months'
p3446
aS'- previous anti-tnf therapy.'
p3447
asS'NCT02065570'
p3448
(lp3449
S'- subject with ulcerative colitis or indeterminate colitis.'
p3450
aS'- subject who has had surgical bowel resections in the past 6 months or is planning resection.'
p3451
aS'- subjects with an ostomy or ileoanal pouch.'
p3452
aS'- subject with symptomatic bowel stricture or abdominal or peri-anal abcess.'
p3453
aS'- subject who has short bowel syndrome.'
p3454
aS'- chronic recurring infections or active tuberculosis (tb).'
p3455
asg1774
(lp3456
S'- prisoner'
p3457
aS'- woman who is currently pregnant or breastfeeding'
p3458
aS'- allergy to linaclotide'
p3459
aS'- patients with known or suspected mechanical gastrointestinal obstruction'
p3460
asg2607
(lp3461
S'- anaemia due to any cause other than iron deficiency'
p3462
aS'- received intramuscular or intravenous injection or administration of a depot iron preparation within 8 weeks of screening'
p3463
aS'- received blood transfusion within 2 weeks of screening'
p3464
aS"- active inflammatory bowel disease as defined by a simple clinical colitis activity index (sccai) score greater than 4 or a crohn's disease activity index (cdai) score greater than 220"
p3465
aS'- known hypersensitivity or allergy to components of ferric maltol or ferric carboxymaltose'
p3466
aS'- reactions to previous doses of intravenous iron (e.g., required observation for > 2 hours, in-patient admission or medical treatment for infusion reactions)'
p3467
aS'- known contraindications for treatment with iron preparations'
p3468
aS'- vitamin b12 or folic acid deficiency'
p3469
aS'- concomitant medical conditions including neurologic or psychiatric symptoms that, in the opinion of the investigator and sponsor would make the subject unsuitable for participation in the study'
p3470
assS'kidney disease-Behavioral'
p3471
(dp3472
sS'fecal microbiota transplantation-Drug'
p3473
(dp3474
g88
(lp3475
S'- diagnosed as uc first time. no history of using biologic,immunomodulatory therapy or corticosteroid therapy. with contraindication of endoscopy.'
p3476
assS'uveitis-Other'
p3477
(dp3478
g371
(lp3479
S'- for iads patients'
p3480
aS'- unauthorized treatment (anticancer chemotherapy)'
p3481
aS'- for healthy volunteers'
p3482
aS'- contra-indications for donating blood except from age'
p3483
aS'- known history of iad (eg: psoriasis)'
p3484
aS'- common exclusion criteria:'
p3485
aS'- pregnant woman'
p3486
aS'- still under the exclusion period from another biomedical study'
p3487
aS'- psychiatric or addiction pathology who could interfere with the ability to fulfill the protocol needs or to provide an informed consent'
p3488
aS'- patient under a legal protection'
p3489
aS'- chronic lifelong viral infection unrelated to the pathology'
p3490
aS'- mild infection within the last 3 months'
p3491
assS'ankylosing spondylitis-Drug'
p3492
(dp3493
g324
(lp3494
S'- known intolerance for il2 (see spc),'
p3495
aS'- administration of a non-authorized treatment and/or iv bolus of corticosteroids in the last 2 months,'
p3496
aS'- vaccination with live attenuated virus in the months preceding the inclusion or planned during the study'
p3497
aS'- other severe or progressive autoimmune/inflammatory pathology,'
p3498
aS'- low white blood cell count<2000/mm3, lymphocytes <600/mm3, platelets <80 000/mm3,'
p3499
aS"- heart failure (\xe2\x89\xa5 grade iii nyha), renal insufficiency (cockcroft< 60ml/mn except patients with lupus or wegener's granulomatosis) or hepatic insufficiency (transaminases> 5n except for patients with autoimmune hepatitis), or lung failure,"
p3500
aS'- significant abnormality in chest x-ray other than these linked to the diseases under investigation'
p3501
aS'- cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or basocellular carcinoma)'
p3502
aS'- poor venous access not allowing repeated blood tests,'
p3503
aS'- restrictive diet or parenteral nutrition,'
p3504
aS'- surgery during the last 2 months or surgery planned during the study,'
p3505
aS'- participation in other biomedical research in the last 3 months or planned during the study.'
p3506
aS'- pregnant or lactating women,'
p3507
aS'- concomitant psychiatric disease or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give informed consent,'
p3508
aS'- positive hiv serology, active hepatitis b or ebv infection,'
p3509
aS'- patients under a measure of legal protection'
p3510
asg444
(lp3511
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p3512
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p3513
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p3514
aS'- known hiv/aids'
p3515
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p3516
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p3517
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p3518
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p3519
aS'- participated in an investigational study within 1 month prior to study entry'
p3520
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p3521
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p3522
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p3523
assS'colorectal cancer-Procedure'
p3524
(dp3525
g290
(lp3526
S'- pregnant woman or lactating woman.'
p3527
aS'- with confirmed distant metastasis in liver, lung, bones, or other organs.'
p3528
aS'- intolerable laparoscopic operation or converted to open surgery.'
p3529
aS'- with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.'
p3530
aS'- with bad compliance or contraindication to enrollment.'
p3531
asg109
(lp3532
S'- patients not capable of informed consent and/or quality of life assessment'
p3533
aS'- planned open procedure for surgical reason'
p3534
aS'- multiple previous abdominal operations'
p3535
aS'- body-mass index > 40'
p3536
asS'NCT01239082'
p3537
(lp3538
S'- symptoms of lower gastrointestinal tract disease warranting colonoscopic evaluation, including:'
p3539
aS'- more than one episode of rectal bleeding within the past 6 months'
p3540
aS'- documented iron deficiency anemia'
p3541
aS'- significant documented unintentional weight loss (>10% of baseline weight) over 6 months'
p3542
aS'- family history of crc in a first degree relative at any age'
p3543
aS'- prior history of colonic disease including:'
p3544
aS"- inflammatory bowel disease (e.g. ulcerative colitis or crohn's disease)"
p3545
aS'- one or more colorectal neoplastic polyps (i.e. adenomas)'
p3546
aS'- colorectal cancer'
p3547
aS'- prior history of colonic resection'
p3548
aS'- prior colonic examination, including:'
p3549
aS'- colonoscopy within the past 9.5 years'
p3550
aS'- sigmoidoscopy within the past 5 years'
p3551
aS'- barium enema within the past 5 years'
p3552
aS'- ct colonography within the past 5 years'
p3553
aS'- gfobt or fit in the past 10 months'
p3554
aS'- stool dna test within the past 3 years'
p3555
aS'- pregnancy'
p3556
aS'- prisoner'
p3557
aS'- significant comorbidity that would preclude benefit from screening or pose significant risk for the performance of colonoscopy (e.g. severe lung disease, end-stage renal disease, end-stage liver disease, severe heart failure, recent diagnosis of cancer (with the exception of non-melanoma skin cancer))'
p3558
aS'- participation in a concurrent interventional study'
p3559
aS'- likely inability to track the individual over time (e.g. no permanent address at the time of screening for study entry)'
p3560
assS'diverticulitis-Procedure'
p3561
(dp3562
g290
(lp3563
S'- pregnant woman or lactating woman.'
p3564
aS'- with confirmed distant metastasis in liver, lung, bones, or other organs.'
p3565
aS'- intolerable laparoscopic operation or converted to open surgery.'
p3566
aS'- with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.'
p3567
aS'- with bad compliance or contraindication to enrollment.'
p3568
asS'NCT01959087'
p3569
(lp3570
S'- digestive stoma in place or planned during the intervention'
p3571
aS'- body mass index > 30 kg/m2'
p3572
aS'- history of previous laparotomy, except mc burney, pfannenstiel ou subcostal'
p3573
aS'- subtotal colectomy'
p3574
aS'- transverse colectomy'
p3575
aS'- proctectomy or total coloproctectomy'
p3576
aS'- synchronous metastasis'
p3577
aS'- preoperative suspicion of t4 colorectal cancer'
p3578
aS'- emergency procedure'
p3579
aS'- associated resection (except appendectomy or liver biopsy)'
p3580
aS'- pregnancy or current breast feeding.'
p3581
assS"wegener's granulomatosis-Drug"
p3582
(dp3583
g324
(lp3584
S'- known intolerance for il2 (see spc),'
p3585
aS'- administration of a non-authorized treatment and/or iv bolus of corticosteroids in the last 2 months,'
p3586
aS'- vaccination with live attenuated virus in the months preceding the inclusion or planned during the study'
p3587
aS'- other severe or progressive autoimmune/inflammatory pathology,'
p3588
aS'- low white blood cell count<2000/mm3, lymphocytes <600/mm3, platelets <80 000/mm3,'
p3589
aS"- heart failure (\xe2\x89\xa5 grade iii nyha), renal insufficiency (cockcroft< 60ml/mn except patients with lupus or wegener's granulomatosis) or hepatic insufficiency (transaminases> 5n except for patients with autoimmune hepatitis), or lung failure,"
p3590
aS'- significant abnormality in chest x-ray other than these linked to the diseases under investigation'
p3591
aS'- cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or basocellular carcinoma)'
p3592
aS'- poor venous access not allowing repeated blood tests,'
p3593
aS'- restrictive diet or parenteral nutrition,'
p3594
aS'- surgery during the last 2 months or surgery planned during the study,'
p3595
aS'- participation in other biomedical research in the last 3 months or planned during the study.'
p3596
aS'- pregnant or lactating women,'
p3597
aS'- concomitant psychiatric disease or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give informed consent,'
p3598
aS'- positive hiv serology, active hepatitis b or ebv infection,'
p3599
aS'- patients under a measure of legal protection'
p3600
assS'medium vessel vasculitis-Procedure'
p3601
(dp3602
sS'intestinal diseases-Dietary Supplement'
p3603
(dp3604
S'NCT02227602'
p3605
(lp3606
S'- history of acute cardiac event, stroke, or cancer, within the last 6 months,'
p3607
aS'- recurrent hospitalizations,'
p3608
aS'- drug treatment of any of the listed conditions within the last 6 months,'
p3609
aS'- abuse of alcohol or substance within the last 6 months,'
p3610
aS'- currently smoking more than 1 pack/week,'
p3611
aS'- seizures,'
p3612
aS'- liver or renal dysfunction,'
p3613
aS'- pregnancy or lactation,'
p3614
aS'- allergy against mangos,'
p3615
aS'- hepatitis b, c, or hiv,'
p3616
aS'- regular exercise (>60 minutes, \xe2\x89\xa5 5 times/wk), due to association of antioxidant and anti-inflammatory effects and moderate exercise.'
p3617
aS'- known lactose intolerance, gluten sensitivity, or celiac disease'
p3618
aS'- patients that have upcoming inflammatory bowel disease-related surgery and inflammatory bowel disease -related intestinal stricture will also be excluded.'
p3619
assS'complex perianal fistula-Biological'
p3620
(dp3621
S'NCT01314092'
p3622
(lp3623
S'- a patient who has participated in other clinical studies within 30 days before this clinical trial or has not passed 5 fold period of a half-life of other investigational drugs.'
p3624
aS'- a patient who has a history of variant creutzfeldt jacobs disease or related diseases'
p3625
aS'- a patient who is allergic to anesthetics, bovine derived proteins or a fibrin glue'
p3626
aS'- a patient who has an autoimmune disease'
p3627
aS'- a patient who has infectious diseases such as hepatitis b virus (hbv), hepatitis c virus (hcv) or human immunodeficiency virus (hiv)'
p3628
aS'- a patient who has sepsis or active tuberculosis'
p3629
aS'- a patient who is pregnant or breast feeding'
p3630
aS'- a patient who has inflammatory bowel disease'
p3631
aS'- over 2cm in diameter of fistula'
p3632
assS'unclassified iad knee and/or hip arthritis, muscular dystrophy-Other'
p3633
(dp3634
g371
(lp3635
S'- for iads patients'
p3636
aS'- unauthorized treatment (anticancer chemotherapy)'
p3637
aS'- for healthy volunteers'
p3638
aS'- contra-indications for donating blood except from age'
p3639
aS'- known history of iad (eg: psoriasis)'
p3640
aS'- common exclusion criteria:'
p3641
aS'- pregnant woman'
p3642
aS'- still under the exclusion period from another biomedical study'
p3643
aS'- psychiatric or addiction pathology who could interfere with the ability to fulfill the protocol needs or to provide an informed consent'
p3644
aS'- patient under a legal protection'
p3645
aS'- chronic lifelong viral infection unrelated to the pathology'
p3646
aS'- mild infection within the last 3 months'
p3647
assS'cancer-Behavioral'
p3648
(dp3649
sS'type 1 diabetes-Other'
p3650
(dp3651
g371
(lp3652
S'- for iads patients'
p3653
aS'- unauthorized treatment (anticancer chemotherapy)'
p3654
aS'- for healthy volunteers'
p3655
aS'- contra-indications for donating blood except from age'
p3656
aS'- known history of iad (eg: psoriasis)'
p3657
aS'- common exclusion criteria:'
p3658
aS'- pregnant woman'
p3659
aS'- still under the exclusion period from another biomedical study'
p3660
aS'- psychiatric or addiction pathology who could interfere with the ability to fulfill the protocol needs or to provide an informed consent'
p3661
aS'- patient under a legal protection'
p3662
aS'- chronic lifelong viral infection unrelated to the pathology'
p3663
aS'- mild infection within the last 3 months'
p3664
assS'fatigue-Behavioral'
p3665
(dp3666
g3
(lp3667
S'- ibd group:'
p3668
aS'- meeting criteria for active alcohol or substance abuse or dependence'
p3669
aS'- current ongoing treatment with wellbutrin'
p3670
aS'- females who are pregnant or plan to become pregnant within three months'
p3671
aS'- sleep disorder such as apnea, restless leg syndrome or use of continuous positive airway pressure therapy (c-pap)/bilevel positive airway pressure (bi-pap)'
p3672
aS'- current ibd flare requiring hospitalization with intravenous steroid treatment'
p3673
aS'- other acute medical conditions or a history of chronic inflammatory condition other than ibd'
p3674
aS'- hemoglobin <10 with age and gender adjustments'
p3675
aS'- history of seizure disorder'
p3676
aS'- acute infection within seven days'
p3677
aS'- healthy volunteer group:'
p3678
aS'- history or current episode of psychiatric disorder by diagnositic and statistical manual (dsm-iv)'
p3679
aS'- current ongoing treatment with psychoactive medications'
p3680
aS'- medications for sleep in previous two weeks'
p3681
aS'- females who are pregnant or plan to become pregnant within three months'
p3682
aS'- history of ibd, epilepsy, rheumatoid arthritis, lupus'
p3683
aS'- sleep disorder such as apnea, restless leg syndrome or use of continuous positive airway pressure therapy (c-pap)/bilevel positive airway pressure (bi-pap)'
p3684
assS'bleeding-Drug'
p3685
(dp3686
sS'transient ischemic attacks-Behavioral'
p3687
(dp3688
sS'adiposity-Other'
p3689
(dp3690
g2673
(lp3691
S'- major congenital or life threatening abnormalities or congenital abnormalities that preclude early milk feeding'
p3692
aS'- inability to randomise infant within 48 hours'
p3693
assS'collagenous colitis-Procedure'
p3694
(dp3695
S'NCT01504048'
p3696
(lp3697
S'- patients who decline to participate'
p3698
aS'- unable to give informed consent'
p3699
assS'sclerosing cholangitis-Biological'
p3700
(dp3701
S'NCT02424175'
p3702
(lp3703
S'- 1. decompensated liver disease'
p3704
aS'- 2. patients who were pregnant or breastfeeding'
p3705
aS'- 3. use of concomitant immune modulators including methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, thalidomide, interleukin-10, or interleukin-11 within 4 weeks prior to receiving the fmt'
p3706
aS'- 4. patients who are unable to give informed consent'
p3707
aS'- 5. patients who are unable or unwilling to undergo colonoscopy with moderate sedation (>asa class ii)'
p3708
aS'- 6. patients who have previously undergone fmt patients who have a confirmed malignancy or cancer'
p3709
aS'- 7. patients who are immunocompromised'
p3710
aS'- 8. treatment within last 8 weeks with infliximab, adalimumab, certolizumab, natalizumab, vedolizumab or thalidomide'
p3711
aS'- 9. antibiotic use within 2-months of start date'
p3712
aS'- 10. participation in a clinical trial in the preceding 30 days or simultaneously during this trial'
p3713
aS'- 11. probiotic use within 30 days of start date'
p3714
aS'- 12. congenital or acquired immunodeficiencies'
p3715
aS'- 13. other comorbidities including:diabetes mellitus, cancer, systemic lupus, must be able to tolerate conscious sedation with colonoscopy'
p3716
aS'- 14. chronic kidney disease as defined by a gfr <60ml/min/1.73m2 44'
p3717
aS'- 15. history of rheumatic heart disease, endocarditis, or valvular disease due to risk of bacteremia from colonoscopy'
p3718
aS'- 16. steroid dose >20mg/day'
p3719
assS'indeterminate colitis-Drug'
p3720
(dp3721
g1788
(lp3722
S"- c0168z02: 17 years of age or older, with the exception of patients who participated in the sponsor's conducted pediatric ibd clinical trials. have other crohn's-like diseases that are associated with genetic diseases (eg, glycogen storage disease). the patient and parent/guardian are not able to adhere to the protocol requirements. are participating in any clinical trial for an investigational agent that is not commercially available. remicadepib4002 and remicadepib4003: less than 6 years of age or 17 years of age or older."
p3723
assS'fmf-Other'
p3724
(dp3725
g371
(lp3726
S'- for iads patients'
p3727
aS'- unauthorized treatment (anticancer chemotherapy)'
p3728
aS'- for healthy volunteers'
p3729
aS'- contra-indications for donating blood except from age'
p3730
aS'- known history of iad (eg: psoriasis)'
p3731
aS'- common exclusion criteria:'
p3732
aS'- pregnant woman'
p3733
aS'- still under the exclusion period from another biomedical study'
p3734
aS'- psychiatric or addiction pathology who could interfere with the ability to fulfill the protocol needs or to provide an informed consent'
p3735
aS'- patient under a legal protection'
p3736
aS'- chronic lifelong viral infection unrelated to the pathology'
p3737
aS'- mild infection within the last 3 months'
p3738
assS'rheumatic diseases-Other'
p3739
(dp3740
g237
(lp3741
S'- lack of consent'
p3742
aS'- patients with evidence of other chronic liver disease,metabolic syndrome, men consuming more than 30 g of alcohol per day and women consuming more than 20 g of alcohol per day, patients with liver decompensation, hcc, previous liver surgery or liver transplantation'
p3743
assS'hepatosplenic t-cell lymphoma-Biological'
p3744
(dp3745
sS'chronic bronchitis-Behavioral'
p3746
(dp3747
sS'iga pemphigus-Procedure'
p3748
(dp3749
sS'amicrobial pustulosis of the folds-Procedure'
p3750
(dp3751
sS"still's disease-Procedure"
p3752
(dp3753
sS'diverticulosis-Behavioral'
p3754
(dp3755
sS'transition from pediatric to adult care.-Behavioral'
p3756
(dp3757
g583
(lp3758
S'- we will exclude any subjects who will not be residing in canada or who will not be enrolled in the ontario health insurance plan (ohip) after exiting pediatric care. registration with ohip, even if residing in a different province, is required for the monitoring of health utilization.'
p3759
assS'hiv reservoirs-Other'
p3760
(dp3761
S'NCT01942655'
p3762
(lp3763
S'- absence of coverage by french health insurance system (social security)'
p3764
aS'- known progressive malignancy'
p3765
aS'- indeterminate colitis'
p3766
aS'- known autoimmune diseases other than ibd'
p3767
aS'- current chemotherapy or radiotherapy'
p3768
aS'- vulnerable populations (children, pregnant women, persons under legal guardianship, or deprived of freedom by judicial or administrative decision)'
p3769
assS'ulcer-Behavioral'
p3770
(dp3771
sS'colon polyps-Biological'
p3772
(dp3773
g100
(lp3774
S'- subjects with known allergy or negative reaction to fluorescein or derivatives.'
p3775
aS'- subjects on active chemotherapy or radiation treatment'
p3776
aS'- pregnant or trying to conceive'
p3777
assS'ankylosing spondylitis-Other'
p3778
(dp3779
g371
(lp3780
S'- for iads patients'
p3781
aS'- unauthorized treatment (anticancer chemotherapy)'
p3782
aS'- for healthy volunteers'
p3783
aS'- contra-indications for donating blood except from age'
p3784
aS'- known history of iad (eg: psoriasis)'
p3785
aS'- common exclusion criteria:'
p3786
aS'- pregnant woman'
p3787
aS'- still under the exclusion period from another biomedical study'
p3788
aS'- psychiatric or addiction pathology who could interfere with the ability to fulfill the protocol needs or to provide an informed consent'
p3789
aS'- patient under a legal protection'
p3790
aS'- chronic lifelong viral infection unrelated to the pathology'
p3791
aS'- mild infection within the last 3 months'
p3792
assS'transient neonatal pustulosis-Procedure'
p3793
(dp3794
sS'kidney calculi-Dietary Supplement'
p3795
(dp3796
S'NCT01735461'
p3797
(lp3798
S'- 1. current pregnancy'
p3799
aS"- 2. patient's without baseline hyperoxaluria (defined as >48 mg or 0.5mmol per 24 hour urine samples)"
p3800
aS'- 3. patients in renal failure assessed by a gfr < 60'
p3801
aS'- 4. inability to provide informed consent'
p3802
aS'- 5. active cancer'
p3803
aS'- 6. hyperparathyroidism'
p3804
aS'- 7. hyperphosphatemia'
p3805
aS'- 8. <19 years of age'
p3806
assS'gastroesophageal reflux-Behavioral'
p3807
(dp3808
sS'quality of life-Behavioral'
p3809
(dp3810
g117
(lp3811
S'- refusal to give necessary oral or written informed consent by patient and/or parent (legal caregiver)'
p3812
aS'- not aged 7 through 20 at start of study'
p3813
aS'- not willing and able to volunteer in the study'
p3814
aS'- has sibling enrolled in this study'
p3815
aS'- has severe physical diseases of the locomotor apparatus, psychotic disorders, severe affective disorders, eating disorders, mental retardation, autism spectrum disorder'
p3816
aS'- inability to communicate and complete questionnaires in german'
p3817
aS'- does not own a functional and nintendo wii-compatible television at home'
p3818
aS'- among female adolescents, pregnancy, breastfeeding or intention to get pregnant during the study'
p3819
aS'- has clinically significant cardiovascular disease'
p3820
aS'- enrolment of the investigator, his/her family members, employees and other dependent persons'
p3821
assS'erythema marginatum-Procedure'
p3822
(dp3823
sS'acute generalized exanthematous pustulosis-Procedure'
p3824
(dp3825
sS'indeterminate colitis-Biological'
p3826
(dp3827
g1788
(lp3828
S"- c0168z02: 17 years of age or older, with the exception of patients who participated in the sponsor's conducted pediatric ibd clinical trials. have other crohn's-like diseases that are associated with genetic diseases (eg, glycogen storage disease). the patient and parent/guardian are not able to adhere to the protocol requirements. are participating in any clinical trial for an investigational agent that is not commercially available. remicadepib4002 and remicadepib4003: less than 6 years of age or 17 years of age or older."
p3829
assS'acute lymphoblastic leukemia (all)-Drug'
p3830
(dp3831
S'NCT02046694'
p3832
(lp3833
S'- allergy to allopurinol'
p3834
aS'- active relapse of all'
p3835
aS'- currently enrolled on any therapeutic research study for the treatment of all'
p3836
assS'constipation (excl faecal impaction)-Biological'
p3837
(dp3838
g2072
(lp3839
S'- no informed consent'
p3840
aS'- non active inflammatory bowel disease.'
p3841
aS'- active infection in either the donor or the recipient,'
p3842
aS'- response to biological agents'
p3843
assS'myositis-Other'
p3844
(dp3845
g371
(lp3846
S'- for iads patients'
p3847
aS'- unauthorized treatment (anticancer chemotherapy)'
p3848
aS'- for healthy volunteers'
p3849
aS'- contra-indications for donating blood except from age'
p3850
aS'- known history of iad (eg: psoriasis)'
p3851
aS'- common exclusion criteria:'
p3852
aS'- pregnant woman'
p3853
aS'- still under the exclusion period from another biomedical study'
p3854
aS'- psychiatric or addiction pathology who could interfere with the ability to fulfill the protocol needs or to provide an informed consent'
p3855
aS'- patient under a legal protection'
p3856
aS'- chronic lifelong viral infection unrelated to the pathology'
p3857
aS'- mild infection within the last 3 months'
p3858
assS'irritable bowel-Behavioral'
p3859
(dp3860
sS'fistula-Other'
p3861
(dp3862
g743
(lp3863
S'- any of inclusion criteria is not met;'
p3864
aS'- females who are pregnant or breast feeding;'
p3865
aS'- anti-tnf use within 6 weeks prior to study entry;'
p3866
aS'- patients who cannot take, or refuse to take concomitant immunosuppressive therapy with either azathioprine, 6-mercaptopurine, or methotrexate; unless patient has been intolerant of these therapies in the past or is contraindicated as determined by the investigator.'
p3867
aS'- patients who cannot take, or refuse to take concomitant antibiotic therapy;'
p3868
aS'- patients with severe anal stenosis or tenderness which would preclude colonoscopy and / or rectal eus;'
p3869
aS'- patients who cannot take or refuse to take certolizumab;'
p3870
aS'- patients with active or latent tuberculosis;'
p3871
aS"- patients who have had systemic antibiotic, antiviral or antifungal treatment(s) within 3 weeks prior to screening for all non-crohn's related infections;"
p3872
aS'- patients concurrently taking anakinra (kineret);'
p3873
aS'- patients with a history of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinomain-situ of the cervix;'
p3874
aS'- patients with chronic hematologic problems such as bleeding dyscrasias;'
p3875
aS'- patients with a history of demyelinating disease (i.e. multiple sclerosis); and'
p3876
aS'- patients with congestive heart failure'
p3877
assS'ulcerative colitis-Device'
p3878
(dp3879
S'NCT01745029'
p3880
(lp3881
S'- known gi related symptoms complaints or gi diseases'
p3882
aS'- swallowing disorders'
p3883
aS'- cancer or other life threatening diseases or conditions'
p3884
aS'- pregnancy or breast-feeding'
p3885
aS'- previous abdominal surgery'
p3886
aS'- abdominal diameter >140cm?'
p3887
aS'- drug abuse or alcoholism'
p3888
aS'- irregular bowel movements'
p3889
aS'- known cardiovascular or pulmonary diseases'
p3890
aS'- participation in any clinical study within the last 30 days'
p3891
aS'- cardiac pacemaker or infusion pump or any other implanted or portable electro-mechanical medical device.'
p3892
aS'- medication affecting gi motility'
p3893
aS'- mri within the next four weeks'
p3894
asS'NCT02610569'
p3895
(lp3896
S'- patient with severe and acute colitis'
p3897
aS"- patient with crohn's disease or non-classified colitis"
p3898
aS'- patient with an indication for surgical management of uc'
p3899
aS'- patient with a history of sub-total or total colectomy, or with colostomy or ileostomy.'
p3900
aS'- patient with a history of intestinal irradiation'
p3901
aS'- patient with a known or suspected intestinal stricture'
p3902
aS'- patient with clinical signs suggestive of intestinal stricture'
p3903
aS'- patient with dysphagia with choking on solid food or swallowing disorders'
p3904
aS'- patient with a contra-indication for an anti tnfalpha treatment'
p3905
aS'- patient with a contra-indication for conventional endoscopy (colonoscopy or recto-sigmoidoscopy)'
p3906
aS'- patient with congestive heart failure or severe renal impairment'
p3907
aS'- patient with a pacemaker or other implanted electronic medical device'
p3908
aS'- patient participating in another interventional clinical trial'
p3909
aS'- pregnant or nursing woman'
p3910
aS'- vulnerable individuals: persons deprived of liberty, under tutelage or guardianship'
p3911
asg93
(lp3912
S'- no health insurance ,'
p3913
aS'- mental disability,'
p3914
aS'- pregnancy'
p3915
asS'NCT01417715'
p3916
(lp3917
S'- inability to provide written informed consent'
p3918
aS'- severe coagulopathy (prothrombin time < 50% of control, partial thromboplastin time > 50 s)'
p3919
aS'- pregnancy or breast feeding'
p3920
aS'- active gastrointestinal bleeding'
p3921
aS'- residing in institutions (e.g. prison)'
p3922
aS'- known allergy against fluorescein'
p3923
aS'- proctocolectomy'
p3924
asS'NCT01882205'
p3925
(lp3926
S'- active ulcerative colitis, > 20 cm from the margo ani'
p3927
aS'- personal history of colorectal cancer'
p3928
aS'- allergy or intolerance to methylene blue'
p3929
aS'- refusing or incapable to agree with informed consent'
p3930
aS'- age younger than 18 years'
p3931
aS'- pregnant women'
p3932
asS'NCT02144129'
p3933
(lp3934
S'- variables that conflicts with wb-ems application (e.g. cardiac pacemakers)'
p3935
aS'- absence of more than two weeks during the interventional period.'
p3936
asS'NCT02772406'
p3937
(lp3938
S'- pregnant patients,unable or unwilling to give informed consent,patients with severe active colitis who would be unsafe to endoscope'
p3939
asS'NCT02370056'
p3940
(lp3941
S'- any preoperative diagnosis other than uc'
p3942
aS'- patient age< 18, or >80'
p3943
aS'- emergency surgery'
p3944
aS'- previous gastrointestinal surgery'
p3945
aS'- bmi>30'
p3946
aS'- pregnancy'
p3947
aS'- presence of any gastrointestinal tract malignancy'
p3948
aS'- segmental colon resections, completion proctectomy, total proctocolectomy, pouch procedures'
p3949
asS'NCT01752361'
p3950
(lp3951
S'- known gi related symptoms complaints or gi diseases'
p3952
aS'- swallowing disorders'
p3953
aS'- cancer or other life threatening diseases or conditions'
p3954
aS'- pregnancy or breast-feeding'
p3955
aS'- previous abdominal surgery'
p3956
aS'- abdominal diameter >140cm?'
p3957
aS'- drug abuse or alcoholism'
p3958
aS'- irregular bowel movements'
p3959
aS'- known cardiovascular or pulmonary diseases'
p3960
aS'- participation in any clinical study within the last 30 days'
p3961
aS'- cardiac pacemaker or infusion pump or any other implanted or portable electro-mechanical medical device.'
p3962
aS'- medication affecting gi motility'
p3963
aS'- mri within the next four weeks'
p3964
asg2243
(lp3965
S'- age < 18 years'
p3966
aS'- mental retardation of the patient with restriction of general judgment and awareness'
p3967
asS'NCT02469103'
p3968
(lp3969
S"- patients with severe uc according to truelove and witts' criteria"
p3970
aS'- current pregnancy/lactating'
p3971
aS'- patients with a pacemaker or other implanted electromedical device'
p3972
aS'- the presence of dysphagia'
p3973
aS"- patients at higher risk of capsule retention (including crohn's disease, small bowel tumor, radiation enteropathy, previous intestinal surgery, acute abdominal pain without regular defecation)"
p3974
aS'- patients with a contraindication to bowel preparation (congestive heart failure, renal insufficiency, a life-threatening condition)'
p3975
aS'- patients with an allergy to polyethylene glycol, sodium phosphate solution, metoclopramide or bisacodyl suppository'
p3976
asS'NCT00816491'
p3977
(lp3978
S'- known intraepithelial neoplasia or colorectal cancer or any other active malignancy'
p3979
aS'- previous colo-rectal surgery'
p3980
aS'- non-treatable coagulopathy or hemostatic dysfunction (prothrombin index < 50% of control or/and partial thromboplastin time > 50 seconds and/or thrombopenia < 60000 / mm3)'
p3981
aS'- pregnancy'
p3982
aS'- inability to give informed consent'
p3983
asS'NCT01417702'
p3984
(lp3985
S'- inability to provide written informed consent'
p3986
aS'- severe coagulopathy (prothrombin time < 50% of control, partial thromboplastin time > 50 s)'
p3987
aS'- pregnancy or breast feeding'
p3988
aS'- active gastrointestinal bleeding'
p3989
aS'- residing in institutions (e.g. prison)'
p3990
aS'- proctocolectomy'
p3991
asg346
(lp3992
S'- pancolitis or acute severe ulcerative colitis requiring immediate treatment'
p3993
aS'- need for admission due to active ulcerative colitis'
p3994
aS'- ulcerative colitis with systemic symptoms (abdominal pain, fever > 37.5 degrees, weight loss exceeding 3 kilograms).'
p3995
aS'- patient with anemia (haemoglobin < 8.3 mmol/l for males and < 7.3 mmol/l for females).'
p3996
aS'- patient with ostomy or pouch.'
p3997
aS'- the patient has had a bowel resection (except appendectomy)'
p3998
aS'- the patient has constipation and/or another known bowel condition than ulcerative colitis such as ibs.'
p3999
aS'- the patient has diabetes.'
p4000
aS'- regular intake of acetylsalicylic acid or nsaids'
p4001
aS'- the patient cannot understand the information material.'
p4002
aS'- the patient has had colon cancer, dysplasia or adenomatous polyps in the colon during the recent 5 year'
p4003
aS'- the patient is in a poor general condition.'
p4004
aS'- the patient has had a food poisoning within the last three months.'
p4005
aS'- the patient is pregnant at the time of inclusion or has planned pregnancy during the period of study.'
p4006
aS'- the patient is in medical treatment with cyclosporine at the beginning of the run in period.'
p4007
aS'- treatment for ulcerative colitis treatment has been changed within two weeks before the first day in the run in period'
p4008
aS'- the patient has commenced treatment with azathioprine, 6-mercaptopurine or methotrexate within 12 weeks before the first day in the run in period.'
p4009
aS'- the patient has commenced treatment with tnf-\xce\xb1 inhibitors within 12 weeks before the first day of the run in period.'
p4010
aS'- the patient suffers from coeliac disease or lactose intolerance.'
p4011
aS'- antibiotic treatment within two weeks before the first day of the run in period.'
p4012
aS'- patient has any medical, surgical condition that excludes the use of ric.'
p4013
asS'NCT02149043'
p4014
(lp4015
S'- inability to preform total colonoscopy'
p4016
aS'- marked abdominal comorbidities'
p4017
aS'- prior abdominal surgery'
p4018
assS'gastrointestinal stromal tumor-Device'
p4019
(dp4020
g290
(lp4021
S'- pregnant woman or lactating woman.'
p4022
aS'- with confirmed distant metastasis in liver, lung, bones, or other organs.'
p4023
aS'- intolerable laparoscopic operation or converted to open surgery.'
p4024
aS'- with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.'
p4025
aS'- with bad compliance or contraindication to enrollment.'
p4026
assS'short bowel syndrome (sbs)-Dietary Supplement'
p4027
(dp4028
g592
(lp4029
S'- 1. infant with birth weight > 1250g;'
p4030
aS'- 2. infant with colostomy;'
p4031
aS'- 3. infants with enterostomy but'
p4032
aS'- unable to obtain written informed consent from parent;'
p4033
aS'- presence of congenital liver, renal, or metabolic diseases or syndromes or perinatal asphyxia;'
p4034
aS'- ostomy caused by surgical treatment for a condition other than nec or small intestine perforation; and'
p4035
aS'- unable to initiate enteral feeding for more than 28 days since ostomy placement.'
p4036
assS'fistula-Device'
p4037
(dp4038
S'NCT02403232'
p4039
(lp4040
S'- patients aged < 18 years old'
p4041
aS'- informed consent refusal'
p4042
aS'- medical or family history of variant creutzfeldt-jakobs disease'
p4043
aS"- activated sever crohn's disease"
p4044
aS'- perianal fistulae >2 cm in diameter'
p4045
aS"- autoimmune disease or inflammatory bowel disease other than crohn's disease"
p4046
aS'- infectious disease including hepatitis b virus, hepatitis c virus and immunodeficiency virus infection'
p4047
aS'- active tuberculosis'
p4048
aS'- signs of septicemia'
p4049
aS'- patients treated with infliximab within 3 months prior to asc treatment.'
p4050
aS'- technically difficult adipose tissue collection due to low levels of fat tissue.'
p4051
aS'- pregnancy'
p4052
assS'cardiovascular disease-Behavioral'
p4053
(dp4054
sS'axial spondyloarthritis (axspa)-Procedure'
p4055
(dp4056
g73
(lp4057
S'- subject has participated in a study of an investigational medicinal product (imp) or medical device within the previous 30 days or 5 half-lives (whichever is longer) prior to screening or is currently participating in another study of an imp or medical device - unless the study is ucb up0016 [nct02154425] or a registry study'
p4058
aS"- subject has any obstetrical or psychiatric condition, or she or her infant(s) has any medical condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study or the outcome of the pregnancy"
p4059
aS'- subject has history of chronic alcohol abuse or drug abuse during pregnancy'
p4060
aS'- subject has any pregnancy-related clinically significant abnormality noted on obstetric ultrasound, or other imaging assessment, or the subject has significant laboratory abnormalities during her pregnancy, as judged by the investigator'
p4061
aS'- subject is taking or has taken any medication with strong positive evidence of a human fetal risk of teratogenicity (e.g., methotrexate or leflunomide) during pregnancy'
p4062
aS'- subject has evidence of a condition suggesting chronic or acute uteroplacental insufficiency such as intrauterine growth restriction, severe maternal hypertensive disorders of pregnancy, or abruption'
p4063
aS'- subject has a documented history of primary or secondary antiphospholipid syndrome or hypercoagulable state'
p4064
aS'- subject has received treatment with any biological therapeutic agent, including anti-tnfs other than certolizumab pegol (czp), during pregnancy'
p4065
aS'- subject has previously participated in this study'
p4066
aS'- subject has a positive or indeterminate quantiferon\xc2\xae-tb gold in tube test at screening. in case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the subject'
p4067
aS"- subject with known tuberculosis (tb) infection, at high risk of acquiring tb infection, or latent tb infection (ltb). if tested within the 6 months prior to screening and the test was negative for tb, and there is no change in the subject's clinical status, nor social, family, or travel history, there is no need for an additional tb testing at screening"
p4068
assS'surgical site infection-Device'
p4069
(dp4070
g290
(lp4071
S'- pregnant woman or lactating woman.'
p4072
aS'- with confirmed distant metastasis in liver, lung, bones, or other organs.'
p4073
aS'- intolerable laparoscopic operation or converted to open surgery.'
p4074
aS'- with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.'
p4075
aS'- with bad compliance or contraindication to enrollment.'
p4076
assS'ulcerative colitis-Other'
p4077
(dp4078
g1096
(lp4079
S"- a history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, suspicion of ischemic, radiation or microscopic colitis, crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, intestinal obstruction, toxic megacolon, or unremoved adenomatous colonic polyps"
p4080
aS'- prior or planned surgery for uc'
p4081
aS'- past or present ileostomy or colostomy'
p4082
aS'- have received non-permitted inflammatory bowel disease (ibd) therapies (including natalizumab, vedolizumab, and efalizumab) as stated in the protocol'
p4083
aS'- chronic hepatitis b or c infection, hiv or tuberculosis (active or latent)'
p4084
asg3933
(lp4085
S'- variables that conflicts with wb-ems application (e.g. cardiac pacemakers)'
p4086
aS'- absence of more than two weeks during the interventional period.'
p4087
asg1452
(lp4088
S"- a history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, suspicion of ischemic, radiation or microscopic colitis, crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, intestinal obstruction, toxic megacolon, or unremoved adenomatous colonic polyps"
p4089
aS'- prior or planned surgery for uc'
p4090
aS'- past or present ileostomy or colostomy'
p4091
aS'- have received non-permitted inflammatory bowel disease (ibd) therapies (including natalizumab, vedolizumab, and efalizumab) as stated in the protocol'
p4092
aS'- history of moderate or severe allergic or anaphylactic/anaphylactoid reactions to chimeric, human, or humanized antibodies; fusion proteins, or murine proteins; hypersensitivity to etrolizumab or any of its excipients'
p4093
aS'- chronic hepatitis b or c infection, hiv or tuberculosis (active or latent)'
p4094
asS'NCT02084550'
p4095
(lp4096
S'- inability to understand written danish, postmenopause, severe asthma, diabetes mellitus, severe rheumatologic disease, severe comorbidity (asa group iii-iv) in general. acute or progressing liver failure, uremia without possibility for dialysis, phenylketonuria, defects in amino acid metabolism. participation in scientific studies in the preceding year, where ionizing radiation has been used, including significant x-ray investigations.'
p4097
asg163
(lp4098
S'- the patients will be excluded from the study if one or more of the following apply:'
p4099
aS'- 1. unable to give consent.'
p4100
aS'- 2. does not meet inclusion criteria above.'
p4101
asS'NCT02640391'
p4102
(lp4103
S'- patients who refuse to participate'
p4104
aS'- patients who have a history of colectomy'
p4105
aS'- patients who have instinal stricture or perforation'
p4106
asg1087
(lp4107
S'- any proven infection such as positive stool culture, parasite or c.difficile.'
p4108
aS'- use of antibiotics'
p4109
aS'- use of steroids in the previous two weeks only'
p4110
aS'- patients that are refractory to full dose steroids ( 1 mg/kg/day)'
p4111
aS'- past acute severe uc.'
p4112
aS'- current extra intestinal manifestation of uc.'
p4113
aS'- pregnancy. a subset of patients who are on steroids and relapse during steroids treatment \xe2\x89\xa40.5 mg/kg with mild to moderate disease activity will act as a second subset for this exploratory study.'
p4114
asS'NCT02084186'
p4115
(lp4116
S'- patients with cardiac, encephalic, hepatic, nephric, hematopoietic system, psychotic or any other serious diseases'
p4117
aS'- pregnancy or lactation'
p4118
asg1216
(lp4119
S"- a history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, suspicion of ischemic, radiation or microscopic colitis, crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, intestinal obstruction, toxic megacolon, or unremoved adenomatous colonic polyps"
p4120
aS'- prior or planned surgery for uc'
p4121
aS'- past or present ileostomy or colostomy'
p4122
aS'- have received non-permitted inflammatory bowel disease (ibd) therapies (including natalizumab, vedolizumab, and efalizumab) as stated in the protocol'
p4123
aS'- chronic hepatitis b or c infection, hiv or tuberculosis (active or latent)'
p4124
asg190
(lp4125
S'- failure to provide informed consent'
p4126
aS'- patients with a contraindication to colonoscopy'
p4127
aS'- known allergy to fluorescein'
p4128
aS'- pregnant or breast-feeding patients'
p4129
aS'- ongoing systemic immunosuppressive therapy with prednisolone, azathioprine or biological agents.'
p4130
asS'NCT02229344'
p4131
(lp4132
S'- participants in an interventional clinical trial with systemic corticosteroid, biologics (including, but not limited to, infliximab, golimumab, adalimumab and vedolizumab, etc) and other drugs (sulfasalazine, medalamine, azathioprine, tofacitinib, etc) for ulcerative colitis'
p4133
aS'- having experienced colectomy such as subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, koch pouch, or ileostomy for ulcerative colitis, or planning surgical treatment within 1 year from enrollment'
p4134
aS"- a current diagnosis of indeterminate colitis, or current diagnosis or history of crohn's disease"
p4135
asS'NCT02120391'
p4136
(lp4137
S'- \xe2\x80\xa2 are on more than one medication for their inflammatory bowel disease'
p4138
asg1394
(lp4139
S"- subject with crohn's disease (cd) or indeterminate colitis (ic)."
p4140
aS'- current diagnosis of fulminant colitis and/or toxic megacolon.'
p4141
aS'- subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.'
p4142
aS'- chronic recurring infections or active tuberculosis (tb).'
p4143
asS'NCT02469220'
p4144
(lp4145
S'- intake of a low fodmap diet within past 6 weeks prior to inclusion'
p4146
aS'- intake of antibiotics within past 6 weeks prior to inclusion'
p4147
aS'- other types of medical treatment than 5-aminosalicylates'
p4148
aS'- celiac disease'
p4149
aS'- pregnancy'
p4150
aS'- abnormal eating habits'
p4151
asS'NCT02138318'
p4152
(lp4153
S'- pregnancy'
p4154
aS'- unwilling or unable to give informed consent'
p4155
aS'- severe active colitis (as assessed by the endoscopist)'
p4156
asg847
(lp4157
S"- crohn's disease and ulcerative colitis"
p4158
aS'- uncontrolled inflammation which will likely require surgery or escalation of therapy in the next 4 weeks'
p4159
aS'- concomitant treatment:corticosteroids > 20mg/day'
p4160
aS'- subject who cannot be expected to comply with the study procedures. - subjects not treated and followed by the gastroenterology team at mt. sinai hospital, toronto'
p4161
asg2147
(lp4162
S'- patient with associated diseases such as diabetes mellitus, hypertension, dyslipidemia, atherosclerosis and malabsorption syndrome.'
p4163
aS"- with autoimmune diseases (lupus, hiv, cancer and hepatitis), colitis (infectious, post-radiation, post-drug, indeterminate) and crohn's disease."
p4164
aS'- abnormal hepatic or renal function'
p4165
aS'- prior history of malignancy'
p4166
aS'- pregnant or unwilling to practice contraceptive therapy or breast feeding females'
p4167
asg856
(lp4168
S'- participation in other clinical studies'
p4169
asS'NCT00790478'
p4170
(lp4171
S'- night shift workers; otherwise, inability to attend morning study visits.'
p4172
aS'- current severe colitis according to the mayo scoring system (>10) or requiring hospital admission, or current very mild colitis (<4).'
p4173
aS'- current supplemental intake of melatonin or currently using tobacco products.'
p4174
aS"- proctitis or crohn's disease"
p4175
aS'- previous gastrectomy or small or large bowel resection'
p4176
aS'- malabsorption syndrome (e.g., pancreatic insufficiency).'
p4177
aS'- history of large bowel resection for any reason.'
p4178
aS'- diagnosed narcotic or alcohol dependence.'
p4179
aS'- on renal dialysis.'
p4180
aS'- active liver disease (a chronic condition or under current therapy)'
p4181
aS'- seizure disorders'
p4182
aS'- immune system disorders'
p4183
aS'- any history of hypo- or hyperparathyroidism.'
p4184
aS'- unable to be off aspirin for 7 days.'
p4185
aS'- use of systemic or rectal steroids in the past 8 weeks.'
p4186
aS'- have a history of allergy or hypersensitivity to melatonin.'
p4187
aS'- history of bleeding disorder or current use of anticoagulant medication.'
p4188
aS'- current use of calcium channel blockers, anticonvulsants, sedatives, hypnotics, or psychotropic medications.'
p4189
aS'- women who are pregnant, breast-feeding, attempting conception, or planning to attempt conception over the following 6 months, or are currently taking hormone replacement therapy (hrt).'
p4190
asg1549
(lp4191
S'- exclusion criteria:'
p4192
aS'- 1. any proven current infection such as positive stool culture, parasite or c. difficile.'
p4193
aS'- 2. antibiotic or steroids use in the past 2 weeks.'
p4194
aS'- 3. pucai >45'
p4195
aS'- 4. acute severe uc in the previous 12 months.'
p4196
aS'- 5. current extra intestinal manifestation of uc.'
p4197
aS'- 6. psc or liver disease'
p4198
aS'- 7. pregnancy.'
p4199
aS'- 8. allergy to one of the antibiotics or age <11 will exclude patients from entering the antibiotic arm'
p4200
asS'NCT01961492'
p4201
(lp4202
S'- severe ulcerative colitis (pucai > 65)'
p4203
asg371
(lp4204
S'- for iads patients'
p4205
aS'- unauthorized treatment (anticancer chemotherapy)'
p4206
aS'- for healthy volunteers'
p4207
aS'- contra-indications for donating blood except from age'
p4208
aS'- known history of iad (eg: psoriasis)'
p4209
aS'- common exclusion criteria:'
p4210
aS'- pregnant woman'
p4211
aS'- still under the exclusion period from another biomedical study'
p4212
aS'- psychiatric or addiction pathology who could interfere with the ability to fulfill the protocol needs or to provide an informed consent'
p4213
aS'- patient under a legal protection'
p4214
aS'- chronic lifelong viral infection unrelated to the pathology'
p4215
aS'- mild infection within the last 3 months'
p4216
asg1628
(lp4217
S'- pregnant or lactating women'
p4218
aS'- any patient who has received probiotic in the preceding 4 weeks'
p4219
aS'- patient with life threatening cardiac, renal, pulmonary or cardiovascular disease'
p4220
aS'- inability to obtain the informed consent'
p4221
aS'- severe disease requiring hospitalization / steroids/ anti-cytokine therapy'
p4222
aS'- patient taking aspirin and other antiplatelet drugs'
p4223
aS'- patient with uncontrolled diabetes'
p4224
aS'- patient with gall stone disease'
p4225
aS'- patient currently on antibiotic,nsaids or indigenous medicine'
p4226
asg226
(lp4227
S'- presence of short bowel syndrome, stoma or pouch.'
p4228
aS'- presence of a condition or disease that, in the opinion of the investigators, may make it exceedingly difficult for the patient to use healthpromise app, including, but not limited to, advanced dementia.'
p4229
asg1163
(lp4230
S'- abnormal baseline laboratory tests:'
p4231
aS'- albumin < 3.0 g/dl'
p4232
aS'- alt, ast, total bilirubin, or alkaline phosphatase > 1.5 x uln'
p4233
aS'- potassium < 3.0 mmol/l or > 5.5 mmol/l'
p4234
aS'- creatinine or cystatin c > uln'
p4235
aS'- wbc \xe2\x89\xa4 3000'
p4236
aS'- platelets \xe2\x89\xa4 105'
p4237
aS'- hemoglobin \xe2\x89\xa4 10g/dl'
p4238
aS'- positive stool test for clostridium difficile, ova and parasites, or routine stool culture'
p4239
aS'- pregnancy (as confirmed by urine pregnancy test at study outset), stated desire to become pregnant during the study period, or refusal/inability to use effective methods of contraception during the study period.'
p4240
aS'- concomitant major comorbidities (renal, hepatic, cardiac, pulmonary or malignancy) to include any medical conditions requiring therapeutic anti-coagulation or anti-platelet therapy.'
p4241
aS'- diagnosis of severe uc (mayo score > 10)'
p4242
aS'- evidence or history of toxic megacolon'
p4243
aS'- patients who received anti-tnf agents within 3 months of screening, or who used oral or rectal corticosteroids within 4 weeks of screening will be excluded.'
p4244
aS'- use of over-the-counter herbal or dietary supplements (excluding vitamin and minerals) two weeks prior to or during the study period.'
p4245
aS'- use of known nephrotoxic medications (including non-steroidal anti-inflammatory drugs (nsaids), cyclosporin a, tacrolimus, aminoglycoside antibiotics, diuretics, angiotensin converting enzyme (ace) inhibitors, or angiotensin receptor blockers) 2 weeks prior to or during the study period'
p4246
aS'- prior surgical bowel resections (excluding appendectomy)'
p4247
aS'- local or systemic complications or other pathological states requiring therapy with corticosteroids and/or immunosuppressive agents.'
p4248
asS'NCT02488954'
p4249
(lp4250
S'- adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty.'
p4251
aS'- psychiatric disease that alter the judgment'
p4252
aS'- stoma'
p4253
aS'- proctocolectomy'
p4254
aS'- severe disease (scci >12, acute severe colitis)'
p4255
aS'- steroid dose > 10 mg/j or introduction of steroid (topic or oral) within 4 weeks'
p4256
aS'- introduction or dose optimization of tnf antagonist within 4 months'
p4257
aS'- introduction or dose optimization of thiopurine'
p4258
aS'- hemoglobin level < 11,5 g/dl, platelets > 400000/mm3, leukocytosis > 10 000/mm3'
p4259
aS'- intolerant to lactose'
p4260
aS'- disease extent limited to the rectum'
p4261
aS'- mayo endoscopic subscore of 3'
p4262
asS'NCT01065571'
p4263
(lp4264
S'- not able to make food choices'
p4265
asS'NCT01010815'
p4266
(lp4267
S'- inability to provide informed consent or'
p4268
aS'- clinically severe or fulminant ulcerative colitis'
p4269
aS'- previous abdominal surgery'
p4270
aS'- pregnancy'
p4271
aS'- clinically or laboratory-confirmed gastroenteritis for at least 3 months before sampling'
p4272
aS'- the use of antibiotics in the past a month before sampling'
p4273
aS'- the use of probiotics in the past a month before sampling'
p4274
aS'- severe cardiovascular or pulmonary disease'
p4275
aS'- severe convulsive disorder and current use of anti-convulsive medication'
p4276
aS'- malignancy'
p4277
aS'- transplantation'
p4278
asg2161
(lp4279
S"- subject with crohn's disease (cd) or indeterminate colitis (ic)."
p4280
aS'- current diagnosis of fulminant colitis and/or toxic megacolon.'
p4281
aS'- subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.'
p4282
aS'- chronic recurring infections or active tuberculosis (tb).'
p4283
asg1953
(lp4284
S'- for all groups:'
p4285
aS'- 1. co-morbidity: severe kidney- and/or liver disease or thyroid abnormalities and impaired clotting'
p4286
aS'- 2. abdominal chirurgy (except for an uncomplicated appendectomy)'
p4287
asg237
(lp4288
S'- lack of consent'
p4289
aS'- patients with evidence of other chronic liver disease,metabolic syndrome, men consuming more than 30 g of alcohol per day and women consuming more than 20 g of alcohol per day, patients with liver decompensation, hcc, previous liver surgery or liver transplantation'
p4290
assS'colonic diseases-Device'
p4291
(dp4292
g616
(lp4293
S'- subjects present with bowel obstruction or perforation'
p4294
aS'- subject undergo emergency surgery'
p4295
aS'- subject with asa iv, v'
p4296
aS'- history of allergy or hypersensitivity against indocyanine green'
p4297
aS'- pregnant or breast-feeding women'
p4298
aS'- subject has uremia (serum creatinine >2.5 mg/dl)'
p4299
aS'- subject is undergoing palliative surgery or who is terminally ill'
p4300
aS'- subject who is unable to discontinue warfarin anticoagulation 5 days before surgery'
p4301
aS'- subject taking phenobarbital, phenylbutazone, primidone, phenytoin, haloperidol, nitrofurantoin, probenecid'
p4302
assS'small vessel vasculitis including urticarial vasculitis-Procedure'
p4303
(dp4304
sS'complications of surgical procedures-Device'
p4305
(dp4306
g290
(lp4307
S'- pregnant woman or lactating woman.'
p4308
aS'- with confirmed distant metastasis in liver, lung, bones, or other organs.'
p4309
aS'- intolerable laparoscopic operation or converted to open surgery.'
p4310
aS'- with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.'
p4311
aS'- with bad compliance or contraindication to enrollment.'
p4312
assS'colorectal cancer-Other'
p4313
(dp4314
S'NCT01739608'
p4315
(lp4316
S'- personal history of crc or polyps'
p4317
aS'- family history of crc or polyps'
p4318
aS'- a terminal illness or inflammatory bowel disease'
p4319
aS'- previous five years complete colonoscopy or a fobt within the previous 2 years'
p4320
aS'- patients who are unable to give informed consent'
p4321
assS"behcet's disease-Drug"
p4322
(dp4323
g324
(lp4324
S'- known intolerance for il2 (see spc),'
p4325
aS'- administration of a non-authorized treatment and/or iv bolus of corticosteroids in the last 2 months,'
p4326
aS'- vaccination with live attenuated virus in the months preceding the inclusion or planned during the study'
p4327
aS'- other severe or progressive autoimmune/inflammatory pathology,'
p4328
aS'- low white blood cell count<2000/mm3, lymphocytes <600/mm3, platelets <80 000/mm3,'
p4329
aS"- heart failure (\xe2\x89\xa5 grade iii nyha), renal insufficiency (cockcroft< 60ml/mn except patients with lupus or wegener's granulomatosis) or hepatic insufficiency (transaminases> 5n except for patients with autoimmune hepatitis), or lung failure,"
p4330
aS'- significant abnormality in chest x-ray other than these linked to the diseases under investigation'
p4331
aS'- cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or basocellular carcinoma)'
p4332
aS'- poor venous access not allowing repeated blood tests,'
p4333
aS'- restrictive diet or parenteral nutrition,'
p4334
aS'- surgery during the last 2 months or surgery planned during the study,'
p4335
aS'- participation in other biomedical research in the last 3 months or planned during the study.'
p4336
aS'- pregnant or lactating women,'
p4337
aS'- concomitant psychiatric disease or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give informed consent,'
p4338
aS'- positive hiv serology, active hepatitis b or ebv infection,'
p4339
aS'- patients under a measure of legal protection'
p4340
assS'chronic hepatitis-Behavioral'
p4341
(dp4342
sS'severe malnutrition-Dietary Supplement'
p4343
(dp4344
g2407
(lp4345
S'- specific cause of malnutrition (e.g. cerebral palsy, other organ disease)'
p4346
aS'- sibling admitted with sam at the same time'
p4347
aS'- unwilling to stay on ward for at least 2 weeks'
p4348
aS'- declined to give consent'
p4349
aS'- participating in another study'
p4350
assS'gastrointestinal diseases-Device'
p4351
(dp4352
g346
(lp4353
S'- pancolitis or acute severe ulcerative colitis requiring immediate treatment'
p4354
aS'- need for admission due to active ulcerative colitis'
p4355
aS'- ulcerative colitis with systemic symptoms (abdominal pain, fever > 37.5 degrees, weight loss exceeding 3 kilograms).'
p4356
aS'- patient with anemia (haemoglobin < 8.3 mmol/l for males and < 7.3 mmol/l for females).'
p4357
aS'- patient with ostomy or pouch.'
p4358
aS'- the patient has had a bowel resection (except appendectomy)'
p4359
aS'- the patient has constipation and/or another known bowel condition than ulcerative colitis such as ibs.'
p4360
aS'- the patient has diabetes.'
p4361
aS'- regular intake of acetylsalicylic acid or nsaids'
p4362
aS'- the patient cannot understand the information material.'
p4363
aS'- the patient has had colon cancer, dysplasia or adenomatous polyps in the colon during the recent 5 year'
p4364
aS'- the patient is in a poor general condition.'
p4365
aS'- the patient has had a food poisoning within the last three months.'
p4366
aS'- the patient is pregnant at the time of inclusion or has planned pregnancy during the period of study.'
p4367
aS'- the patient is in medical treatment with cyclosporine at the beginning of the run in period.'
p4368
aS'- treatment for ulcerative colitis treatment has been changed within two weeks before the first day in the run in period'
p4369
aS'- the patient has commenced treatment with azathioprine, 6-mercaptopurine or methotrexate within 12 weeks before the first day in the run in period.'
p4370
aS'- the patient has commenced treatment with tnf-\xce\xb1 inhibitors within 12 weeks before the first day of the run in period.'
p4371
aS'- the patient suffers from coeliac disease or lactose intolerance.'
p4372
aS'- antibiotic treatment within two weeks before the first day of the run in period.'
p4373
aS'- patient has any medical, surgical condition that excludes the use of ric.'
p4374
assS'bacteria-Procedure'
p4375
(dp4376
g88
(lp4377
S'- diagnosed as uc first time. no history of using biologic,immunomodulatory therapy or corticosteroid therapy. with contraindication of endoscopy.'
p4378
assS'gastrointestinal hemorrhage-Drug'
p4379
(dp4380
g279
(lp4381
S'- evidence of active gi bleeding during current hospitalization prior to study entry'
p4382
aS'- admission to icu with primary diagnosis of burn injury'
p4383
aS'- closed head injury or increased intracranial pressure'
p4384
aS'- partial or complete gastrectomy'
p4385
aS'- pregnancy or lactation'
p4386
assS'bowel-associated dermatosis-arthritis syndrome-Procedure'
p4387
(dp4388
sS"crohn's disease-Procedure"
p4389
(dp4390
g73
(lp4391
S'- subject has participated in a study of an investigational medicinal product (imp) or medical device within the previous 30 days or 5 half-lives (whichever is longer) prior to screening or is currently participating in another study of an imp or medical device - unless the study is ucb up0016 [nct02154425] or a registry study'
p4392
aS"- subject has any obstetrical or psychiatric condition, or she or her infant(s) has any medical condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study or the outcome of the pregnancy"
p4393
aS'- subject has history of chronic alcohol abuse or drug abuse during pregnancy'
p4394
aS'- subject has any pregnancy-related clinically significant abnormality noted on obstetric ultrasound, or other imaging assessment, or the subject has significant laboratory abnormalities during her pregnancy, as judged by the investigator'
p4395
aS'- subject is taking or has taken any medication with strong positive evidence of a human fetal risk of teratogenicity (e.g., methotrexate or leflunomide) during pregnancy'
p4396
aS'- subject has evidence of a condition suggesting chronic or acute uteroplacental insufficiency such as intrauterine growth restriction, severe maternal hypertensive disorders of pregnancy, or abruption'
p4397
aS'- subject has a documented history of primary or secondary antiphospholipid syndrome or hypercoagulable state'
p4398
aS'- subject has received treatment with any biological therapeutic agent, including anti-tnfs other than certolizumab pegol (czp), during pregnancy'
p4399
aS'- subject has previously participated in this study'
p4400
aS'- subject has a positive or indeterminate quantiferon\xc2\xae-tb gold in tube test at screening. in case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the subject'
p4401
aS"- subject with known tuberculosis (tb) infection, at high risk of acquiring tb infection, or latent tb infection (ltb). if tested within the 6 months prior to screening and the test was negative for tb, and there is no change in the subject's clinical status, nor social, family, or travel history, there is no need for an additional tb testing at screening"
p4402
asg1117
(lp4403
S'- diarrhea activity scores < 3'
p4404
aS'- severely active disease with perianal diseases'
p4405
aS'- severely active disease with indication of surgery.'
p4406
aS'- diagnosis as ibd first time or first year.'
p4407
aS'- no history of using 5-asa, biological (antibody), immunomodulatory therapy, corticosteroid therapy'
p4408
asg2681
(lp4409
S'- patients unable to give informed consent'
p4410
aS'- patients requiring formation of a stoma at the time of surgical resection'
p4411
aS'- patients having less than 200cm of small bowel as assessed intra-operatively'
p4412
aS'- simultaneous strictureplasty or small bowel resection'
p4413
aS'- age <16 or >80'
p4414
asg4039
(lp4415
S'- patients aged < 18 years old'
p4416
aS'- informed consent refusal'
p4417
aS'- medical or family history of variant creutzfeldt-jakobs disease'
p4418
aS"- activated sever crohn's disease"
p4419
aS'- perianal fistulae >2 cm in diameter'
p4420
aS"- autoimmune disease or inflammatory bowel disease other than crohn's disease"
p4421
aS'- infectious disease including hepatitis b virus, hepatitis c virus and immunodeficiency virus infection'
p4422
aS'- active tuberculosis'
p4423
aS'- signs of septicemia'
p4424
aS'- patients treated with infliximab within 3 months prior to asc treatment.'
p4425
aS'- technically difficult adipose tissue collection due to low levels of fat tissue.'
p4426
aS'- pregnancy'
p4427
asS'NCT00383344'
p4428
(lp4429
S'- men or women less than 18 years of age'
p4430
aS'- pregnancy'
p4431
aS'- breastfeeding'
p4432
aS'- renal failure'
p4433
aS"- suspicion of a crohn's disease infectious complication (abscess,fistula)"
p4434
aS'- infectious colitis determined at the initial checkup'
p4435
aS'- diabetes'
p4436
aS'- severe allergy to iode contrast'
p4437
asS'NCT01671579'
p4438
(lp4439
S'- subjects with suspected or newly diagnosed crohn disease'
p4440
aS'- subject who have the following in their body may not undergo mre imaging:'
p4441
aS'- metal chips/shrapnel'
p4442
aS'- surgical clips'
p4443
aS'- artificial joints'
p4444
aS'- metallic bone plates'
p4445
aS'- prosthetic devices'
p4446
aS'- heart pacemakers'
p4447
aS'- clips in or around the eye balls'
p4448
aS'- artificial heart valves'
p4449
aS'- bullet fragments'
p4450
aS'- chemotherapy or insulin pumps'
p4451
asg2958
(lp4452
S'- diarrhea activity scores < 3)'
p4453
aS'- severely active disease with perianal diseases'
p4454
aS'- severely active disease with indication of surgery.'
p4455
aS'- diagnosis as cd first time or first year.'
p4456
aS'- no history of using 5-asa, biological (antibody), immunomodulatory therapy, corticosteroid therapy'
p4457
asS'NCT00886327'
p4458
(lp4459
S'- intestinal obstruction as suspected by anamnesis or clinical/technical investigation'
p4460
aS'- dysphagia or ileus'
p4461
aS"- non-passage of the intact 'agile patency capsule' within 72 hours"
p4462
aS'- pregnancy'
p4463
asg3569
(lp4464
S'- digestive stoma in place or planned during the intervention'
p4465
aS'- body mass index > 30 kg/m2'
p4466
aS'- history of previous laparotomy, except mc burney, pfannenstiel ou subcostal'
p4467
aS'- subtotal colectomy'
p4468
aS'- transverse colectomy'
p4469
aS'- proctectomy or total coloproctectomy'
p4470
aS'- synchronous metastasis'
p4471
aS'- preoperative suspicion of t4 colorectal cancer'
p4472
aS'- emergency procedure'
p4473
aS'- associated resection (except appendectomy or liver biopsy)'
p4474
aS'- pregnancy or current breast feeding.'
p4475
asg62
(lp4476
S'- pregnant or breastfeeding women,'
p4477
aS'- patient having a perineal abscess,'
p4478
aS'- patient with a high anovaginal fistula that cannot be treated, according to the investigator ,with fistulotomy, gluing, biodegradable plug or advancement flap,'
p4479
aS'- patient treated with a daily dose of corticosteroids of more than 20 mg (a dose of more than 20 mg daily will be authorized during the study),'
p4480
aS'- contraindication to proctological surgery on the drained fistula(s),'
p4481
aS'- patient presenting with somatic or psychic signs or symptoms that are not compatible with his/her participation in the trial according to the investigator,'
p4482
aS'- patient who participate in another clinical trial.'
p4483
asS'NCT02542904'
p4484
(lp4485
S'- concomitant anastomosis/strictureplasty at another site of the gastrointestinal tract, and required a temporary fecal diversion'
p4486
asS'NCT01505842'
p4487
(lp4488
S'- patients who decline to participate'
p4489
aS'- unable to give informed consent'
p4490
aS'- increased risk of bleeding (i.e. warfarin, bleeding disorders, clopidogrel)'
p4491
asS'NCT02631967'
p4492
(lp4493
S'- age > 75 years'
p4494
aS'- age < 18 years'
p4495
aS'- inability to give the consent to the participation in the trial'
p4496
aS'- refusal to participate in the trial after receiving accurate information'
p4497
asg694
(lp4498
S'- patients with severe cardiopulmonary disease or other severe disease.'
p4499
aS'- patients who are psychopath, pregnant, and child without capacity for civil conduct.'
p4500
aS'- patients with complete intestinal obstruction.'
p4501
aS'- patients with abdominal cavity infection.'
p4502
aS'- patients who are treating by drug such as adrenal cortical hormone and immune inhibitors, chemotherapy drugs, radiation and so on.'
p4503
aS'- patients who need to accept the anastomosis between rectum and colon.'
p4504
aS'- patients who are required to accept intestinal anastomosis twice or more.'
p4505
aS'- patients who are required to accept the treatment of colostomy.'
p4506
aS'- other conditions that render a patient unsuitable for the trial as determined by the study investigators.'
p4507
asS'NCT02330458'
p4508
(lp4509
S"- ulcerative colitis or non-crohn's disease patients"
p4510
aS'- lack of small bowel disease'
p4511
aS'- patients started on alternative therapy'
p4512
aS'- unable or unwilling to provide consent'
p4513
assS'psoriatic arthritis-Drug'
p4514
(dp4515
g444
(lp4516
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p4517
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p4518
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p4519
aS'- known hiv/aids'
p4520
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p4521
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p4522
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p4523
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p4524
aS'- participated in an investigational study within 1 month prior to study entry'
p4525
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p4526
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p4527
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p4528
assS'enteropathic arthritis-Biological'
p4529
(dp4530
g444
(lp4531
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p4532
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p4533
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p4534
aS'- known hiv/aids'
p4535
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p4536
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p4537
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p4538
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p4539
aS'- participated in an investigational study within 1 month prior to study entry'
p4540
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p4541
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p4542
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p4543
assS'children with a deficiency of alpha-1 antitrypsin-Other'
p4544
(dp4545
S'NCT01862211'
p4546
(lp4547
S'- - lack of consent'
p4548
assS'diverticular disease-Device'
p4549
(dp4550
g616
(lp4551
S'- subjects present with bowel obstruction or perforation'
p4552
aS'- subject undergo emergency surgery'
p4553
aS'- subject with asa iv, v'
p4554
aS'- history of allergy or hypersensitivity against indocyanine green'
p4555
aS'- pregnant or breast-feeding women'
p4556
aS'- subject has uremia (serum creatinine >2.5 mg/dl)'
p4557
aS'- subject is undergoing palliative surgery or who is terminally ill'
p4558
aS'- subject who is unable to discontinue warfarin anticoagulation 5 days before surgery'
p4559
aS'- subject taking phenobarbital, phenylbutazone, primidone, phenytoin, haloperidol, nitrofurantoin, probenecid'
p4560
assS'erythema elevatum diutinum-Procedure'
p4561
(dp4562
sS'rheumatoid arthritis-Procedure'
p4563
(dp4564
g73
(lp4565
S'- subject has participated in a study of an investigational medicinal product (imp) or medical device within the previous 30 days or 5 half-lives (whichever is longer) prior to screening or is currently participating in another study of an imp or medical device - unless the study is ucb up0016 [nct02154425] or a registry study'
p4566
aS"- subject has any obstetrical or psychiatric condition, or she or her infant(s) has any medical condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study or the outcome of the pregnancy"
p4567
aS'- subject has history of chronic alcohol abuse or drug abuse during pregnancy'
p4568
aS'- subject has any pregnancy-related clinically significant abnormality noted on obstetric ultrasound, or other imaging assessment, or the subject has significant laboratory abnormalities during her pregnancy, as judged by the investigator'
p4569
aS'- subject is taking or has taken any medication with strong positive evidence of a human fetal risk of teratogenicity (e.g., methotrexate or leflunomide) during pregnancy'
p4570
aS'- subject has evidence of a condition suggesting chronic or acute uteroplacental insufficiency such as intrauterine growth restriction, severe maternal hypertensive disorders of pregnancy, or abruption'
p4571
aS'- subject has a documented history of primary or secondary antiphospholipid syndrome or hypercoagulable state'
p4572
aS'- subject has received treatment with any biological therapeutic agent, including anti-tnfs other than certolizumab pegol (czp), during pregnancy'
p4573
aS'- subject has previously participated in this study'
p4574
aS'- subject has a positive or indeterminate quantiferon\xc2\xae-tb gold in tube test at screening. in case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the subject'
p4575
aS"- subject with known tuberculosis (tb) infection, at high risk of acquiring tb infection, or latent tb infection (ltb). if tested within the 6 months prior to screening and the test was negative for tb, and there is no change in the subject's clinical status, nor social, family, or travel history, there is no need for an additional tb testing at screening"
p4576
assS'sneddon-wilkinson disease-Procedure'
p4577
(dp4578
sS'psoriasis-Biological'
p4579
(dp4580
g444
(lp4581
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p4582
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p4583
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p4584
aS'- known hiv/aids'
p4585
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p4586
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p4587
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p4588
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p4589
aS'- participated in an investigational study within 1 month prior to study entry'
p4590
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p4591
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p4592
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p4593
assS'aminosalicylic acid-Drug'
p4594
(dp4595
g1324
(lp4596
S'- allergic to mesalazine'
p4597
aS'- prior bowel surgery except appendectomy'
p4598
aS'- hepatic or renal dysfunction'
p4599
aS'- malignant disease within 5 years'
p4600
aS'- pregnancy or breast feeding or women of child-bearing age without regular use of contraception'
p4601
aS'- on anti-tumor necrosis factor therapy'
p4602
aS'- terminal illness'
p4603
assS'autoimmune disease-Drug'
p4604
(dp4605
g1639
(lp4606
S'- 1. subject, who, for any reason, is judged by the investigator to be inappropriate for this study;'
p4607
aS'- 2. subject has a medical history of other clinically significant diseases/disorders;'
p4608
aS"- 3. subject's uc had failed to respond to more than one biologic treatment (e.g., infliximab, adalimumab, or golimumab);"
p4609
aS'- 4. subject requires prescription treatment for uc, except for the stable, oral treatment of uc for 4 weeks prior to screening.'
p4610
aS'- 5. subject has received any of the following prior treatments or treatments within the specified time prior to the baseline visit:'
p4611
aS'- natalizumab, efalizumab, rituximab or other lymphocyte-depleting treatments, including but not limited, to alkylating agents (such as cyclophosphamide or chlorambucil) and total lymphoid irradiation at any time;'
p4612
aS'- tnf antagonists within 8 weeks, or 5 half-lives (up to 12 weeks);'
p4613
aS'- vedolizumab within 16 weeks;'
p4614
aS'- methotrexate, cyclosporine, mycophenolate, tacrolimus, thalidomide, or other immune altering drugs within 4 weeks (ophthalmologic preparations are permitted);'
p4615
aS'- 5-asa enema, steroid enema or suppository use within 2 weeks ; and/or'
p4616
aS'- investigational agents within 8 weeks or 5 half-lives (whichever is longer).'
p4617
aS'- 6. subject with recent, suspected or confirmed symptomatic stenosis of the colon, abdominal abscess, or ischemic colitis based on clinical or radiographic data; a history of toxic megacolon; or who had any previous surgery for uc;'
p4618
aS'- 7. subject with known colonic dysplasia, adenomas or polyposis;'
p4619
aS'- 8. subject had major surgery within 4 weeks prior to screening or an anticipated requirement for major surgery;'
p4620
aS'- 9. subject with enteric pathogens (including clostridium difficile);'
p4621
aS'- 10. subject with any of the following hematological and chemistry laboratory values:'
p4622
aS'- platelet count < 100,000/mm3;'
p4623
aS'- neutrophils < 1500/mm3;'
p4624
aS'- serum creatinine \xe2\x89\xa5 1.6 mg/dl (\xe2\x89\xa5 144.4 \xce\xbcmol/l);'
p4625
aS'- alkaline phosphatase > 3 times the upper limit of normal (uln);'
p4626
aS'- ast or alt > 2 times uln;'
p4627
aS"- total bilirubin > 2 mg/dl, unless due to gilbert's syndrome;"
p4628
aS'- serum albumin < 3 g/dl;'
p4629
aS'- hemoglobin < 9 g/dl;'
p4630
aS'- glycated serum hemoglobin a1c \xe2\x89\xa5 9%.'
p4631
aS'- 11. subject has clinically significant cardiac disease;'
p4632
aS'- 12. subject is pregnant or breastfeeding;'
p4633
aS'- 13. subject has had major immunologic reaction;'
p4634
aS'- 14. subject is hepatitis b core antibody or surface antigen positive and/or hepatitis c antibody positive with detectable rna;'
p4635
aS'- 15. subject has a history of human immunodeficiency virus (hiv) positivity, tests positive for hiv, or has congenital or acquired immunodeficiency;'
p4636
aS'- 16. subject has or has had active tb, suspected extra-pulmonary tb, a history of incompletely treated tb, or latent tb or other latent infection. subjects with latent tb (clinical findings, purified protein derivative [ppd] or interferon gamma release assay [igra]) may be included in the study if prophylactic therapy for latent tb is started at least 4 weeks prior to screening. subjects with a potentially untreated other infection (clinical findings) are to be excluded.'
p4637
aS'- 17. subject has bacterial infections requiring treatment with oral or parenteral antibiotics, within 2 and 4 weeks, respectively.'
p4638
aS'- 18. subject has a history of systemic opportunistic infection or recurrent infections'
p4639
aS'- 19. subject has malignancy or history of malignancy, except for adequately treated basal cell skin cancer or adequately treated carcinoma in-situ of the cervix without recurrence at least 5 years.'
p4640
aS'- 20. subject who received a bacille calmette-gu\xc3\xa9rin (bcg) vaccine within 6 months of randomization or live vaccination (e.g., measles, mumps, rubella [mmr]; herpes zoster; varicella, intranasal influenza; and oral poliomyelitis) within 4 weeks of randomization.'
p4641
aS'- 21. subject with a history of or active substance abuse.'
p4642
aS'- 22. subject has other severe acute or chronic medical or psychiatric condition or laboratory abnormality.'
p4643
assS'microrna profile-Other'
p4644
(dp4645
g2673
(lp4646
S'- major congenital or life threatening abnormalities or congenital abnormalities that preclude early milk feeding'
p4647
aS'- inability to randomise infant within 48 hours'
p4648
assS'macular degeneration-Drug'
p4649
(dp4650
g629
(lp4651
S'- are participating in another clinical study requiring follow up examinations'
p4652
aS'- have received any other experimental drug within 12 weeks prior to enrollment'
p4653
aS'- are unwilling or unable to follow or comply with all study-related procedures'
p4654
aS'- inability to obtain photographs, fluorescein angiography, or optical coherence tomography to document cnv, e.g. due to media opacity, allergy to fluorescein dye or lack of venous access'
p4655
aS'- aphakia or pseudophakia with the absence of posterior capsule (unless it resulted from a yttrium aluminum garner [yag]) posterior capsulotomy)'
p4656
aS'- within two months prior to screening, have had intraocular surgery (including cataract surgery) in the study eye'
p4657
aS'- within 1 month prior to screening had yag laser in the study eye'
p4658
aS'- have had intravitreal anti vegf or intravitreal steroids in the last 6 weeks'
p4659
aS'- have had previous pars plana vitrectomy in the study eye'
p4660
aS'- are pregnant or are trying to become pregnant'
p4661
aS'- any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated'
p4662
aS'- have a history of allergies to murine monoclonal antibodies, mice or mouse products.'
p4663
assS"crohn's disease-Device"
p4664
(dp4665
S'NCT02624414'
p4666
(lp4667
S'- patients must not:'
p4668
aS'- have known/suspected gastrointestinal obstruction'
p4669
aS'- have swallowing disorder'
p4670
aS'- have a known oesophageal stricture'
p4671
aS'- have severe gastroparesis'
p4672
aS'- have dementia'
p4673
aS'- have a cardiac pacemaker or other implanted medical device'
p4674
aS'- have sever cardiac or renal insufficiency'
p4675
aS'- have a previous allergy or contraindication to bowel preparation'
p4676
aS'- be pregnant'
p4677
aS'- prior major abdominal surgery'
p4678
aS'- colonoscopy is contraindicated'
p4679
asg93
(lp4680
S'- no health insurance ,'
p4681
aS'- mental disability,'
p4682
aS'- pregnancy'
p4683
asg4039
(lp4684
S'- patients aged < 18 years old'
p4685
aS'- informed consent refusal'
p4686
aS'- medical or family history of variant creutzfeldt-jakobs disease'
p4687
aS"- activated sever crohn's disease"
p4688
aS'- perianal fistulae >2 cm in diameter'
p4689
aS"- autoimmune disease or inflammatory bowel disease other than crohn's disease"
p4690
aS'- infectious disease including hepatitis b virus, hepatitis c virus and immunodeficiency virus infection'
p4691
aS'- active tuberculosis'
p4692
aS'- signs of septicemia'
p4693
aS'- patients treated with infliximab within 3 months prior to asc treatment.'
p4694
aS'- technically difficult adipose tissue collection due to low levels of fat tissue.'
p4695
aS'- pregnancy'
p4696
asS'NCT01881490'
p4697
(lp4698
S'- 1. young children requiring anesthesia for lack of cooperation will be excluded (since the enteric contrast cannot be administered during the 2 hours before anesthesia and it is crucial that the contrast be given just prior the test).'
p4699
aS'- 2. for the first 120 children only, subjects not expected to be available for 18 month follow-up, will be excluded (the last 120 subjects may be enrolled as they are not followed longitudinally).'
p4700
asg3984
(lp4701
S'- inability to provide written informed consent'
p4702
aS'- severe coagulopathy (prothrombin time < 50% of control, partial thromboplastin time > 50 s)'
p4703
aS'- pregnancy or breast feeding'
p4704
aS'- active gastrointestinal bleeding'
p4705
aS'- residing in institutions (e.g. prison)'
p4706
aS'- proctocolectomy'
p4707
asS'NCT01569503'
p4708
(lp4709
S'- known cardiac pathology'
p4710
aS'- vns contraindication'
p4711
aS'- anoperineal cd only or associated with ileocolic lesion'
p4712
aS'- diagnosis of indeterminate colitis, positive stool culture for enteric pathogens'
p4713
aS'- cd surgery within 3 months before screening'
p4714
aS'- short small intestine (<1m)'
p4715
aS'- koenig syndrome'
p4716
aS'- intra-abdominal abscess'
p4717
aS'- fistula with clinical or radiological abscess evidence'
p4718
aS'- anoperineal cd with or without rectal involvement'
p4719
aS'- ileostomy, colostomy, enteral or parenteral feeding'
p4720
aS"- clinical condition medically or surgically unstable that, at the discretion of the investigator would not be compatible with the patient's participation in the study"
p4721
aS'- any recent neoplasia, in the year prior to screening'
p4722
asS'NCT02311660'
p4723
(lp4724
S'- celiac disease'
p4725
aS'- diagnosis of ulcerative or indeterminate colitis'
p4726
aS'- enterocutaneous, abdominal or pelvic fistulae with abscesses, or fistulae likely to require surgery during the course of the study period'
p4727
aS"- bowel surgery, other than appendectomy, within 12 weeks prior to week -4 visit and/or has planned surgery or deemed likely to need surgery for crohn's disease during the study period"
p4728
aS'- extensive colonic resection, subtotal or total colectomy'
p4729
aS'- presence of ileostomies, colostomies or rectal pouches'
p4730
aS'- fixed symptomatic stenoses of small bowel or colon'
p4731
aS'- history of more than 3 small bowel resections or diagnosis of short bowel syndrome'
p4732
aS'- use of prohibited medications inside the specified washout period (prior to week -4 visit), and throughout the study. prohibited medications include the following:'
p4733
aS'- use of any tnf alpha inhibitor, vedolizumab or natalizumab within 8 weeks'
p4734
aS'- use of glucocorticoids at doses greater than 10 mg prednisone orally qd, or an equivalent dose of other oral or parenteral glucocorticoids within 4 weeks'
p4735
aS'- use of cyclosporine, tacrolimus, sirolimus or mycophenolate mofetil within 4 weeks'
p4736
aS"- use of intravenous antibiotics for crohn's disease within 4 weeks"
p4737
aS'- use of tube or enteral feeding, or elemental diet within 2 weeks'
p4738
aS'- rectal treatment: use of 5-aminosalicylates or corticosteroid enemas or suppositories within 2 weeks'
p4739
aS'- azathioprine, 6-mercaptopurine and methotrexate can be continued throughout the trial. these medications must have been used for >12 weeks, at stable dose for at least 3 weeks prior to the week -4 visit.'
p4740
aS'- leukocytopheresis or granulocytopheresis within 2 weeks prior to week -4 visit'
p4741
aS'- positive immunoassay for clostridium difficile at week -4 visit'
p4742
aS'- known hiv infection'
p4743
aS'- known active in infection with hepatitis b virus or hepatitis c virus'
p4744
aS'- current evidence of, or has been treated for a malignancy within the past five years (other than localized basal cell or squamous cell skin cancer, cervical dysplasia, or any cancer which has been fully staged as in situ and has been fully resected)'
p4745
aS'- history of evidence of adenomatous colonic polyps that have not been removed.'
p4746
aS'- use of any investigational product within 30 days prior to week -4 visit for small molecules, or 8 weeks prior for monoclonal antibodies'
p4747
aS'- significant psychiatric disease or substance abuse'
p4748
aS'- history of unilateral or bilateral vagotomy'
p4749
aS'- history of recurrent vaso-vagal syncope episodes'
p4750
aS'- known obstructive sleep apnea'
p4751
aS'- known history of cardiac rhythm disturbances, atrio-ventricular block of greater than first degree, or cardiac conduction pathway abnormalities other than isolated right bundle branch block or isolated left anterior fascicle block'
p4752
aS'- significant pharyngeal dysfunction or swallowing difficulties'
p4753
aS'- pre-existing clinically significant vocal cord damage or hoarseness'
p4754
aS'- previously implanted electrically active medical devices (e.g., cardiac pacemakers, automatic implantable cardioverter-defibrillators)'
p4755
aS'- asthma or chronic obstructive pulmonary disease not controlled by medications, or any other disease causing clinically significant dyspnea at time of screening'
p4756
aS'- a greater than or equal to 40 pack-year smoking history'
p4757
aS'- active peptic ulcer disease'
p4758
asg2898
(lp4759
S'- patients who had been treated with anti tnf \xce\xb1 4 weeks before the study'
p4760
aS'- as well as those who received corticosteroids within 1 week before the study.'
p4761
aS'- dm, ihd, crf, smoker'
p4762
asg2658
(lp4763
S'- pregnant women'
p4764
aS'- black skin'
p4765
aS'- chronic renal insufficiency (mdrd <30 ml/min)'
p4766
asg48
(lp4767
S'- no patient informed consent.'
p4768
aS'- stenosis complicated with abscess, fistula or important activity associated with your ec not limited to the stenosis area.'
p4769
aS'- patients with stenosis already known and previously treated with stent and / or dilation with <1 year asymptomatic.'
p4770
aS'- pregnancy and lactation'
p4771
aS'- any clinical situation that prevents the performance of endoscopy'
p4772
aS'- stenosis not accessible by endoscopy'
p4773
aS'- asymptomatic patient'
p4774
aS'- length of stenosis \xe2\x89\xa5 10 cm.'
p4775
aS'- submit> 2 stenosis.'
p4776
aS'- severe coagulation disorders (platelets <70000; inr> 1.8)'
p4777
asS'NCT02488005'
p4778
(lp4779
S'- lack of small bowel disease'
p4780
aS'- inability to give consent or adhere to study protocol'
p4781
aS'- infliximab-experienced'
p4782
aS'- presence of active infections'
p4783
aS'- presence of abscess or strictures'
p4784
aS'- current or planned pregnancy for the 14 week study duration'
p4785
asg3916
(lp4786
S'- inability to provide written informed consent'
p4787
aS'- severe coagulopathy (prothrombin time < 50% of control, partial thromboplastin time > 50 s)'
p4788
aS'- pregnancy or breast feeding'
p4789
aS'- active gastrointestinal bleeding'
p4790
aS'- residing in institutions (e.g. prison)'
p4791
aS'- known allergy against fluorescein'
p4792
aS'- proctocolectomy'
p4793
asS'NCT02559037'
p4794
(lp4795
S'- 1. pregnant or lactating patients;'
p4796
aS'- 2. associated with heart, brain, liver, kidney and hematopoietic system of serious diseases;'
p4797
aS'- 3. mental illness;'
p4798
aS'- 4. other serious diseases;'
p4799
aS'- 5. the presence of skin disease, fistula, sinus, mutilation and other conditions in the acupoints selected in the study that can not be implemented moxibustion treatment.'
p4800
asg2243
(lp4801
S'- age < 18 years'
p4802
aS'- mental retardation of the patient with restriction of general judgment and awareness'
p4803
assS'iron deficiency anemia-Drug'
p4804
(dp4805
S'NCT02774057'
p4806
(lp4807
S'- age below 18'
p4808
aS'- hemoglobin level < 8 g/dl'
p4809
aS'- recently hospitalized for disease flare (within 3 months)'
p4810
aS'- hemoglobinopathies (including thalassemia)'
p4811
aS'- isolated proctitis'
p4812
aS'- indeterminate colitis'
p4813
aS'- known liver or kidney disease'
p4814
aS'- known celiac disease'
p4815
aS'- small bowel resection'
p4816
aS'- use of anticoagulants or aspirin'
p4817
aS'- known intolerance to oral iron therapy'
p4818
aS'- uninvestigated anemia'
p4819
aS'- pregnant or lactating women'
p4820
aS'- known hypersensitivity to iron sulfate'
p4821
aS'- transfusion within the last 4 weeks'
p4822
aS'- erythropoetin within the last 8 weeks'
p4823
aS'- rheumatoid arthritis'
p4824
aS'- history of menometrorrhagia or frequent epistaxis'
p4825
aS'- use of stomach acid-reducing product (classical antacids, proton pump inhibitors, h2-receptors inhibitors)'
p4826
aS'- gastritis'
p4827
asS'NCT02546154'
p4828
(lp4829
S'- patients diagnosed with both ckd and ibd'
p4830
assS'colorectal cancer-Device'
p4831
(dp4832
g290
(lp4833
S'- pregnant woman or lactating woman.'
p4834
aS'- with confirmed distant metastasis in liver, lung, bones, or other organs.'
p4835
aS'- intolerable laparoscopic operation or converted to open surgery.'
p4836
aS'- with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.'
p4837
aS'- with bad compliance or contraindication to enrollment.'
p4838
assS'vitamin d deficiency-Drug'
p4839
(dp4840
g3147
(lp4841
S'- children less than 8 years or greater than 18 years at the time of study screening'
p4842
aS'- patients with a documented history of hypercalcemia, renal insufficiency, or nephrolithiasis'
p4843
aS'- patients taking cholestyramine'
p4844
aS'- patients who have a gi tract in discontinuity (ostomy)'
p4845
aS'- patients who have serum 25-oh vitamin d levels of >50 ng/ml at the time of study screening'
p4846
assS'iron deficiency anemia (ida) secondary to inflammatory bowel disease (ibd) or gastric bypass-Drug'
p4847
(dp4848
S'NCT02086968'
p4849
(lp4850
S'- hypersensitivity reaction to any component of iv injectafer or oral iron'
p4851
aS'- requires dialysis for treatment of chronic kidney disease (ckd)'
p4852
aS'- during the 30 day period prior to screening has been treated with iv iron'
p4853
aS'- no evidence of iron deficiency'
p4854
aS'- during the 30 day period prior to screening has been treated with a red blood cell transfusion.'
p4855
aS'- any non-viral infection'
p4856
aS'- known positive hepatitis with evidence of active disease'
p4857
aS'- received an investigational drug within 30 days of screening'
p4858
aS'- active malignancy within 5 years. basal or squamous cell skin cancer is not exclusionary'
p4859
aS'- alcohol or drug abuse within the past 6 months'
p4860
aS'- hemochromatosis or other iron storage disorders'
p4861
aS'- pregnant'
p4862
aS"- any other laboratory abnormality, medical condition, or psychiatric disorders which in the opinion of the investigator would put the subject's disease management at risk or may result in the subject being unable to comply with the study requirements"
p4863
assS'surgical site infection-Procedure'
p4864
(dp4865
g290
(lp4866
S'- pregnant woman or lactating woman.'
p4867
aS'- with confirmed distant metastasis in liver, lung, bones, or other organs.'
p4868
aS'- intolerable laparoscopic operation or converted to open surgery.'
p4869
aS'- with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.'
p4870
aS'- with bad compliance or contraindication to enrollment.'
p4871
assS'chronic diarrhea-Procedure'
p4872
(dp4873
g3696
(lp4874
S'- patients who decline to participate'
p4875
aS'- unable to give informed consent'
p4876
assS'stenosis-Device'
p4877
(dp4878
g48
(lp4879
S'- no patient informed consent.'
p4880
aS'- stenosis complicated with abscess, fistula or important activity associated with your ec not limited to the stenosis area.'
p4881
aS'- patients with stenosis already known and previously treated with stent and / or dilation with <1 year asymptomatic.'
p4882
aS'- pregnancy and lactation'
p4883
aS'- any clinical situation that prevents the performance of endoscopy'
p4884
aS'- stenosis not accessible by endoscopy'
p4885
aS'- asymptomatic patient'
p4886
aS'- length of stenosis \xe2\x89\xa5 10 cm.'
p4887
aS'- submit> 2 stenosis.'
p4888
aS'- severe coagulation disorders (platelets <70000; inr> 1.8)'
p4889
assS'fistula-Procedure'
p4890
(dp4891
g4039
(lp4892
S'- patients aged < 18 years old'
p4893
aS'- informed consent refusal'
p4894
aS'- medical or family history of variant creutzfeldt-jakobs disease'
p4895
aS"- activated sever crohn's disease"
p4896
aS'- perianal fistulae >2 cm in diameter'
p4897
aS"- autoimmune disease or inflammatory bowel disease other than crohn's disease"
p4898
aS'- infectious disease including hepatitis b virus, hepatitis c virus and immunodeficiency virus infection'
p4899
aS'- active tuberculosis'
p4900
aS'- signs of septicemia'
p4901
aS'- patients treated with infliximab within 3 months prior to asc treatment.'
p4902
aS'- technically difficult adipose tissue collection due to low levels of fat tissue.'
p4903
aS'- pregnancy'
p4904
asg62
(lp4905
S'- pregnant or breastfeeding women,'
p4906
aS'- patient having a perineal abscess,'
p4907
aS'- patient with a high anovaginal fistula that cannot be treated, according to the investigator ,with fistulotomy, gluing, biodegradable plug or advancement flap,'
p4908
aS'- patient treated with a daily dose of corticosteroids of more than 20 mg (a dose of more than 20 mg daily will be authorized during the study),'
p4909
aS'- contraindication to proctological surgery on the drained fistula(s),'
p4910
aS'- patient presenting with somatic or psychic signs or symptoms that are not compatible with his/her participation in the trial according to the investigator,'
p4911
aS'- patient who participate in another clinical trial.'
p4912
assS'indeterminate colitis-Behavioral'
p4913
(dp4914
g530
(lp4915
S'- diagnosis of pervasive developmental disorder in patient or parent'
p4916
aS'- diagnosis of serious mental illness (e.g., schizophrenia) in patient or parent'
p4917
assS'chronic obstructive pulmonary disease (copd)-Behavioral'
p4918
(dp4919
sS'urinary tract problem-Behavioral'
p4920
(dp4921
sS'metabolomic profile-Other'
p4922
(dp4923
g2673
(lp4924
S'- major congenital or life threatening abnormalities or congenital abnormalities that preclude early milk feeding'
p4925
aS'- inability to randomise infant within 48 hours'
p4926
assS'abdominal pain-Drug'
p4927
(dp4928
g1639
(lp4929
S'- 1. subject, who, for any reason, is judged by the investigator to be inappropriate for this study;'
p4930
aS'- 2. subject has a medical history of other clinically significant diseases/disorders;'
p4931
aS"- 3. subject's uc had failed to respond to more than one biologic treatment (e.g., infliximab, adalimumab, or golimumab);"
p4932
aS'- 4. subject requires prescription treatment for uc, except for the stable, oral treatment of uc for 4 weeks prior to screening.'
p4933
aS'- 5. subject has received any of the following prior treatments or treatments within the specified time prior to the baseline visit:'
p4934
aS'- natalizumab, efalizumab, rituximab or other lymphocyte-depleting treatments, including but not limited, to alkylating agents (such as cyclophosphamide or chlorambucil) and total lymphoid irradiation at any time;'
p4935
aS'- tnf antagonists within 8 weeks, or 5 half-lives (up to 12 weeks);'
p4936
aS'- vedolizumab within 16 weeks;'
p4937
aS'- methotrexate, cyclosporine, mycophenolate, tacrolimus, thalidomide, or other immune altering drugs within 4 weeks (ophthalmologic preparations are permitted);'
p4938
aS'- 5-asa enema, steroid enema or suppository use within 2 weeks ; and/or'
p4939
aS'- investigational agents within 8 weeks or 5 half-lives (whichever is longer).'
p4940
aS'- 6. subject with recent, suspected or confirmed symptomatic stenosis of the colon, abdominal abscess, or ischemic colitis based on clinical or radiographic data; a history of toxic megacolon; or who had any previous surgery for uc;'
p4941
aS'- 7. subject with known colonic dysplasia, adenomas or polyposis;'
p4942
aS'- 8. subject had major surgery within 4 weeks prior to screening or an anticipated requirement for major surgery;'
p4943
aS'- 9. subject with enteric pathogens (including clostridium difficile);'
p4944
aS'- 10. subject with any of the following hematological and chemistry laboratory values:'
p4945
aS'- platelet count < 100,000/mm3;'
p4946
aS'- neutrophils < 1500/mm3;'
p4947
aS'- serum creatinine \xe2\x89\xa5 1.6 mg/dl (\xe2\x89\xa5 144.4 \xce\xbcmol/l);'
p4948
aS'- alkaline phosphatase > 3 times the upper limit of normal (uln);'
p4949
aS'- ast or alt > 2 times uln;'
p4950
aS"- total bilirubin > 2 mg/dl, unless due to gilbert's syndrome;"
p4951
aS'- serum albumin < 3 g/dl;'
p4952
aS'- hemoglobin < 9 g/dl;'
p4953
aS'- glycated serum hemoglobin a1c \xe2\x89\xa5 9%.'
p4954
aS'- 11. subject has clinically significant cardiac disease;'
p4955
aS'- 12. subject is pregnant or breastfeeding;'
p4956
aS'- 13. subject has had major immunologic reaction;'
p4957
aS'- 14. subject is hepatitis b core antibody or surface antigen positive and/or hepatitis c antibody positive with detectable rna;'
p4958
aS'- 15. subject has a history of human immunodeficiency virus (hiv) positivity, tests positive for hiv, or has congenital or acquired immunodeficiency;'
p4959
aS'- 16. subject has or has had active tb, suspected extra-pulmonary tb, a history of incompletely treated tb, or latent tb or other latent infection. subjects with latent tb (clinical findings, purified protein derivative [ppd] or interferon gamma release assay [igra]) may be included in the study if prophylactic therapy for latent tb is started at least 4 weeks prior to screening. subjects with a potentially untreated other infection (clinical findings) are to be excluded.'
p4960
aS'- 17. subject has bacterial infections requiring treatment with oral or parenteral antibiotics, within 2 and 4 weeks, respectively.'
p4961
aS'- 18. subject has a history of systemic opportunistic infection or recurrent infections'
p4962
aS'- 19. subject has malignancy or history of malignancy, except for adequately treated basal cell skin cancer or adequately treated carcinoma in-situ of the cervix without recurrence at least 5 years.'
p4963
aS'- 20. subject who received a bacille calmette-gu\xc3\xa9rin (bcg) vaccine within 6 months of randomization or live vaccination (e.g., measles, mumps, rubella [mmr]; herpes zoster; varicella, intranasal influenza; and oral poliomyelitis) within 4 weeks of randomization.'
p4964
aS'- 21. subject with a history of or active substance abuse.'
p4965
aS'- 22. subject has other severe acute or chronic medical or psychiatric condition or laboratory abnormality.'
p4966
assS'hypertension-Behavioral'
p4967
(dp4968
sS'ulcerative colitis-Dietary Supplement'
p4969
(dp4970
g1258
(lp4971
S'- patients who are in remission from ulcerative colitis, or who have a partial mayo index score of 0 or 1'
p4972
aS'- patients who have been taking azathioprine or mercaptopurine for <12 weeks for the treatment of their ulcerative colitis'
p4973
aS'- patients who are taking steroids or biologic agents for the treatment of their ulcerative colitis'
p4974
aS'- patients who have severe ulcerative colitis, or who have a partial mayo index score of 7 or above'
p4975
aS'- patients who are noncompliant with medication or regular follow up visits'
p4976
aS'- patients who are unable to or unwilling to record their responses in survey form'
p4977
aS'- patients with comorbid illnesses, including: diabetes mellitus, stage iii or above congestive heart failure, chronic pancreatitis, severe liver or renal disease'
p4978
aS'- patients who have current gallstones or any biliary dysfunction'
p4979
aS'- patients with anemia (hemoglobin <10), thrombocytopenia, abnormal lymphocyte counts, or coagulation abnormalities'
p4980
aS'- patients who currently have an ongoing severe infection/sepsis'
p4981
aS'- patients with a history of malignancy'
p4982
aS'- patients who are currently pregnant or nursing'
p4983
aS'- patients who are current smokers'
p4984
asg2542
(lp4985
S'- serious disease,'
p4986
aS'- biological treatment,'
p4987
aS'- pregnancy.'
p4988
asS'NCT01783119'
p4989
(lp4990
S'- autoimmune diseases (lupus, hiv, cancer and any hepatitis).'
p4991
aS"- another type of colitis (indeterminate, infectious drug and crohn's disease."
p4992
aS'- previous total colectomy.'
p4993
aS'- body mass index less than 19.9 kg/m2 or greater than 40 kg/m2.'
p4994
aS'- patients in remission histology, clinical and endoscopic.'
p4995
aS'- under treatment with steroids, azathioprine, diuretics and anticoagulants.'
p4996
aS'- use aloe vera or some natural therapy.'
p4997
asS'NCT02179372'
p4998
(lp4999
S"- patients affected by ulcerative colitis and crohn's disease respectively with a sccai \xe2\x89\xa5 1 and a cdai \xe2\x89\xa5150."
p5000
aS'- patients on steroid therapy.'
p5001
aS'- patients in therapy wih warfarin or other anticoagulants.'
p5002
aS'- known or supposed ipersensitivity to eicosapentaenoic acid/omega 3.'
p5003
aS'- women in fertile age which refuse to use contracceptives specified in the study (oral contraception, iud) and breastfeed women.'
p5004
aS'- patients with severe clinical conditions which the investigator consider to controindicate patient partecipation at the study.'
p5005
aS'- therapy modifications and/or assumption of sperimental therapies within three months before the study inclusion.'
p5006
aS'- patients unable to follow protocol procedures and to sign the informate consent.'
p5007
asg4095
(lp5008
S'- inability to understand written danish, postmenopause, severe asthma, diabetes mellitus, severe rheumatologic disease, severe comorbidity (asa group iii-iv) in general. acute or progressing liver failure, uremia without possibility for dialysis, phenylketonuria, defects in amino acid metabolism. participation in scientific studies in the preceding year, where ionizing radiation has been used, including significant x-ray investigations.'
p5009
asg4263
(lp5010
S'- not able to make food choices'
p5011
asg2529
(lp5012
S'- patient with associated diseases such as diabetes mellitus, hypertension, dyslipidemia, atherosclerosis and malabsorption syndrome.'
p5013
aS"- with autoimmune diseases (lupus, hiv, cancer and hepatitis), colitis (infectious, post-radiation, post-drug, indeterminate) and crohn's disease."
p5014
aS'- if the patient use drugs that inhibit fat absorption.'
p5015
aS'- patients after partial or total resection of stomach or small intestine.'
p5016
aS'- steroid users.'
p5017
aS'- patients in remission histology, clinical and endoscopic.'
p5018
aS'- patients treated with fan-3,6 or 9.'
p5019
asg2538
(lp5020
S'- patients unable to take medications by mouth, pregnant, with liver/kidney failure, receiving anticonvulsant medications (specifically, phenobarbital, carbamazepine and phenytoin, since they lead to increased vitamin d metabolism through hepatic induction of the cytochrome p450 (cyp450) hydroxylase enzymes), regularly attending a tanning salon (once weekly or more), currently being treated for hypovitaminosis d with therapeutic doses of vitamin d (> 800 iu per day) and unwilling to discontinue this regimen.'
p5021
aS'- patients on growth hormone, anabolic steroid hormones, calcitonin, bisphosphonates (maintenance trial only)'
p5022
asg4170
(lp5023
S'- night shift workers; otherwise, inability to attend morning study visits.'
p5024
aS'- current severe colitis according to the mayo scoring system (>10) or requiring hospital admission, or current very mild colitis (<4).'
p5025
aS'- current supplemental intake of melatonin or currently using tobacco products.'
p5026
aS"- proctitis or crohn's disease"
p5027
aS'- previous gastrectomy or small or large bowel resection'
p5028
aS'- malabsorption syndrome (e.g., pancreatic insufficiency).'
p5029
aS'- history of large bowel resection for any reason.'
p5030
aS'- diagnosed narcotic or alcohol dependence.'
p5031
aS'- on renal dialysis.'
p5032
aS'- active liver disease (a chronic condition or under current therapy)'
p5033
aS'- seizure disorders'
p5034
aS'- immune system disorders'
p5035
aS'- any history of hypo- or hyperparathyroidism.'
p5036
aS'- unable to be off aspirin for 7 days.'
p5037
aS'- use of systemic or rectal steroids in the past 8 weeks.'
p5038
aS'- have a history of allergy or hypersensitivity to melatonin.'
p5039
aS'- history of bleeding disorder or current use of anticoagulant medication.'
p5040
aS'- current use of calcium channel blockers, anticonvulsants, sedatives, hypnotics, or psychotropic medications.'
p5041
aS'- women who are pregnant, breast-feeding, attempting conception, or planning to attempt conception over the following 6 months, or are currently taking hormone replacement therapy (hrt).'
p5042
asg1196
(lp5043
S'- patients who are currently experiencing symptomatic flares of mild or moderate ulcerative colitis, or have a partial mayo index score of 2 or greater'
p5044
aS'- patients who have been taking azathioprine or mercaptopurine for <12 weeks for the treatment of their ulcerative colitis'
p5045
aS'- patients who are taking steroids, immunosuppressants, or biologic agents for the treatment of their ulcerative colitis'
p5046
aS'- patients who have severe ulcerative colitis'
p5047
aS'- patients who are noncompliant with medication or regular follow up visits'
p5048
aS'- patients who are unable or unwilling to record their responses in survey form'
p5049
aS'- patients with comorbid illnesses, including: diabetes mellitus, stage iii or above congestive heart failure, chronic pancreatitis, severe liver or renal disease'
p5050
aS'- patients who have current gallstones or biliary dysfunction'
p5051
aS'- patients with anemia (hemoglobin <10), thrombocytopenia, abnormal lymphocyte counts, or coagulation abnormalities'
p5052
aS'- patients with current sepsis or current ongoing infection, including c. difficile colitis or enteritis'
p5053
aS'- patients with a history of malignancy'
p5054
aS'- patients who are currently pregnant or nursing'
p5055
aS'- patients who are current smokers'
p5056
asS'NCT01765439'
p5057
(lp5058
S'- use of bile acids'
p5059
aS'- use of bile acids sequestrants'
p5060
aS'- use of farnesoid x receptor agonists/antagonists'
p5061
aS'- recent colonoscopy(less than 1 month before inclusion)'
p5062
aS'- diabetes'
p5063
asS'NCT00793130'
p5064
(lp5065
S'- active chronic inflammatory or autoimmune disease other than uc.'
p5066
aS'- active infection, including viral infection.'
p5067
aS'- active peptic ulcer disease.'
p5068
aS'- infectious/ ischemic colitis.'
p5069
aS'- acute or chronic cardiac, renal failure (serum creatinine >300 mmol/l)'
p5070
aS'- abnormal liver function - (liver function tests greater than 1.5 times upper range of normal).'
p5071
aS"- crohn's disease."
p5072
aS'- use of rectal corticosteroids within 4 weeks before study entry.'
p5073
aS'- patients with known or suspected bleeding tendency.'
p5074
aS'- patients with severe active ulcerative colitis.'
p5075
aS'- present or a history of colorectal cancer.'
p5076
aS'- serious other disease(s) that according to physicians judgment should preclude the patient from participation in the study.'
p5077
aS'- toxic megacolon.'
p5078
aS'- prior bowel resection.'
p5079
aS'- baseline positive stool culture or c diff toxin assay.'
p5080
aS'- existing or intended pregnancy.'
p5081
assS'inflammatory bowel disease-Drug'
p5082
(dp5083
g1537
(lp5084
S'- has severe extensive colitis and is at imminent risk of colectomy'
p5085
aS'- has uc limited to the rectum only or to < 20 centimeters (cm) of the colon'
p5086
aS'- presence of a stoma or history of a fistula'
p5087
aS'- participants with history of extensive colonic resection (for example, less than 30 cm of colon remaining) that would prevent adequate evaluation of the effect of study agent on clinical disease activity'
p5088
aS'- participants with history of colonic mucosal dysplasia. participants will not be excluded from the study because of a pathology finding of "indefinite dysplasia with reactive atypia\'\''
p5089
asS'NCT02453776'
p5090
(lp5091
S'- - dilatation or resectional surgery because of stenotic ibd in the past year'
p5092
asg1479
(lp5093
S'- patients refusing to participate by not giving their informed consent'
p5094
asg2445
(lp5095
S"- previous severe pancreatitis requiring prolonged hospital admission or intensive care involvement, or ranson's criteria \xe2\x89\xa5 3"
p5096
aS'- no clinical need to reintroduce a thiopurine for management of ibd at the time of the study (e.g. stable on another medication, or mild phenotype of disease), based on clinical assessment of treating gastroenterologist'
p5097
aS'- diagnosis of recurrent pancreatitis syndrome'
p5098
aS'- diabetes mellitus or any other neuropathy which may dampen the clinical presentation of pancreatitis'
p5099
aS'- known or suspected allergy or intolerance to thiopurines, besides previous pancreatitis'
p5100
aS'- any other laboratory or clinical condition that the investigator considers clinically significant that could impact the outcome of the study or the safety of the patient.'
p5101
asg2849
(lp5102
S'- age< 18 years;'
p5103
aS'- patients treated with ifx at non-standard doses;'
p5104
aS"- diagnosis of ulcerative colitis, pouchitis, indeterminate colitis or crohn's disease involving the upper gi tract or perianal disease without involvement of small bowel or colon;"
p5105
aS'- concomitant therapy with cyclosporine, methotrexate or other immunosuppressant other than thiopurine and ifx, treatment with ifx or ifx/thiopurine combination for > 12 months;'
p5106
aS'- pregnancy'
p5107
asS'NCT02694588'
p5108
(lp5109
S'- pregnancy, breast feeding'
p5110
aS'- no written informed consent to participate in the study'
p5111
asS'NCT02464020'
p5112
(lp5113
S'- antibiotic use within 30 days of initial study visit'
p5114
aS'- probiotic use within 30 days of initial study visit'
p5115
aS'- extensive ileal disease'
p5116
aS'- severe of fulminant ibd'
p5117
aS'- diabetes and/or metabolic syndrome'
p5118
aS'- chronic disease state deemed unacceptable for the study per investigator review'
p5119
aS'- decompensated cirrhosis'
p5120
aS'- females who are pregnant or breastfeeding'
p5121
asS'NCT02437591'
p5122
(lp5123
S'- subject has received more than one day of dosing of any cdi therapy within the 48 hrs prior to enrolment'
p5124
aS'- subject is unable to swallow oral study medication'
p5125
aS'- presence of an ostomy or short bowel syndrome'
p5126
aS'- subject has a current diagnosis of toxic megacolon'
p5127
aS'- subject is not willing to adhere to the provisions of treatment and observation specified in the protocol'
p5128
aS'- subject has been enrolled into this study previously, has taken any investigational drug within 28 days or 5 half-lives, whichever is longer, prior to enrollment, or is currently participating in another clinical study which may influence the assessment of efficacy and/or safety endpoints of this study, in the opinion of the sponsor'
p5129
aS'- subject has previously participated in a cdi vaccine study'
p5130
aS'- subject has hypersensitivity to fdx or any of its components'
p5131
aS"- subject has a condition which, in the investigator's opinion, makes the subject unsuitable for study participation"
p5132
asg2958
(lp5133
S'- diarrhea activity scores < 3)'
p5134
aS'- severely active disease with perianal diseases'
p5135
aS'- severely active disease with indication of surgery.'
p5136
aS'- diagnosis as cd first time or first year.'
p5137
aS'- no history of using 5-asa, biological (antibody), immunomodulatory therapy, corticosteroid therapy'
p5138
asg2607
(lp5139
S'- anaemia due to any cause other than iron deficiency'
p5140
aS'- received intramuscular or intravenous injection or administration of a depot iron preparation within 8 weeks of screening'
p5141
aS'- received blood transfusion within 2 weeks of screening'
p5142
aS"- active inflammatory bowel disease as defined by a simple clinical colitis activity index (sccai) score greater than 4 or a crohn's disease activity index (cdai) score greater than 220"
p5143
aS'- known hypersensitivity or allergy to components of ferric maltol or ferric carboxymaltose'
p5144
aS'- reactions to previous doses of intravenous iron (e.g., required observation for > 2 hours, in-patient admission or medical treatment for infusion reactions)'
p5145
aS'- known contraindications for treatment with iron preparations'
p5146
aS'- vitamin b12 or folic acid deficiency'
p5147
aS'- concomitant medical conditions including neurologic or psychiatric symptoms that, in the opinion of the investigator and sponsor would make the subject unsuitable for participation in the study'
p5148
asg3
(lp5149
S'- ibd group:'
p5150
aS'- meeting criteria for active alcohol or substance abuse or dependence'
p5151
aS'- current ongoing treatment with wellbutrin'
p5152
aS'- females who are pregnant or plan to become pregnant within three months'
p5153
aS'- sleep disorder such as apnea, restless leg syndrome or use of continuous positive airway pressure therapy (c-pap)/bilevel positive airway pressure (bi-pap)'
p5154
aS'- current ibd flare requiring hospitalization with intravenous steroid treatment'
p5155
aS'- other acute medical conditions or a history of chronic inflammatory condition other than ibd'
p5156
aS'- hemoglobin <10 with age and gender adjustments'
p5157
aS'- history of seizure disorder'
p5158
aS'- acute infection within seven days'
p5159
aS'- healthy volunteer group:'
p5160
aS'- history or current episode of psychiatric disorder by diagnositic and statistical manual (dsm-iv)'
p5161
aS'- current ongoing treatment with psychoactive medications'
p5162
aS'- medications for sleep in previous two weeks'
p5163
aS'- females who are pregnant or plan to become pregnant within three months'
p5164
aS'- history of ibd, epilepsy, rheumatoid arthritis, lupus'
p5165
aS'- sleep disorder such as apnea, restless leg syndrome or use of continuous positive airway pressure therapy (c-pap)/bilevel positive airway pressure (bi-pap)'
p5166
asg3005
(lp5167
S'- previous primary non-response to an anti-tnf'
p5168
aS'- uncontrolled medical or psychiatric disease (a. degenerative neurologic condition, b.unstable angina, c.class iii/iv congestive heart failure, d.severe asthma or chronic obstructive pulmonary disease, e.symptomatic peripheral vascular disease, f. chronic renal insufficiency (creatinine > 2.0), g. malignancy within the last 3 years (excluding squamous or basal cell cancers of the skin), h. poorly controlled depression, mania, and schizophrenia, i. active infection, j. acquired immunodeficiency syndrome)'
p5169
aS'- inability to adhere to the protocol'
p5170
aS'- need for imminent surgery other than an exam under anesthesia'
p5171
aS'- under 18 years of age.'
p5172
aS'- pregnancy'
p5173
aS'- use of concurrent prednisone >30 mg per day in the anti-tnf groups'
p5174
asS'NCT01974869'
p5175
(lp5176
S'- no patients will be excluded'
p5177
asg4806
(lp5178
S'- age below 18'
p5179
aS'- hemoglobin level < 8 g/dl'
p5180
aS'- recently hospitalized for disease flare (within 3 months)'
p5181
aS'- hemoglobinopathies (including thalassemia)'
p5182
aS'- isolated proctitis'
p5183
aS'- indeterminate colitis'
p5184
aS'- known liver or kidney disease'
p5185
aS'- known celiac disease'
p5186
aS'- small bowel resection'
p5187
aS'- use of anticoagulants or aspirin'
p5188
aS'- known intolerance to oral iron therapy'
p5189
aS'- uninvestigated anemia'
p5190
aS'- pregnant or lactating women'
p5191
aS'- known hypersensitivity to iron sulfate'
p5192
aS'- transfusion within the last 4 weeks'
p5193
aS'- erythropoetin within the last 8 weeks'
p5194
aS'- rheumatoid arthritis'
p5195
aS'- history of menometrorrhagia or frequent epistaxis'
p5196
aS'- use of stomach acid-reducing product (classical antacids, proton pump inhibitors, h2-receptors inhibitors)'
p5197
aS'- gastritis'
p5198
asg2025
(lp5199
S'- bacterial, viral or other microbial infection(including hiv).'
p5200
aS'- orally administered corticosteroids within 3 weeks before enrollment, inhaled or dermatologic preparations for the treatment of other diseases are acceptable.'
p5201
aS'- used of infliximab or immunosuppressant within 2 months before enrollment.'
p5202
aS'- previous use of prescription doses of nsaids without efficacy.'
p5203
aS'- treatment with narcotic pain medications(anti-diarrheal agents such as loperamide and diphenoxylate are permitted).'
p5204
aS'- history of pancreatitis, except for subjects with a known but removed cause(such as gallstone pancreatitis).'
p5205
aS'- history of abnormal liver function tests, including ast or alt >1.5 times upper limit of normal, alkaline phosphatase >2 times upper limit of normal, total bilirubin >2.5 mg/dl at screening (or within the previous 6 months, if known).'
p5206
aS'- history of malignancy.'
p5207
aS'- women who are pregnant or lactating at the time of enrollment, or who intend to be during the study period.'
p5208
aS'- participation in other clinical trial within the past 3 months.'
p5209
asS'NCT02566889'
p5210
(lp5211
S'- must not require, or must not have required, within the 2 months prior to screening, surgery for active gastrointestinal bleeding, peritonitis, intestinal obstruction, or intraabdominal or pancreatic abscess requiring surgical drainage, or other conditions possibly confounding the evaluation of benefit from infliximab treatment'
p5212
aS'- must not have presence or history of colonic or small bowel obstruction within 6 months prior to screening, confirmed by objective radiographic or endoscopic evidence of a stricture with resulting obstruction (example, dilation of the colon or small bowel proximal to the stricture on barium radiograph or an inability to traverse the stricture at endoscopy)'
p5213
aS'- must not have local manifestations of cd, such as fistulae, strictures, abscesses, or other disease complications for which surgery might be indicated. enterocutaneuous fistulae for which surgery is not indicated, are allowed'
p5214
aS'- must not have presence of a stoma'
p5215
aS'- must not have documented short bowel syndrome (more than 100 centimeter in total of small bowel resected)'
p5216
asg1147
(lp5217
S'- previous noncompliant with medications'
p5218
aS'- < 18 years of age or >80 years of age.'
p5219
aS'- congestive heart failure'
p5220
aS'- abnormal liver tests alanine aminotransferase (alt) or aspartate aminotransferase (ast) 2 \xc3\x97 the upper limit of normal (uln) or leucopenia wbc count <3 \xc3\x97 109/l'
p5221
aS'- pregnant or planning on becoming pregnant.'
p5222
aS'- active tuberculosis or hepatitis b infection'
p5223
aS'- any cancer within the past 5 years. (exception non-melanomatous skin cancer.)'
p5224
aS'- receiving any immunomodulator therapy within the past 3 months'
p5225
aS'- evidence of or treatment for c. difficile infection within 60 days or other intestinal pathogen within 30 days prior to enrollment'
p5226
aS'- clinically significant extra-intestinal infection (e.g., pneumonia, pyelonephritis) within 30 days of the initial screening visit'
p5227
aS'- any live vaccinations within 30 days prior to study drug administration except for the influenza vaccine'
p5228
aS'- any identified congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, human immunodeficiency virus [hiv] infection, organ transplantation)'
p5229
aS'- any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise patient safety'
p5230
aS'- unable to give own informed consent'
p5231
asg1788
(lp5232
S"- c0168z02: 17 years of age or older, with the exception of patients who participated in the sponsor's conducted pediatric ibd clinical trials. have other crohn's-like diseases that are associated with genetic diseases (eg, glycogen storage disease). the patient and parent/guardian are not able to adhere to the protocol requirements. are participating in any clinical trial for an investigational agent that is not commercially available. remicadepib4002 and remicadepib4003: less than 6 years of age or 17 years of age or older."
p5233
asS'NCT02460705'
p5234
(lp5235
S'- female patients who are pregnant.'
p5236
aS'- patients with severe immunosuppression (absolute neutrophil count < 1000 or cd4 count <200).'
p5237
aS'- patients with untreated enteric infection.'
p5238
aS'- patients with colon cancer or dysplasia'
p5239
asg3253
(lp5240
S'- patients in whom corticosteroid therapy is contraindicated: immunocompromised (active cancer on chemotherapy or radiation treatment), severe liver disease (decompensated cirrhosis, active alcoholic hepatitis), end-stage renal disease on dialysis, aids or aids-defining illness; myocardial infarction within the past year; nyha class 4 heart failure'
p5241
aS'- patients on systemic corticosteroid therapy currently or within the past 8 weeks'
p5242
aS'- patients not on stable doses of immunomodulators or biologics for at least 8 weeks'
p5243
aS'- infectious colitis (e.g., c. difficile, cmv, hsv)'
p5244
aS'- systemic infections (bacteremia, fungal infections)'
p5245
aS"- fulminant crohn's disease"
p5246
aS'- patients who require imminent surgery'
p5247
aS'- abscess'
p5248
aS'- pregnancy'
p5249
aS'- weight <35 kg'
p5250
asg1117
(lp5251
S'- diarrhea activity scores < 3'
p5252
aS'- severely active disease with perianal diseases'
p5253
aS'- severely active disease with indication of surgery.'
p5254
aS'- diagnosis as ibd first time or first year.'
p5255
aS'- no history of using 5-asa, biological (antibody), immunomodulatory therapy, corticosteroid therapy'
p5256
asg1623
(lp5257
S'- 1. any reported contraindications for inflectra or remicade, according to the smpc.'
p5258
aS'- 2. known hypersensitivity (including severe, acute infusion reactions) to infliximab, its excipients or other murine proteins, at the time of enrolment.'
p5259
aS'- 3. prior history of failure to respond to remicade or inflectra.'
p5260
asg1639
(lp5261
S'- 1. subject, who, for any reason, is judged by the investigator to be inappropriate for this study;'
p5262
aS'- 2. subject has a medical history of other clinically significant diseases/disorders;'
p5263
aS"- 3. subject's uc had failed to respond to more than one biologic treatment (e.g., infliximab, adalimumab, or golimumab);"
p5264
aS'- 4. subject requires prescription treatment for uc, except for the stable, oral treatment of uc for 4 weeks prior to screening.'
p5265
aS'- 5. subject has received any of the following prior treatments or treatments within the specified time prior to the baseline visit:'
p5266
aS'- natalizumab, efalizumab, rituximab or other lymphocyte-depleting treatments, including but not limited, to alkylating agents (such as cyclophosphamide or chlorambucil) and total lymphoid irradiation at any time;'
p5267
aS'- tnf antagonists within 8 weeks, or 5 half-lives (up to 12 weeks);'
p5268
aS'- vedolizumab within 16 weeks;'
p5269
aS'- methotrexate, cyclosporine, mycophenolate, tacrolimus, thalidomide, or other immune altering drugs within 4 weeks (ophthalmologic preparations are permitted);'
p5270
aS'- 5-asa enema, steroid enema or suppository use within 2 weeks ; and/or'
p5271
aS'- investigational agents within 8 weeks or 5 half-lives (whichever is longer).'
p5272
aS'- 6. subject with recent, suspected or confirmed symptomatic stenosis of the colon, abdominal abscess, or ischemic colitis based on clinical or radiographic data; a history of toxic megacolon; or who had any previous surgery for uc;'
p5273
aS'- 7. subject with known colonic dysplasia, adenomas or polyposis;'
p5274
aS'- 8. subject had major surgery within 4 weeks prior to screening or an anticipated requirement for major surgery;'
p5275
aS'- 9. subject with enteric pathogens (including clostridium difficile);'
p5276
aS'- 10. subject with any of the following hematological and chemistry laboratory values:'
p5277
aS'- platelet count < 100,000/mm3;'
p5278
aS'- neutrophils < 1500/mm3;'
p5279
aS'- serum creatinine \xe2\x89\xa5 1.6 mg/dl (\xe2\x89\xa5 144.4 \xce\xbcmol/l);'
p5280
aS'- alkaline phosphatase > 3 times the upper limit of normal (uln);'
p5281
aS'- ast or alt > 2 times uln;'
p5282
aS"- total bilirubin > 2 mg/dl, unless due to gilbert's syndrome;"
p5283
aS'- serum albumin < 3 g/dl;'
p5284
aS'- hemoglobin < 9 g/dl;'
p5285
aS'- glycated serum hemoglobin a1c \xe2\x89\xa5 9%.'
p5286
aS'- 11. subject has clinically significant cardiac disease;'
p5287
aS'- 12. subject is pregnant or breastfeeding;'
p5288
aS'- 13. subject has had major immunologic reaction;'
p5289
aS'- 14. subject is hepatitis b core antibody or surface antigen positive and/or hepatitis c antibody positive with detectable rna;'
p5290
aS'- 15. subject has a history of human immunodeficiency virus (hiv) positivity, tests positive for hiv, or has congenital or acquired immunodeficiency;'
p5291
aS'- 16. subject has or has had active tb, suspected extra-pulmonary tb, a history of incompletely treated tb, or latent tb or other latent infection. subjects with latent tb (clinical findings, purified protein derivative [ppd] or interferon gamma release assay [igra]) may be included in the study if prophylactic therapy for latent tb is started at least 4 weeks prior to screening. subjects with a potentially untreated other infection (clinical findings) are to be excluded.'
p5292
aS'- 17. subject has bacterial infections requiring treatment with oral or parenteral antibiotics, within 2 and 4 weeks, respectively.'
p5293
aS'- 18. subject has a history of systemic opportunistic infection or recurrent infections'
p5294
aS'- 19. subject has malignancy or history of malignancy, except for adequately treated basal cell skin cancer or adequately treated carcinoma in-situ of the cervix without recurrence at least 5 years.'
p5295
aS'- 20. subject who received a bacille calmette-gu\xc3\xa9rin (bcg) vaccine within 6 months of randomization or live vaccination (e.g., measles, mumps, rubella [mmr]; herpes zoster; varicella, intranasal influenza; and oral poliomyelitis) within 4 weeks of randomization.'
p5296
aS'- 21. subject with a history of or active substance abuse.'
p5297
aS'- 22. subject has other severe acute or chronic medical or psychiatric condition or laboratory abnormality.'
p5298
asg2643
(lp5299
S'- known hypersensibility to active principle or excipients'
p5300
aS'- pregnant or lactating women'
p5301
aS'- clinically active ibd (harvey bradshaw index >6; mayo clinical score >3 or c-reactive protein >2.5 mg/l'
p5302
aS'- renal failure (egfr<60)'
p5303
aS'- history of adrenal insufficiency'
p5304
aS'- history of autoimmune diseases'
p5305
aS'- history of malignancies'
p5306
aS'- depression'
p5307
aS'- any current or recent signs or symptoms of viral infectious diseases'
p5308
aS'- recent psycho-traumatic events'
p5309
aS'- hemoglobin levels < 12.5 g/dl (men) or <11.5 g/dl (women)'
p5310
asg88
(lp5311
S'- diagnosed as uc first time. no history of using biologic,immunomodulatory therapy or corticosteroid therapy. with contraindication of endoscopy.'
p5312
assS'healthy-Other'
p5313
(dp5314
g847
(lp5315
S"- crohn's disease and ulcerative colitis"
p5316
aS'- uncontrolled inflammation which will likely require surgery or escalation of therapy in the next 4 weeks'
p5317
aS'- concomitant treatment:corticosteroids > 20mg/day'
p5318
aS'- subject who cannot be expected to comply with the study procedures. - subjects not treated and followed by the gastroenterology team at mt. sinai hospital, toronto'
p5319
asS'NCT02717117'
p5320
(lp5321
S'- patients with a history of inflammatory bowel disease.'
p5322
aS'- smokers.'
p5323
aS'- a history of bowel resections or any gastric surgery.'
p5324
aS'- history of pancreatic insufficiency, thyroid disease or/and diabetes.'
p5325
aS'- protein-pump inhibitor usage or any medication that affects gastric emptying or small bowel transit.'
p5326
aS'- any potential participants scoring very highly on the depression scale questionnaire.'
p5327
aS'- standard mri exclusion criteria (e.g. pacemaker).'
p5328
aS'- malignant disease'
p5329
aS'- stricturing or penetrating disease'
p5330
aS'- smoking history'
p5331
aS'- history of bowel resections or any gastric surgery'
p5332
aS'- significant cardiovascular or respiratory disease'
p5333
aS'- current infection'
p5334
aS'- neurological or cognitive impairment'
p5335
aS'- significant physical disability'
p5336
aS'- significant hepatic disease or renal failure'
p5337
aS'- subjects currently (or in the last three months) participating in another research project'
p5338
aS'- pregnancy or breastfeeding'
p5339
assS'clostridium difficile-Biological'
p5340
(dp5341
g2119
(lp5342
S'- 1. patients <3 years old'
p5343
aS'- 2. patients with other co-morbid intestinal infectious processes'
p5344
aS'- 3. patients will be excluded if on immunosuppressive therapy within 2 weeks of fmt. clinical care will not be adjusted in order to meet criteria of this study.'
p5345
aS'- 4. patients currently receiving chemotherapy'
p5346
aS'- 5. recipients with a history of severe (anaphylactic) food allergy'
p5347
aS'- 6. if female, participants of childbearing potential (females aged 11 and older or those who have already begun menstruating) will be required to have a urine pregnancy test on the day of the fmt procedure. patients who are pregnant will not be enrolled.'
p5348
assS"crohn's disease-Biological"
p5349
(dp5350
g73
(lp5351
S'- subject has participated in a study of an investigational medicinal product (imp) or medical device within the previous 30 days or 5 half-lives (whichever is longer) prior to screening or is currently participating in another study of an imp or medical device - unless the study is ucb up0016 [nct02154425] or a registry study'
p5352
aS"- subject has any obstetrical or psychiatric condition, or she or her infant(s) has any medical condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study or the outcome of the pregnancy"
p5353
aS'- subject has history of chronic alcohol abuse or drug abuse during pregnancy'
p5354
aS'- subject has any pregnancy-related clinically significant abnormality noted on obstetric ultrasound, or other imaging assessment, or the subject has significant laboratory abnormalities during her pregnancy, as judged by the investigator'
p5355
aS'- subject is taking or has taken any medication with strong positive evidence of a human fetal risk of teratogenicity (e.g., methotrexate or leflunomide) during pregnancy'
p5356
aS'- subject has evidence of a condition suggesting chronic or acute uteroplacental insufficiency such as intrauterine growth restriction, severe maternal hypertensive disorders of pregnancy, or abruption'
p5357
aS'- subject has a documented history of primary or secondary antiphospholipid syndrome or hypercoagulable state'
p5358
aS'- subject has received treatment with any biological therapeutic agent, including anti-tnfs other than certolizumab pegol (czp), during pregnancy'
p5359
aS'- subject has previously participated in this study'
p5360
aS'- subject has a positive or indeterminate quantiferon\xc2\xae-tb gold in tube test at screening. in case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the subject'
p5361
aS"- subject with known tuberculosis (tb) infection, at high risk of acquiring tb infection, or latent tb infection (ltb). if tested within the 6 months prior to screening and the test was negative for tb, and there is no change in the subject's clinical status, nor social, family, or travel history, there is no need for an additional tb testing at screening"
p5362
asg1001
(lp5363
S'- for the uc/cd prospective cohort:'
p5364
aS'- 1. is greater than (>) 19 completed weeks gestation prior to enrollment,'
p5365
aS'- 2. has first contact with otis after prenatal diagnosis of any major structural defect,'
p5366
aS'- 3. has enrolled in this registry with a previous pregnancy,'
p5367
aS"- 4. has had an exposure to the known or suspected human teratogens: chlorambucil. cyclophosphamide, mycophenylate mofetil. for the 'no chronic disease' prospective cohort:"
p5368
aS'- 5. is >19 completed weeks gestation prior to enrollment,'
p5369
aS'- 6. has first contact with otis after prenatal diagnosis of any major structural defect,'
p5370
aS'- 7. has enrolled in this registry with a previous pregnancy,'
p5371
aS'- 8. has had an exposure to the known or suspected human teratogens: chlorambucil, cyclophosphamide, mycophenylate mofetil. note: women exposed to entyvio during pregnancy but not meeting the above criteria can enroll into the entyvio pregnancy exposure case series component of this registry.'
p5372
asg2072
(lp5373
S'- no informed consent'
p5374
aS'- non active inflammatory bowel disease.'
p5375
aS'- active infection in either the donor or the recipient,'
p5376
aS'- response to biological agents'
p5377
asS'NCT01024647'
p5378
(lp5379
S'- short bowel syndrome'
p5380
aS'- ostomy'
p5381
aS'- anti-tnf therapy within 4 weeks'
p5382
aS'- prior certolizumab therapy'
p5383
asS'NCT01288053'
p5384
(lp5385
S'- 1. hiv positive.'
p5386
aS'- 2. history of coronary artery disease, or congestive heart failure.'
p5387
aS'- 3. uncontrolled diabetes mellitus or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemotherapy.'
p5388
aS'- 4. prior history of malignancy except localized basal cell or squamous skin cancer. other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage i breast cancer will be considered on an individual basis'
p5389
aS'- 5. positive pregnancy test, lactation, inability or unwillingness to pursue effective means of birth control, failure to accept or comprehend irreversible sterility as a side effect of therapy.'
p5390
aS'- 6. psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible.'
p5391
aS'- 7. fev 1/fvc < 50% of predicted, dlco < 50% of predicted.'
p5392
aS'- 8. resting lvef < 50%.'
p5393
aS"- 9. bilirubin > 2.0 mg/dl, transferase (ast) > 2x upper limit of normal, unless the abnormalities are secondary to crohn's disease."
p5394
aS'- 10. serum creatinine > 2.0 mg/dl.'
p5395
aS'- 11. platelet count less than 100,000/ul, anc less than 1500/ul.'
p5396
aS'- 12. patients presenting with intestinal perforation or toxic megacolon, or a suppurative problem that will require urgent surgery. in addition, the patient may not have any active infection. the presence of intestinal stomas does not exclude the patient from study.'
p5397
aS'- 13. pre-study peripheral blood counts must include a platelet count greater than 100,000/ul and an absolute neutrophil count greater than 1500/ul.'
p5398
aS'- 14. creatinine clearance more than 20% below lower limit of normal for age and sex.'
p5399
aS"- 15. short gut syndrome. donor eligibility inclusion criteria 1. donor must be an hla 6 out of 6 matched sibling exclusion criteria of hla matched sibling donor 1. physiologic age > 50 years old or <18 years old 2. hiv positive 3. active ischemic heart disease or heart failure 4. acute or chronic active hepatitis 5. uncontrolled diabetes mellitus or any other illness that in the opinion of the investigators would jeopardize the ability of the donor to tolerate stem cell collection 6. prior history of malignancy except localized basal cell or squamous skin cancer. other malignancies for which the patient is judged to be cured by local surgical therapy, such as (but not limited to) head and neck cancer, or stage i or ii breast cancer will be considered on an individual basis. 7. positive pregnancy test 8. psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible 9. major hematological abnormalities such as platelet count less than 100,000/ul, anc less than 1000/ul 10. donor has history of crohn's or ulcerative colitis"
p5400
asg2119
(lp5401
S'- 1. patients <3 years old'
p5402
aS'- 2. patients with other co-morbid intestinal infectious processes'
p5403
aS'- 3. patients will be excluded if on immunosuppressive therapy within 2 weeks of fmt. clinical care will not be adjusted in order to meet criteria of this study.'
p5404
aS'- 4. patients currently receiving chemotherapy'
p5405
aS'- 5. recipients with a history of severe (anaphylactic) food allergy'
p5406
aS'- 6. if female, participants of childbearing potential (females aged 11 and older or those who have already begun menstruating) will be required to have a urine pregnancy test on the day of the fmt procedure. patients who are pregnant will not be enrolled.'
p5407
asS'NCT01440699'
p5408
(lp5409
S'- medical history with variant creutzfeldt jacobs disease'
p5410
aS'- allergic to anesthetics or bovine protein or fibrin glue'
p5411
aS"- autoimmune disease other than crohn's disease"
p5412
aS'- infectious disease'
p5413
aS'- sepsis or active tuberculosis'
p5414
aS'- pregnant or breast feeding woman'
p5415
aS"- inflammatory bowel disease other than crohn's disease"
p5416
aS"- active crohn's disease with cdai score > 200"
p5417
aS'- malignant tumor'
p5418
aS"- fistula's diameter > 2 cm"
p5419
asS'NCT01874015'
p5420
(lp5421
S'- pregnancy'
p5422
asg444
(lp5423
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p5424
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p5425
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p5426
aS'- known hiv/aids'
p5427
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p5428
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p5429
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p5430
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p5431
aS'- participated in an investigational study within 1 month prior to study entry'
p5432
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p5433
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p5434
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p5435
asS'NCT02580617'
p5436
(lp5437
S"- 1. subject with gastro-intestinal tract a. crohn's disease which is invaded only proximal ileum. b. the evidence of an intra abdominal abscess during screening period. c. the evidence of an abscess around the anus during screening period. d. conditions of subtotal colectomy or total colectomy. e. short bowel syndrome. f. subject who conduct elemental diet, tube feeding or parenteral nutrition within 3 weeks before enrollment. g. subject who have ileostomy or colostomy. h subject who have bowel stricture of large intestine during screening period. i. in case that the pi anticipates that patients need to get a surgical intestinal tract surgery caused by crohn's disease. j. subject who have adenoma of large intestine k. subject who have chronic inflammation-associated dysplasia."
p5438
aS'- 2. subjects who have been received biological therapy within 60 days of enrollment..'
p5439
aS'- 3. subject with infectious disease a. acute or chronic active hbv, hav and hiv b. active tuberculosis. c. igra (interferon-gamma release assay) positive d. all kinds of live vaccine inoculation except influenza vaccine within 4weeks before registration e. pneumonia, pyelonephritis and infection of clostridium within 4weeks during screening visit. f.subject has history of bacteremia or other serious bacterial or fungal infection in past 3 months.'
p5440
aS'- 4. subject who has malignant tumor or which is not cured yet'
p5441
aS'- 5. subject has any serious disease, in the opinion of the investigator, would interfere with the evaluation of the study.'
p5442
aS'- 6. subject who has history of blood clots and other pathological arterial thrombosis or venous thrombosis'
p5443
aS'- 7. subject who has a hypersensitive reaction to bovine-derived proteins'
p5444
aS'- 8. subject who is surgery or trauma within 6 weeks before registration'
p5445
aS'- 9. subject who is pregnant or breast-feeding.'
p5446
aS'- 10. subjects who are unwilling to use an "effective" method of contraception during the study'
p5447
aS'- 11. subject who is experienced stem cell therapy'
p5448
aS'- 12. subject who has been enrolled in another clinical study within 4weeks days of screening'
p5449
aS'- 13. subject who has history of alcohol or drug abuse.'
p5450
aS'- 14. subject who is not able to understand the objective of this study or to comply with the study requirements'
p5451
asS'NCT01540292'
p5452
(lp5453
S'- any condition not fulfilling inclusion criteria'
p5454
aS'- indication for surgery'
p5455
aS'- symptomatic stricture'
p5456
aS'- undrained perianal or intraabdominal abscess'
p5457
aS'- change in mesalazine dosage within the last 4 weeks, change in steroid dosage within the last two weeks, change in immunosuppressant dosage within the last 3 months, use of anti-tnf treatment within the last two months'
p5458
aS'- hiv positive'
p5459
aS'- uncontrolled infection, arrhythmia or hypertension'
p5460
aS'- terminal organ failure:'
p5461
aS'- renal: anuria, serious fluid overload, gfr < 30 ml/min, dialysis;'
p5462
aS'- pulmonary: dlco < 35% and/or receiving supplementary continuous oxygen;'
p5463
aS'- hepatic: fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dl, and symptomatic biliary disease;'
p5464
aS'- cardiac: symptomatic coronary artery disease or other cardiac failure requiring therapy; ejection fraction < 35%; uncontrolled arrhythmia, uncontrolled hypertension'
p5465
asg782
(lp5466
S'- subject with ulcerative colitis or indeterminate colitis.'
p5467
aS'- subject who has had a surgical bowel resection within the past 6 months or who is planning any resection at any time point in the future.'
p5468
aS'- subject with an ostomy or ileoanal pouch.'
p5469
aS'- subject who has short bowel syndrome.'
p5470
aS'- subject with symptomatic known obstructive strictures.'
p5471
aS'- subject with an internal or external fistula (with the exception of an anal fistula without abscess).'
p5472
aS'- active, or chronic or recurring infections, or active tuberculosis.'
p5473
asg1788
(lp5474
S"- c0168z02: 17 years of age or older, with the exception of patients who participated in the sponsor's conducted pediatric ibd clinical trials. have other crohn's-like diseases that are associated with genetic diseases (eg, glycogen storage disease). the patient and parent/guardian are not able to adhere to the protocol requirements. are participating in any clinical trial for an investigational agent that is not commercially available. remicadepib4002 and remicadepib4003: less than 6 years of age or 17 years of age or older."
p5475
asS'NCT00692939'
p5476
(lp5477
S'- patients <5 years of age or >26 years of age.'
p5478
aS'- patients who have not been treated with adequate dosing of 6-mp, 5-aminosalicylate products and metronidazole.'
p5479
aS'- patients who sustained a decrement of 70 points on the cdai or 15 points on the pcdai, and maintain a cdai < 250 and pcdai < 30 after at least one 4 month course of prior anti-tumor necrosis factor alpha (infliximab).'
p5480
aS"- patient has localized area of crohn's disease of intestine which is surgically correctable."
p5481
aS'- patients with toxic megacolon, intestinal perforation'
p5482
aS'- dlco < 60% of normal value for age'
p5483
aS'- hepatic: conjugated bilirubin greater than 2.0 mg/dl. evidence of autoimmune chronic active hepatitis or sclerosing cholangitis'
p5484
aS'- patients with fever > 39o c or active infection within 1 week of stem cell mobilization and/or admission for conditioning regimen'
p5485
aS'- uncontrolled diabetes mellitus or other illness that would preclude study participation'
p5486
aS'- pregnancy or nursing mother'
p5487
aS'- massive splenomegaly'
p5488
aS'- presence of increased anesthetic risk if central line will be inserted or other procedure is expected to be performed under anesthesia.'
p5489
aS'- hiv/htlv seropositive, hep b surface antigen positive, or hcv rna positive by pcr'
p5490
asg2174
(lp5491
S"- current relapse defined as a crohn's disease activity index (cdai) >150 for patients with crohn's disease or a modified truelove-witts activity index (mtwai) >10 for patients with ulcerative colitis"
p5492
aS'- actually pregnant or planned pregnancy in the next month'
p5493
aS'- immunization with a pneumococcal vaccine (conjugated or polysaccharide) in the previous 5 years'
p5494
aS'- previous severe systemic reaction to immunization (respiratory or circulative)'
p5495
aS'- episode of fever in the last 24 hours'
p5496
asS'NCT02622763'
p5497
(lp5498
S'- 1. no injuries in pre-screening resonance'
p5499
aS'- 2. pregnancy, lactation or women of childbearing age not taking appropriate contraceptive measures'
p5500
aS'- 3. patients hiv + and hepatitis c virus + hepatitis b virus +'
p5501
aS'- 4. serious concomitant disease:'
p5502
aS'- renal failure with creatinine clearance < 40ml / min'
p5503
aS'- heart disease: congestive heart failure with ejection fraction < 45 % , atrial fibrillation treated with oral anticoagulants, uncontrolled ventricular arrhythmias , pericarditis , pleural effusion with hemodynamic'
p5504
aS'- neoplasms or myelodysplasia'
p5505
aS'- psychiatric disorders including alcohol and drugs'
p5506
aS"- 5. symptoms attributable to fibrotic strictures in crohn's disease at the discretion of the investigators"
p5507
aS'- 6. diarrhea attributable to " short bowel syndrome"'
p5508
aS'- 7. active infection , including tuberculosis'
p5509
aS'- 8. participation in research studies of new drugs in the 3 months prior to inclusion.'
p5510
aS'- 9. vaccination with live/attenuated germs in the previous 3 months'
p5511
aS'- 10. personal history of cancer (active or complete remission) or known family history of hereditary cancer.'
p5512
aS'- 11. patients in whom , after observation of the state of their veins , these are considered inaccessible and impossible to perform apheresis'
p5513
asS'NCT02000362'
p5514
(lp5515
S"- 1. exclusion criteria of gastrointestinal tract 1. crohn's disease which is invaded only proximal ileum."
p5516
aS'- 2. the evidence of an intra-abdominal abscess during screening period.'
p5517
aS'- 3. the evidence of an abscess around the anus during screening period.'
p5518
aS'- 4. conditions of subtotal colectomy or total colectomy.'
p5519
aS'- 5. short bowel syndrome.'
p5520
aS'- 6. subjects who conduct elemental diet, tube feeding or parenteral nutrition within 3 weeks before registration.'
p5521
aS'- 7. subjects who have ileostomy or colostomy.'
p5522
aS'- 8. subjects who remove existing seton before screening period.'
p5523
aS'- 9. fixed bowel stricture which has symptoms.'
p5524
aS"- 10. in case that the pi anticipate that subjects need to get a surgical intestinal tract surgery caused by crohn's disease."
p5525
aS'- 11. non-removal of large intestine adenoma.'
p5526
aS'- 12. chronic inflammation-associated dysplasia. 2. exclusion criteria of drugs 1. in case subjects administered more than one drug within 4 weeks before enrollment.'
p5527
aS'- cyclosporine, tacrolimus, thalidomide'
p5528
aS'- adalimumab'
p5529
aS'- intravenous adrenocortical steroid'
p5530
aS'- 2. in case subjects administered more than one drug within 10 weeks before enrollment. - infliximab'
p5531
aS'- cetolizumab pegol'
p5532
aS'- all kinds of biologicals'
p5533
aS'- 3. in case subjects administered 5-asa or corticosteroid local treatment(a suppository or enema) within 2 weeks before enrollment.'
p5534
aS'- 4. in case concomitant drug use for cd treatment cannot observe stable dosage during clinical study period or specified period like below.'
p5535
aS'- use of oral 5-asa compound at least 4 weeks before enrollment'
p5536
aS'- use of oral corticosteroid (prednisolone \xe2\x89\xa4 20mg/day or budesonide \xe2\x89\xa49mg/day) at least 2 weeks before enrollment'
p5537
aS'- use of antibiotics for cd treatment at least 2 weeks before enrollment. (ex. metronidazole)'
p5538
aS'- use of immunosuppressant at least 4 weeks before enrollment.'
p5539
aS'- 3. exclusion criteria of infectious disease 1. acute or chronic hepatitis like below(typea, typeb, typec).'
p5540
aS'- igm anti-hav positive'
p5541
aS'- hbs-ag, igm anti-hbc, igg anti-hbc positive. (it is possible to enroll the clinical study when a subject is anti-hbs ab positive, given that the subject is both hbs-ag and igm anti-hbc negative or igg anti-hbc positive.)'
p5542
aS'- hcv-ab positive'
p5543
aS'- 2. tuberculosis'
p5544
aS'- status present active tuberculosis'
p5545
aS'- latent tuberculosis : subjects who is applicable to more than 1 case below.'
p5546
aS'- quantiferon tb-gold positive or 2times continuous indeterminate within 4weeks before registration.'
p5547
aS'- more than 10mm in tuberculin skin test within 3 months before registration.(when subjects got injected prednisolone more than 15mg per day, limited tuberculin skin test value is 5mm)'
p5548
aS'- in case of observation of pulmonary tuberculosis cicatrix through x-ray within 3months before registration.'
p5549
aS'- 3. all kinds of congenital or acquired immunodeficiency syndrome.'
p5550
aS'- 4. all kinds of live vaccine inoculation except influenza vaccine within 4weeks before registration.'
p5551
aS'- 5. clinically significant infection with in 4weeks before screening visit or during screening visit.(pneumonia, pyelonephritis, infection of clostridium difficile etc.) 4. general exclusion criteria a. subjects who experienced stem cell therapy. b. history of a malignant tumor except as noted below.'
p5552
aS'- properly cured non-metastatic basal cell skin cancer'
p5553
aS'- properly cured pinacocyte skin cancer which is not recurred at least 1 year before registration.'
p5554
aS'- properly cured carcinoma in situ of uterine cervix which has not recurred at least 3 years before registration. c. malignant tumor which is not cured yet. d. subjects who are breast-feeding. e. unstable and not regulated disease(associated with cardiovascular, lung, liver, kidney, gastrointestinal tract, urogenital organs, hematologic, immune, endocrine/metabolism, etc.) which has possibility to hamper safety of subjects or cause confusion in clinical study. f. subjects who got general anesthesia surgery within 4weeks before registration or subjects who anticipated necessity of general anesthesia surgery during clinical study. g. major neurological history including stroke, multiple sclerosis, encephaloma, neurological degenerative disease. h. history of hypersensitive reaction about mr contrast medium. i. history of addictive drugs or alcohol with 1 years. j. active psychiatric problem which can hamper participation of clinical study. k. all kinds of problems which has possibility to hamper participation of study visit and observance of study procedure. l. any other condition which the pi judges would make subject unsuitable for study participation. m. subjects who got injected other investigational product within 4 weeks or at present.'
p5555
assS'inflammatory arthritis-Drug'
p5556
(dp5557
g444
(lp5558
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p5559
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p5560
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p5561
aS'- known hiv/aids'
p5562
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p5563
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p5564
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p5565
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p5566
aS'- participated in an investigational study within 1 month prior to study entry'
p5567
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p5568
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p5569
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p5570
assS'colorectal neoplasms-Device'
p5571
(dp5572
g2658
(lp5573
S'- pregnant women'
p5574
aS'- black skin'
p5575
aS'- chronic renal insufficiency (mdrd <30 ml/min)'
p5576
assS'irritable bowel syndrome-Other'
p5577
(dp5578
g856
(lp5579
S'- participation in other clinical studies'
p5580
asg176
(lp5581
S'- 1. individuals unable or unwilling to provide a stool specimen.'
p5582
aS'- 2. individuals with known intestinal cancer, intestinal infection, upper gastrointestinal disease'
p5583
aS'- 3. individuals receiving chemotherapy or systemic immunosuppressive drugs.'
p5584
aS'- 4. individuals who have taken, within the previous 2 weeks, protein pump inhibitors or h2-receptor antagonists.'
p5585
aS'- 5. individuals with previously diagnosed inflammatory bowel disease managed with immunomodulators, 5-asa (5-aminosalicylic acid) or biologic therapies or who have undergone a surgical resection or diversion procedure.'
p5586
aS'- 6. individuals who have taken nsaids (nonsteroidal anti-inflammatory drugs), including aspirin, on 7 or more days during the 2 weeks before providing the sample.'
p5587
assS'atrial fibrillation-Drug'
p5588
(dp5589
sS'musculoskeletal pain-Behavioral'
p5590
(dp5591
sS'irritable bowel syndrome-Procedure'
p5592
(dp5593
S'NCT00742118'
p5594
(lp5595
S'- disrupted coagulation results'
p5596
aS'- cancer even healed'
p5597
aS'- known food allergy.'
p5598
aS'- alcohol consumption >30g/day'
p5599
assS'ibs-Other'
p5600
(dp5601
g1953
(lp5602
S'- for all groups:'
p5603
aS'- 1. co-morbidity: severe kidney- and/or liver disease or thyroid abnormalities and impaired clotting'
p5604
aS'- 2. abdominal chirurgy (except for an uncomplicated appendectomy)'
p5605
assS'graft versus host disease-Drug'
p5606
(dp5607
S'NCT01385124'
p5608
(lp5609
S'- 1. previous history of psychosis.'
p5610
aS'- 2. consumption of cannabis during the last 2 moths before transplantation. -'
p5611
asS'NCT01596075'
p5612
(lp5613
S'- 1. acute gvhd grade > ii'
p5614
aS'- 2. history of psychosis'
p5615
aS'- 3. history of asthma'
p5616
assS'axial spondyloarthritis (axspa)-Biological'
p5617
(dp5618
g73
(lp5619
S'- subject has participated in a study of an investigational medicinal product (imp) or medical device within the previous 30 days or 5 half-lives (whichever is longer) prior to screening or is currently participating in another study of an imp or medical device - unless the study is ucb up0016 [nct02154425] or a registry study'
p5620
aS"- subject has any obstetrical or psychiatric condition, or she or her infant(s) has any medical condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study or the outcome of the pregnancy"
p5621
aS'- subject has history of chronic alcohol abuse or drug abuse during pregnancy'
p5622
aS'- subject has any pregnancy-related clinically significant abnormality noted on obstetric ultrasound, or other imaging assessment, or the subject has significant laboratory abnormalities during her pregnancy, as judged by the investigator'
p5623
aS'- subject is taking or has taken any medication with strong positive evidence of a human fetal risk of teratogenicity (e.g., methotrexate or leflunomide) during pregnancy'
p5624
aS'- subject has evidence of a condition suggesting chronic or acute uteroplacental insufficiency such as intrauterine growth restriction, severe maternal hypertensive disorders of pregnancy, or abruption'
p5625
aS'- subject has a documented history of primary or secondary antiphospholipid syndrome or hypercoagulable state'
p5626
aS'- subject has received treatment with any biological therapeutic agent, including anti-tnfs other than certolizumab pegol (czp), during pregnancy'
p5627
aS'- subject has previously participated in this study'
p5628
aS'- subject has a positive or indeterminate quantiferon\xc2\xae-tb gold in tube test at screening. in case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the subject'
p5629
aS"- subject with known tuberculosis (tb) infection, at high risk of acquiring tb infection, or latent tb infection (ltb). if tested within the 6 months prior to screening and the test was negative for tb, and there is no change in the subject's clinical status, nor social, family, or travel history, there is no need for an additional tb testing at screening"
p5630
assS'vasculitis-Other'
p5631
(dp5632
g371
(lp5633
S'- for iads patients'
p5634
aS'- unauthorized treatment (anticancer chemotherapy)'
p5635
aS'- for healthy volunteers'
p5636
aS'- contra-indications for donating blood except from age'
p5637
aS'- known history of iad (eg: psoriasis)'
p5638
aS'- common exclusion criteria:'
p5639
aS'- pregnant woman'
p5640
aS'- still under the exclusion period from another biomedical study'
p5641
aS'- psychiatric or addiction pathology who could interfere with the ability to fulfill the protocol needs or to provide an informed consent'
p5642
aS'- patient under a legal protection'
p5643
aS'- chronic lifelong viral infection unrelated to the pathology'
p5644
aS'- mild infection within the last 3 months'
p5645
assS'fatigue-Other'
p5646
(dp5647
g264
(lp5648
S'- patients who are participating in other clinical studies.'
p5649
aS'- associated tumor disease .'
p5650
aS'- pregnant or breast feeding women .'
p5651
aS'- anemia hemoglobin determined under 12 in women and 14 in men.'
p5652
aS'- patients who have suffered minor adverse reactions to acupuncture.'
p5653
aS'- prior acupuncture.'
p5654
assS'hyperlipidemia-Behavioral'
p5655
(dp5656
sS'postoperative disease recurrence-Procedure'
p5657
(dp5658
g4484
(lp5659
S'- concomitant anastomosis/strictureplasty at another site of the gastrointestinal tract, and required a temporary fecal diversion'
p5660
assS"crohn's disease, remission (6a: with ibs symptoms, 6b: without ibs symptoms)-Other"
p5661
(dp5662
g1953
(lp5663
S'- for all groups:'
p5664
aS'- 1. co-morbidity: severe kidney- and/or liver disease or thyroid abnormalities and impaired clotting'
p5665
aS'- 2. abdominal chirurgy (except for an uncomplicated appendectomy)'
p5666
assS'motor activity-Behavioral'
p5667
(dp5668
g117
(lp5669
S'- refusal to give necessary oral or written informed consent by patient and/or parent (legal caregiver)'
p5670
aS'- not aged 7 through 20 at start of study'
p5671
aS'- not willing and able to volunteer in the study'
p5672
aS'- has sibling enrolled in this study'
p5673
aS'- has severe physical diseases of the locomotor apparatus, psychotic disorders, severe affective disorders, eating disorders, mental retardation, autism spectrum disorder'
p5674
aS'- inability to communicate and complete questionnaires in german'
p5675
aS'- does not own a functional and nintendo wii-compatible television at home'
p5676
aS'- among female adolescents, pregnancy, breastfeeding or intention to get pregnant during the study'
p5677
aS'- has clinically significant cardiovascular disease'
p5678
aS'- enrolment of the investigator, his/her family members, employees and other dependent persons'
p5679
assS'mild to moderate ulcerative colitis-Drug'
p5680
(dp5681
S'NCT01039597'
p5682
(lp5683
S'- 1. a clinically significant medical history, medical finding or an ongoing medical or psychiatric condition which, in the opinion of the investigator, could jeopardize the safety of the subject, impact the validity of the study results, or interfere with the completion of treatment according to this protocol.'
p5684
aS'- 2. subject has an alt or serum creatinine greater than 1.5 times the upper limit of normal range for the reference lab at screening.'
p5685
aS'- 3. subject who, in the opinion of the investigator, is febrile at screening.'
p5686
aS'- 4. subject had used the following treatments for ibd: steroids or any or biologic immunomodulators or any topical treatments (e.g. enemas) within the last 4 weeks prior to baseline, immunosuppressants or antimetabolites within the preceding 6 weeks, antibiotic use within the previous 7 days or chronic use of any anti-inflammatory drugs (except aminosalicylates) within 7 days.'
p5687
aS"- 5. history of illicit drug abuse or positive urine screen for drugs of abuse or history of alcohol abuse if acknowledged at the screening visit or noted in the subject's medical record at screening."
p5688
aS'- 6. subject has a positive blood screen for hiv, hepatitis b (hbsag), or hepatitis c.'
p5689
aS'- 7. subject has evidence of infectious colitis, e.g., clostridium difficile, amoebiasis, giardia lamblia by stool examination of at screening.'
p5690
aS'- 8. subject has evidence for gastrointestinal parasites as per stool ova and parasites testing at screening.'
p5691
aS'- 9. subject has evidence of tuberculosis by blood interferon gamma release assay at screening.'
p5692
aS'- 10. any uncontrolled, intercurrent illness (e.g., active infection).'
p5693
aS'- 11. history of gastrointestinal cancer.'
p5694
aS'- 12. abdominal surgery or any major surgery within the preceding 28 days of the screening visit.'
p5695
assS'clostridium difficile colitis-Other'
p5696
(dp5697
g279
(lp5698
S'- evidence of active gi bleeding during current hospitalization prior to study entry'
p5699
aS'- admission to icu with primary diagnosis of burn injury'
p5700
aS'- closed head injury or increased intracranial pressure'
p5701
aS'- partial or complete gastrectomy'
p5702
aS'- pregnancy or lactation'
p5703
assS'gastrointestinal diseases-Drug'
p5704
(dp5705
g1639
(lp5706
S'- 1. subject, who, for any reason, is judged by the investigator to be inappropriate for this study;'
p5707
aS'- 2. subject has a medical history of other clinically significant diseases/disorders;'
p5708
aS"- 3. subject's uc had failed to respond to more than one biologic treatment (e.g., infliximab, adalimumab, or golimumab);"
p5709
aS'- 4. subject requires prescription treatment for uc, except for the stable, oral treatment of uc for 4 weeks prior to screening.'
p5710
aS'- 5. subject has received any of the following prior treatments or treatments within the specified time prior to the baseline visit:'
p5711
aS'- natalizumab, efalizumab, rituximab or other lymphocyte-depleting treatments, including but not limited, to alkylating agents (such as cyclophosphamide or chlorambucil) and total lymphoid irradiation at any time;'
p5712
aS'- tnf antagonists within 8 weeks, or 5 half-lives (up to 12 weeks);'
p5713
aS'- vedolizumab within 16 weeks;'
p5714
aS'- methotrexate, cyclosporine, mycophenolate, tacrolimus, thalidomide, or other immune altering drugs within 4 weeks (ophthalmologic preparations are permitted);'
p5715
aS'- 5-asa enema, steroid enema or suppository use within 2 weeks ; and/or'
p5716
aS'- investigational agents within 8 weeks or 5 half-lives (whichever is longer).'
p5717
aS'- 6. subject with recent, suspected or confirmed symptomatic stenosis of the colon, abdominal abscess, or ischemic colitis based on clinical or radiographic data; a history of toxic megacolon; or who had any previous surgery for uc;'
p5718
aS'- 7. subject with known colonic dysplasia, adenomas or polyposis;'
p5719
aS'- 8. subject had major surgery within 4 weeks prior to screening or an anticipated requirement for major surgery;'
p5720
aS'- 9. subject with enteric pathogens (including clostridium difficile);'
p5721
aS'- 10. subject with any of the following hematological and chemistry laboratory values:'
p5722
aS'- platelet count < 100,000/mm3;'
p5723
aS'- neutrophils < 1500/mm3;'
p5724
aS'- serum creatinine \xe2\x89\xa5 1.6 mg/dl (\xe2\x89\xa5 144.4 \xce\xbcmol/l);'
p5725
aS'- alkaline phosphatase > 3 times the upper limit of normal (uln);'
p5726
aS'- ast or alt > 2 times uln;'
p5727
aS"- total bilirubin > 2 mg/dl, unless due to gilbert's syndrome;"
p5728
aS'- serum albumin < 3 g/dl;'
p5729
aS'- hemoglobin < 9 g/dl;'
p5730
aS'- glycated serum hemoglobin a1c \xe2\x89\xa5 9%.'
p5731
aS'- 11. subject has clinically significant cardiac disease;'
p5732
aS'- 12. subject is pregnant or breastfeeding;'
p5733
aS'- 13. subject has had major immunologic reaction;'
p5734
aS'- 14. subject is hepatitis b core antibody or surface antigen positive and/or hepatitis c antibody positive with detectable rna;'
p5735
aS'- 15. subject has a history of human immunodeficiency virus (hiv) positivity, tests positive for hiv, or has congenital or acquired immunodeficiency;'
p5736
aS'- 16. subject has or has had active tb, suspected extra-pulmonary tb, a history of incompletely treated tb, or latent tb or other latent infection. subjects with latent tb (clinical findings, purified protein derivative [ppd] or interferon gamma release assay [igra]) may be included in the study if prophylactic therapy for latent tb is started at least 4 weeks prior to screening. subjects with a potentially untreated other infection (clinical findings) are to be excluded.'
p5737
aS'- 17. subject has bacterial infections requiring treatment with oral or parenteral antibiotics, within 2 and 4 weeks, respectively.'
p5738
aS'- 18. subject has a history of systemic opportunistic infection or recurrent infections'
p5739
aS'- 19. subject has malignancy or history of malignancy, except for adequately treated basal cell skin cancer or adequately treated carcinoma in-situ of the cervix without recurrence at least 5 years.'
p5740
aS'- 20. subject who received a bacille calmette-gu\xc3\xa9rin (bcg) vaccine within 6 months of randomization or live vaccination (e.g., measles, mumps, rubella [mmr]; herpes zoster; varicella, intranasal influenza; and oral poliomyelitis) within 4 weeks of randomization.'
p5741
aS'- 21. subject with a history of or active substance abuse.'
p5742
aS'- 22. subject has other severe acute or chronic medical or psychiatric condition or laboratory abnormality.'
p5743
asg2025
(lp5744
S'- bacterial, viral or other microbial infection(including hiv).'
p5745
aS'- orally administered corticosteroids within 3 weeks before enrollment, inhaled or dermatologic preparations for the treatment of other diseases are acceptable.'
p5746
aS'- used of infliximab or immunosuppressant within 2 months before enrollment.'
p5747
aS'- previous use of prescription doses of nsaids without efficacy.'
p5748
aS'- treatment with narcotic pain medications(anti-diarrheal agents such as loperamide and diphenoxylate are permitted).'
p5749
aS'- history of pancreatitis, except for subjects with a known but removed cause(such as gallstone pancreatitis).'
p5750
aS'- history of abnormal liver function tests, including ast or alt >1.5 times upper limit of normal, alkaline phosphatase >2 times upper limit of normal, total bilirubin >2.5 mg/dl at screening (or within the previous 6 months, if known).'
p5751
aS'- history of malignancy.'
p5752
aS'- women who are pregnant or lactating at the time of enrollment, or who intend to be during the study period.'
p5753
aS'- participation in other clinical trial within the past 3 months.'
p5754
assS'diverticular disease-Procedure'
p5755
(dp5756
g109
(lp5757
S'- patients not capable of informed consent and/or quality of life assessment'
p5758
aS'- planned open procedure for surgical reason'
p5759
aS'- multiple previous abdominal operations'
p5760
aS'- body-mass index > 40'
p5761
asg616
(lp5762
S'- subjects present with bowel obstruction or perforation'
p5763
aS'- subject undergo emergency surgery'
p5764
aS'- subject with asa iv, v'
p5765
aS'- history of allergy or hypersensitivity against indocyanine green'
p5766
aS'- pregnant or breast-feeding women'
p5767
aS'- subject has uremia (serum creatinine >2.5 mg/dl)'
p5768
aS'- subject is undergoing palliative surgery or who is terminally ill'
p5769
aS'- subject who is unable to discontinue warfarin anticoagulation 5 days before surgery'
p5770
aS'- subject taking phenobarbital, phenylbutazone, primidone, phenytoin, haloperidol, nitrofurantoin, probenecid'
p5771
assS'dietary modification-Other'
p5772
(dp5773
g827
(lp5774
S'- 1. acute or chronic illness (defined as illness which requires regular visits to health services)'
p5775
aS'- 2. positive or negative energy balance (recent weight gain or loss, \xc2\xb12 kg the past month)'
p5776
aS'- 3. history of gut surgery'
p5777
aS'- 4. use of antibiotics or steroids the last 3 months'
p5778
assS'osteoporosis-Behavioral'
p5779
(dp5780
sS'oral ulcer-Drug'
p5781
(dp5782
g3431
(lp5783
S'- contraindications to study drugs.'
p5784
aS'- underwent or will accept oral surgery.'
p5785
aS'- patients are not able to sign the informed consent or not comply with the study protocol.'
p5786
aS'- planning for pregnancy, pregnancy and lactating women.'
p5787
aS'- enrolled in other clinical trials in the past 30 days.'
p5788
aS'- patients with concurrent / new other serious diseases will affect the effectiveness and safety evaluation.'
p5789
assS'colonic diseases-Drug'
p5790
(dp5791
g1639
(lp5792
S'- 1. subject, who, for any reason, is judged by the investigator to be inappropriate for this study;'
p5793
aS'- 2. subject has a medical history of other clinically significant diseases/disorders;'
p5794
aS"- 3. subject's uc had failed to respond to more than one biologic treatment (e.g., infliximab, adalimumab, or golimumab);"
p5795
aS'- 4. subject requires prescription treatment for uc, except for the stable, oral treatment of uc for 4 weeks prior to screening.'
p5796
aS'- 5. subject has received any of the following prior treatments or treatments within the specified time prior to the baseline visit:'
p5797
aS'- natalizumab, efalizumab, rituximab or other lymphocyte-depleting treatments, including but not limited, to alkylating agents (such as cyclophosphamide or chlorambucil) and total lymphoid irradiation at any time;'
p5798
aS'- tnf antagonists within 8 weeks, or 5 half-lives (up to 12 weeks);'
p5799
aS'- vedolizumab within 16 weeks;'
p5800
aS'- methotrexate, cyclosporine, mycophenolate, tacrolimus, thalidomide, or other immune altering drugs within 4 weeks (ophthalmologic preparations are permitted);'
p5801
aS'- 5-asa enema, steroid enema or suppository use within 2 weeks ; and/or'
p5802
aS'- investigational agents within 8 weeks or 5 half-lives (whichever is longer).'
p5803
aS'- 6. subject with recent, suspected or confirmed symptomatic stenosis of the colon, abdominal abscess, or ischemic colitis based on clinical or radiographic data; a history of toxic megacolon; or who had any previous surgery for uc;'
p5804
aS'- 7. subject with known colonic dysplasia, adenomas or polyposis;'
p5805
aS'- 8. subject had major surgery within 4 weeks prior to screening or an anticipated requirement for major surgery;'
p5806
aS'- 9. subject with enteric pathogens (including clostridium difficile);'
p5807
aS'- 10. subject with any of the following hematological and chemistry laboratory values:'
p5808
aS'- platelet count < 100,000/mm3;'
p5809
aS'- neutrophils < 1500/mm3;'
p5810
aS'- serum creatinine \xe2\x89\xa5 1.6 mg/dl (\xe2\x89\xa5 144.4 \xce\xbcmol/l);'
p5811
aS'- alkaline phosphatase > 3 times the upper limit of normal (uln);'
p5812
aS'- ast or alt > 2 times uln;'
p5813
aS"- total bilirubin > 2 mg/dl, unless due to gilbert's syndrome;"
p5814
aS'- serum albumin < 3 g/dl;'
p5815
aS'- hemoglobin < 9 g/dl;'
p5816
aS'- glycated serum hemoglobin a1c \xe2\x89\xa5 9%.'
p5817
aS'- 11. subject has clinically significant cardiac disease;'
p5818
aS'- 12. subject is pregnant or breastfeeding;'
p5819
aS'- 13. subject has had major immunologic reaction;'
p5820
aS'- 14. subject is hepatitis b core antibody or surface antigen positive and/or hepatitis c antibody positive with detectable rna;'
p5821
aS'- 15. subject has a history of human immunodeficiency virus (hiv) positivity, tests positive for hiv, or has congenital or acquired immunodeficiency;'
p5822
aS'- 16. subject has or has had active tb, suspected extra-pulmonary tb, a history of incompletely treated tb, or latent tb or other latent infection. subjects with latent tb (clinical findings, purified protein derivative [ppd] or interferon gamma release assay [igra]) may be included in the study if prophylactic therapy for latent tb is started at least 4 weeks prior to screening. subjects with a potentially untreated other infection (clinical findings) are to be excluded.'
p5823
aS'- 17. subject has bacterial infections requiring treatment with oral or parenteral antibiotics, within 2 and 4 weeks, respectively.'
p5824
aS'- 18. subject has a history of systemic opportunistic infection or recurrent infections'
p5825
aS'- 19. subject has malignancy or history of malignancy, except for adequately treated basal cell skin cancer or adequately treated carcinoma in-situ of the cervix without recurrence at least 5 years.'
p5826
aS'- 20. subject who received a bacille calmette-gu\xc3\xa9rin (bcg) vaccine within 6 months of randomization or live vaccination (e.g., measles, mumps, rubella [mmr]; herpes zoster; varicella, intranasal influenza; and oral poliomyelitis) within 4 weeks of randomization.'
p5827
aS'- 21. subject with a history of or active substance abuse.'
p5828
aS'- 22. subject has other severe acute or chronic medical or psychiatric condition or laboratory abnormality.'
p5829
assS'primary sclerosing cholangitis-Drug'
p5830
(dp5831
g5112
(lp5832
S'- antibiotic use within 30 days of initial study visit'
p5833
aS'- probiotic use within 30 days of initial study visit'
p5834
aS'- extensive ileal disease'
p5835
aS'- severe of fulminant ibd'
p5836
aS'- diabetes and/or metabolic syndrome'
p5837
aS'- chronic disease state deemed unacceptable for the study per investigator review'
p5838
aS'- decompensated cirrhosis'
p5839
aS'- females who are pregnant or breastfeeding'
p5840
asS'NCT00161148'
p5841
(lp5842
S'- pregnancy'
p5843
aS'- use of probiotics within one month before the study'
p5844
aS'- use of antibiotics within one month before the study'
p5845
aS'- a history of bacterial cholangitis'
p5846
assS'lymphocytic colitis-Procedure'
p5847
(dp5848
g3696
(lp5849
S'- patients who decline to participate'
p5850
aS'- unable to give informed consent'
p5851
assS'prematurity-Dietary Supplement'
p5852
(dp5853
g592
(lp5854
S'- 1. infant with birth weight > 1250g;'
p5855
aS'- 2. infant with colostomy;'
p5856
aS'- 3. infants with enterostomy but'
p5857
aS'- unable to obtain written informed consent from parent;'
p5858
aS'- presence of congenital liver, renal, or metabolic diseases or syndromes or perinatal asphyxia;'
p5859
aS'- ostomy caused by surgical treatment for a condition other than nec or small intestine perforation; and'
p5860
aS'- unable to initiate enteral feeding for more than 28 days since ostomy placement.'
p5861
assS'enteropathic arthritis-Drug'
p5862
(dp5863
g444
(lp5864
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p5865
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p5866
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p5867
aS'- known hiv/aids'
p5868
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p5869
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p5870
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p5871
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p5872
aS'- participated in an investigational study within 1 month prior to study entry'
p5873
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p5874
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p5875
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p5876
assS'short bowel syndrome-Drug'
p5877
(dp5878
g24
(lp5879
S'- complications associated with surgery'
p5880
aS'- non-radical surgery'
p5881
aS'- chemotherapy'
p5882
aS'- poor compliance'
p5883
aS'- other serious illness'
p5884
assS'non-radiographic evidence-axspa-Biological'
p5885
(dp5886
g73
(lp5887
S'- subject has participated in a study of an investigational medicinal product (imp) or medical device within the previous 30 days or 5 half-lives (whichever is longer) prior to screening or is currently participating in another study of an imp or medical device - unless the study is ucb up0016 [nct02154425] or a registry study'
p5888
aS"- subject has any obstetrical or psychiatric condition, or she or her infant(s) has any medical condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study or the outcome of the pregnancy"
p5889
aS'- subject has history of chronic alcohol abuse or drug abuse during pregnancy'
p5890
aS'- subject has any pregnancy-related clinically significant abnormality noted on obstetric ultrasound, or other imaging assessment, or the subject has significant laboratory abnormalities during her pregnancy, as judged by the investigator'
p5891
aS'- subject is taking or has taken any medication with strong positive evidence of a human fetal risk of teratogenicity (e.g., methotrexate or leflunomide) during pregnancy'
p5892
aS'- subject has evidence of a condition suggesting chronic or acute uteroplacental insufficiency such as intrauterine growth restriction, severe maternal hypertensive disorders of pregnancy, or abruption'
p5893
aS'- subject has a documented history of primary or secondary antiphospholipid syndrome or hypercoagulable state'
p5894
aS'- subject has received treatment with any biological therapeutic agent, including anti-tnfs other than certolizumab pegol (czp), during pregnancy'
p5895
aS'- subject has previously participated in this study'
p5896
aS'- subject has a positive or indeterminate quantiferon\xc2\xae-tb gold in tube test at screening. in case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the subject'
p5897
aS"- subject with known tuberculosis (tb) infection, at high risk of acquiring tb infection, or latent tb infection (ltb). if tested within the 6 months prior to screening and the test was negative for tb, and there is no change in the subject's clinical status, nor social, family, or travel history, there is no need for an additional tb testing at screening"
p5898
assS'diverticulitis-Device'
p5899
(dp5900
g290
(lp5901
S'- pregnant woman or lactating woman.'
p5902
aS'- with confirmed distant metastasis in liver, lung, bones, or other organs.'
p5903
aS'- intolerable laparoscopic operation or converted to open surgery.'
p5904
aS'- with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.'
p5905
aS'- with bad compliance or contraindication to enrollment.'
p5906
assS'clostridium difficile infection (cdi)-Drug'
p5907
(dp5908
g5122
(lp5909
S'- subject has received more than one day of dosing of any cdi therapy within the 48 hrs prior to enrolment'
p5910
aS'- subject is unable to swallow oral study medication'
p5911
aS'- presence of an ostomy or short bowel syndrome'
p5912
aS'- subject has a current diagnosis of toxic megacolon'
p5913
aS'- subject is not willing to adhere to the provisions of treatment and observation specified in the protocol'
p5914
aS'- subject has been enrolled into this study previously, has taken any investigational drug within 28 days or 5 half-lives, whichever is longer, prior to enrollment, or is currently participating in another clinical study which may influence the assessment of efficacy and/or safety endpoints of this study, in the opinion of the sponsor'
p5915
aS'- subject has previously participated in a cdi vaccine study'
p5916
aS'- subject has hypersensitivity to fdx or any of its components'
p5917
aS"- subject has a condition which, in the investigator's opinion, makes the subject unsuitable for study participation"
p5918
assS'healthy controls-Other'
p5919
(dp5920
g1953
(lp5921
S'- for all groups:'
p5922
aS'- 1. co-morbidity: severe kidney- and/or liver disease or thyroid abnormalities and impaired clotting'
p5923
aS'- 2. abdominal chirurgy (except for an uncomplicated appendectomy)'
p5924
assS'pyoderma gangrenosum-Procedure'
p5925
(dp5926
sS'psoriasis-Drug'
p5927
(dp5928
g324
(lp5929
S'- known intolerance for il2 (see spc),'
p5930
aS'- administration of a non-authorized treatment and/or iv bolus of corticosteroids in the last 2 months,'
p5931
aS'- vaccination with live attenuated virus in the months preceding the inclusion or planned during the study'
p5932
aS'- other severe or progressive autoimmune/inflammatory pathology,'
p5933
aS'- low white blood cell count<2000/mm3, lymphocytes <600/mm3, platelets <80 000/mm3,'
p5934
aS"- heart failure (\xe2\x89\xa5 grade iii nyha), renal insufficiency (cockcroft< 60ml/mn except patients with lupus or wegener's granulomatosis) or hepatic insufficiency (transaminases> 5n except for patients with autoimmune hepatitis), or lung failure,"
p5935
aS'- significant abnormality in chest x-ray other than these linked to the diseases under investigation'
p5936
aS'- cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or basocellular carcinoma)'
p5937
aS'- poor venous access not allowing repeated blood tests,'
p5938
aS'- restrictive diet or parenteral nutrition,'
p5939
aS'- surgery during the last 2 months or surgery planned during the study,'
p5940
aS'- participation in other biomedical research in the last 3 months or planned during the study.'
p5941
aS'- pregnant or lactating women,'
p5942
aS'- concomitant psychiatric disease or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give informed consent,'
p5943
aS'- positive hiv serology, active hepatitis b or ebv infection,'
p5944
aS'- patients under a measure of legal protection'
p5945
asg444
(lp5946
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p5947
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p5948
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p5949
aS'- known hiv/aids'
p5950
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p5951
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p5952
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p5953
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p5954
aS'- participated in an investigational study within 1 month prior to study entry'
p5955
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p5956
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p5957
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p5958
asS'NCT01657513'
p5959
(lp5960
S'- severe psychiatric disorder'
p5961
aS'- no indication for treatment with tnf-alfa blocking drug'
p5962
aS'- pregnancy'
p5963
aS'- breastfeeding'
p5964
aS'- no written informed consent'
p5965
assS'healthy volunteer, ulcerative colitis-Drug'
p5966
(dp5967
S'NCT02749630'
p5968
(lp5969
S'- general exclusion criteria:'
p5970
aS'- history of inflammatory skin disorders'
p5971
aS'- history of any cancer'
p5972
aS'- history of anaphylaxis, hypersensitivity, or drug allergies'
p5973
aS'- history of alcoholism or drug addiction'
p5974
aS'- positive tests indicating infection for hepatitis c, hepatitis b , or hiv'
p5975
aS'- use of a non-biologic investigational drug or participation in an investigational study with a non-biologic drug within 30 days prior to study drug administration'
p5976
aS'- use of a biologic investigational therapy or participation in an investigational study involving biologic therapy within 90 days or 5 half-lives'
p5977
aS'- history or presence of an abnormal ecg that is clinically significant'
p5978
aS"- any acute or chronic condition that would limit the subject's ability to complete and/or participate in this clinical study"
p5979
aS'- pregnant or lactating, or intending to become pregnant for duration of study for hv only:'
p5980
aS'- known family history of gastrointestinal (gi) and/or colon cancer'
p5981
aS'- prior exposure to uttr1147a for uc patients only:'
p5982
aS'- significant uncontrolled co-morbidity, such as neurological, cardiac, pulmonary, renal, hepatic, endocrine, or gastrointestinal (gi) disorders'
p5983
aS'- history of primary sclerosing cholangitis'
p5984
aS'- active anti-tnf induced psoriasiform or eczematous lesions'
p5985
aS'- moderate to severe anemia'
p5986
aS'- presence of an ileostomy or colostomy'
p5987
aS'- total proctocolectomy'
p5988
aS'- positive screening test for latent mycobacterial tuberculosis infection'
p5989
aS'- impaired renal function'
p5990
aS'- impaired hepatic function'
p5991
assS'inflammatory bowel disease-Procedure'
p5992
(dp5993
g290
(lp5994
S'- pregnant woman or lactating woman.'
p5995
aS'- with confirmed distant metastasis in liver, lung, bones, or other organs.'
p5996
aS'- intolerable laparoscopic operation or converted to open surgery.'
p5997
aS'- with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.'
p5998
aS'- with bad compliance or contraindication to enrollment.'
p5999
asg109
(lp6000
S'- patients not capable of informed consent and/or quality of life assessment'
p6001
aS'- planned open procedure for surgical reason'
p6002
aS'- multiple previous abdominal operations'
p6003
aS'- body-mass index > 40'
p6004
asS'NCT02461784'
p6005
(lp6006
S"- 1. men with previously documented problems with male reproductive health such as known hypothalamic-pituitary disorders (e.g. pituitary macroadenomas, pituitary infarction), primary hypogonadism (e.g. cryptorchidism, klinefelter's syndrome), or disorders of sperm transport (e.g. erectile dysfunction, history of vasectomy)"
p6007
aS'- 2. current use of alkylating agents, ketoconazole, sulfalsalazine, h2-receptor antagonists or spironolactone'
p6008
aS'- 3. men who have undergone ileal pouch anal anastomosis within 3 months of study entry'
p6009
asS'NCT01653054'
p6010
(lp6011
S'- i. patients with hiv, transplant recipients, men who have sex with men as they already represent high risk groups'
p6012
aS'- ii. women with a history of an abnormal cervical pap test within the past 2 years.'
p6013
aS'- iii. patients with active proctitis as defined by an abnormal sigmoidoscopy or colonoscopy, rectal bleeding or tenesmus.'
p6014
asg2958
(lp6015
S'- diarrhea activity scores < 3)'
p6016
aS'- severely active disease with perianal diseases'
p6017
aS'- severely active disease with indication of surgery.'
p6018
aS'- diagnosis as cd first time or first year.'
p6019
aS'- no history of using 5-asa, biological (antibody), immunomodulatory therapy, corticosteroid therapy'
p6020
asg1117
(lp6021
S'- diarrhea activity scores < 3'
p6022
aS'- severely active disease with perianal diseases'
p6023
aS'- severely active disease with indication of surgery.'
p6024
aS'- diagnosis as ibd first time or first year.'
p6025
aS'- no history of using 5-asa, biological (antibody), immunomodulatory therapy, corticosteroid therapy'
p6026
asg88
(lp6027
S'- diagnosed as uc first time. no history of using biologic,immunomodulatory therapy or corticosteroid therapy. with contraindication of endoscopy.'
p6028
asg616
(lp6029
S'- subjects present with bowel obstruction or perforation'
p6030
aS'- subject undergo emergency surgery'
p6031
aS'- subject with asa iv, v'
p6032
aS'- history of allergy or hypersensitivity against indocyanine green'
p6033
aS'- pregnant or breast-feeding women'
p6034
aS'- subject has uremia (serum creatinine >2.5 mg/dl)'
p6035
aS'- subject is undergoing palliative surgery or who is terminally ill'
p6036
aS'- subject who is unable to discontinue warfarin anticoagulation 5 days before surgery'
p6037
aS'- subject taking phenobarbital, phenylbutazone, primidone, phenytoin, haloperidol, nitrofurantoin, probenecid'
p6038
asS'NCT02389075'
p6039
(lp6040
S'- pregnancy'
p6041
aS'- use of antibiotics within the past 14 days'
p6042
aS'- current diagnosis of colon cancer'
p6043
aS'- diagnosis of celiac disease'
p6044
aS'- diagnosis of any other rheumatologic disease such as ra, sle, etc.'
p6045
aS'- chemotherapy or radiation therapy for any malignancy within the past year'
p6046
aS'- daily use of aspirin or nsaids with inability to hold the drug 7 days before and after the procedure'
p6047
aS'- current use of anticoagulation (lmwh, warfarin,etc.)'
p6048
aS'- a diagnosis of hiv'
p6049
aS'- clostridium difficile within the past 3 months'
p6050
aS'- evidence of inflammatory spinal or axial arthritis or disease based on chart review such as inflammation seen on radiographs or a diagnosis of sacroiliitis as: inclusion criteria:'
p6051
aS'- diagnosed with an axial spondyloarthritis (spa) by a rheumatologist -'
p6052
aS'- meet the assessment of spondyloarthritis international society (asas) axial spondyloarthritis (spa) criteria exclusion criteria:'
p6053
aS'- pregnancy'
p6054
aS'- use of antibiotics within the past 14 days'
p6055
aS'- current diagnosis of colon cancer'
p6056
aS'- diagnosis of celiac disease'
p6057
aS'- diagnosis of any other rheumatologic disease such as ra, sle, etc.'
p6058
aS'- chemotherapy or radiation therapy for any malignancy within the past year'
p6059
aS'- daily use of aspirin or nsaids with inability to hold the drug 7 days before and after the procedure'
p6060
aS'- current use of anticoagulation (lmwh,warfarin,etc.)'
p6061
aS'- a diagnosis of hiv'
p6062
aS'- clostridium dificile within the past 3 months'
p6063
aS'- a known history of idiopathic macroscopic or microscopic colitis'
p6064
asS'NCT02304666'
p6065
(lp6066
S'- patients with contradication for anesthesia'
p6067
aS'- patient undergoind aspirin or anitinflamatory drugs within 72 hours of the colonoscopy'
p6068
asS'NCT02098798'
p6069
(lp6070
S'- known intraepithelial neoplasia or colorectal cancer or other neoplasia coagulopathy which may prevent biopsies pregnancy inability to obtain informed consent'
p6071
asg4508
(lp6072
S"- ulcerative colitis or non-crohn's disease patients"
p6073
aS'- lack of small bowel disease'
p6074
aS'- patients started on alternative therapy'
p6075
aS'- unable or unwilling to provide consent'
p6076
assS'microbiota-Procedure'
p6077
(dp6078
g88
(lp6079
S'- diagnosed as uc first time. no history of using biologic,immunomodulatory therapy or corticosteroid therapy. with contraindication of endoscopy.'
p6080
assS'bacteria-Drug'
p6081
(dp6082
g88
(lp6083
S'- diagnosed as uc first time. no history of using biologic,immunomodulatory therapy or corticosteroid therapy. with contraindication of endoscopy.'
p6084
assS'ulcerative colitis associated pouchitis-Biological'
p6085
(dp6086
S'NCT02049502'
p6087
(lp6088
S'- age <18 years or >65 years of age'
p6089
aS'- exposure to immunosuppressive therapy (defined as steroid, etanercept, or anti-tumor necrosis factor (tnf)agents) within 1 month prior to enrollment'
p6090
aS'- concomitant clostridium difficile infection'
p6091
aS"- suspected crohn's disease"
p6092
aS'- documented active infection of any kind'
p6093
aS'- patients on anti-coagulant therapy, with platelet count less than 50,000, significant anemia with hemoglobin less than 7 or those with other conditions that place them at increased risk of bleeding'
p6094
aS'- absolute neutrophil count (anc) less than 1000 or history of opportunistic infection'
p6095
aS'- administration of investigational drug within one month prior to planned fmt'
p6096
aS'- pregnant or breastfeeding women'
p6097
assS'severe malnutrition-Other'
p6098
(dp6099
g2407
(lp6100
S'- specific cause of malnutrition (e.g. cerebral palsy, other organ disease)'
p6101
aS'- sibling admitted with sam at the same time'
p6102
aS'- unwilling to stay on ward for at least 2 weeks'
p6103
aS'- declined to give consent'
p6104
aS'- participating in another study'
p6105
assS'ulcerative colitis-Procedure'
p6106
(dp6107
S'NCT00534131'
p6108
(lp6109
S'- patients under the age of 16'
p6110
aS'- patients in whom sphincter preservation has already been deemed inappropriate for medical or surgical reasons (e.g. by an mdt for oncological cure), or in whom surgery has been deemed generally inappropriate.'
p6111
asS'NCT01111708'
p6112
(lp6113
S'- pregnancy'
p6114
aS'- malignancy'
p6115
aS'- psychiatric disease or inability to assess follow-up'
p6116
asg3925
(lp6117
S'- active ulcerative colitis, > 20 cm from the margo ani'
p6118
aS'- personal history of colorectal cancer'
p6119
aS'- allergy or intolerance to methylene blue'
p6120
aS'- refusing or incapable to agree with informed consent'
p6121
aS'- age younger than 18 years'
p6122
aS'- pregnant women'
p6123
asg4266
(lp6124
S'- inability to provide informed consent or'
p6125
aS'- clinically severe or fulminant ulcerative colitis'
p6126
aS'- previous abdominal surgery'
p6127
aS'- pregnancy'
p6128
aS'- clinically or laboratory-confirmed gastroenteritis for at least 3 months before sampling'
p6129
aS'- the use of antibiotics in the past a month before sampling'
p6130
aS'- the use of probiotics in the past a month before sampling'
p6131
aS'- severe cardiovascular or pulmonary disease'
p6132
aS'- severe convulsive disorder and current use of anti-convulsive medication'
p6133
aS'- malignancy'
p6134
aS'- transplantation'
p6135
asg1117
(lp6136
S'- diarrhea activity scores < 3'
p6137
aS'- severely active disease with perianal diseases'
p6138
aS'- severely active disease with indication of surgery.'
p6139
aS'- diagnosis as ibd first time or first year.'
p6140
aS'- no history of using 5-asa, biological (antibody), immunomodulatory therapy, corticosteroid therapy'
p6141
asS'NCT02144350'
p6142
(lp6143
S'- complication requiring urgent surgical intervention (in the opinion of the investigators) clinically significant cardiac, renal, neurological, endocrine, respiratory or hepatic impairment in the opinion of the investigator, including but not limited to:'
p6144
aS'- pulmonary i. copd with co2 retention; previous/current imaging showing hyperinflation/air trapping/bullous disease/blebs (opinion of investigators) ii. current pneumothorax or previous spontaneous pneumothorax iii. bronchogenic cyst(s)'
p6145
aS'- cardiac i. uncontrolled htn (systolic >160 or diastolic >100) ii. unstable angina or myocardial infarction within the previous 3 months iii. ejection fraction < 35% iv. current or previous amiodarone use v. icd in place vi. pacemaker in place not approved for chamber use'
p6146
aS'- hematological/oncological i. current chemotherapeutic drug use, and past history of bleomycin use. ii. hereditary spherocytosis iii. sickle cell anemia'
p6147
aS"- gastrointestinal and infectious disease i. known or suspected crohn's disease ii. previous infection with mycobacterium, fungus, hiv, hepatitis b or c iii. gastrointestinal or systemic infection including, but not limited to, --clostridium difficile iv. current capsule endoscopy or previously non-retrieved capsule endocrinology i. uncontrolled hyperthyroidism neurological and psychological i. vagal or other nerve stimulators ii. uncontrolled seizure disorder iii. medications or medical conditions that lower seizure threshold (in the opinion of the investigator) iv. drug or alcohol abuse/dependence v. current treatment for alcohol cessation with disulfiram vi. current or recent (within past week) use of baclofen head and neck i. previous middle ear damage, surgery or infection(s) which may increase the risk for needing ear tubes (in the opinion of the investigator) ii. current or previous retinal detachment or optic neuritis iii. retinal or vitreous surgery within the past 3 months miscellaneous i. implanted devices not on the approved list for use with hbot women who are pregnant or nursing. women with childbearing potential were required to use effective birth control if not surgically sterile or postmenopausal for >2 years."
p6148
asS'NCT02049775'
p6149
(lp6150
S'- patients known to be intolerant to endoscopy.'
p6151
aS'- patients with severe lifethreatening comorbidity as judged by the investigator.'
p6152
aS'- patients on therapy with anticoagulation that may preclude taking any biopsies'
p6153
aS'- pregnant women or breast feeding mothers'
p6154
aS'- patient with toxic megacolon'
p6155
aS'- patients on medications known to cause bowel inflammation.'
p6156
asS'NCT00292175'
p6157
(lp6158
S'- pregnant patients'
p6159
aS'- unable or unwilling to give informed consent'
p6160
aS'- patients with severe active colitis who would be unsafe to endoscope'
p6161
asg4014
(lp6162
S'- inability to preform total colonoscopy'
p6163
aS'- marked abdominal comorbidities'
p6164
aS'- prior abdominal surgery'
p6165
asg88
(lp6166
S'- diagnosed as uc first time. no history of using biologic,immunomodulatory therapy or corticosteroid therapy. with contraindication of endoscopy.'
p6167
asg4487
(lp6168
S'- patients who decline to participate'
p6169
aS'- unable to give informed consent'
p6170
aS'- increased risk of bleeding (i.e. warfarin, bleeding disorders, clopidogrel)'
p6171
asg3968
(lp6172
S"- patients with severe uc according to truelove and witts' criteria"
p6173
aS'- current pregnancy/lactating'
p6174
aS'- patients with a pacemaker or other implanted electromedical device'
p6175
aS'- the presence of dysphagia'
p6176
aS"- patients at higher risk of capsule retention (including crohn's disease, small bowel tumor, radiation enteropathy, previous intestinal surgery, acute abdominal pain without regular defecation)"
p6177
aS'- patients with a contraindication to bowel preparation (congestive heart failure, renal insufficiency, a life-threatening condition)'
p6178
aS'- patients with an allergy to polyethylene glycol, sodium phosphate solution, metoclopramide or bisacodyl suppository'
p6179
assS'colitis, ischemic-Procedure'
p6180
(dp6181
g6108
(lp6182
S'- patients under the age of 16'
p6183
aS'- patients in whom sphincter preservation has already been deemed inappropriate for medical or surgical reasons (e.g. by an mdt for oncological cure), or in whom surgery has been deemed generally inappropriate.'
p6184
assS'other specified inflammatory disorders of skin or subcutaneous tissue-Procedure'
p6185
(dp6186
sS'ulcerative colitis-Behavioral'
p6187
(dp6188
g530
(lp6189
S'- diagnosis of pervasive developmental disorder in patient or parent'
p6190
aS'- diagnosis of serious mental illness (e.g., schizophrenia) in patient or parent'
p6191
asS'NCT02357537'
p6192
(lp6193
S'- 1. prior extensive colonic resection, subtotal or total colectomy or planned surgery for uc'
p6194
aS'- 2. past or present ileostomy or colostomy'
p6195
aS'- 3. short bowel syndrome'
p6196
aS'- 4. diagnosis of indeterminate colitis, fulminant colitis, toxic megacolon'
p6197
aS'- 5. past or present fistula or abdominal abscess'
p6198
aS'- 6. history or current evidence of colonic mucosal dysplasia'
p6199
aS'- 7. use of tube feeding, defined formula diets or parenteral alimentation/nutrition which has not been discontinued \xe2\x89\xa53 weeks prior to study enrollment'
p6200
aS'- 8. use of anticoagulants, herbal supplements and omega-3/fish oil supplements during the study'
p6201
aS"- 9. crohn's disease"
p6202
aS'- 10. significant uncontrolled co-morbidity, such as neurological, cardiac (e.g., moderate to severe heart failure nyha class iii/iv), pulmonary, renal, hepatic, endocrine or gastrointestinal disorders'
p6203
aS'- 11. history of alcohol, drug or chemical abuse within 6 months prior to screening'
p6204
aS'- 12. pregnant females, those intending to become pregnant, and those who are lactating'
p6205
aS'- 13. current participation in any other clinical trial'
p6206
asg544
(lp6207
S'- insufficient danish language skills'
p6208
aS'- lack of intellectual capacity'
p6209
aS'- growth retardation'
p6210
asg117
(lp6211
S'- refusal to give necessary oral or written informed consent by patient and/or parent (legal caregiver)'
p6212
aS'- not aged 7 through 20 at start of study'
p6213
aS'- not willing and able to volunteer in the study'
p6214
aS'- has sibling enrolled in this study'
p6215
aS'- has severe physical diseases of the locomotor apparatus, psychotic disorders, severe affective disorders, eating disorders, mental retardation, autism spectrum disorder'
p6216
aS'- inability to communicate and complete questionnaires in german'
p6217
aS'- does not own a functional and nintendo wii-compatible television at home'
p6218
aS'- among female adolescents, pregnancy, breastfeeding or intention to get pregnant during the study'
p6219
aS'- has clinically significant cardiovascular disease'
p6220
aS'- enrolment of the investigator, his/her family members, employees and other dependent persons'
p6221
asS'NCT02093780'
p6222
(lp6223
S'- use of prednisone (or steroid equivalent) at the time of enrollment.'
p6224
aS'- use of anti-tnf drugs within 3 months of enrollment.'
p6225
aS'- use of antibiotics (washout period of at least 2 weeks is required).'
p6226
aS'- pregnancy or lactation.'
p6227
aS'- history of colectomy.'
p6228
aS'- significant chronic disorders such as severe cardiac disease, significant renal failure, severe pulmonary disease (need for oxygen).'
p6229
aS'- active gastrointestinal infection.'
p6230
aS'- severe psychiatric disorder.'
p6231
aS'- unable or unwilling to consent'
p6232
asg549
(lp6233
S'- pregnancy or plans to be pregnant'
p6234
aS'- inability to make own health care decisions'
p6235
aS'- inability to participate in the study phone calls'
p6236
aS'- uncontrolled psychiatric illness'
p6237
aS'- enrollment in another clinical trial outside of the standard clinic ibd registry'
p6238
asg129
(lp6239
S'- ibd patients with parental report of mental retardation'
p6240
aS'- ibd patients receiving psychopharmacological treatment (antidepressants or benzodiazepines) for depression or anxiety'
p6241
aS'- no mastery of the dutch language'
p6242
aS'- ibd patients with diagnosed: bipolar disorder, schizophrenia/psychotic disorder, autism spectrum disorders, obsessive-compulsive disorder, posttraumatic stress disorder/acute stress disorder, or substance use disorder'
p6243
aS'- physician reported substance abuse (alcohol, drugs) in the past month'
p6244
aS'- clinician reported selective mutism'
p6245
aS'- ibd patients already participating in an (psychological of psychopharmacological) intervention study'
p6246
aS'- ibd patients who received 8 sessions of manualized cognitive behavioral therapy last year'
p6247
aS'- current psychological treatment'
p6248
asS'NCT01491997'
p6249
(lp6250
S'- other forms of colitis, such as clostridium difficile colitis or indeterminate colitis'
p6251
aS'- current use of oral steroids within the last 30 days, topical agents (i.e. steroids or 5-asa) within the last 14 days'
p6252
aS'- history of colon resection'
p6253
aS'- antibiotic use within the last 14 days'
p6254
aS'- women: cannot be pregnant'
p6255
assS'painful neuropathy-Drug'
p6256
(dp6257
S'NCT01667029'
p6258
(lp6259
S'- other severe pain'
p6260
aS'- anticipated difficulty weaning off medications'
p6261
aS'- past or current psychiatric disorder as determined by mini international neuropsychiatric interview'
p6262
aS'- medical contraindication to sulfasalazine'
p6263
aS'- not proficient in english (due to heavy use of questionaires)'
p6264
aS'- pregnant or breast feeding women'
p6265
assS"crohn's disease-Dietary Supplement"
p6266
(dp6267
S'NCT02193750'
p6268
(lp6269
S'- unable to provide informed consent;'
p6270
aS'- have significant hepatic, renal, endocrine, respiratory, neurological, or cardiovascular disease;'
p6271
aS'- confirmed diagnosis of celiac disease, or have suspected celiac disease and are following a gluten-free diet to manage symptoms with an elevated screening anti-tissue transglutaminase antibody test;'
p6272
aS'- significant complications of cd which includes a history of extensive colonic resection, including subtotal or total colectomy, history of >/= 3 small bowel resections or received a diagnosis of short bowel syndrome, current ileostomy, colostomy or ileal-anal pouch, or a fixed symptomatic intestinal stenosis;'
p6273
aS'- antibiotic use in the 4 weeks prior to study start;'
p6274
aS'- use of any rectal preparations in the 2 weeks prior to study start;'
p6275
aS'- use of any non-steroidal anti-inflammatory drugs in the 2 weeks prior to study start;'
p6276
aS'- use of commercial probiotic supplements in the 4 weeks prior to study start'
p6277
aS'- change in cd therapy in the 4 weeks prior to study start (excluding steroid taper, however steroid dosing must be stable for 2 weeks prior to study start);'
p6278
aS'- recently been adhering to a novel dietary intervention for alternative health issues within the last 4 weeks prior to study start.'
p6279
asg3797
(lp6280
S'- 1. current pregnancy'
p6281
aS"- 2. patient's without baseline hyperoxaluria (defined as >48 mg or 0.5mmol per 24 hour urine samples)"
p6282
aS'- 3. patients in renal failure assessed by a gfr < 60'
p6283
aS'- 4. inability to provide informed consent'
p6284
aS'- 5. active cancer'
p6285
aS'- 6. hyperparathyroidism'
p6286
aS'- 7. hyperphosphatemia'
p6287
aS'- 8. <19 years of age'
p6288
asg2542
(lp6289
S'- serious disease,'
p6290
aS'- biological treatment,'
p6291
aS'- pregnancy.'
p6292
asS'NCT01548014'
p6293
(lp6294
S'- patients who has proven to have infliximab antibody'
p6295
asS'NCT02201693'
p6296
(lp6297
S'- patients with b2 or b3 disease behavior (intestinal/colonic stenosis (including ileo-caecal valve), intrabdominal abscess, fistulizing disease)'
p6298
aS'- patients not in remission on induction therapy (wpcdai>12.5)'
p6299
aS'- patients with isolated and severe perianal disease'
p6300
aS'- patients requiring surgical therapy at inclusion'
p6301
aS'- ongoing steroid medication'
p6302
aS'- ongoing immunosuppressor or biologics therapy'
p6303
aS'- no informed consent'
p6304
aS'- currently participating or having participated in another interventional clinical trial during the last 4 weeks prior to the beginning of this study'
p6305
asS'NCT02538354'
p6306
(lp6307
S'- swallowing disorders'
p6308
aS'- pregnancy and lactation'
p6309
aS'- use of antibiotic drugs, probiotics (i.e.yakult, vifit, activia etc) or specific prebiotic supplements in the 3 weeks prior to the riboflavin intervention'
p6310
aS'- use of methotrexate drugs'
p6311
aS'- colonoscopy and colon cleansing in last 3 months'
p6312
aS'- use of a vitamin b2 supplement, or multivitamin complexes containing vitamin b (i.e. vitamin b-complex) in the 3 weeks prior to the riboflavin intervention'
p6313
aS"- severe crohn's disease (hbi > 12)"
p6314
asg3443
(lp6315
S'- subjects consuming prebiotic supplements (inulin, fos, galactooligosaccharides (gos)) in their regular diet.'
p6316
aS'- antibiotic use within the past 2 months'
p6317
aS'- previous anti-tnf therapy.'
p6318
asg2538
(lp6319
S'- patients unable to take medications by mouth, pregnant, with liver/kidney failure, receiving anticonvulsant medications (specifically, phenobarbital, carbamazepine and phenytoin, since they lead to increased vitamin d metabolism through hepatic induction of the cytochrome p450 (cyp450) hydroxylase enzymes), regularly attending a tanning salon (once weekly or more), currently being treated for hypovitaminosis d with therapeutic doses of vitamin d (> 800 iu per day) and unwilling to discontinue this regimen.'
p6320
aS'- patients on growth hormone, anabolic steroid hormones, calcitonin, bisphosphonates (maintenance trial only)'
p6321
asg5057
(lp6322
S'- use of bile acids'
p6323
aS'- use of bile acids sequestrants'
p6324
aS'- use of farnesoid x receptor agonists/antagonists'
p6325
aS'- recent colonoscopy(less than 1 month before inclusion)'
p6326
aS'- diabetes'
p6327
asg3301
(lp6328
S"- previous treatment for crohn's disease with liquid diet or glucocorticoid therapy"
p6329
aS'- isolated orofacial granulomatosis'
p6330
aS'- intravenous glucocorticoid therapy immediately indicated'
p6331
aS'- planned surgical intervention for cd'
p6332
asg4998
(lp6333
S"- patients affected by ulcerative colitis and crohn's disease respectively with a sccai \xe2\x89\xa5 1 and a cdai \xe2\x89\xa5150."
p6334
aS'- patients on steroid therapy.'
p6335
aS'- patients in therapy wih warfarin or other anticoagulants.'
p6336
aS'- known or supposed ipersensitivity to eicosapentaenoic acid/omega 3.'
p6337
aS'- women in fertile age which refuse to use contracceptives specified in the study (oral contraception, iud) and breastfeed women.'
p6338
aS'- patients with severe clinical conditions which the investigator consider to controindicate patient partecipation at the study.'
p6339
aS'- therapy modifications and/or assumption of sperimental therapies within three months before the study inclusion.'
p6340
aS'- patients unable to follow protocol procedures and to sign the informate consent.'
p6341
assS'erosive pustular dermatosis of the scalp-Procedure'
p6342
(dp6343
sS'enteritis-Other'
p6344
(dp6345
g2407
(lp6346
S'- specific cause of malnutrition (e.g. cerebral palsy, other organ disease)'
p6347
aS'- sibling admitted with sam at the same time'
p6348
aS'- unwilling to stay on ward for at least 2 weeks'
p6349
aS'- declined to give consent'
p6350
aS'- participating in another study'
p6351
assS'pediatric-Drug'
p6352
(dp6353
g2877
(lp6354
S'- antibiotic therapy within 4 weeks prior to inclusion immunosuppressive therapy within 4 weeks prior to inclusion not willing to collaborate isolated oral or perianal involvement'
p6355
assS'systemic lupus erythematosus-Drug'
p6356
(dp6357
g324
(lp6358
S'- known intolerance for il2 (see spc),'
p6359
aS'- administration of a non-authorized treatment and/or iv bolus of corticosteroids in the last 2 months,'
p6360
aS'- vaccination with live attenuated virus in the months preceding the inclusion or planned during the study'
p6361
aS'- other severe or progressive autoimmune/inflammatory pathology,'
p6362
aS'- low white blood cell count<2000/mm3, lymphocytes <600/mm3, platelets <80 000/mm3,'
p6363
aS"- heart failure (\xe2\x89\xa5 grade iii nyha), renal insufficiency (cockcroft< 60ml/mn except patients with lupus or wegener's granulomatosis) or hepatic insufficiency (transaminases> 5n except for patients with autoimmune hepatitis), or lung failure,"
p6364
aS'- significant abnormality in chest x-ray other than these linked to the diseases under investigation'
p6365
aS'- cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or basocellular carcinoma)'
p6366
aS'- poor venous access not allowing repeated blood tests,'
p6367
aS'- restrictive diet or parenteral nutrition,'
p6368
aS'- surgery during the last 2 months or surgery planned during the study,'
p6369
aS'- participation in other biomedical research in the last 3 months or planned during the study.'
p6370
aS'- pregnant or lactating women,'
p6371
aS'- concomitant psychiatric disease or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give informed consent,'
p6372
aS'- positive hiv serology, active hepatitis b or ebv infection,'
p6373
aS'- patients under a measure of legal protection'
p6374
assS'inflammatory arthritis-Biological'
p6375
(dp6376
g444
(lp6377
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p6378
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p6379
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p6380
aS'- known hiv/aids'
p6381
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p6382
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p6383
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p6384
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p6385
aS'- participated in an investigational study within 1 month prior to study entry'
p6386
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p6387
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p6388
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p6389
assS'fecal incontinence-Other'
p6390
(dp6391
sS"alzheimer's disease-Behavioral"
p6392
(dp6393
sS'non-ibd colitis-Device'
p6394
(dp6395
g93
(lp6396
S'- no health insurance ,'
p6397
aS'- mental disability,'
p6398
aS'- pregnancy'
p6399
assS'autoimmune hepatitis-Drug'
p6400
(dp6401
g324
(lp6402
S'- known intolerance for il2 (see spc),'
p6403
aS'- administration of a non-authorized treatment and/or iv bolus of corticosteroids in the last 2 months,'
p6404
aS'- vaccination with live attenuated virus in the months preceding the inclusion or planned during the study'
p6405
aS'- other severe or progressive autoimmune/inflammatory pathology,'
p6406
aS'- low white blood cell count<2000/mm3, lymphocytes <600/mm3, platelets <80 000/mm3,'
p6407
aS"- heart failure (\xe2\x89\xa5 grade iii nyha), renal insufficiency (cockcroft< 60ml/mn except patients with lupus or wegener's granulomatosis) or hepatic insufficiency (transaminases> 5n except for patients with autoimmune hepatitis), or lung failure,"
p6408
aS'- significant abnormality in chest x-ray other than these linked to the diseases under investigation'
p6409
aS'- cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or basocellular carcinoma)'
p6410
aS'- poor venous access not allowing repeated blood tests,'
p6411
aS'- restrictive diet or parenteral nutrition,'
p6412
aS'- surgery during the last 2 months or surgery planned during the study,'
p6413
aS'- participation in other biomedical research in the last 3 months or planned during the study.'
p6414
aS'- pregnant or lactating women,'
p6415
aS'- concomitant psychiatric disease or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give informed consent,'
p6416
aS'- positive hiv serology, active hepatitis b or ebv infection,'
p6417
aS'- patients under a measure of legal protection'
p6418
assS'dermatitis herpetiformis-Procedure'
p6419
(dp6420
sS'haematopoietic stem cell transplantation-Device'
p6421
(dp6422
sS'pustular psoriasis-Procedure'
p6423
(dp6424
sS'ulcerative colitis, active-Other'
p6425
(dp6426
g1953
(lp6427
S'- for all groups:'
p6428
aS'- 1. co-morbidity: severe kidney- and/or liver disease or thyroid abnormalities and impaired clotting'
p6429
aS'- 2. abdominal chirurgy (except for an uncomplicated appendectomy)'
p6430
assS'rheumatoid arthritis-Drug'
p6431
(dp6432
g324
(lp6433
S'- known intolerance for il2 (see spc),'
p6434
aS'- administration of a non-authorized treatment and/or iv bolus of corticosteroids in the last 2 months,'
p6435
aS'- vaccination with live attenuated virus in the months preceding the inclusion or planned during the study'
p6436
aS'- other severe or progressive autoimmune/inflammatory pathology,'
p6437
aS'- low white blood cell count<2000/mm3, lymphocytes <600/mm3, platelets <80 000/mm3,'
p6438
aS"- heart failure (\xe2\x89\xa5 grade iii nyha), renal insufficiency (cockcroft< 60ml/mn except patients with lupus or wegener's granulomatosis) or hepatic insufficiency (transaminases> 5n except for patients with autoimmune hepatitis), or lung failure,"
p6439
aS'- significant abnormality in chest x-ray other than these linked to the diseases under investigation'
p6440
aS'- cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or basocellular carcinoma)'
p6441
aS'- poor venous access not allowing repeated blood tests,'
p6442
aS'- restrictive diet or parenteral nutrition,'
p6443
aS'- surgery during the last 2 months or surgery planned during the study,'
p6444
aS'- participation in other biomedical research in the last 3 months or planned during the study.'
p6445
aS'- pregnant or lactating women,'
p6446
aS'- concomitant psychiatric disease or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give informed consent,'
p6447
aS'- positive hiv serology, active hepatitis b or ebv infection,'
p6448
aS'- patients under a measure of legal protection'
p6449
asg444
(lp6450
S'- prior use of the zoster vaccine (zostavax\xc2\xae, merck)'
p6451
aS'- glucocorticoids at a prednisone-equivalent daily dose > 10mg/day'
p6452
aS'- any known contraindication to zostavax\xc2\xae vaccine, including allergy or sensitivity to gelatin or any other vaccine component'
p6453
aS'- known hiv/aids'
p6454
aS'- currently receiving radiation or chemotherapy for any type of malignancy'
p6455
aS'- any current use (within the last 30 days) of acyclovir, valacyclovir, or famciclovir'
p6456
aS'- receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products [e.g., dt, pneumococcal vaccine, hepatitis a vaccine, hepatitis b vaccine]), or scheduled within 6 weeks after recruitment.'
p6457
aS'- active infection or inter-current illness (e.g., urinary tract infection, influenza)'
p6458
aS'- participated in an investigational study within 1 month prior to study entry'
p6459
aS'- active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study'
p6460
aS'- significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)'
p6461
aS'- any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy < 1 year)patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.'
p6462
assS'digestive system diseases-Drug'
p6463
(dp6464
g1639
(lp6465
S'- 1. subject, who, for any reason, is judged by the investigator to be inappropriate for this study;'
p6466
aS'- 2. subject has a medical history of other clinically significant diseases/disorders;'
p6467
aS"- 3. subject's uc had failed to respond to more than one biologic treatment (e.g., infliximab, adalimumab, or golimumab);"
p6468
aS'- 4. subject requires prescription treatment for uc, except for the stable, oral treatment of uc for 4 weeks prior to screening.'
p6469
aS'- 5. subject has received any of the following prior treatments or treatments within the specified time prior to the baseline visit:'
p6470
aS'- natalizumab, efalizumab, rituximab or other lymphocyte-depleting treatments, including but not limited, to alkylating agents (such as cyclophosphamide or chlorambucil) and total lymphoid irradiation at any time;'
p6471
aS'- tnf antagonists within 8 weeks, or 5 half-lives (up to 12 weeks);'
p6472
aS'- vedolizumab within 16 weeks;'
p6473
aS'- methotrexate, cyclosporine, mycophenolate, tacrolimus, thalidomide, or other immune altering drugs within 4 weeks (ophthalmologic preparations are permitted);'
p6474
aS'- 5-asa enema, steroid enema or suppository use within 2 weeks ; and/or'
p6475
aS'- investigational agents within 8 weeks or 5 half-lives (whichever is longer).'
p6476
aS'- 6. subject with recent, suspected or confirmed symptomatic stenosis of the colon, abdominal abscess, or ischemic colitis based on clinical or radiographic data; a history of toxic megacolon; or who had any previous surgery for uc;'
p6477
aS'- 7. subject with known colonic dysplasia, adenomas or polyposis;'
p6478
aS'- 8. subject had major surgery within 4 weeks prior to screening or an anticipated requirement for major surgery;'
p6479
aS'- 9. subject with enteric pathogens (including clostridium difficile);'
p6480
aS'- 10. subject with any of the following hematological and chemistry laboratory values:'
p6481
aS'- platelet count < 100,000/mm3;'
p6482
aS'- neutrophils < 1500/mm3;'
p6483
aS'- serum creatinine \xe2\x89\xa5 1.6 mg/dl (\xe2\x89\xa5 144.4 \xce\xbcmol/l);'
p6484
aS'- alkaline phosphatase > 3 times the upper limit of normal (uln);'
p6485
aS'- ast or alt > 2 times uln;'
p6486
aS"- total bilirubin > 2 mg/dl, unless due to gilbert's syndrome;"
p6487
aS'- serum albumin < 3 g/dl;'
p6488
aS'- hemoglobin < 9 g/dl;'
p6489
aS'- glycated serum hemoglobin a1c \xe2\x89\xa5 9%.'
p6490
aS'- 11. subject has clinically significant cardiac disease;'
p6491
aS'- 12. subject is pregnant or breastfeeding;'
p6492
aS'- 13. subject has had major immunologic reaction;'
p6493
aS'- 14. subject is hepatitis b core antibody or surface antigen positive and/or hepatitis c antibody positive with detectable rna;'
p6494
aS'- 15. subject has a history of human immunodeficiency virus (hiv) positivity, tests positive for hiv, or has congenital or acquired immunodeficiency;'
p6495
aS'- 16. subject has or has had active tb, suspected extra-pulmonary tb, a history of incompletely treated tb, or latent tb or other latent infection. subjects with latent tb (clinical findings, purified protein derivative [ppd] or interferon gamma release assay [igra]) may be included in the study if prophylactic therapy for latent tb is started at least 4 weeks prior to screening. subjects with a potentially untreated other infection (clinical findings) are to be excluded.'
p6496
aS'- 17. subject has bacterial infections requiring treatment with oral or parenteral antibiotics, within 2 and 4 weeks, respectively.'
p6497
aS'- 18. subject has a history of systemic opportunistic infection or recurrent infections'
p6498
aS'- 19. subject has malignancy or history of malignancy, except for adequately treated basal cell skin cancer or adequately treated carcinoma in-situ of the cervix without recurrence at least 5 years.'
p6499
aS'- 20. subject who received a bacille calmette-gu\xc3\xa9rin (bcg) vaccine within 6 months of randomization or live vaccination (e.g., measles, mumps, rubella [mmr]; herpes zoster; varicella, intranasal influenza; and oral poliomyelitis) within 4 weeks of randomization.'
p6500
aS'- 21. subject with a history of or active substance abuse.'
p6501
aS'- 22. subject has other severe acute or chronic medical or psychiatric condition or laboratory abnormality.'
p6502
asg2025
(lp6503
S'- bacterial, viral or other microbial infection(including hiv).'
p6504
aS'- orally administered corticosteroids within 3 weeks before enrollment, inhaled or dermatologic preparations for the treatment of other diseases are acceptable.'
p6505
aS'- used of infliximab or immunosuppressant within 2 months before enrollment.'
p6506
aS'- previous use of prescription doses of nsaids without efficacy.'
p6507
aS'- treatment with narcotic pain medications(anti-diarrheal agents such as loperamide and diphenoxylate are permitted).'
p6508
aS'- history of pancreatitis, except for subjects with a known but removed cause(such as gallstone pancreatitis).'
p6509
aS'- history of abnormal liver function tests, including ast or alt >1.5 times upper limit of normal, alkaline phosphatase >2 times upper limit of normal, total bilirubin >2.5 mg/dl at screening (or within the previous 6 months, if known).'
p6510
aS'- history of malignancy.'
p6511
aS'- women who are pregnant or lactating at the time of enrollment, or who intend to be during the study period.'
p6512
aS'- participation in other clinical trial within the past 3 months.'
p6513
assS'colonic diseases-Procedure'
p6514
(dp6515
g3569
(lp6516
S'- digestive stoma in place or planned during the intervention'
p6517
aS'- body mass index > 30 kg/m2'
p6518
aS'- history of previous laparotomy, except mc burney, pfannenstiel ou subcostal'
p6519
aS'- subtotal colectomy'
p6520
aS'- transverse colectomy'
p6521
aS'- proctectomy or total coloproctectomy'
p6522
aS'- synchronous metastasis'
p6523
aS'- preoperative suspicion of t4 colorectal cancer'
p6524
aS'- emergency procedure'
p6525
aS'- associated resection (except appendectomy or liver biopsy)'
p6526
aS'- pregnancy or current breast feeding.'
p6527
asg694
(lp6528
S'- patients with severe cardiopulmonary disease or other severe disease.'
p6529
aS'- patients who are psychopath, pregnant, and child without capacity for civil conduct.'
p6530
aS'- patients with complete intestinal obstruction.'
p6531
aS'- patients with abdominal cavity infection.'
p6532
aS'- patients who are treating by drug such as adrenal cortical hormone and immune inhibitors, chemotherapy drugs, radiation and so on.'
p6533
aS'- patients who need to accept the anastomosis between rectum and colon.'
p6534
aS'- patients who are required to accept intestinal anastomosis twice or more.'
p6535
aS'- patients who are required to accept the treatment of colostomy.'
p6536
aS'- other conditions that render a patient unsuitable for the trial as determined by the study investigators.'
p6537
asg616
(lp6538
S'- subjects present with bowel obstruction or perforation'
p6539
aS'- subject undergo emergency surgery'
p6540
aS'- subject with asa iv, v'
p6541
aS'- history of allergy or hypersensitivity against indocyanine green'
p6542
aS'- pregnant or breast-feeding women'
p6543
aS'- subject has uremia (serum creatinine >2.5 mg/dl)'
p6544
aS'- subject is undergoing palliative surgery or who is terminally ill'
p6545
aS'- subject who is unable to discontinue warfarin anticoagulation 5 days before surgery'
p6546
aS'- subject taking phenobarbital, phenylbutazone, primidone, phenytoin, haloperidol, nitrofurantoin, probenecid'
p6547
assS'stem cell transplantation-Drug'
p6548
(dp6549
sS'rectal cancer-Procedure'
p6550
(dp6551
g6108
(lp6552
S'- patients under the age of 16'
p6553
aS'- patients in whom sphincter preservation has already been deemed inappropriate for medical or surgical reasons (e.g. by an mdt for oncological cure), or in whom surgery has been deemed generally inappropriate.'
p6554
asg616
(lp6555
S'- subjects present with bowel obstruction or perforation'
p6556
aS'- subject undergo emergency surgery'
p6557
aS'- subject with asa iv, v'
p6558
aS'- history of allergy or hypersensitivity against indocyanine green'
p6559
aS'- pregnant or breast-feeding women'
p6560
aS'- subject has uremia (serum creatinine >2.5 mg/dl)'
p6561
aS'- subject is undergoing palliative surgery or who is terminally ill'
p6562
aS'- subject who is unable to discontinue warfarin anticoagulation 5 days before surgery'
p6563
aS'- subject taking phenobarbital, phenylbutazone, primidone, phenytoin, haloperidol, nitrofurantoin, probenecid'
p6564
assS'inflammatory bowel disease-Biological'
p6565
(dp6566
g2049
(lp6567
S'- active participation in another therapeutic trial'
p6568
aS'- unable to give informed consent, or assent'
p6569
aS'- active clostridium difficile infection'
p6570
aS'- significant change in medication dose or treatment modality within preceding 12 weeks of start of trial'
p6571
aS'- new treatments or significant change in medication dosing during trial'
p6572
aS'- significant, consecutive rise in pucai score during trial'
p6573
aS'- hospitalization during trial'
p6574
asg2058
(lp6575
S'- 1. patients in a clinical remission (pucai < 9).'
p6576
aS'- 2. patients considered to have toxic megacolon.'
p6577
aS'- 3. treatment na\xc3\xafve patients, i.e., patients must be intolerant to or not have responded to aminosalicylates.'
p6578
aS'- 4. patients with a known drug allergy to vancomycin, metronidazole or polymyxin.'
p6579
aS'- 5. patients with a history of aspiration, gastroparesis, surgery involving the upper gastrointestinal tract (that might affect upper gastrointestinal motility) or unable to swallow pills.'
p6580
aS'- 6. patients with esophageal dysmotility or swallowing dysfunction.'
p6581
aS'- 7. patients with known food allergies.'
p6582
aS'- 8. patients with positive test results for hbv, hcv, or hiv.'
p6583
aS'- 9. female patients with a positive test result on a urine hcg test.'
p6584
aS'- 10. patients unwilling or unable to give consent or participate in all study requirements.'
p6585
aS'- 11. patients unable or unwilling to receive a retention enema for purposes of induction therapy'
p6586
aS'- 12. children with recent (within 4 weeks) dose change of biologics, 5-asa, steroids or immunomodulators'
p6587
asS'NCT02150551'
p6588
(lp6589
S'- patients < 5 years of age or >22 years of age'
p6590
aS'- biologic therapy (i.e. infliximab or adalimumab) in the preceding 8 weeks.'
p6591
aS'- pregnant or breastfeeding. serum pregnancy test must be negative at screening for female subjects of childbearing potential. urine pregnancy test must remain negative at each of 8 infusion visits'
p6592
aS'- patients with toxic mega-colon or intestinal perforation'
p6593
aS'- evidence of autoimmune chronic active hepatitis or sclerosing cholangitis.'
p6594
aS'- patients with fever > 39\xc2\xb0 c or clinically significant active infection within 1 week (i.e. chronic infections including hepatitis b/c or hiv or acute infections, including urinary tract infection and respiratory tract infection)'
p6595
aS'- received an agent not approved by the fda for marketed use in any indication or any small molecule inhibitors (i.e. naltrexone) within 60 days of enrollment'
p6596
aS'- subjects who are taking greater than 20 mg (or if body weight <40 kg, 0.5 mg/kg) of prednisone daily'
p6597
aS'- abnormal biochemical and hematological parameters, including:'
p6598
aS'- neutrophil count < 1000 cells/mm3'
p6599
aS'- hemoglobin < 8 g/dl'
p6600
aS'- platelet count \xe2\x89\xa4 130 cells/mm3'
p6601
aS'- creatinine \xe2\x89\xa5 1.2 x the upper limit of normal'
p6602
aS'- alanine aminotransferase (alt) and/or aspartate aminotransferase (ast) \xe2\x89\xa5 2x the upper limit of normal'
p6603
aS'- conjugated bilirubin greater than 2.0 mg/dl'
p6604
aS'- has active infection with enteric pathogens as evidenced by positive microbiological culture of stool or c.difficile toxin pcr'
p6605
aS'- had bowel surgery other than perianal procedures (fistulotomy, seton placement, abscess drainage) within 6 months of enrollment'
p6606
asg2119
(lp6607
S'- 1. patients <3 years old'
p6608
aS'- 2. patients with other co-morbid intestinal infectious processes'
p6609
aS'- 3. patients will be excluded if on immunosuppressive therapy within 2 weeks of fmt. clinical care will not be adjusted in order to meet criteria of this study.'
p6610
aS'- 4. patients currently receiving chemotherapy'
p6611
aS'- 5. recipients with a history of severe (anaphylactic) food allergy'
p6612
aS'- 6. if female, participants of childbearing potential (females aged 11 and older or those who have already begun menstruating) will be required to have a urine pregnancy test on the day of the fmt procedure. patients who are pregnant will not be enrolled.'
p6613
asS'NCT01531075'
p6614
(lp6615
S'- pregnant women'
p6616
aS'- diagnosis of chronic viral hepatitis b'
p6617
aS'- any major acute medical event in the 30 days prior to recruitment that necessitated hospitalization ( acute myocardial infarction, cva, pulmonary emboli, sepsis, major trauma)'
p6618
aS'- any other chronic inflammatory condition not related to ibd ( connective tissue disease, chronic liver disease, copd, poorly controlled diabetes mellitus)'
p6619
aS'- active hematologic or oncologic diseases'
p6620
asg1788
(lp6621
S"- c0168z02: 17 years of age or older, with the exception of patients who participated in the sponsor's conducted pediatric ibd clinical trials. have other crohn's-like diseases that are associated with genetic diseases (eg, glycogen storage disease). the patient and parent/guardian are not able to adhere to the protocol requirements. are participating in any clinical trial for an investigational agent that is not commercially available. remicadepib4002 and remicadepib4003: less than 6 years of age or 17 years of age or older."
p6622
asg100
(lp6623
S'- subjects with known allergy or negative reaction to fluorescein or derivatives.'
p6624
aS'- subjects on active chemotherapy or radiation treatment'
p6625
aS'- pregnant or trying to conceive'
p6626
asg2174
(lp6627
S"- current relapse defined as a crohn's disease activity index (cdai) >150 for patients with crohn's disease or a modified truelove-witts activity index (mtwai) >10 for patients with ulcerative colitis"
p6628
aS'- actually pregnant or planned pregnancy in the next month'
p6629
aS'- immunization with a pneumococcal vaccine (conjugated or polysaccharide) in the previous 5 years'
p6630
aS'- previous severe systemic reaction to immunization (respiratory or circulative)'
p6631
aS'- episode of fever in the last 24 hours'
p6632
asS'NCT01971970'
p6633
(lp6634
S'- ibd patients who initiate ifx or ada immediately after diagnosis.'
p6635
aS'- presence of severe perianal disease as primary indication to start anti-tnf treatment.'
p6636
aS'- age < 6 years when anti-tnf maintenance treatment is initiated.'
p6637
assS'asthma-Behavioral'
p6638
(dp6639
sS'ankylosing spondylitis-Procedure'
p6640
(dp6641
g6039
(lp6642
S'- pregnancy'
p6643
aS'- use of antibiotics within the past 14 days'
p6644
aS'- current diagnosis of colon cancer'
p6645
aS'- diagnosis of celiac disease'
p6646
aS'- diagnosis of any other rheumatologic disease such as ra, sle, etc.'
p6647
aS'- chemotherapy or radiation therapy for any malignancy within the past year'
p6648
aS'- daily use of aspirin or nsaids with inability to hold the drug 7 days before and after the procedure'
p6649
aS'- current use of anticoagulation (lmwh, warfarin,etc.)'
p6650
aS'- a diagnosis of hiv'
p6651
aS'- clostridium difficile within the past 3 months'
p6652
aS'- evidence of inflammatory spinal or axial arthritis or disease based on chart review such as inflammation seen on radiographs or a diagnosis of sacroiliitis as: inclusion criteria:'
p6653
aS'- diagnosed with an axial spondyloarthritis (spa) by a rheumatologist -'
p6654
aS'- meet the assessment of spondyloarthritis international society (asas) axial spondyloarthritis (spa) criteria exclusion criteria:'
p6655
aS'- pregnancy'
p6656
aS'- use of antibiotics within the past 14 days'
p6657
aS'- current diagnosis of colon cancer'
p6658
aS'- diagnosis of celiac disease'
p6659
aS'- diagnosis of any other rheumatologic disease such as ra, sle, etc.'
p6660
aS'- chemotherapy or radiation therapy for any malignancy within the past year'
p6661
aS'- daily use of aspirin or nsaids with inability to hold the drug 7 days before and after the procedure'
p6662
aS'- current use of anticoagulation (lmwh,warfarin,etc.)'
p6663
aS'- a diagnosis of hiv'
p6664
aS'- clostridium dificile within the past 3 months'
p6665
aS'- a known history of idiopathic macroscopic or microscopic colitis'
p6666
asg73
(lp6667
S'- subject has participated in a study of an investigational medicinal product (imp) or medical device within the previous 30 days or 5 half-lives (whichever is longer) prior to screening or is currently participating in another study of an imp or medical device - unless the study is ucb up0016 [nct02154425] or a registry study'
p6668
aS"- subject has any obstetrical or psychiatric condition, or she or her infant(s) has any medical condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study or the outcome of the pregnancy"
p6669
aS'- subject has history of chronic alcohol abuse or drug abuse during pregnancy'
p6670
aS'- subject has any pregnancy-related clinically significant abnormality noted on obstetric ultrasound, or other imaging assessment, or the subject has significant laboratory abnormalities during her pregnancy, as judged by the investigator'
p6671
aS'- subject is taking or has taken any medication with strong positive evidence of a human fetal risk of teratogenicity (e.g., methotrexate or leflunomide) during pregnancy'
p6672
aS'- subject has evidence of a condition suggesting chronic or acute uteroplacental insufficiency such as intrauterine growth restriction, severe maternal hypertensive disorders of pregnancy, or abruption'
p6673
aS'- subject has a documented history of primary or secondary antiphospholipid syndrome or hypercoagulable state'
p6674
aS'- subject has received treatment with any biological therapeutic agent, including anti-tnfs other than certolizumab pegol (czp), during pregnancy'
p6675
aS'- subject has previously participated in this study'
p6676
aS'- subject has a positive or indeterminate quantiferon\xc2\xae-tb gold in tube test at screening. in case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the subject'
p6677
aS"- subject with known tuberculosis (tb) infection, at high risk of acquiring tb infection, or latent tb infection (ltb). if tested within the 6 months prior to screening and the test was negative for tb, and there is no change in the subject's clinical status, nor social, family, or travel history, there is no need for an additional tb testing at screening"
p6678
assS'rheumatoid arthritis-Behavioral'
p6679
(dp6680
sS'clostridium difficile-Other'
p6681
(dp6682
S'NCT02730325'
p6683
(lp6684
S'- subjects positive for enteric pathogens aside from c. difficile at screening visit.'
p6685
aS'- subjects with history of constipation within a week of the screening visit; or any serious hepatic, renal, cardiovascular, neurological or hematological disorder in the opinion of the investigator.'
p6686
aS'- subjects with history of drug or alcohol abuse, history of psychiatric disorders, known allergy or hypersensitivity to beef or any component of sbi.'
p6687
aS'- subjects with a history of antibiotic treatment within the 4 weeks prior to enrollment.'
p6688
aS'- subjects using anti-diarrheal medications (e.g., loperamide and bismuth subsalicylate).'
p6689
aS'- note: anti-diarrheal medications will be prohibited throughout the study.'
p6690
aS'- subjects who have been admitted to the hospital more than 48 hours prior to enrollment.'
p6691
aS'- women who are pregnant.'
p6692
assS'gastrointestinal stromal tumor-Procedure'
p6693
(dp6694
g290
(lp6695
S'- pregnant woman or lactating woman.'
p6696
aS'- with confirmed distant metastasis in liver, lung, bones, or other organs.'
p6697
aS'- intolerable laparoscopic operation or converted to open surgery.'
p6698
aS'- with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.'
p6699
aS'- with bad compliance or contraindication to enrollment.'
p6700
assS'inflammatory epidermolysis bullosa aquisita-Procedure'
p6701
(dp6702
sS'sleep-Behavioral'
p6703
(dp6704
g117
(lp6705
S'- refusal to give necessary oral or written informed consent by patient and/or parent (legal caregiver)'
p6706
aS'- not aged 7 through 20 at start of study'
p6707
aS'- not willing and able to volunteer in the study'
p6708
aS'- has sibling enrolled in this study'
p6709
aS'- has severe physical diseases of the locomotor apparatus, psychotic disorders, severe affective disorders, eating disorders, mental retardation, autism spectrum disorder'
p6710
aS'- inability to communicate and complete questionnaires in german'
p6711
aS'- does not own a functional and nintendo wii-compatible television at home'
p6712
aS'- among female adolescents, pregnancy, breastfeeding or intention to get pregnant during the study'
p6713
aS'- has clinically significant cardiovascular disease'
p6714
aS'- enrolment of the investigator, his/her family members, employees and other dependent persons'
p6715
assS'ulcerative colitis associated pouchitis-Procedure'
p6716
(dp6717
g6087
(lp6718
S'- age <18 years or >65 years of age'
p6719
aS'- exposure to immunosuppressive therapy (defined as steroid, etanercept, or anti-tumor necrosis factor (tnf)agents) within 1 month prior to enrollment'
p6720
aS'- concomitant clostridium difficile infection'
p6721
aS"- suspected crohn's disease"
p6722
aS'- documented active infection of any kind'
p6723
aS'- patients on anti-coagulant therapy, with platelet count less than 50,000, significant anemia with hemoglobin less than 7 or those with other conditions that place them at increased risk of bleeding'
p6724
aS'- absolute neutrophil count (anc) less than 1000 or history of opportunistic infection'
p6725
aS'- administration of investigational drug within one month prior to planned fmt'
p6726
aS'- pregnant or breastfeeding women'
p6727
assS'intestinal diseases-Device'
p6728
(dp6729
g346
(lp6730
S'- pancolitis or acute severe ulcerative colitis requiring immediate treatment'
p6731
aS'- need for admission due to active ulcerative colitis'
p6732
aS'- ulcerative colitis with systemic symptoms (abdominal pain, fever > 37.5 degrees, weight loss exceeding 3 kilograms).'
p6733
aS'- patient with anemia (haemoglobin < 8.3 mmol/l for males and < 7.3 mmol/l for females).'
p6734
aS'- patient with ostomy or pouch.'
p6735
aS'- the patient has had a bowel resection (except appendectomy)'
p6736
aS'- the patient has constipation and/or another known bowel condition than ulcerative colitis such as ibs.'
p6737
aS'- the patient has diabetes.'
p6738
aS'- regular intake of acetylsalicylic acid or nsaids'
p6739
aS'- the patient cannot understand the information material.'
p6740
aS'- the patient has had colon cancer, dysplasia or adenomatous polyps in the colon during the recent 5 year'
p6741
aS'- the patient is in a poor general condition.'
p6742
aS'- the patient has had a food poisoning within the last three months.'
p6743
aS'- the patient is pregnant at the time of inclusion or has planned pregnancy during the period of study.'
p6744
aS'- the patient is in medical treatment with cyclosporine at the beginning of the run in period.'
p6745
aS'- treatment for ulcerative colitis treatment has been changed within two weeks before the first day in the run in period'
p6746
aS'- the patient has commenced treatment with azathioprine, 6-mercaptopurine or methotrexate within 12 weeks before the first day in the run in period.'
p6747
aS'- the patient has commenced treatment with tnf-\xce\xb1 inhibitors within 12 weeks before the first day of the run in period.'
p6748
aS'- the patient suffers from coeliac disease or lactose intolerance.'
p6749
aS'- antibiotic treatment within two weeks before the first day of the run in period.'
p6750
aS'- patient has any medical, surgical condition that excludes the use of ric.'
p6751
assS'haematopoietic stem cell transplantation-Procedure'
p6752
(dp6753
s.